https://www.analysisgroup.com/about/locations/beijing/cn/heor/2025-10-15T17:58:46+00:00weekly0.5https://www.analysisgroup.com/about/locations/beijing/cn/market-access/2025-10-15T17:59:02+00:00weekly0.5https://www.analysisgroup.com/about/locations/beijing/cn/epidemiology/2025-10-15T17:58:54+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/biologics-biosimilars-and-generics/biologics-biosimilars-and-generics/2024-04-29T16:22:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/behind-the-headlines-in-pharmaceutical-investigations/2024-10-07T20:52:24+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/using-epidemiology-to-identify-unmet-need/2024-04-29T16:25:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/using-canadian-provincial-health-plan-claims/2024-10-07T20:52:35+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/evaluating-international-marketing-access/2024-04-29T16:26:34+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/also-on-analysisgroup.com2024-04-29T16:27:05+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/big-data-in-health-care/2024-10-07T20:53:02+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/assessing-the-economic-burden-of-alzheimers-disease/2024-10-07T20:53:09+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/monitoring-online-signals--implications-of-internet-data-in-pharmacovigilance/2024-10-07T20:53:15+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/addressing-health-care-demand-and-big-data-in-china/2024-10-07T20:52:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/a-look-inside-health-care-big-data/2024-10-07T20:53:24+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/diagnostics-and-next-generation-genetic-sequencing/2024-10-07T20:53:31+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/improper-promotion-and-kickback-allegations/2024-04-29T16:33:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/the-depth-of-provider-data/2024-04-29T16:34:13+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/also-on-analysisgroup.com2024-04-29T16:34:27+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/the-growing-economic-burden-of-depression-in-the-united-states/2026-03-31T19:04:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/developments-in-medical-big-data-research---what-makes-data-different-today-/2026-03-31T19:05:03+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/new-challenges-and-initiatives-in-big-data-processing/2026-03-31T19:06:03+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/the-obesity-epidemic--a-new-look-at-the-urgency-challenges-and-opportunities/2026-03-31T19:06:11+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/anti-obesity-drug-development-risks-and-expectations/2026-03-31T19:06:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/also-on-analysisgroup.com2024-04-29T16:44:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/the-biosimilar-revolution-is-just-beginning-in-the-us/2026-03-31T19:07:29+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/viewing-recent-opioid-regulations-in-context/2026-03-31T19:08:14+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/economic-burden-of-schizophrenia-in-the-us-exceeded-155-billion-in-2013/2026-03-31T19:08:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/machine-learning-algorithms-in-health-care-litigation/2026-03-31T19:09:32+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/the-myth-of-price-disconnects-in-us-pharma-markets/2026-03-31T19:09:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/payments-to-doctors--causal-inferences-require-a-closer-look/2026-03-31T19:10:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/evaluating-real-world-effectiveness-in-prescription-coverages/2026-03-31T19:11:06+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/new-academic-affiliate-dr-john-e-ware-jr-renowned-pro-expert/2026-03-31T19:11:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/also-on-analysisgroup.com2024-04-29T16:56:13+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/making-the-right-call--som-for-prescription-opioids/2026-03-31T19:12:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/abuse-deterrent-opioids-and-the-economic-costs-of-abuse/2026-03-31T19:13:27+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/why-biosimilar-introduction-may-be-different/2026-03-31T19:13:38+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/causation-in-product-liability--taking-a-new-look/2026-03-31T19:13:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/patient-reported-outcomes--emerging-developments-and-innovative-approaches/2026-03-31T19:13:58+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/biopharma-value-based-pricing--how-to-make-it-work-/2026-03-31T19:14:08+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/spotlight-on-europe/2026-03-31T19:14:16+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/a-new-landscape-for-comparative-effectiveness-research/2026-03-31T19:14:25+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/making-more-precise-health-care-decisions-with-machine-learning/2026-03-31T19:14:34+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/planting-trees-to-reduce-health-related-costs/2026-03-31T19:14:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/analysis-group-expert-david-dranove-highlighted-in-historic-health-care-merger-review/2026-03-31T19:14:54+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/also-on-analysisgroup.com2024-04-29T17:08:32+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-spring-2012/enhancing-product-value-propositions-in-the-pipeline/2024-10-07T20:57:18+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-spring-2012/methods-for-indirect-comparisons-in-outcomes-research/2024-10-07T20:57:24+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/wolf-pack-activism--a-quick-look/2024-10-07T20:37:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/assessing-commercial-success-at-the-u.s.-patent-trial-and-appeal-board2024-10-07T20:37:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/statistics-and-sports--deflategate/2024-10-07T20:38:01+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/forecasting-corporate-failure--a-look-at-statistical-and-theoretical-approaches/2024-10-07T20:38:08+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/the-myth-of-divided-antitrust-economics/2024-10-07T20:38:16+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/a-closer-look-at-the-use-of-consumer-surveys-in-litigation/2024-10-07T20:38:24+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/the-reality-of-u.s.-pharmaceutical-spending2024-10-07T20:38:32+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/assessing-the-epas-clean-power-plan/2024-10-07T20:38:39+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/recent-litigation/2025-12-23T17:12:33+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/also-on-analysisgroup.com2024-04-29T22:23:15+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/can-epidemiology-be-applied-to-auto-safety-analysis-/2024-10-07T20:39:01+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/analyzing-causation-damages-in-data-breaches/2024-10-07T20:39:10+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/common-threads-in-mortgage-backed-securities-cases/2024-10-07T20:39:18+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/changes-ahead-for-credit-rating-agencies/2024-10-07T20:39:26+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/economic-solutions-to-water-conflicts/2024-10-07T20:39:33+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/a-look-at-patent-litigation-and-valuation-post-reform/2024-10-07T20:39:41+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/where-policy-economics-intersect/2024-10-07T20:39:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/a-new-approach-to-regression-analysis-and-antitrust-litigation/2024-04-24T19:27:21+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/assessing-financial-issues-in-tribal-trust-fund-litigation/2024-10-07T20:40:02+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/customer-behavior-and-class-actions/customer-behavior-and-class-actions/2024-04-24T20:35:48+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/economic-analysis-in-erisa-litigation/economic-analysis-in-erisa-litigation/2024-04-24T20:37:12+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/patent-litigation-and-the-innovation-economy/2024-10-07T20:40:36+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/anticipating-exclusion--upward-pricing-pressure-in-vertical-transactions/2025-01-09T21:17:54+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/consolidation-coordination-and-competition---a-challenging-prescription-for-health-care/2024-10-07T20:40:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/what-is-a-prudent-investment--using-simulation-to-evaluate-investment-selections/2024-10-07T20:41:03+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/also-on-analysisgroup.com2024-04-24T20:43:48+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/featured-engagements/2024-04-24T20:44:20+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/an-inside-look-at-itcs-expedited-investigations-pilot-program/2025-01-22T16:41:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/international-enforcement-in-a-global-economy/2024-10-07T20:41:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/reconsidering-the-hypothetical-negotiation/2024-10-07T20:41:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/what-is-water-worth-/2024-10-07T20:41:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/the-role-of-clinical-trials-in-mass-torts-and-related-shareholder-suits/2024-10-07T20:42:35+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/also-on-analysisgroup.com2024-04-24T20:49:27+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/featured-engagements/2024-04-24T20:49:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/perspectives-on-investment-management-disputes/perspectives-on-investment-management-disputes/2024-10-07T20:42:51+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/presenting-demand-models-in-antitrust-litigation/presenting-demand-models-in-antitrust-litigation/2024-10-07T20:43:03+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/using-machine-learning-in-litigation/2024-10-07T20:43:14+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/qand-a-with-austan-goolsbee/2025-12-19T21:39:41+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/implications-of-the-tyson-ruling-for-class-certification/2024-10-07T20:43:27+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/qand-a-with-affiliate-david-dranove/2024-10-07T20:43:34+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/the-biosimilar-revolution-is-just-beginning-in-the-u.s2024-10-07T20:43:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/affiliate-spotlight--oliver-hart/2024-10-07T20:43:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/will-expanded-eeo-1-data-collection-yield-new-insights-into-discrimination-/2024-10-07T20:43:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/affiliate-roundtable--privacy-and-data-security/2024-10-07T20:44:05+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/data-corner--resolution-of-federal-privacy-and---data-security-cases--19992016/2024-10-07T20:44:13+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/evaluating-potential-development-of-a-broader-market-for-co2-allowance-trading/2024-10-07T20:44:20+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/also-on-analysisgroup.com2024-04-25T14:54:27+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2017/featured-engagements/2024-04-25T14:54:14+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2013/the-causes-and-consequences-of-currency-wars/2024-10-07T20:44:41+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2013/assessing-the-duration-of-damages-in-food-safety-cases/2024-10-07T20:44:48+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2013/investigating-adverse-effects-using-epidemiology/2024-10-07T20:44:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2013/In-this-Issue/2024-04-25T15:04:51+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2013/recent-litigation/2024-04-25T15:06:20+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/the-missing-data-challenge/the-missing-data-challenge--using-clinical-trials-results/2024-10-07T20:45:10+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/the-role-of-the-economic-expert-in-class-certification/the-role-of-the-economic-expert-in-class-certification/2024-10-07T20:45:19+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/when-all-natural-may-not-be/2024-10-07T20:45:32+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/when-price-fixing-is-alleged/2024-10-07T20:45:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/royalty-payments-bundled-goods-and-chicago-style-red-hots/2024-10-07T20:45:48+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/mobile-broadband--competition-spectrum-and-consumers/2026-01-21T15:40:08+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/featured-engagements/2024-04-25T15:15:24+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/featured-publishing/2024-04-25T15:15:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/artificial-intelligence-can-open-the-door-to-better-learning-better-care-and-better-coverage/2026-03-31T19:17:09+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/a-new-way-to-quantify-quality-of-life/2026-03-31T19:17:01+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/protecting-access-encouraging-innovation-a-discussion-about-drug-pricing/2026-03-31T19:16:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/a-collaboration-to-advance-hematology-research/2026-03-31T19:16:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/also-on-analysisgroup.com2024-04-29T17:37:58+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/interactive-shortcut/2024-01-11T10:35:51+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/contracts-and-crisis-nobel-laureate-oliver-hart-on-contract-theory-and-the-world-of-the-pandemic/2024-09-24T14:13:24+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/learning-from-lehman-lessons-for-today/2024-09-24T14:13:16+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/recent-case-highlights/2024-04-25T17:37:05+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/contributions-to-recently-published-books/2024-04-25T17:36:38+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/note-from-martha-s-samuelson/2024-04-25T17:35:47+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/in-combatting-a-global-pandemic-build-public-confidence-first/2024-09-24T14:13:09+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/zombie-over-levered-or-shocked-but-sound-pandemic-induced-bankruptcies-and-related-valuation-questions/2024-09-23T19:01:35+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/will-there-be-another-mortgage-crisis-lessons-from-the-great-recession/2024-09-24T14:12:58+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/assessing-the-evidence-from-covid-19-deaths-a-qa-with-christopher-knittel/2024-09-24T14:12:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/challenges-of-analyzing-health-care-data-in-the-covid-19-era/2024-09-24T14:12:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/financial-impacts-for-hospitals-from-covid-19/2024-09-24T14:12:32+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/innovation-drug-pricing-and-the-pandemic-a-qa-with-craig-garthwaite/2024-09-24T14:12:22+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/outlook-for-oil-prices-and-the-industry-in-turbulent-times-a-qa-with-philip-k.-verleger2024-09-24T14:12:07+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/forward-looking-statements-and-transparency-esther-mills-on-accounting-for-pandemic-related-losses/2024-09-24T14:11:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/powering-through--and-beyond--the-crisis/2024-09-24T14:11:47+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/platforms-competition-and-the-crisis-arun-sundararajan-on-how-restaurants-have-adapted-during-the-pandemic/2024-09-24T14:11:29+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/staffing-tracking-and-testing-for-covid-19-in-elder-care-facilities-a-qa-with-david-grabowski/2024-09-24T14:11:21+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/accounting-for-the-coronavirus-subjectivity-and-judgment-during-times-of-crisis/2024-09-24T14:11:12+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/seeing-is-not-the-same-thing-as-looking-anupam-b.-jena-m.d.-ph.d.-on-learning-from-natural-experiments2024-09-24T14:11:04+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/covid-19-and-bottom-line-impacts-in-trademark-litigation-a-qa-with-joel-steckel/2024-09-24T14:10:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/applying-data-science-to-meet-real-world-health-care-challenges/2026-03-31T19:16:30+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/synthesizing-evidence-secure-coverage-reimbursement/2026-03-31T19:16:20+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/expanded-role-real-world-evidence/2026-03-31T19:16:10+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/recalibrating-predictions-survival-benefits-novel-cancer-therapies/2026-03-31T19:15:39+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/precision-medicine-to-market/2026-03-31T19:15:30+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/new-payment-strategies/2026-03-31T19:15:21+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/asia-spotlight-beijing-forum/2026-03-31T19:15:13+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/also-on-analysisgroup.com2024-04-29T17:34:00+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/the-tyranny-of-market-shares-incorporating-survey-based-evidence-into-merger-analysis/2025-07-28T19:20:25+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/using-machine-learning-to-estimate-the-prevalence-and-onset-of-a-disease/2024-10-07T20:49:38+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/whats-in-the-record-implications-of-the-asacol-case-for-pharmaceutical-class-actions/2024-10-07T20:49:31+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/leveraging-cap-and-trades-market-incentives-in-climate-policies/2024-10-07T20:49:23+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/taxing-questions-managing-the-taxation-complexities-of-smart-contracts/2024-10-07T20:49:16+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/similar-but-not-the-same-charting-the-course-of-biosimilar-ip-litigation-in-the-us/2024-04-25T15:39:03+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/valuation-in-international-arbitration-a-growing-topic-in-investor-state-disputes/2024-10-07T20:49:04+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/franchise-no-poach-agreements-face-antitrust-scrutiny/2024-10-07T20:48:57+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/how-much-is-enough-applying-the-rule-of-reason-to-data-security/2024-10-07T20:48:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/symposium-examines-critical-economic-issues-in-life-sciences-litigation/2024-10-07T20:48:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/recent-case-highlights/2024-04-25T15:42:26+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/economic-consulting-in-the-data-science-era/2024-10-07T20:46:19+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/how-data-scientists-can-leverage-online-reviews-in-ip-and-antitrust-disputes/2024-10-07T20:46:26+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/the-ongoing-evolution-of-cryptocurrency-regulation-and-litigation/2024-10-07T20:46:35+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/exclusionary-abuses-and-multi-sided-platforms/2024-10-07T20:46:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/will-retail-debt-and-financial-distress-continue-to-grow-/2024-10-07T20:46:51+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/the-outlook-for-resilience-in-electricity-generation-and-distribution/2024-10-07T20:47:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/lng-contracts-taking-new-shape-in-europe-and-globally/2024-10-07T20:47:52+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/challenges-and-opportunities--suspicious-order-monitoring-of-prescription-opioids/2024-10-07T20:48:01+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/more-than-dollars-and-cents--prescription-drug-pricing-and-value/2024-10-07T20:48:09+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/building-a-foundation-for-essentiality-in-standard-essential-patents/2024-10-07T20:48:16+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/introducing-surveys-into-evidence--how-to-avoid-bias/2024-10-07T20:48:26+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/recent-case-highlights/2025-12-23T17:08:15+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/contributions-to-recently-published-books/2024-04-25T15:34:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/progress-on-hta-and-pharmacoeconomics-in-asia/2026-03-31T19:18:09+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/meeting-the-burden-the-predominance-requirement-in-pharmaceutical-class-actions/2026-03-31T19:17:58+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/a-real-world-view-of-the-health-care-costs-of-air-pollution/2026-03-31T19:17:48+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/also-on-analysisgroup.com2024-04-29T17:40:26+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/award-winning-research/2026-03-31T19:17:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/value-through-the-product-life-cycle-2021-law--economics-symposium/2026-03-31T19:17:28+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/the-economic-burden-of-depression-finding-hope-amid-despair/2026-03-31T19:17:19+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/determining-the-price-for-one-when-all-you-have-is-the-price-for-many/2024-09-24T14:19:33+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/new-bottles-for-old-wine-a-new-focus-on-antitrust-in-labor-markets/2024-09-24T14:19:24+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/aba-mock-trial-would-a-merger-of-online-platforms-lessen-competition/2024-04-25T17:49:05+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/aba-panel-the-ongoing-tale-of-two-sided-markets/2024-04-25T17:48:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/analysis-group-at-the-2022-aba-antitrust-law-spring-meeting/2024-09-24T14:21:13+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/recent-case-highlights/2025-12-23T16:59:14+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/esg-reporting-and-greenwashing-a-qa-with-david-w.-richardson2024-10-16T14:22:46+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/the-business-of-cybersecurity-is-business-kevin-powers-on-managing-the-risks-and-consequences-of-cyberattacks-and-data-breaches/2024-04-25T17:47:04+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/state-collaboration-could-strengthen-pathways-to-decarbonize-new-englands-electrical-grid/2024-04-25T17:46:49+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/esg-investments-and-disclosures-in-todays-corporate-world-a-qa-with-christianna-wood/2024-09-24T14:25:23+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/deceptively-simple-survey-evidence-in-food-and-beverage-false-labeling-class-actions/2024-04-25T17:46:11+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/changing-the-pattern-asthma-inhaler-use-societal-costs-and-health-benefits/2024-04-25T17:45:45+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2022-selected-highlights/pricing-litigation-enforcement-the-2022-law--economics-symposium-in-review/2026-03-31T19:18:50+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2022-selected-highlights/fulfilling-the-promise-real-world-data-and-real-world-evidence-in-action/2026-03-31T19:18:42+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2022-selected-highlights/untangling-competitive-relationships-in-health-care-mergers/2026-03-31T19:18:29+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2022-selected-highlights/expanding-occupational-licensing-in-health-care-a-qa-with-professor-brian-phelan/2026-03-31T19:18:20+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2022-selected-highlights/also-on-analysisgroup.com2024-04-29T17:44:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/a-new-gold-standard-how-digital-health-technologies-can-be-used-to-monitor-patient-progress/2024-09-24T14:32:17+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/fiduciary-duty-and-esg-a-qa-with-oliver-hart/2024-09-24T14:31:55+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/of-note/2025-12-23T16:56:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/a-richer-way-to-work-martha-samuelson-and-andrea-okie-explore-the-topic-of-women-and-diversity-in-antitrust/2025-01-09T15:27:26+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/if-you-build-it-will-they-come-indirect-network-effects-and-the-chicken-or-egg-dilemma-in-the-nascent-electric-vehicle-market/2024-09-24T14:30:37+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/venture-debt-and-the-failure-of-silicon-valley-bank-a-qa-with-yael-hochberg-and-sabrina-howell/2024-09-24T14:30:09+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/confusing-funny-just-plain-bad-surveys-and-trademark-litigation-after-jack-daniels/2024-09-24T14:29:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/expert-testimony-in-investor-state-disputes/2024-09-24T14:29:14+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/can-patent-infringement-harm-be-truly-irreparable-to-an-economist-a-qa-with-john-jarosz-and-robert-vigil/2024-09-24T14:27:48+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/high-power-and-high-stakes-a-qa-on-machine-learning-in-diagnostics/2024-09-24T15:22:06+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/shared-learning-without-waiting-for-shared-data-using-federated-analytics-for-health-care-research-across-multiple-institutions-and-countries/2024-09-24T15:21:20+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/distinctive-insights-our-physician-economists/2024-09-24T15:23:02+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/law-economics-symposium-webinar-on-antitrust-in-life-sciences-and-pharmaceuticals/2024-09-24T15:19:10+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/artificial-intelligence-and-real-world-evidence-in-oncology-research/2024-04-29T17:47:32+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/quantitative-approaches-to-stress-testing-scientific-claims-in-health-care/2024-09-24T15:15:06+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/of-note/2024-04-29T17:46:18+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/who-covers-what-untangling-the-intricacies-of-administering-prescription-drug-benefits-with-professor-amanda-starc/2024-09-24T15:23:29+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2024/innovating-finance-to-meet-emissions-reduction-goals-a-qa-with-peter-tufano/2024-09-24T14:36:40+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2024/depressions-spillover-effects-living-in-a-household-with-an-adult-with-depressive-symptoms/2024-09-24T14:36:17+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2024/of-note/2025-12-23T16:55:17+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2024/setting-the-antitrust-agenda-a-qa-with-anne-catherine-faye/2025-01-08T16:46:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2024/the-art-of-ai-using-large-language-models-in-economic-consulting/2025-11-14T21:03:10+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2024/how-does-your-business-grow-the-importance-of-growth-assumptions-in-delaware-appraisal-rulings/2025-11-14T21:03:36+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2024/biometric-information-privacy-laws-and-the-privacy-paradox-a-qa-with-simon-blanchard/2026-03-30T13:50:00+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2024/the-aftermath-of-jarkesy-accounting-experts-s-p-kothari-and-robert-conway-explore-potential-impacts-on-litigation-and-the-role-of-experts/2024-11-07T16:43:33+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2025/a-dialogue-on-leadership-martha-samuelson-and-pierre-cremieux/2025-06-17T19:22:21+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2025/one-of-these-things-is-not-like-the-others-proper-and-improper-uses-of-logit-models-in-expert-analysis/2025-06-17T19:22:10+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2025/the-intersection-of-accounting-reporting-and-capital-markets-a-qa-with-marc-siegel/2025-11-14T20:51:17+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2025/of-note/2026-01-07T18:03:46+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2025/the-future-of-privacy-and-ai-risks-a-qa-with-peter-lefkowitz/2025-09-24T20:45:27+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2025/event-studies-in-international-arbitrations-applications-in-merits-and-quantum/2025-09-24T20:45:56+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2025/the-economics-of-influencer-marketing-a-qa-with-dina-mayzlin/2025-09-24T20:46:16+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2026/when-code-becomes-evidence-untangling-software-and-algorithms-in-litigation/2026-03-09T19:54:29+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2026/steering-through-uncertainty-antitrust-regimes-on-both-sides-of-the-atlantic/2026-03-03T15:30:59+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2026/of-note/2026-01-28T20:10:34+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2026/when-theory-meets-practice-a-conversation-with-mark-egan-on-firm-behavior-and-market-dynamics/2026-03-31T14:39:53+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/priming-the-pump-for-economic-recovery-by-investing-in-advanced-energy/2024-09-24T14:08:34+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/does-acquihiring-lead-to-better-outcomes-in-the-technology-sector/2024-04-25T17:42:26+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/in-future-editions/2024-04-25T17:42:02+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/recent-case-highlights/2025-12-23T17:02:12+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/has-the-covid-19-pandemic-changed-economic-analysis-in-merger-review/2024-09-24T14:09:43+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/tracking-the-path-of-covid-19--in-haiti/2024-04-25T17:41:34+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/vaccines-incentives-and-innovation-the-lessons-of-covid-19-for-the-pharmaceutical-industry/2024-09-24T14:09:11+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/the-role-of-due-diligence-in-mitigating-spac-litigation-risks/2024-09-24T14:10:44+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/machine-power-applications-of-natural-language-processing-in-economic-consulting/2024-09-24T14:10:23+00:00weekly0.5https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/defending-a-socially-conscious-brand-a-qa-with-professor-tulin-erdem/2024-09-24T14:10:04+00:00weekly0.5https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/epidemiology-biostatistics/biostatistical-analysis/2024-01-11T10:36:13+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/epidemiology-biostatistics/epidemiology-capabilities-and-services/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/landing-page/analysis-group-and-antitrust/2024-04-29T20:02:49+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/landing-page/promouvoir-lexcellence-et-linnovation-dans-la-recherche-en-sante/2024-09-26T17:47:00+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/landing-page/highlights-from-our-recent-and-ongoing-heor-work/2024-11-05T16:19:15+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/landing-page/thank-you-for-your-interest-in-aghealth-ai/2025-05-22T18:52:41+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/landing-page/analysis-group-highlights-from-our-litigation-work-in-canada/2025-11-17T22:08:51+00:00weekly0.6https://www.analysisgroup.com/careers/career-path/recruiting-events/analyst-engagement-series/2026-01-29T19:30:38+00:00weekly0.6https://www.analysisgroup.com/careers/career-path/recruiting-events/associate-engagement-series/2026-01-29T19:29:26+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/deal-metrics/a-quick-look-at-topping-bids/2024-04-25T17:56:19+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/deal-metrics/go-shops-and-topping-bids/2024-04-25T17:56:34+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/energy-and-environment/alleged-market-manipulation-in-energy-markets/2025-11-14T21:01:39+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/energy-and-environment/energy-and--environment-litigation-case-examples/2025-11-14T21:02:19+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/energy-and-environment/health-related-cost-impacts-from-pollutant-reductions/2024-04-25T17:57:17+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/energy-and-environment/analyzing-competition-in-the-low-level-radioactive-waste-llrw-market/2024-04-29T16:07:26+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/biologics-biosimilars-and-generics/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2013/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2014/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2015/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/fall-2016/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-2018/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-spring-2012/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winterspring-2019/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/winter-20192020/2024-01-11T10:36:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2021/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2022-selected-highlights/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2023/2024-01-11T10:36:13+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2015-year-in-review/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/analysis-group-forum/2021-02-02T18:41:18+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/customer-behavior-and-class-actions/2018-11-05T14:37:46+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/economic-analysis-in-erisa-litigation/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-2014/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/fall-winter-2013/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/perspectives-on-investment-management-disputes/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/presenting-demand-models-in-antitrust-litigation/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2013/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/the-missing-data-challenge/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/the-role-of-the-economic-expert-in-class-certification/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/winter-2013-forum/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/summer-2018/2018-10-05T20:23:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/spring-2019/2024-01-11T10:36:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2020/2024-01-11T10:36:02+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2021/2024-04-25T17:39:35+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2022/2024-04-25T17:45:29+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/forum-2023/2024-04-25T17:51:14+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/transformation-of-the-nation-s-electric-infrastructure-and-implications-for-reliability/2024-04-29T17:53:05+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/assessing-transmission-for-renewables-projects/2024-10-07T20:59:14+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/performance-and-economic-analyses-to-support-the-siting-approval-of-a-new-natural-gas-peaker-plant/2024-04-29T17:52:21+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/assessing-market-needs-to-evaluate-natural-gas-pipeline-development/2024-04-29T17:54:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/capacity-market-impacts-of-future-resources-scenarios-in-the-iso-ne-system/2024-10-07T20:59:26+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/the-economics-of-different-ownership-structures-for-water-utilities/2024-10-07T20:59:32+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/revisiting-the-debate-over-natural-gas-pipeline-certifications/2024-10-07T20:59:38+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/also-on-analysisgroup.com2024-04-29T17:57:19+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/energy-technology-and-the-future-a-conversation-with-ferc-commissioner-cheryl-lafleur-and-former-epa-administrator-gina-mccarthy/2024-10-07T20:59:45+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/infrastructure/perspectives-on-the-future-of-the-u.s.-power-grid2024-04-29T17:58:26+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/cap-and-trade-and-allowance-allocations/2024-11-05T21:08:05+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/reading-the-tea-leaves-in-mand-a-litigation/2024-11-05T21:09:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/reinstatement-and-bankruptcy-litigation/2024-11-05T21:09:17+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/the-real-story-behind-mutual-fund-fees/2024-11-06T21:49:33+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/antitrust-experts-discuss-a-state-of-the-art-merger-tool/2024-11-06T21:49:42+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/a-focus-on-proxy-puts--change-of-control-provisions-in-perspective/2024-11-06T21:49:58+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/is-big-data-a-true-source-of-market-power-/2024-11-06T21:50:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/the-impact-of-data-breaches-and-hacking/2024-11-06T21:50:15+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/consumer-class-action-litigation--understanding-consumer-decision-making-can-make-the-difference/2024-11-06T21:50:27+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/privacy-and-cybersecurity--the-corporate-perspective/2024-11-06T21:50:37+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/labor-and-employment-issues-in-the-gig-economy--qand-a-with-professor-paul-oyer/2024-11-06T21:50:44+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/gender-identity-discrimination-in-the-greater-boston-housing-market/2024-11-06T21:50:52+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/examining-key-economic-issues-in-anti-poaching-and-pay-equity-litigation/2024-11-06T21:51:01+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/blockchain-economics-and-litigation/2024-11-06T21:51:09+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/materialization-of-risk-in-securities-event-driven-fraud-class-actions/2024-04-29T18:40:29+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/statistical-approaches-to-pay-equity-issues--a-qand-a-with-affiliate-anthony-losasso/2024-11-06T21:51:30+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/the-use-of-reverse-termination-fees-in-merger-reviews/2024-11-06T21:51:46+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/does_acquihiring_lead_to_better_outcomes/2024-11-06T21:51:18+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/mayo-setting-the-record-straight/2024-11-06T21:51:54+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/conjoint-surveys-can-lead-to-inflated-values-of-minor-product-features/2024-11-06T21:52:23+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/managing-information-security-and-data-in-the-modern-business/2024-11-06T21:52:31+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/a-discussion-with-dr.-serena-koenig-about-the-why-when-and-how-of-novel-coronavirus-testing2024-11-06T21:52:37+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/markets-data-and-the-value-of-high-tech-patents-a-qa-with-christopher-knittel/2024-11-06T21:52:46+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/using-economics-in-policymaking-for-digital-platforms-a-qa-with-jeffrey-t.-prince2024-11-06T21:52:54+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/accounting-for-adverse-events-in-merger-deals-a-discussion-with-professor-david-j.-denis2024-11-06T21:53:03+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/listening-to-the-voice-of-the-consumer-a-qa-with-peter-golder/2024-04-29T19:57:57+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/analyzing-the-dynamics-of-shopping-and-consumption-a-qa-with-professor-edward-j.-fox2024-04-29T19:30:40+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/understanding-algorithms-data-structures-and-technical-systems-in-litigation/2024-09-25T18:41:29+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/using-implan-as-a-springboard-for-complex-economic-impact-analysis-a-qa-with-pavel-darling/2024-07-23T19:22:46+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/the-role-of-accounting-in-esg-reporting-a-qa-with-d.-scott-showalter2024-11-06T21:53:35+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/reconceptualizing-treatment-value-a-qa-with-professor-lou-garrison-on-augmented-cost-effectiveness-analyses/2024-07-23T19:13:23+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/finding-common-ground-a-qa-on-valuing-biotech-valuing-and-investments/2024-07-23T19:15:03+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/examining-trends-in-drug-development-a-qa-with-michael-kinch/2024-07-23T19:17:26+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/artificial-intelligence-and-real-world-evidence-in-oncology-research-a-qa-with-eric-wu/2024-09-09T17:12:55+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/data-driven-approaches-to-assessing-the-value-of-innovations-in-health-care-a-qa-with-professor-amol-navathe/2025-11-14T21:05:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/advancing-health-care-quality-and-controlling-costs-a-qa-with-ashish-jha/2024-09-24T14:02:10+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/labor-dynamics-and-wages-in-the-health-care-sector-a-qa-with-professor-david-grabowski/2024-10-31T14:56:40+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/bridging-the-gap-between-technical-fluency-and-economic-impact-a-qa-with-peter-finch-and-nathan-trujillo/2025-08-19T20:43:57+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/q-and-a/understanding-obesity-in-conversation-with-professor-john-cawley-and-dr-fatima-cody-stanford/2026-02-11T17:55:06+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/settlement-in-microsoft-iowa-litigation/settlement-in-microsoft-iowa-litigation--overview/2024-04-29T19:35:41+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/settlement-in-microsoft-iowa-litigation/settlement-in-microsoft-iowa-litigation--working-with-academic-experts/2024-04-29T19:36:14+00:00weekly0.6https://www.analysisgroup.com/Insights/ag-feature/settlement-in-microsoft-iowa-litigation/settlement-in-microsoft-iowa-litigation--key-concepts-in-the-litigation/2024-04-29T19:46:29+00:00weekly0.6https://www.analysisgroup.com/about/locations/beijing/cn/2026-03-19T15:15:45+00:00weekly0.6https://www.analysisgroup.com/about/locations/brussels/fr/2025-05-01T13:32:56+00:00weekly0.6https://www.analysisgroup.com/about/locations/paris/fr/2025-01-09T21:20:23+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/lisa/2024-04-30T20:33:12+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/ajay/2023-03-08T15:44:37+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/bruce/2022-07-27T19:46:41+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/laura/2025-05-02T15:57:10+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/lauren/2025-05-02T15:58:24+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/david/2025-03-24T15:01:04+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/mark/2023-05-09T14:14:00+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/na/2024-06-24T15:07:14+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/rebecca/2022-07-28T17:58:08+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/andrew/2022-07-27T19:44:26+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/martha/2025-01-08T17:58:53+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/patrick/2022-07-28T17:46:17+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/Natacha/2025-01-08T18:07:23+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/megan/2024-01-11T10:36:12+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/priyanka/2025-05-02T15:55:50+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/maral/2024-05-03T14:23:40+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/elyse/2024-05-03T15:29:07+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/rajeev/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/yao/2025-01-29T19:14:56+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/catherine/2025-10-27T14:07:40+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/david-g/2024-03-07T22:18:52+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/elizabeth/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/schuyler/2024-01-11T10:36:07+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/stefano/2026-01-02T18:08:19+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/garrett/2026-01-21T16:34:43+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/william/2024-09-12T13:46:26+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/mario/2025-02-20T20:56:40+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/peter/2026-03-24T19:39:34+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/lamiya/2024-01-11T10:36:05+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/kari/2024-01-11T10:36:05+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/ngoc/2024-01-11T10:36:04+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/sam/2024-01-11T10:36:03+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/erica/2024-03-18T19:07:38+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/nisha/2025-04-30T15:15:55+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/amanda/2024-01-11T10:36:04+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/kristin/2024-06-24T15:10:15+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/anne-catherine/2025-05-02T15:58:01+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/khalilah/2026-01-21T16:32:32+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/kale/2025-01-07T18:00:09+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/riccardo/2026-01-02T16:43:02+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/cassie/2025-01-08T21:28:41+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/andres/2025-10-14T20:05:58+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/celeste/2025-01-08T16:18:49+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/jeanne/2025-01-08T16:48:46+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/max/2024-10-24T15:10:52+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/upamanyu/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/seth/2024-01-11T10:36:01+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/mahir/2025-09-12T18:18:52+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/lohit/2025-10-28T14:09:15+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/talissa/2025-05-14T17:07:08+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/samuel/2024-01-11T15:02:31+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/gleb/2024-01-11T10:36:13+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/etienne/2024-01-11T10:36:00+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/samantha/2025-10-28T14:11:07+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/james-l/2026-01-21T16:35:49+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/aditi/2025-05-14T17:06:48+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/jean-louis/2025-04-08T17:56:21+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/klara/2024-08-28T20:50:06+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/hadrien/2025-05-02T15:59:08+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/hongbo/2025-05-02T16:00:43+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/anne/2025-05-02T15:56:40+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/olivia/2025-09-30T20:15:31+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/ali/2025-09-30T20:13:50+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/hongjue/2025-09-30T20:14:19+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/alessio/2025-09-30T20:08:52+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/francesca/2025-09-30T20:14:05+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/joanne/2025-09-30T20:14:29+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/john/2026-04-02T14:39:39+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/grace/2026-04-01T18:36:04+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/malcom/2026-04-02T16:47:46+00:00weekly0.6https://www.analysisgroup.com/careers/why-analysis-group/our-people/alexandra/2026-04-02T14:31:23+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/burden-of-illness-research/2022-01-13T19:26:58+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/comparative-effectiveness-research/2022-01-13T19:27:06+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/patient-reported-outcomes/2022-01-13T19:27:16+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/clinical-research-and-study-design/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/personalized-medicine/2022-01-13T19:27:32+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/rare-disease-and-orphan-drug-research/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/health-care/litigation-services/antitrust-litigation/2026-03-13T13:10:31+00:00weekly0.6https://www.analysisgroup.com/practices/health-care/litigation-services/drug-safety-litigation/2026-03-13T13:11:41+00:00weekly0.6https://www.analysisgroup.com/practices/health-care/litigation-services/government-investigations-and-qui-tam-litigation/2026-03-13T13:11:18+00:00weekly0.6https://www.analysisgroup.com/practices/health-care/litigation-services/intellectual-property-disputes/2026-03-13T13:11:34+00:00weekly0.6https://www.analysisgroup.com/practices/health-care/litigation-services/payer-disputes/2026-03-13T13:11:26+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/modeling-and-analytics/big-data-research/2023-12-14T15:17:43+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/modeling-and-analytics/health-technology-assessment-hta/2022-01-13T19:29:08+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/modeling-and-analytics/machine-learning-in-health-care/2024-01-11T10:36:13+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/market-access-and-commercial-strategy/value-proposition-and-evidence-strategy/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/market-access-and-commercial-strategy/forecasting-and-modeling/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/market-access-and-commercial-strategy/payer-provider-and-other-stakeholder-research/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/market-access-and-commercial-strategy/pricing-contracting-and-reimbursement/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/market-access-and-commercial-strategy/evidence-dossiers-and-communication-tools/2023-01-13T12:44:39+00:00weekly0.6https://www.analysisgroup.com/practices/insurance/claims-handling-and-payment/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/insurance/pricing-coverage-and-management-issues/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/insurance/sales-practices-and-product-performance/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/itc-section-337-investigations/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/frand-royalty-rates-and-terms/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/commercial-success/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/ip-damages/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/injunctive-relief/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/ip-surveys-and-market-research/2024-01-11T10:42:20+00:00weekly0.7https://www.analysisgroup.com/practices/intellectual-property/technicaltechnology-evaluation/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/practices/labor-and-employment/class-certification/2024-01-11T10:36:15+00:00weekly0.7https://www.analysisgroup.com/practices/labor-and-employment/discrimination-and-pay-equity/2024-01-11T10:36:15+00:00weekly0.7https://www.analysisgroup.com/practices/labor-and-employment/labor-market-antitrust/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/practices/labor-and-employment/surveys-experiments-and-other-primary-data-collection-in-labor-and-employment-litigation/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/practices/labor-and-employment/wage-and-hour-litigation/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/practices/labor-and-employment/worker-misclassification/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/practices/media-entertainment-and-communications/copyright-disputes/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/media-entertainment-and-communications/wireless-communications-and-spectrum-valuation/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/media-entertainment-and-communications/cable-and-satellite-distribution/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/investment-suitability/2023-12-14T15:09:04+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/market-microstructure/2022-10-27T15:17:01+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/mutual-funds-and-hedge-funds/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/securities-fraud/2026-01-09T15:08:32+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/structured-finance-and-derivatives/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/financial-services-banking-practices/2025-12-19T21:35:43+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/private-equity-venture-capital/2025-05-09T15:17:11+00:00weekly0.7https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/cryptocurrency-decentralized-finance/2025-10-24T14:34:16+00:00weekly0.7https://www.analysisgroup.com/practices/strategy-policy-and-analytics/modeling-and-decision-tools/2024-03-29T18:18:50+00:00weekly0.7https://www.analysisgroup.com/practices/strategy-policy-and-analytics/public-policy-and-economic-impact-analysis/2024-08-27T16:55:15+00:00weekly0.7https://www.analysisgroup.com/practices/strategy-policy-and-analytics/analytics/2024-03-29T18:14:05+00:00weekly0.7https://www.analysisgroup.com/practices/marketing-consumer-behavior-surveys/class-actions-product-liability/2026-02-09T16:45:40+00:00weekly0.7https://www.analysisgroup.com/practices/marketing-consumer-behavior-surveys/consumer-protection-privacy/2026-03-30T13:51:44+00:00weekly0.7https://www.analysisgroup.com/practices/marketing-consumer-behavior-surveys/false-advertising/2026-02-09T16:35:05+00:00weekly0.7https://www.analysisgroup.com/practices/marketing-consumer-behavior-surveys/mergers-antitrust/2026-02-09T16:33:40+00:00weekly0.7https://www.analysisgroup.com/practices/marketing-consumer-behavior-surveys/patents-and-other-intellectual-property/2026-02-09T16:32:35+00:00weekly0.7https://www.analysisgroup.com/practices/marketing-consumer-behavior-surveys/trademarks-trade-dress/2026-02-09T16:27:49+00:00weekly0.7https://www.analysisgroup.com/practices/marketing-consumer-behavior-surveys/defamation-reputational-harm/2025-11-19T20:47:27+00:00weekly0.7https://www.analysisgroup.com/practices/accounting/accounting-liability-issues/2025-06-05T18:30:39+00:00weekly0.7https://www.analysisgroup.com/practices/accounting/damages-and-materiality-analyses/2025-06-05T18:33:30+00:00weekly0.7https://www.analysisgroup.com/practices/technology/engineering-systems/2024-07-26T18:04:39+00:00weekly0.7https://www.analysisgroup.com/practices/technology/policy-and-strategy/2024-07-24T17:24:04+00:00weekly0.7https://www.analysisgroup.com/practices/technology/technology-industries/2024-05-10T18:24:20+00:00weekly0.7https://www.analysisgroup.com/practices/technology/software/2024-07-24T17:25:53+00:00weekly0.7https://www.analysisgroup.com/practices/technology/coding-analytics-digital-forensics/2024-07-24T17:22:59+00:00weekly0.7https://www.analysisgroup.com/practices/transaction-and-governance-litigation/appraisal/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/transaction-and-governance-litigation/hostile-bids-and-activism/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/transaction-and-governance-litigation/governance-and-contract-disputes/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/transaction-and-governance-litigation/post-merger-disputes/2022-09-16T20:30:57+00:00weekly0.7https://www.analysisgroup.com/practices/valuation/financial-instrument-valuation/2025-04-01T20:27:17+00:00weekly0.7https://www.analysisgroup.com/practices/valuation/business-enterprise-valuation/2020-07-10T18:13:36+00:00weekly0.7https://www.analysisgroup.com/practices/valuation/valuation-of-other-assets/2020-07-16T17:12:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/microsoft-private-litigations/2025-01-08T16:19:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/vitamins-antitrust-litigation/2025-01-10T16:04:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-doj-v--mastercard-international-and-visa/2025-01-08T16:35:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/brand-name-prescription-drug-litigation/2024-12-31T12:59:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/virgin-atlantic-v--british-airways/2024-12-31T12:59:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/carnival-corporation-merger/2024-12-31T12:59:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/class-action-v--allstate-insurance/2026-02-02T20:02:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/colgate-v--procter---gamble-company/2024-12-31T12:59:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-ex-rel--jordan-v--northrop-grumman-corporation/2024-12-31T12:59:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/procter-gamble-co-v-haugen/2026-02-02T21:06:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evergreen-international-airlines-v--asiana-airlines/2024-12-31T12:59:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ferc-market-based-rate-applications-for-renewable-energy-power-plants/2024-12-31T12:59:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/distribution-system-reliability--estimation-using-sampling-and-statistical-analysis/2024-12-31T12:59:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/option-valuation-of-peaking-capacity/2024-12-31T12:59:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/industry-restructuring-evaluation/2024-12-31T12:59:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/modeling-of-bidding-behavior-in-competitive-electricity-markets/2024-12-31T12:59:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-strategic-bidding-and-withholding/2024-12-31T12:59:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wholesale-market-design-analysis/2024-12-31T12:59:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/market-modeling--electricity-pricing-analyses/2024-12-31T12:59:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pricing-and-retail-contract-analysis/2024-12-31T12:59:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/valuation-of-a-new-hydroelectric-plant/2024-12-31T12:59:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/market-monitoring-and-mitigation/2024-12-31T12:59:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/environmental-economics-and-policy-for-the-electric-and-gas-industries/2024-12-31T12:59:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/independent-market-monitoring/2024-12-31T12:59:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/contract-and-regulatory-disputes/2024-12-31T12:59:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/damages-analysis-regarding-price-risk-management-strategy/2024-12-31T12:59:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/energy-facility-siting/2024-12-31T12:59:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/developing-a-technical-computing-framework/2024-12-31T12:59:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/energizing-a-portfolio-for-the-deregulated-marketplace/2024-12-31T12:59:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bmi-royalty-rates-analysis/2024-12-31T12:59:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-haulers-association-v--oneida-herkimer-solid-waste-management-authority/2024-12-31T12:59:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-and-environmental-impacts-of-energy-infrastructure/2024-12-31T12:59:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/negotiations-regarding-insurance-coverage-of-environmental-liabilities/2024-12-31T12:59:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pfizer-asbestos-settlement/2024-12-31T12:59:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/3250-wilshire-blvd--building-v--metropolitan-life-insurance-company/2024-12-31T12:59:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sheldon-h--solow-v--w--r--grace---company/2024-12-31T12:59:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/florida-state-board-of-administration-v--alliance-capital-management/2024-12-31T12:59:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/richard-duhaime-v--john-hancock-mutual-life-insurance-company/2024-12-31T12:59:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/csr-v--lloyd-s-underwriters/2026-02-02T19:43:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mortgage-insurance-industry-respa-cases/2024-12-31T12:59:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/class-action-v--ohio-national-life-insurance-company/2026-02-02T20:03:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/winstar-damages-litigation/2025-07-01T14:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sumitomo-corporation-v--major-investment-banks/2024-12-31T12:59:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/corporate-partners-v--coopers---lybrand/2024-12-31T12:59:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/reinsurance-arbitrations/2024-12-31T12:59:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/orange-county-bankruptcy/2024-12-31T12:59:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/risk-characteristics-of-swaps/2024-12-31T12:59:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/developing-a-comprehensive-product-strategy/2024-12-31T12:59:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/developing-a-growth-strategy-under-constraints/2024-12-31T12:59:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/achieving-commercial-results-in-managed-markets/2024-12-31T12:59:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/emc-corp--v--karwowska/2025-01-10T15:57:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/boston-symphony-orchestra-compensation-analysis/2025-01-10T15:43:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-nursing-home-compensation/2024-12-31T12:59:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-clarent-corporation-securities-litigation/2026-02-02T20:06:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/california-amplifier-10b-5-litigation/2024-12-31T12:59:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/parnes-v--bally-entertainment-corp-/2024-12-31T12:59:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/emeritus-corporation-v--arv-assisted-living/2024-12-31T12:59:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/westside-cellular-v--new-par/2024-12-31T12:59:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/telecom-excise-tax-challenges/2024-12-31T12:59:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/digital-television-receiver-requirement/2024-12-31T12:59:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-new-product-development/2024-12-31T12:59:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/achieving-higher-levels-of-customer-satisfaction/2024-12-31T12:59:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/private-aerospace-manufacturer/2024-12-31T12:59:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/alkus-v--ods-technologies/2024-12-31T12:59:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-class-action-lawsuits/2026-02-02T20:07:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/optimizing-a-go-to-market-capability/2024-12-31T12:59:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/brokerage-company-class-action/2024-12-31T12:59:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/aerospace-workers-class-action/2024-12-31T12:59:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/overtime-pay-dispute/2024-12-31T12:59:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/media-information-business--growth-strategy/2024-12-31T12:59:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-advertising-effectiveness/2024-12-31T12:59:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/commercializing-new-technologies/2024-12-31T12:59:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/expanding-an-r-d-portfolio/2024-12-31T12:59:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/health-care-economics-and-reimbursement-strategy/2024-12-31T12:59:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/identifying-drivers-of-growth/2024-12-31T12:59:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/modeling-the-economics-of-growth-opportunities/2024-12-31T12:59:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/maintaining-competitive-advantage-in-the-face-of-rapid-commoditization/2024-12-31T12:59:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/rapid-response-to-shifting-industry-structure/2024-12-31T12:59:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/value-of-pharmaceuticals-to-society/2024-12-31T12:59:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/understanding-the-challenges-of-alternative-energy-structures/2024-12-31T12:59:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/moving-from-follower-to-market-leader/2024-12-31T12:59:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/retail-banking-customer-satisfaction/2024-12-31T12:59:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/retail-banking-performance-metrics/2024-12-31T12:59:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/segmentation-and-contracting-strategy/2024-12-31T12:59:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/venture-capital-firm-v--home-furnishings-company/2025-07-01T15:01:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mci-worldcom-bankruptcy/2024-12-31T12:59:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/globalizing-product-development/2024-12-31T12:59:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-lorazepam---clorazepate-antitrust-litigation/2024-12-31T12:59:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-impact-of-public-sewer-investments/2024-12-31T12:59:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lapd-racial-profiling-analysis/2024-12-31T12:59:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/stranded-cost-measurement/2024-12-31T12:59:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-unwired-acquisition/2026-02-02T21:08:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/regents-of-the-university-of-california-v--monsanto-company/2024-12-31T12:59:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v--henry-yuen/2024-12-31T12:59:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/steadfast-insurance-company-v--purdue-frederick-company/2024-12-31T12:59:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-department-of-justice-v--tenet-healthcare-corporation/2024-12-31T12:59:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/energy-infrastructure-development/2024-12-31T12:59:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/auction-design-for-wholesale-power-procurement/2024-12-31T12:59:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cost-benefit-analysis-of-wholesale-competition/2024-12-31T12:59:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/baker-v--american-century-investment-management/2025-01-08T16:12:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/putnam-investment-management/2024-12-31T12:59:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nyse-merger/2025-01-08T16:12:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/innogenetics-nv-v--abbott-laboratories/2024-12-31T12:59:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/proyectos-y-construcciones-procisa-v--continental-tire-of-north-america/2024-12-31T12:59:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/archipelago-merger-litigation/2024-12-31T12:59:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/new-world-tmt-v--prediwave/2024-12-31T12:59:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/microsoft-iowa-settlement/2025-01-08T16:17:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bouygues-telecom-v--tekelec/2024-12-31T12:59:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mutual-fund-excessive-fee-case/2025-01-08T16:20:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lost-earnings-analysis-in-wrongful-termination-case/2024-12-31T12:59:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-loss-analyses-in-wrongful-death-case/2024-12-31T12:59:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/using-cps-data-to-compare-wages-by-race/2024-12-31T12:59:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sargon-enterprises-v--university-of-southern-california/2024-12-31T12:59:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/first-marblehead-corporation-v--gregory-house/2024-12-31T12:59:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/energy-policy-act-section-1813-comments--report-of-the-ute-indian-tribe-of-the-uintah-and-ouray-reservation-for-submission-to-the-us-departments-of-energy-and-interior/2024-12-31T12:59:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/vitascan-v--ge-healthcare/2024-12-31T12:59:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/general-american-liquidation-litigation/2024-12-31T12:59:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/coachella-valley-housing-coalition-v--city-of-moreno-valley/2024-12-31T12:59:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/robins-v--roland/2024-12-31T12:59:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/subprime-automobile-loan-portfolio-analysis/2024-12-31T12:59:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/computer-hard-drive-manufacturer-v--commissioner-of-internal-revenue/2024-12-31T12:59:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/managing-risk-under-new-climate-legislation/2024-12-31T12:59:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/black---decker-corp--v--united-states/2025-07-01T14:51:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/damages-calculation-in-dispute-involving-tax-sharing-agreement/2024-12-31T12:59:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dunkin-donuts-v--michael-panagakos/2024-12-31T12:59:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/flat-top-insurance-agency-v--us-dept--of-justice-taxation-division/2025-07-01T14:54:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/otto-candies-v--us-dept--of-justice-taxation-division/2025-07-01T14:56:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/rogers-v--united-states/2024-12-31T12:59:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/semiconductor-company-v--commissioner-of-internal-revenue/2024-12-31T12:59:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluation-of-transfer-pricing-of-intercompany-services-of-a-global-oil-and-gas-company/2024-12-31T12:59:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/global-transfer-pricing-planning-for-an-automotive-parts-supplier/2024-12-31T12:59:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/transfer-pricing-for-a-software-company/2024-12-31T12:59:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/valuing-financial-guarantees/2024-12-31T12:59:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/allegations-of-bid-rigging-by-major-insurers/2024-12-31T12:59:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/peoplesoft-v--oracle/2026-02-02T21:05:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/reducing-a-heavy-carbon-footprint/2024-12-31T12:59:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-market-impact-of-greenhouse-gas-legislation/2024-12-31T12:59:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/interactivecorp-/2025-12-15T20:16:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/slaughter-v--kohl/2024-12-31T12:59:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/jones-v--harris-associates/2024-12-31T12:59:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/awg-leasing-trust-v--united-states-of-america/2024-12-31T12:59:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nanovation-technologies-v--bearingpoint/2024-12-31T12:59:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/carlyle-realty-partners-v--vweb-corporation/2024-12-31T12:59:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-managed-care-litigation/2024-12-31T12:59:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/compilation-and-analysis-of-plaintiff-medical-records/2024-12-31T12:59:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/extrapolating-from-proposed-payout-matrices-to-assess-overall-exposure/2024-12-31T12:59:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/identification-of-the-timing-of-adverse-events-relative-to-drug-use/2024-12-31T12:59:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-assistance-in-connection-with-class-certification/2024-12-31T12:59:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessment-of-excess-risk-for-causation-analysis/2024-12-31T12:59:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/smithkline-v--revenue-canada/2024-12-31T12:59:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/biotechnology-stock-drop-matter/2024-12-31T12:59:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/development-of-a-framework-for-litigation-decision-making/2024-12-31T13:00:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cost-comparison-of-painful-conditions/2024-12-31T13:00:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-roi-for-bariatric-surgery/2025-01-10T15:41:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/quantifying-the-economic-burden-of-depression/2024-12-31T13:00:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-burden-of-opioid-abuse/2024-12-31T13:00:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/effects-of-depression-relative-to-other-health-problems/2024-12-31T13:00:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/costs-associated-with-adhd-patients-and-families/2024-12-31T13:00:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/comparison-of-escitalopram-and-citalopram/2024-12-31T13:00:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/epidemiology-studies-on-spinal-cord-injury/2024-12-31T13:00:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/epidemiology-studies-on-rare-childhood-cancers/2024-12-31T13:00:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/documenting-the-need-for-care-management-in-elderly-hypertensive-patients/2024-12-31T13:00:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/studies-to-assess-incidence-of-renal-injury-in-cancer-patients-using-bisphosphonates/2024-12-31T13:00:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/study-of-safety-and-efficacy-of-vegf-inhibitors-in-actual-use/2024-12-31T13:00:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/studies-of-adverse-events/2024-12-31T13:00:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/impact-of-aromatase-inhibitors-on-bone-loss-in-breast-cancer-patients/2024-12-31T13:00:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/establishing-a-health-outcomes-organization/2024-12-31T13:00:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/developing-a-new-drug-value-profile-to-inform-clinical-trials/2024-12-31T13:00:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/determining-product-value-proposition/2024-12-31T13:00:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/using-sensitivity-analysis-to-drive-pricing-strategy/2024-12-31T13:00:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/priority-customer-segmentation-strategy/2024-12-31T13:00:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/refining-contracting-strategies-in-the-face-of-competition/2024-12-31T13:00:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cardiovascular-acquisition-analysis/2024-12-31T13:00:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/investment-and-acquisition-strategy/2024-12-31T13:00:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/identifying-and-benchmarking-acquisition-targets/2024-12-31T13:00:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/payer-billing-disputes/2024-12-31T13:00:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-v--schiff/2024-12-31T13:00:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-williams-securities-litigation/2026-02-02T20:09:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-bear-stearns-litigation/2024-12-31T13:00:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/major-music-publisher-profitability-analysis/2024-12-31T13:00:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/multiple-attorneys-general-v--sony-music/2024-12-31T13:00:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/warner-brothers-television-international-distribution-v--golden-channels---co-/2024-12-31T13:00:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/equity-broadcasting-corporation-v--pax-tv/2024-12-31T13:00:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-report-on-california-proposition-71/2026-02-02T20:05:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluating-opportunities-to-expand-oncology-franchise/2024-12-31T13:00:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/go-to-market-strategy-for-a-solar-cell-start-up/2024-12-31T13:00:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/financial-analysis-of-infrastructure-investments/2024-12-31T13:00:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/scenario-analysis-of-product-and-franchise-performance/2024-12-31T13:00:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/strategy-and-analysis-of-investment-options-for-global-pharmaceutical-company/2024-12-31T13:00:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/financial-risk-management-for-a-chemical-company/2024-12-31T13:00:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cap-and-trade-system-design/2024-12-31T13:00:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessment-of-alternative-climate-policies/2024-12-31T13:00:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/erisa-class-action/2024-12-31T13:00:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/calpine-corporation-bankruptcy-settlement/2024-12-31T13:00:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/son-of-boss-matters/2024-12-31T13:00:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/rohm-and-haas-co--v--the-dow-chemical-co-/2024-12-31T13:00:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/restructuring-of-american-airlines/2024-12-31T13:00:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/structuring-a-successful-turnaround/2024-12-31T13:00:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/official-committee-of-asbestos-claimants-v--g-i-holdings/2024-12-31T13:00:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/global-crossing-bankruptcy-bondholder-suit/2024-12-31T13:00:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/shopping-center-management-fee-litigation/2026-02-02T19:46:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-parmalat-securities-litigation/2024-12-31T13:00:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/at-t-v--united-states-of-america/2024-12-31T13:00:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-oracle-securities-litigation/2026-02-02T20:08:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-v--cioffi/2024-12-31T13:00:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lawrence-e--jaffe-pension-plan-v--household-international-inc-/2024-12-31T13:00:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-american-funds-fee-litigation/2024-12-31T13:00:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/microsoft-california-class-action/2024-12-31T13:00:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/walmart-et-al--v--visa-and-mastercard/2024-12-31T13:00:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-property-values-amid-allegations-of-contamination/2024-12-31T13:00:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/an-economic-perspective-on-complex-climate-legislation/2024-12-31T13:00:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mastercard-antitrust-litigations/2024-12-31T13:00:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/innovating-to-reduce-emissions-and-energy-use/2024-12-31T13:00:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sofamor-danek-group-v--spine-tech/2024-12-31T13:00:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mylan-pharmaceuticals-v--procter---gamble-co-/2024-12-31T13:00:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/kwaak-et-al-v--pfizer-inc-/2024-12-31T13:00:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cleaning-appliance-manufacturer-false-superiority-claims/2024-12-31T13:00:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/false-superiority-claims-in-personal-hygiene-products-case/2024-12-31T13:00:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/price-comparison-claims-made-by-big-box-retailer/2024-12-31T13:00:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mtbe-water-contamination-litigations/2024-12-31T13:00:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-wetlands-contamination-case/2024-12-31T13:00:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-case-involving-a-major-oil-company/2024-12-31T13:00:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cost-benefit-analysis-on-behalf-of-brayton-point-station/2024-12-31T13:00:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/central-basin-municipal-water-district-v--metropolitan-water-district-of-southern-california/2024-12-31T13:00:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-agricultural-industries-in-antitrust-litigation/2024-12-31T13:00:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/identifying-high-impact-disruptive-technologies/2024-12-31T13:00:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/new-product-development-strategy-for-international-joint-venture/2024-12-31T13:00:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/kia-safety-class-actions/2024-12-31T13:00:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/developing-an-alternative-propulsion-roadmap/2024-12-31T13:00:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/business-impact-of-ghg-emissions-limits/2024-12-31T13:00:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/air-canada-v--toronto-port-authority-and-porter-airlines/2024-12-31T13:00:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/allegations-of-price-fixing-by-lcd-manufacturers/2024-12-31T13:00:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evan-weiner-et-al-v-snapple-beverage-corporation/2026-02-17T19:16:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pharmaceutical-off-label-promotion---kickbacks-settlements/2025-11-25T20:58:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pre-merger-investigation-of-medtronic-acquisition/2024-12-31T13:00:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/otsuka-pharmaceuticals-abilify-litigations/2024-12-31T13:00:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/revenue-decoupling-and-other-ratemaking-approaches-for-utility-energy-efficiency/2024-12-31T13:00:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/transmission-policy/2024-12-31T13:00:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/establishing-utility-revenue-requirements/2024-12-31T13:00:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-california-electricity-markets/2024-12-31T13:00:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/music-licensing-royalty-rate-analyses/2024-12-31T13:00:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/personal-audio-llc-v--apple-inc-/2026-02-17T19:23:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/e-i--du-pont-de-nemours---co--v--kolon-industries-inc-/2024-12-31T13:00:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-countrywide-financial-corp--mortgage-marketing-and-sales-practices-litigation/2024-12-31T13:00:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nevada-power-rate-proceeding/2024-12-31T13:00:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-competitiveness-of-retail-electricity-market-in-pennsylvania/2024-12-31T13:00:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/consumer-benefits-of-competition-in-the-telecommunications-industry/2024-12-31T13:00:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-at-t-marketing-practices/2024-12-31T13:00:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-health-care-patent-infringement-claims/2025-04-30T17:07:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-adverse-events/2025-01-10T15:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-pharmaceutical-mass-tort-matter/2025-01-22T16:43:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-onstar-contract-litigation/2024-12-31T13:00:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/procter---gamble-company-v--united-states/2024-12-31T13:00:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-securities-lending-litigations/2024-12-31T13:00:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-google-adwords-litigation/2024-12-31T13:00:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-potential-drug-safety-issues-for-a-major-pharmaceutical-company/2024-12-31T13:00:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-certain-ground-fault-circuit-interrupters-and-products-containing-same/2024-12-31T13:00:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analyzing-causation-and-damages-in-data-breach-litigation/2024-12-31T13:00:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/rabin-v--mony-life-insurance-company/2024-12-31T13:00:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-government-instrumentality-factors-in-fcpa-prosecution/2024-12-31T13:00:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/at-t-telecommunications-dispute-over-u-verse-equipment/2024-12-31T13:00:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-erisa-litigation/2024-12-31T13:00:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-marsh-erisa-litigation/2024-12-31T13:00:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/the-board-of-trustees-of-the-southern-california-ibew-neca-defined-contribution-plan-et-al--v--the-bank-of-new-york-mellon-corporation-et-al-/2024-12-31T13:00:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/multiple-antitrust-litigations-on-behalf-of-large-semiconductor-manufacturer/2025-01-10T16:01:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-reorganization-plan-for-spectrum-brands/2024-12-31T13:00:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/morpho-detection-inc--v--smiths-detection-inc-/2024-12-31T13:00:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/market-research-in-support-of-pricing-strategies/2024-12-31T13:00:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pharmaceutical-product-development-and-launch/2024-12-31T13:00:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/false-advertising-claims-in-consumer-beverages-market/2024-12-31T13:00:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/netscape-v--microsoft/2024-12-31T13:00:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/patent-infringement-matter-related-to-consumer-electronics/2024-12-31T13:00:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/trademark-infringement-related-to-luxury-goods/2024-12-31T13:00:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/alta-bates-and-summit-medical-centers-merger-antitrust-suit/2024-12-31T13:00:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analyzing-design-issues-in-a-product-safety-matter/2024-12-31T13:00:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/patent-valuation-and-food-industry-r-d/2024-12-31T13:00:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/chemtech-royalty-associates-l-p--v--united-states-of-america/2025-07-01T14:53:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/rincon-ev-realty-llc-et-al--v--cp-iii-rincon-towers-inc-/2024-12-31T13:00:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analyzing-safety-preparedness-in-high-risk-work-environments/2024-12-31T13:00:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/justice-department-investigation-into-health-care-fraud/2024-12-31T13:00:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/erisa-class-action-against-provider-of-retirement-plan-services-to-small--and-mid-sized-plans/2025-01-10T15:23:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/erisa-class-action-litigations-involving-plans-that-held-investment-options-affiliated-with-the-plan-sponsor/2024-12-31T13:00:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/consultants-study-ceo-perspectives-and-recommendations-on-california-s-advanced-energy-policies/2024-12-31T13:00:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/conducting-a-review-of-the-regional-greenhouse-gas-initiative-s-impact-on-consumer-electricity-bills/2024-12-31T13:00:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/effingo-wireless-inc--v--motorola-mobility-llc/2024-12-31T13:00:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/washington-state-hospital-association-medicaid-supplemental-payments-matter/2026-02-02T21:09:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/batsheva-ackerman-et-al--v--the-coca-cola-company-and-energy-brands-inc-/2024-12-31T13:00:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/eplus-inc--v--lawson-software-inc-/2026-02-17T19:15:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sean-turnbow-et-al--v--life-partners-inc--et-al-/2024-12-31T13:00:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analyzing-the-performance-of-iso-ne-power-generation-resources/2024-12-31T13:00:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-depth-new-analyses-on-the-use-of-renewable-energy-for-power-system-operations/2024-12-31T13:00:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/newire-inc--v--southwire-company/2024-12-31T13:00:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/saint-alphonsus-medical-center---nampa-et-al--v--st--luke-s-health-system-ltd-/2024-12-31T13:00:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sunset-drive-corporation-v--city-of-redlands/2024-12-31T13:00:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/casino-developments/2024-12-31T13:00:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-and-fiscal-impacts-of-clean-fuels-project-alternative-in-kern-county/2024-12-31T13:00:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ferc-market-based-rate-authorization-and-market-power-analyses-in-wholesale-electric-markets/2024-12-31T13:00:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/toyota-industries-and-cascade-corporation-transaction/2025-01-10T16:03:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nxp-b-v--v--blackberry-limited-and-blackberry-corporation/2024-12-31T13:00:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/levi-jones-et-al-v-conagra-foods-inc-/2026-02-17T19:20:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/corvex-management-et-al--v--commonwealth-reit-et-al-/2025-01-08T16:13:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/demand-study-regarding-a-potential-combination-drug-for-a-major-pharmaceutical-company/2024-12-31T13:00:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/blue-cross-blue-shield-of-minnesota-et-al-v--wells-fargo-bank-n-a-/2024-12-31T13:00:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sec-investigation-into-accounting-and-disclosure-practices/2024-12-31T13:00:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-transmission-for-renewables-projects/2024-12-31T13:00:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/class-action-v--horace-mann-life-insurance-et-al-/2026-02-02T20:03:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/comcast-ip-holdings-i-llc-v--sprint-communications-co--lp-et-al-/2025-01-08T18:01:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pricing-and-positioning-of-complex-consumer-products/2024-12-31T13:00:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/center-partners-ltd--et-al--v--urban-shopping-centers-lp--et-al-/2024-12-31T13:00:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mobile-telecommunications-technologies-llc-v--samsung-telecommunications-america-llc/2024-12-31T13:00:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sec-v--mark-a--jackson-and-james-j--ruehlen/2024-12-31T13:00:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/colgate-softsoap-false-advertising-consumer-class-action/2024-12-31T13:00:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/product-liability-class-action--treated-wood-products/2024-12-31T13:00:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/developing-a-go-to-market-strategy/2024-12-31T13:00:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/postova-banka-as-and-istrokapital-se-v--the-hellenic-republic/2024-12-31T13:00:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wfc-holdings-corporation-v--united-states-of-america/2025-07-01T15:03:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/tax-investigation-analysis/2025-07-01T14:58:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessment-of-alleged-postal-fraud/2025-07-01T14:49:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-investment-performance/2025-07-01T14:48:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/earn-out-dispute-in-acquisition-of-engineering-and-project-management-firm/2024-12-31T13:00:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fox-broadcasting-company-et-al-v--dish-network-llc-et-al/2024-12-31T13:00:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluating-the-economic-impact-of-early-diagnosis-of-alzheimer-s-disease/2024-12-31T13:00:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-economic-benefits-of-diabetic-foot-ulcer-treatment/2024-12-31T13:00:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/miriam-haskins-at-al--v--first-american-title-insurance-company/2024-12-31T13:00:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/st--clair-intellectual-property-consultants-inc--v--toshiba-corp--et-al-/2024-12-31T13:00:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/e-retailer-false-advertising-matter/2024-12-31T13:00:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/crtc-review-of-wholesale-wireline-services-and-associated-policies/2025-05-01T15:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bayer-healthcare-pharmaceuticals-inc--v--glenmark-pharmaceuticals-ltd-/2024-12-31T13:00:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-impact-analysis-of-direct-lender-ondeck/2024-12-31T13:00:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/at-t-acquisition-of-directv----survey-of-consumer-preferences/2024-12-31T13:00:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-potential-impacts-of-california-climate-policies/2024-12-31T13:00:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/report-on-the-economic-effects-of-mandatory-energy-labeling-for-buildings/2024-12-31T13:00:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluating-the-epa-s-clean-air-transport-rule/2024-12-31T13:00:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/contentguard-holdings-inc--v--google-inc-/2024-12-31T13:00:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-in-nfl-players-association-deflategate-matter/2025-01-10T15:39:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bittitan-inc-v-skykick-inc/2024-12-31T13:00:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/phigenix-v--immunogen/2024-12-31T13:00:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wisconsin-alumni-research-foundation-v--apple/2025-12-31T17:47:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/medtronic-minimed-v-nova-biomedical/2024-12-31T13:00:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nes-financial-corp--v--jpmorgan-chase-bank/2024-12-31T13:00:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/romag-fasteners-inc--v--fossil-inc--et-al-/2024-12-31T13:00:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/class-action-sales-practices-litigation-surrounding-vanishing-premium-sales/2026-02-02T20:01:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-regulatory-matter-involving-alleged-failure-to-annuitize-variable-annuities/2026-02-02T20:04:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wellbutrin-xl-antitrust-litigation/2025-01-10T15:36:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/controlled-substance-suspicious-order-monitoring-modeling/2024-12-31T13:00:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/controlled-substance-monitoring-and-effective-controls-against-diversion--investigations-and-settlements/2024-12-31T13:00:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/tribunal-de-commerce-francophone-de-bruxelles---patrinvest-v--sa-ageas/2024-12-31T13:00:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bmg-rights-management-et-al-v-cox-communications/2024-12-31T13:00:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-deposit-insurance-corporation-as-receiver-for-vantus-bank-v--officers-and-directors-of-vantus-bank/2024-12-31T13:00:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/solyndra-antitrust-litigation/2026-02-02T19:47:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/philip-morris-v--uruguay/2024-12-31T13:00:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/petition-to-the-governor-in-council-concerning-telecom-regulatory-policy-crtc-2015-326/2024-12-31T13:00:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/daiichi-sankyo-and-ranbaxy-laboratories-damages-arbitration/2025-01-08T16:14:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/tax-dispute-concerning-charitable-easements/2024-12-31T13:00:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/innopharma-licensing-inc--et-al--v--senju-pharmaceutical-co--ltd--et-al-/2024-12-31T13:00:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fresenius-kabi-usa-llc-v-fera-pharmaceuticals-llc-et-al/2024-12-31T13:00:25+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-impact-of-rwandan-hospital-on-its-community-is-examined-pro-bono-by-analysis-group-at-request-of-pih/2025-01-10T15:57:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-group-pro-bono-team-assists-harvard-medical-school-in-tb-genome-machine-learning-project/2025-01-10T15:38:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-group-team-works-pro-bono-with-gheskio-to-study-characteristics-of-sexual-assault-in-haiti/2024-12-31T13:00:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-group-team-provides-pro-bono-assistance-to--major-homeless-shelter-initiative-in-massachusetts/2024-12-31T13:00:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dang-v-san-francisco-forty-niners-ltd-et-al/2024-12-31T13:00:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sec-v-stifel-nicolaus-co-inc-and-david-w-noack/2024-12-31T13:00:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/city-of-claremont-v--golden-state-water-company/2024-12-31T13:00:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-et-al--v--anthem-inc--et-al/2025-09-19T13:23:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/kenneth-hobbs-v-brother-international-corporation-et-al/2026-02-17T19:19:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lapd-pedestrian-and-motor-vehicle-stop-data-analyses/2024-12-31T13:00:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-fedex-ground-package-system-inc-employment-practices-litigation/2025-05-28T14:07:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/drivers-v-united-parcel-services-inc/2024-12-31T13:00:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/high-tech-employee-class-action-involving-alleged-no-poaching-agreements/2025-04-07T15:34:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pat-cason-merenda-et-al-v-detroit-medical-center-et-al/2025-01-10T16:03:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-group-pro-bono-team-assists-suffolk-law-school-in-examining-gender-identity-discrimination-in-the-metro-boston-rental-housing-market/2024-12-31T13:00:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/denimafia-inc-v-new-balance-athletic-shoe-inc-et-al-and-new-balance-athletic-shoe-inc-v-denimafia-inc/2024-12-31T13:00:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/basis-pac-rim-opportunity-fund-index-master-et-al-vs-tcw-asset-management-company/2024-12-31T13:00:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/overall-survival-with-ponatinib-versus-allogeneic-stem-cell-transplantation-in-philadelphia-chromosome-positive-leukemias-with-the-t315i-mutation/2024-12-31T13:00:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-appraisal-of-petsmart-inc-2017-bl-177567-del-ch-no-10782/2025-12-15T20:13:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/adidas-america-inc-et-al-v-skechers-usa-inc/2024-12-31T13:00:28+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-appraisal-of-sws-group-inc-ca-no-10554-vcg/2025-07-09T19:09:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wex-inc-acquisition-of-electronic-funds-source-llc/2025-04-30T17:05:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-of-america-et-al-ex-rel-brown-v-celgene-corp/2024-12-31T13:00:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/western---southern-life-insurance-co-et-al-v-bank-of-new-york-mellon/2025-10-08T13:01:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/syngenta-crop-protection-llc-v-willowood-llc-et-al/2024-12-31T13:00:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-william-tirrell-before-the-us-securities-and-exchange-commission/2024-12-31T13:00:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cftc-v--hunter-and-ferc-v--hunter/2024-12-31T13:00:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/central-vermont-public-service-corporation-and-green-mountain-power-corporation-v--entergy-nuclear-vermont-yankee/2024-12-31T13:00:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/market-analysis-in-a-contractual-dispute/2024-12-31T13:00:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-of-economic-feasibility-of-proposed-coal-plant/2024-12-31T13:00:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bankruptcy-filing-in-the-offshore-drilling-industry/2024-12-31T13:00:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-analysis-in-a-water-rights-dispute/2024-12-31T13:00:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/shareholder-derivative-suit-following-an-operational-incident/2024-12-31T13:00:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-lynn-tilton-et-al-before-the-us-securities-and-exchange-commission/2024-12-31T13:00:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ferc-v-national-fuel-marketing-llc/2024-12-31T13:00:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/btg-international-inc-v-wellstat-therapeutics-corporation/2024-12-31T13:00:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluating-the-capacity-market-consequences-of-alternate-resource-portfolios/2024-12-31T13:00:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/capacity-resource-performance-in-nyiso-markets--an-assessment-of-wholesale-market-options/2024-12-31T13:00:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-appraisal-of-dell-inc/2026-02-02T20:06:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re--alere-abbott-merger-litigation/2024-12-31T13:00:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/argentinian-economic-crisis/2024-12-31T13:00:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/itc-investigation-of-standard-essential-patents/2024-12-31T13:00:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/debt-covenant-litigations-involving-caesars/2024-12-31T13:00:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re--optical-disk-drive-products-antitrust-litigation/2025-01-08T16:15:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v--nauman-a--aly/2024-12-31T13:00:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-northeast-and-mid-atlantic-states/2024-12-31T13:00:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-airways-v-british-airways/2024-12-31T13:00:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluation-of-materiality-of-actions-constituting-default-by-an-insurer/2024-12-31T13:00:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/patent-infringement-matter-against-e-commerce-retailer/2026-02-17T19:24:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/allegations-of-insider-trading-against-major-shareholder-of-french-biotech-corporation/2024-12-31T13:00:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluation-of-materiality-of-actions-constituting-default-by-an-insurer-6442449825/2024-12-31T13:00:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ticofrut-s.a.-v.-e.i.-dupont-de-nemours-and--co.-inc2024-12-31T13:00:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cashmere-and--camel-hair-manufacturers-institute-and-l.w.-packard-and--company-v.-harve-benard2025-01-08T15:31:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/co-options-inc.-v.-news-america-marketing2024-12-31T13:00:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/swan-magnetics-v.-mitsumi-electric-co.-ltd2024-12-31T13:00:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wholesale-market-policy-changes-to-provider-of-last-resort-polr-program-design/2024-12-31T13:00:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/clean-water-act-section-316b-engagements/2024-12-31T13:00:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-matter-analysis-of-environmental-contamination-claims/2024-12-31T13:00:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-matter-determination-of-financial-solvency-tests/2024-12-31T13:00:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/enviro-petroleum-inc.-v.-kondur-petroleum-s.a2024-12-31T13:00:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ben-s-branch-trustee-of-bank-of-new-england-corporation-v-federal-deposit-insurance-corporation/2025-11-14T18:53:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/honeywell-international-inc.-v.-air-products-and-chemicals2024-12-31T13:00:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/anodyne-v.-klaas-law-o-meara-and--malkin2024-12-31T13:00:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/study-of-exchange-traded-fund-products-for-american-stock-exchange-nasd-and-american-express/2024-12-31T13:00:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/resonate-inc.-v.-nortel-networks2024-12-31T13:00:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/twister-communications-network-inc.-v.-mci-worldcom-network-services-inc2024-12-31T13:00:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/professional-services-company--performance-rankings/2024-12-31T13:00:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/class-action-v.-helping-hands-company-inc2024-12-31T13:00:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/valassis-communications-inc.-v.-advo-inc2024-12-31T13:00:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/glaxosmithkline-holdings-americas-inc.-v.-commissioner-of-the-irs2025-01-10T15:58:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/heuft-systemtechnik-gmbh-v.-industrial-dynamics-co.-ltd2024-12-31T13:00:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v.-biopure-corporation-et-al2024-12-31T13:00:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/netflix-inc.-v-blockbuster-inc2024-12-31T13:00:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/phibro-tech-inc.-v.-osmose-inc2024-12-31T13:00:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lee-conrad-v.-eps-solutions-corporation2024-12-31T13:00:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cogent-systems-inc.-v.-northrop-grumman-corporation2024-12-31T13:00:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/slm-corporation-sallie-mae-v.-j.c.-flowers-ii-l.p2024-12-31T13:00:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fdic-v.-bright-first-republic-bank-of-dallas2024-12-31T13:00:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/commonwealth-court-building-inc.-v.-criimi-mae-services2024-12-31T13:00:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/national-westminster-bank-natwest-v.-us-dept.-of-justice-taxation-division2025-07-01T14:56:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/authorized-generics-competition-and-consumer-prices/2025-07-01T15:11:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/boeing-satellite-systems-international-inc.-v.-ico-global-communications-operations-ltd2024-12-31T13:00:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/louisiana-wholesale-drug-co.-inc.-v.-sanofi-aventis2025-01-10T16:01:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/401k-fee-litigation/2024-12-31T13:00:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/surface-transportation-board--stb-ex-parte-no.-664-sub-no.-12024-12-31T13:00:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/samsung-electronics-co.-ltd.-v.-on-semiconductor-corp.-and-on-semiconductor-corp.-v.-samsung-electronics-co.-ltd2025-01-08T18:18:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bracco-diagnostics-inc.-v.-amersham-health-inc2025-01-10T15:54:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-retek-inc.-securities-litigation2024-12-31T13:00:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lkf-x-investments-lkf-x-capital-corporation-tax-matters-partner-v.-the-commissioner-of-internal-revenue2025-07-01T14:55:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ventas-inc.-v.-hcp-inc2025-01-08T16:38:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/raymond-road-associates-blue-back-square-v.-taubman-centers2024-12-31T13:00:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/palm-canyon-x-investments-llc-ah-investment-holdings-inc.-tax-matters-partner-v.-commissioner-of-internal-revenue-service2024-12-31T13:00:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bavarian-nordic-v.-acambis-plc-inv.-no.-337-ta-5502024-12-31T13:00:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/american-express-v.-visa-and-mastercard-and-related-litigations2024-12-31T13:00:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/playtex-products-inc.-v.-procter-and--gamble-company2024-12-31T13:00:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pbm-products-inc.-v.-mead-johnson2024-12-31T13:00:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/astrazeneca-v.-tap-pharmaceuticals-inc2024-12-31T13:00:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/johnette-c.-alexander-et-al.-v.-kia-motors-america-inc2024-12-31T13:00:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/minuteman-trucks-inc.-v.-hn80-corporation-and-sterling-truck-corp2024-12-31T13:00:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sp-syntax-silver-point-capital-lp-v-ernst-and-young-llp/2026-02-17T19:26:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/gallus-et-al.-v.-ameriprise-financial-inc2024-12-31T13:00:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/st.-jude-medical-inc.-v.-access-closure-inc2024-12-31T13:00:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/new-jersey-carpenters-vacation-fund-et-al.-v.-the-royal-bank-of-scotland-group-plc-et-al2025-05-01T18:04:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/air-products-and--chemicals-inc.-v.-airgas-inc2024-12-31T13:00:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cheetah-omni-llc-v.-verizon-services-corporation-et-al2024-12-31T13:00:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bedrock-computer-technologies-llc-v-google-inc/2026-02-17T19:08:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/biotechnology-firm-10b-5-matter--phase-iii-testing/2024-12-31T13:00:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/biotechnology-firm-10b-5-matter--human-testing/2024-12-31T13:00:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bedrock-computer-technologies-llc-v-yahoo/2026-02-17T21:58:33+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/convolve-inc-v-dell-inc-western-digital-corporation-hitachi-global-storage-technologies-inc-and-hitachi-ltd/2026-02-17T19:12:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/vietnam-telecom-international-v.-eddie-inyang-et-al2024-12-31T13:00:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/the-citri-lite-company-v.-cott-beverages-inc2024-12-31T13:00:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fairview-donut-inc.-et-al.-v.-the-tdl-group-tim-hortons2025-05-01T15:39:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/safeco-insurance-company-of-america-et-al.-v.-aig-et-al2024-12-31T13:00:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ceats-inc-v-continental-airlines-inc-et-al/2026-02-17T19:11:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fresh-del-monte-produce-inc.-v.-del-monte-foods-co.-et-al2024-12-31T13:00:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/t.-jeffrey-simpson-et-al.-v.-homestore.com-inc.-et-al2024-12-31T13:00:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bone-care-international-v.-roxane-labs-et-al2025-01-10T15:08:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/peter-claydon-v.-nestle-waters-north-america-inc.-et-al2024-12-31T13:00:39+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/martin-marietta-materials-inc.-v.-vulcan-materials-company2024-12-31T13:00:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/augustus-et-al-v-american-commercial-security-services-inc-et-al-abm-security-services-inc/2026-02-02T20:00:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fishman-transducers-inc.-v.-stephen-paul-dba-esteban-et-al2024-12-31T13:00:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/galderma-laboratories-et-al.-v.-tolmar-inc2024-12-31T13:00:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ddr-holdings-llc-v-hotelscom-lp-et-al/2026-02-17T19:14:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/adelphia-recovery-trust-v.-bank-of-america-et-al2024-12-31T13:00:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-injunction-ruling-december-20122024-12-31T13:00:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/tyco-healthcare-group-lp-et-al.-v.-ethicon-endo-surgery-inc2024-12-31T13:00:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/hitachi-consumer-electronics-co.-ltd.-and-hitachi-advanced-digital-inc.-v.-top-victory-electronics-taiwan-co.-ltd.-et-al2024-12-31T13:00:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-industry-practices-associated-with-swaps-high-yield-loans/2024-12-31T13:00:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-optionsxpress-inc.-thomas-e.-stern-and-jonathan-i.-feldman2024-12-31T13:00:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-the-finances-of-the-city-of-vernon-california/2024-12-31T13:00:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lake-cherokee-hard-drive-technologies-llc-v.-marvell-semiconductor-inc2024-12-31T13:00:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re--tft-lcd-flat-panel-antitrust-litigation/2025-01-10T16:00:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-certain-products-having-laminated-packaging-laminated-packaging-and-components-thereof/2025-01-08T18:05:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/universal-electronics-inc.-v.-universal-remote-control-inc2024-12-31T13:00:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/quantifying-energy-savings-and-emission-reductions-under-the-section-111d-carbon-pollution-standard/2024-12-31T13:00:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fraley-et-al.-v.-facebook-inc.-et-al2024-12-31T13:00:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-certain-integrated-circuit-chips-and-products-containing-the-same-inv.-no.-337-ta-8592025-01-08T18:03:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-injunction-ruling-july-20142024-12-31T13:00:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-trial-may-20142025-01-08T15:33:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-trial-may-2014--professor-judith-chevalier2024-12-31T13:00:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-trial-may-2014--professor-tulin-erdem2024-12-31T13:00:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-trial-may-2014--professor-george-foster2025-07-23T18:04:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-v.-samsung-trial-may-2014--professor-david-reibstein2024-12-31T13:00:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/simpleair-v.-google-et-al2024-12-31T13:00:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-of-america-v.-robert-j.-gagalis-et-al2024-12-31T13:00:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/veleron-holding-bv-v.-bnp-paribas-sa-et-al2025-01-08T16:36:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/alfa-gomma-s.p.a.-v.-veyance-technologies-inc2024-12-31T13:00:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/j.c.-van-apeldoorn-and-e.t.-meijer-in-their-capacity-as-trustees-in-bankruptcy-for-kpnqwest-n.v.-et-al.-v.-qwest-communications-international-inc.-qwest-et-al2025-07-01T14:41:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-dole-food-company-inc.-stockholder-litigation2024-12-31T13:00:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lightbourne-v.-cbs-interactive-et-al2025-01-08T16:17:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of--certain-footwear-products-investigation-number-337-ta-936/2024-12-31T13:00:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/c5-medical-werks-llc-v.-ceramtec-gmbh2024-12-31T13:00:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-of-america-v-energysolutions-inc-et-al/2025-09-19T13:33:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/american-tradition-institute-and-rod-lueck-v.-epel-et-al2024-12-31T13:00:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/state-of-north-carolina-ex-rel.-roy-cooper-attorney-general-v.-tennessee-valley-authority2024-12-31T13:00:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-v.-mark-david-radley-et-al2025-07-01T15:01:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mount-olympus-mortgage-company-v.-anderson-et-al2024-12-31T13:00:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/noven-pharmaceuticals-inc.-v.-actavis-laboratories-ut-inc2024-12-31T13:00:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/morgantown-ol1-llc-et-al.-v.-genon-mid-atlantic-llc-et-al2024-12-31T13:00:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cotromano-et-al.-v.-united-technologies-corp.-et-al.-and-adinolfe-et-al.-v.-united-technologies-corp2024-12-31T13:00:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/huff-fund-investment-partnership-v.-ckx-inc2025-02-03T17:11:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/david-t.-stevenson-et-al.-v.-delaware-department-of-natural-resources-et-al2024-12-31T13:00:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/application-of-california-american-water-company-for-authorization-to-modify-conservation-and-rationing-rules-rate-design-and-other-related-issues-for-the-monterey-district/2024-12-31T13:00:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-trade-commission-et-al.-v.-penn-state-hershey-medical-center-et-al2024-12-31T13:00:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/maxell-ltd.-v.-zte-usa-inc2025-01-08T18:17:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ftc-v-wilhelm-wilhelmsen-et-al/2025-10-10T14:46:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re--appraisal-of-solera-holdings-inc/2026-02-02T20:11:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/collins-et-al.-v.-city-of-milwaukee-et-al2024-12-31T13:00:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/marfin-investment-group-holdings-sa-alexandros-bakatselos-and-others-v-republic-of-cyprus/2025-12-15T20:10:36+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/predicting-the-essentiality-of-standard-essential-patents/2024-12-31T13:00:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/retrospective-study-of-medication-adherence-among-adults-with-metastatic-colorectal-cancer/2024-12-31T13:00:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sanjiv-goel-md-inc-v-blue-shield-of-california/2026-02-02T21:07:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/margie-daniel-et-al.-v.-ford-motor-company2024-12-31T13:00:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/paul-b.-butler-v.-porsche-cars-north-america-inc2024-12-31T13:00:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ghg-cap-and-trade-implications-for-effective-and-efficient-climate-policy-in-oregon/2024-12-31T13:00:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/erisa-health-care-litigation-related-to-deductibles-and-out-of-pocket-expenses/2024-12-31T13:00:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/hospital-erisa-class-action-matter/2024-12-31T13:00:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/key-issues-facing-californias-ghg-cap-and-trade-system-for-20212030/2025-11-14T21:07:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/merger-of-altagas-ltd-and-wgl-holdings-inc/2025-11-14T21:09:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wellesley-municipal-light-plant-greenhouse-gas-emission-reduction-study/2025-11-14T21:10:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/v.-ross-morrison-v.-her-majesty-the-queen2024-12-31T13:00:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/viacom-international-inc.-v.-mga-entertainment-inc2024-12-31T13:00:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-commodity-futures-trading-commission-v-donald-r-wilson-and-drw-investments-llc/2025-11-14T21:11:19+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lovepop-inc.-vs.-paper-pop-cards-inc2024-12-31T13:00:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/oil-dri-corporation-of-america-v.-nestle-purina-petcare-company2024-12-31T13:00:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/south-carolina-electric--gas-company-preliminary-injunction-hearing-and-rate-proceeding/2025-07-01T14:57:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/kt-engcore-corporation-v.-asi-corporation-et-al2024-12-31T13:00:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-senate-committee-hearing-to-examine-the-electricity-sector-in-a-changing-climate/2024-12-31T13:00:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/vintage-rodeo-parent-llc-et-al.-v.-rent-a-center-inc2025-05-01T18:05:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/saab-et-al.-v.-the-republic-of-cyprus2024-12-31T13:00:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-starz-stockholder-litigation/2024-12-31T13:00:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/panjing-dongxing-oil-well-measure-service-co.-ltd.-v.-petrochina-inc2024-12-31T13:00:48+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-securities-and-exchange-commission-vs.-elon-musk2024-12-31T13:00:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-group-teams-pro-bono-analysis-of-towing-fees-and-their-economic-impact-on-the-poor/2024-12-31T13:00:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nte-connecticut-llc-application-for-a-certificate-of-environmental-compatibility-and-public-need/2024-12-31T13:00:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-john-q.-hammons-fall-2006-llc2024-12-31T13:00:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-certain-magnetic-data-storage-tapes-and-cartridges-containing-the-same-inv.-no.-337-ta-10122024-12-31T13:00:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/toby-schechner-et-al-v-whirlpool-corporation/2026-02-17T19:27:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/alberta-electric-system-operator-proceedings-for-capacity-market-design-and-implementation/2024-12-31T13:00:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bayer-cropscience-ag-and-bayer-cropscience-nv-v.-dow-agrosciences-llc-et-al2024-12-31T13:00:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v.-john-t.-place-et-al2024-12-31T13:00:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/scalia-v.-wpn-corp.-et-al2024-12-31T13:00:49+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-sears-holdings-corporation-et-al.-chapter-11-bankruptcy-proceedings2024-12-31T13:00:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-nine-west-holdings-inc.-et-al.-chapter-11-bankruptcy-proceedings2024-12-31T13:00:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/joshua-wasser-et-al.-v.-all-market-inc2024-12-31T13:00:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/discovery-communications-inc.-acquisition-of-scripps-networks-interactive-inc2024-12-31T13:00:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-appraisal-of-jarden-corp/2024-12-31T13:00:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-alibaba-group-holding-limited-securities-litigation/2026-02-02T20:10:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/analysis-group-team-joins-partners-in-health-for-pro-bono-data-analysis-in-lesotho/2024-12-31T13:00:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-v-boustani-et-al/2026-01-02T17:45:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/amazon-inc.--subsidiaries-v.-commissioner-of-internal-revenue2024-12-31T13:00:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-appraisal-of-panera-bread-company/2024-12-31T13:00:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sony-music-entertainment-et-al-v-cox-communications-inc-et-al/2024-12-31T13:00:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ts-media-inc.-et-al.-v.-public-broadcasting-service2024-12-31T13:00:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lincoln-electric-co-et-al-v-harbor-freight-tools-usa-inc/2025-11-14T21:12:20+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/apple-inc-v-qualcomm-inc-antitrust/2025-12-31T17:44:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/qualcomm-inc.-v.-apple-inc.-patent-infringement2024-12-31T13:00:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-certain-mobile-electronic-devices-and-radio-frequency-and-processing-components-thereof-inv.-no.-337-ta-10932025-01-08T18:03:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/snmp-research-international-et-al.-v.-nortel-networks-et-al2024-12-31T13:00:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/alliance-des-professionnels-et-des-professionnelles-de-la-ville-de-quebec-et-al.-v.-la-procureure-generale-du-quebec2024-12-31T13:00:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/william-r.-kruse-v.-synapse-wireless-inc2024-12-31T13:00:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-the-application-of-transource-maryland-llc-for-a-certificate-of-public-convenience-and-necessity/2024-12-31T13:00:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-market-needs-to-evaluate-natural-gas-pipeline-development/2024-12-31T13:00:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-the-environmental-impact-of-the-siting-of-a-natural-gas-power-plant/2024-12-31T13:00:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/evaluation-of-a-fraud-detection-system/2024-12-31T13:00:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-trade-commission-v.-qualcomm-inc2024-12-31T13:00:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dolby-international-ab-ge-video-compression-llc-and-koninklijke-philips-nv-v.-mas-elektronik-aktiengesellschaft2024-12-31T13:00:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/prevalence-of-pericarditis-for-orphan-drug-designation-application/2024-12-31T13:00:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-epipen-erisa-litigation/2025-08-28T17:08:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/innovation-sciences-llc-v-amazoncom-inc-et-al/2026-02-17T19:18:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-skipjack-offshore-energy-llcs-qualified-offshore-wind-projects-compliance-with-conditions-approved-in-2017/2024-12-31T13:00:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fantasy-cookie-corporation-et-al.-v.-harold-rothman-et-al2024-12-31T13:00:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-securities-and-exchange-commission-v.-penn-west-petroleum-ltd.-et-al2025-05-01T18:05:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/jeffrey-i.-golden-v.-omelveny--myers-llp-et-al2024-12-31T13:00:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/telephone-consumer-protection-act-matter/2024-12-31T13:00:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/abbvie-inc.s-acquisition-of-allergan-plc2024-12-31T13:00:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mv3-partners-llc-v.-roku-inc.-et-al2024-12-31T13:00:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/obeslo-et-al.-v.-great-west-capital-management-et-al2025-04-30T16:32:29+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/post-discharge-outcomes-among-hyperkalemic-patients-treated-with-and-without-sodium-polystyrene-sulfonate-in-the-inpatient-setting/2024-12-31T13:00:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/coba-et-al.-v.-ford-motor-company2024-12-31T13:00:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v.-rpm-international-inc2024-12-31T13:00:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/the-vineyard-house-llc-v.-constellation-brands-u.s.-operations-inc.-and-constellation-brands-u.s.-operations-inc.-v.-the-vineyard-house-llc2024-12-31T13:00:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/travelport-worldwide-limited-et-al.-v.-wex-inc2024-12-31T13:00:54+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wildman-v.-american-century-services-llc-et-al2024-12-31T13:00:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/chill-et-al.-v.-calamos-advisors-llc2025-04-30T16:31:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/forescout-technologies-inc.-v.-ferrari-group-holdings-lp-et-al2024-12-31T13:00:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/florida-v.-georgia2024-12-31T13:00:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/windstream-holdings-inc.-et-al.-v.-charter-communications-inc.-and-charter-communications-operating-llc2024-12-31T13:00:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/simon-property-group-inc.-et-al.-v.-taubman-centers-inc.-et-al2024-12-31T13:00:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/comtech-telecommunications-corp.-and-convoy-ltd.-v.-gilat-satellite-networks-ltd2024-12-31T13:00:55+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/qc-manufacturing-inc.-v.-solatube-international-inc.-et-al2024-12-31T13:00:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-patent-and-trademark-office-et-al.-v.-booking.com-b.v2024-12-31T13:00:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/residential-mortgage-backed-securities-rmbs-matters/2024-12-31T13:00:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/kona-coffee-farmers-litigation-settlement/2024-12-31T13:00:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-certain-beverage-dispensing-systems-and-components-thereof-itc-inv.-no.-337-ta-11302025-01-08T18:02:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/occ-administrative-actions-against-rohan-ramchandani-former-head-of-european-fx-spot-trading-at-citibank-and-richard-usher-former-head-of-emea-fx-spot-trading-at-jpmorgan-chase/2025-07-16T19:53:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-v.-richard-usher-et-al2025-01-10T16:04:18+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-impact-reporting-for-exelon-corporation/2024-12-31T13:00:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/uniloc-usa-inc.-uniloc-luxembourg-s.a.-uniloc-2017-llc-v.-samsung-electronics-america-inc.-samsung-electronics-co.-ltd2024-12-31T13:00:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-niaspan-antitrust-litigation/2024-12-31T13:00:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ingevity-corp.-et-al.-v.-basf-corp2024-12-31T13:00:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lanxess-acquisition-of-emerald-kalama-chemical/2024-12-31T13:00:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lvmh-moet-hennessy-louis-vuitton-se-acquisition-of-tiffany--co/2024-12-31T13:00:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/davis-v.-stadion-money-management-llc2024-12-31T13:00:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/charles-tillage-et-al-v-comcast-corporation-et-al/2026-02-02T19:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sean-rad-et-al.-v.-iacinteractivecorp-et-al2024-12-31T13:00:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/aramark-management-llc-et-al.-v.-steve-borgquist-et-al2024-12-31T13:00:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/using-real-world-data-to-understand-treatment-patterns-and-outcomes-of-blood-disease-patients-in-china/2024-12-31T13:00:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/steinhoff-international-holdings-n.v.-shareholder-litigation2025-07-08T18:26:23+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dotstrategy-co-individually-and-on-behalf-of-all-other-similarly-situated-plaintiff-v-facebook-inc-defendant/2026-01-02T18:45:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/centenemagellan-merger-review-in-california/2024-12-31T13:00:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/travelpass-group-llc-et-al.-v.-caesars-entertainment-corp.-et-al2025-01-04T00:00:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/huntsman-international-llc-v.-albemarle-corporation-et-al2024-12-31T13:00:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/student-loan-lawsuits-against-navient-corporation/2024-12-31T13:00:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ams-sensors-usa-inc.-v.-renesas-electronics-america-inc2024-12-31T13:00:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nuvasive-inc-v-alphatec-holdings-inc-et-al/2026-02-17T19:22:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-v.-davita-inc.-and-kent-thiry2025-01-10T15:35:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-trade-commission-v.-intuit-inc2024-12-31T13:00:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/malden-transportation-company-inc.-et-al.-v.-uber-technologies-inc.-and-rasier-llc2025-05-01T15:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/elmagin-capital-llc-v-chao-chen-karl-petty-entergrid-llc-and-entergrid-fund-i-llc/2025-09-19T13:32:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/veoliasuez-merger-approval/2024-12-31T13:00:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/absorption-pharmaceuticals-llc-v.-reckitt-benckiser-llc2024-12-31T13:01:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/decision-21-d-14-of-french-competition-authority-fca-regarding-karcher-sas/2024-12-31T13:01:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/joseph-c-bamford-et-al-v-penfold-lp-et-al/2026-02-04T16:40:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/us-v.-penn-et-al2024-12-31T13:01:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/molson-coors-llc-v.-anheuser-busch-companies-llc2024-12-31T13:01:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/leonid-falberg-v.-the-goldman-sachs-group-inc.-et-al2024-12-31T13:01:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-foreign-exchange-benchmark-rates-antitrust-litigation/2026-01-02T18:37:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/joel-weiss-v.-loomis-sayles--co2024-12-31T13:01:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/bial---portela--ca-s.a.-et-al.-v.-torrent-pharmaceuticals-ltd.-et-al2024-12-31T13:01:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pirnik-v.-fiat-chrysler-automobiles-nv-et-al2024-12-31T13:01:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/usa-v.-michael-j.-avenatti2024-12-31T13:01:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/janssen-pharma.-inc.-et-al.-v.-teva-pharma.-usa-inc2025-01-08T18:15:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/john-cepelak-et-al.-v.-hp-inc2024-12-31T13:01:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-allergan-plc-securities-litigation/2024-12-31T13:01:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/worldline-acquisition-of-ingenico/2024-12-31T13:01:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/endless-river-technologies-llc-v.-transunion-llc2024-12-31T13:01:01+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/gramercy-funds-management-llc-and-gramercy-peru-holdings-llc-v-republic-of-peru/2026-02-05T21:20:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/avanzalia-solar-sl-et-al.-v.-goldwind-usa-inc2024-12-31T13:01:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-certain-casual-footwear-and-packaging-thereof/2024-12-31T13:01:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/jessica-julien-and-hollywood-smiles-atl-llc-plaintiffs-v.-georgia-board-of-dentistry-et-al.-defendants2025-04-30T17:02:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-lamictal-direct-purchaser-antitrust-litigation/2024-12-31T13:01:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/value-drug-company-v.-takeda-pharmaceuticals-usa-inc.-et-al2025-07-07T13:47:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/competitive-analysis-of-canadian-pacifickansas-city-southern-railway-merger/2026-01-02T17:55:17+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-analysis-in-cma-cgm-shipping-matter/2024-12-31T13:01:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-corsica-linea-pso-france-objet/2024-12-31T13:01:02+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/reworld-mediaarnoldo-mondadori-editore-merger-approval/2024-12-31T13:01:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-the-matter-of-yellowstone-capital-llc-et-al/2024-12-31T13:01:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-trade-commission-v.-meta-platforms-inc.-et-al2024-12-31T13:01:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/genetically-modified-rice-litigation/2024-12-31T13:01:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/town-of-apple-valley-v.-apple-valley-ranchos-water-corp2024-12-31T13:01:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pharmacyclics-llc-et-al-v-fresenius-kabi-usa-llc-et-al/2026-02-27T16:28:52+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v-philip-r-jacoby-jr-et-al/2024-12-31T13:01:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/quebec-coalition-for-tobacco-control-data-visualization-of-smoking-and-vaping/2025-04-08T17:59:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessing-industry-norms-for-security-research-in-a-copyright-infringement-lawsuit/2024-12-31T13:01:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/class-issues-involving-the-collection-of-biometric-data/2024-12-31T13:01:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/irish-data-protection-commissions-investigation-of-meta/2024-12-31T13:01:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-investigation-of-a-financial-services-corporations-regulatory-cybersecurity-practices/2024-12-31T13:01:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/deceptive-conduct-litigation-related-to-consumer-data/2024-12-31T13:01:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-political-ad-disclosure-litigation/2024-12-31T13:01:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/software-license-agreement-litigation/2024-12-31T13:01:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/roche-holding-ag-et-al-v-french-competition-authority/2024-12-31T13:01:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/serene-e-warren-v-acova-inc-et-al/2024-12-31T13:01:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/todd-j-mortier-v-livanova-usa-inc/2025-01-07T22:21:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-hiv-antitrust-litigation/2025-07-01T15:12:16+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/hope-medical-enterprises-inc-v-fagron-compounding-services-llc-et-al/2024-12-31T13:01:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/joseph-vellali-et-al-v-yale-university-et-al/2026-01-08T14:02:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/revisions-to-iso-ne-inventoried-energy-program/2024-12-31T13:01:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/davis-v-amazon-canada-fulfillment-services-ulc/2024-12-31T13:01:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/twitter-v-elon-musk-et-al/2025-04-30T17:03:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/george-r-golson-v-provident-life-and-accident-insurance-company-et-al/2024-12-31T13:01:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/confidential-class-actions-involving-data-collections/2024-12-31T13:01:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/janssen-pharmaceuticals-inc-et-al-v-mylan-laboratories-limited/2025-01-08T18:16:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lynne-houserman-v-comtech-telecommunications-corporation-et-al-and-telecommunication-systems-inc-v-lynne-houserman-et-al/2026-01-02T18:44:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sec-v-pacific-west-capital-group-et-al/2024-12-31T13:01:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/humana-inc-v-celgene-corp/2024-12-31T13:01:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/assessment-of-class-certification-lawsuit-involving-targeted-advertising-data/2024-12-31T13:01:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/wml-gryphon-fund-llc-et-al-v-wood-hat-silver-llc-et-al/2024-12-31T13:01:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-the-allstate-corporation-securities-litigation/2026-02-02T19:44:06+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/world-trade-center-properties-et-al-v-american-airlines-et-al/2024-12-31T13:01:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/proslide-technology-inc-v-whitewater-west-industries-ltd/2024-12-31T13:01:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ya-global-investments-lp-et-al.-v.-commissioner-of-internal-revenue2024-12-31T13:01:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/san-jose-neurospine-v-blue-shield-of-california/2026-02-02T19:45:24+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/california-spine-neurosurgery-institute-v-blue-shield-of-california/2026-02-02T19:41:37+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/oakland-bulk--oversized-terminal-llc-v.-city-of-oakland2024-12-31T13:01:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pilot-corporation-v-greg-abel-et-al/2024-12-31T13:01:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dillon-trust-company-et-al-v-united-states-of-america/2025-07-01T14:40:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dexon-computer-inc-v-cisco-systems-inc-and-cdw-corporation/2026-02-18T19:50:07+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/energy-harbor-corp-vistra-corp/2025-02-19T21:23:14+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/metas-response-to-eu-order-re-data-transfers/2024-12-31T13:01:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/impinj-inc-v-nxp-usa-inc/2024-12-31T13:01:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/collision-communications-inc-v-nokia-solutions-and-networks-oy/2026-01-02T18:40:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sight-sciences-inc-v-ivantis-inc-et-al/2024-12-31T13:01:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/petconnect-rescue-inc-et-al-v-david-salinas-et-al/2026-02-17T21:56:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ioengine-llc-v-roku-inc/2024-12-31T13:01:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/zunum-aero-inc-v-the-boeing-company-et-al/2024-12-31T13:01:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-ex-rel-dr-susan-nedza-v-american-imaging-management-inc-et-al/2024-12-31T13:01:08+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/arbitration-between-managed-care-organization-and-hospital-system/2026-02-02T19:59:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/theodoros-adamakopoulos-and-others-v-republic-of-cyprus/2025-11-12T16:49:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/airlines-fuel-surcharge-price-fixing-matters/2024-12-31T13:01:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/the-people-of-the-state-of-california-v-vitol-inc-et-al-and-in-re-california-gasoline-spot-market-antitrust-litigation/2024-12-31T13:01:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-lipitor-antitrust-litigation/2025-02-20T20:33:32+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/breach-of-contract-litigation-involving-a-biopharmaceutical-innovation/2024-12-31T13:01:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/hachette-book-group-inc-et-al-v-internet-archive-et-al/2025-01-03T23:32:13+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/consumer-financial-protection-bureau-v-navient-corporation-et-al/2024-12-31T13:01:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-icap-enterprises-inc-et-al/2024-12-31T13:01:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/incyte-corporation-et-al-v-sun-pharmaceutical-industries-ltd-et-al/2024-12-31T13:01:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/leon-gilbert-and-michael-mcgarvey-v-unisys-corporation/2024-12-31T13:01:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-social-capital-arbitration/2025-06-09T19:18:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-ftx-trading-ltd-et-al/2025-01-02T19:28:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/the-people-of-the-state-of-california-v-ashford-university-llc-et-al/2025-01-03T23:32:50+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-trade-commission-et-al-v-the-kroger-company-et-al/2024-12-31T13:01:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cma-cgm-group-sa-acquisition-of-bollore-logistics/2024-12-31T13:01:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/review-of-credit-agricole-and-worldline-joint-venture/2024-12-31T13:01:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/dleteren-group-acquisition-of-parts-holding-europe/2024-12-31T13:01:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/fnac-darty-acquisition-of-nature-decouvertes/2024-12-31T13:01:10+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/groupe-canal-plus-acquisition-of-ocs-and-orange-studio/2024-12-31T13:01:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/san-marina-acquisition-of-minelli-sas/2024-12-31T13:01:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/cts-eventimfnac-darty-merger/2024-12-31T13:01:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lactalis-group-acquisition-of-ambrosi/2024-12-31T13:01:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/agpm-acquisition-of-gmpa/2024-12-31T13:01:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/groupe-bertrand-acquisition-of-leon-de-bruxelles/2024-12-31T13:01:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/european-camping-group-acquisition-of-vacanceselect/2024-12-31T13:01:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/daucy-triskalia-merger/2024-12-31T13:01:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/audika-groupe-s-a-s-audilab-s-a-merger/2024-12-31T13:01:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lactalis-group-acquisition-of-nuova-castelli/2024-12-31T13:01:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/lactalis-group-acquisition-of-leerdammer/2024-12-31T13:01:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/carrefour-acquisition-of-makro-dossier-gulliver/2024-12-31T13:01:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/insulet-corporation-v-eoflow-co-ltd-et-al/2025-05-05T16:11:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/novelis-acquisition-of-aleris-corporation/2026-02-05T21:24:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/intercontinental-exchange-acquisition-of-black-knight/2024-12-31T13:01:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/northside-hospital-acquisition-of-gwinnett-health-system/2024-12-31T13:01:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-trade-commission-et-al-v-sanford-health-et-al/2024-12-31T13:01:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/university-hospitalslake-health-merger/2024-12-31T13:01:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/sika-ag-acquisition-of-mbcc-group/2025-01-03T22:44:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/review-of-broadcom-inc-acquisition-of-vmware-inc/2025-02-13T15:07:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/review-of-psav-acquisition-of-encore-event-technologies/2025-01-03T22:53:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/review-of-cintas-corporation-acquisition-of-gk-services-inc/2025-01-03T22:58:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/review-of-campbell-soup-company-acquisition-of-sovos-brands-inc/2025-01-03T23:02:53+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/payment-logistics-limited-v-lighthouse-network-llc-et-al/2026-02-27T16:27:41+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/the-successor-agency-to-the-former-emeryville-redevelopment-agency-and-the-city-of-emeryville-v-swagelok-company-et-al/2025-07-01T15:00:09+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/nippon-shinyaku-co-ltd-et-al-v-sarepta-therapeutics-inc-et-al/2026-01-04T22:15:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/maximilian-klein-et-al-v-meta-platforms-inc-user-plaintiffs/2025-10-01T19:29:12+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/doubleline-capital-gp-llc-et-al-v-philip-barach-et-al/2025-02-05T13:59:57+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/headwater-research-llc-v-samsung-electronics-co-ltd-et-al/2025-02-07T16:31:03+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/selex-galileo-inc-v-nomir-medical-technologies-inc/2025-03-07T18:58:05+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/walmart-acquisition-of-vizio/2026-02-05T21:25:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/rogers-communications-acquisition-of-shaw-communications/2025-05-06T20:31:44+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/erisa-class-action-litigation/2025-05-28T18:04:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pascal-metrics-inc-v-health-catalyst-inc/2025-10-17T14:05:21+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/enhabit-inc-et-al-v-nautic-partners-ix-lp-et-al/2025-06-02T18:31:04+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/european-commission-investigation-of-csl-vifor-pharmacosmos-uk-ltd-v-csl-vifor-pharma-ltd-pharmacosmos-as-et-al-v-vifor-pharma-nederland-b-v-et-al/2025-06-03T17:29:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/maxell-ltd-v-samsung-electronics-co-ltd-et-al/2025-06-04T13:00:45+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/regeneron-pharmaceuticals-inc-v-amgen-inc/2025-10-17T14:04:40+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/intervenor-testimony-on-behalf-of-ameren-in-gridliance-heartland-cpcn-petition/2025-06-10T13:30:59+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/national-fire-protection-association-inc-v-upcodes-inc-et-al/2026-01-23T23:06:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-wesco-aircraft-holdings-inc-et-al-v-ssd-investments-ltd-et-al/2025-07-11T15:54:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/jeffrey-albert-sjobring-et-al-v-first-american-title-insurance-company-et-al/2026-02-02T19:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/openai-inc-v-open-artificial-intelligence-inc-et-al-steckel/2025-09-23T21:11:11+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/talen-energy-corporation-power-plant-retirement/2026-01-04T22:07:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/alicia-marshall-et-al-v-prestamos-cdfi-llc-et-al/2025-10-17T14:03:26+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/brian-waldner-v-natixis-investment-managers-l-p-et-al/2026-01-08T13:50:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/openai-inc-v-open-artificial-intelligence-inc-et-al-mitzenmacher/2025-09-24T15:56:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/purple-buyer-holdings-llc-et-al-v-taylor-sports-group-inc-et-al/2026-01-04T22:12:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/federal-trade-commission-v-meta-platforms-inc/2026-02-18T19:51:43+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-et-al-ex-rel-jaime-siegel-v-novo-nordisk-inc/2025-11-24T14:37:58+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-libor-based-financial-instruments-antitrust-litigation/2025-12-03T20:32:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/united-states-v-eduardo-lopez/2025-12-12T15:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/23xi-racing-et-al-v-national-association-for-stock-car-auto-racing-llc-et-al/2026-02-02T20:44:22+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/mark-stoyas-v-toshiba-corporation-et-al/2026-01-08T19:53:15+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/in-re-google-digital-advertising-antitrust-litigation/2026-01-15T16:40:31+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/minnesota-electric-vehicle-proceeding/2026-01-15T20:21:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-analysis-of-default-electricity-service-rate-filing/2026-01-15T20:36:30+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/rate-analysis-for-citizens-energy-group/2026-01-15T20:36:51+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/electricity-rate-analysis/2026-01-15T20:33:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/northwest-rural-public-power-district-v-basin-electric-power-cooperative/2026-01-15T20:38:46+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/pjm-capacity-market-affidavit-filing/2026-01-15T20:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/economic-analysis-of-the-california-electricity-crisis/2026-01-15T20:49:38+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/ferc-proceeding-basin-electric-power-cooperativemckenzie-electric-cooperative/2026-01-15T20:52:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/illinois-transmission-project/2026-03-02T16:38:42+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/missouri-transmission-project/2026-01-15T20:57:00+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/constellation-energy-corporation-acquisition-of-calpine-corporation/2026-01-28T16:24:34+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/methanex-acquisition-of-oci-global/2026-02-10T19:31:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/facebook-inc-derivative-litigation/2026-03-24T15:24:47+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/janet-garcia-et-al-v-the-city-of-los-angeles/2026-03-30T14:35:56+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/hdmi-licensing-administrator-inc-v-availink-inc/2026-03-31T18:22:35+00:00weekly0.7https://www.analysisgroup.com/Insights/cases/securities-and-exchange-commission-v-vidul-prakash/2026-04-03T15:45:40+00:00weekly0.7https://www.analysisgroup.com/practices/antitrust-competition/collusion/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/antitrust-competition/mergers-and-acquisitions/2026-03-26T20:56:16+00:00weekly0.7https://www.analysisgroup.com/practices/antitrust-competition/monopolization-and-exclusionary-practices/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/antitrust-competition/vertical-restraints/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/antitrust-competition/classcollective-actions/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/class-certification/types-of-class-actions/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/class-certification/industry-experience/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/commercial-disputes/mass-torts/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/commercial-disputes/breach-of-contract/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/commercial-disputes/false-advertising/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/commercial-disputes/professional-malpractice/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/damages/specialized-expertise/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/damages/industry-experience/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/damages/causes-of-actions/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/energy-and-environment-litigation/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/energy-environmental-climate-policy/2023-04-10T13:33:15+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/infrastructure-valuation-investment-and-siting/2023-04-10T13:33:26+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/utility-ratemaking-and-regulation/2023-04-10T13:33:35+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/power-system-market-design-and-analysis/2023-04-10T13:33:43+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/mergers-and-industry-structure/2026-01-28T16:50:51+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/resource-planning-and-management/2023-12-14T15:09:04+00:00weekly0.7https://www.analysisgroup.com/practices/energy-climate-natural-resources/natural-resources-agricultural-economics/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/health-economics-and-outcomes-research-heor/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/modeling-and-analytics/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/market-access-and-commercial-strategy/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/epidemiology-biostatistics/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/practices/erisa/company-stock-issues/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/erisa/defined-benefit-plans/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/erisa/erisa-class-actions/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/erisa/excessive-fees-issues/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/erisa/process-of-monitoring-and-selecting-investments/2024-01-11T10:36:16+00:00weekly0.7https://www.analysisgroup.com/practices/erisa/erisa-health-care-claims/2024-01-11T10:40:38+00:00weekly0.7https://www.analysisgroup.com/practices/government-and-corporate-investigations/antitrust-investigations/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/government-and-corporate-investigations/health-care-investigations/2020-02-06T23:20:41+00:00weekly0.7https://www.analysisgroup.com/practices/government-and-corporate-investigations/securities-investigations/2022-11-08T21:35:22+00:00weekly0.7https://www.analysisgroup.com/practices/government-and-corporate-investigations/tax-and-other-types-of-investigations/2023-01-13T12:44:39+00:00weekly0.7https://www.analysisgroup.com/practices/health-care/litigation-services/2026-03-13T13:10:14+00:00weekly0.7https://www.analysisgroup.com/practices/health-care/health-care-policy/2026-03-13T13:11:56+00:00weekly0.7https://www.analysisgroup.com/practices/health-care/controlled-substance-monitoring-and-analytics/2026-03-13T13:12:05+00:00weekly0.7https://www.analysisgroup.com/practices/health-care/life-sciences-corporate-disputes/2026-03-13T13:12:12+00:00weekly0.7https://www.analysisgroup.com/practices/health-care/food-and-nutrition-litigation/2026-03-13T13:12:19+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/analyst/2025-12-24T17:47:10+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/associate/2025-12-24T17:48:30+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/administrative/2025-12-24T17:49:00+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/summer-analyst-intern/2025-11-06T21:48:21+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/manager/2025-12-24T17:47:40+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/recruiting-events/2026-02-13T16:32:53+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/summer-associate-intern/2025-11-06T21:48:32+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/interview-resources/2025-12-03T19:19:18+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/data-scientists/2025-12-24T17:49:27+00:00weekly0.7https://www.analysisgroup.com/careers/career-path/vice-president/2025-12-24T21:53:56+00:00weekly0.5https://www.analysisgroup.com/Insights/videos/pierre-cremieux---how-we-work/2025-01-09T20:55:29+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/paul-greenberg---pharmaceutical-off-label-promotion/2024-07-18T15:11:22+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/martha-samuelson--yale-school-of-management-leaders-forum-values/2025-01-08T16:50:23+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/martha-samuelson---yale-school-of-management-leaders-forum-developing-talent/2025-01-08T16:50:37+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/martha-samuelson---yale-school-of-management-leaders-forum-culture/2025-01-08T16:49:40+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/martha-samuelson---our-culture-of-collaboration/2025-01-08T16:50:08+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/jill-linberg---why-analysis-group/2024-07-18T15:09:51+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/edward-snyder--pierre-cremieux---the-macro--and-microcommonality-tests/2025-01-09T20:57:06+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/edward-snyder---do-common-issues-predominate/2024-07-18T15:09:07+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/crystal-pike-and-kenneth-weinstein---using-data-in-suspicious-order-monitoring-of-opioids/2024-07-18T15:08:42+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/eric-wu-and-min-yang---patient-reported-outcomes/2024-07-18T15:09:34+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/noam-kirson---balancing-drug-pricing-with-value/2024-07-18T15:10:45+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/paul-greenberg---a-diverse-health-care-practice/2024-07-18T15:11:14+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/richard-mortimer---the-competitive-landscape-for-biosimilars/2024-07-18T15:11:57+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/james-signorovitch---rare-diseases/2024-07-18T15:15:46+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/patrick-lefebvre---the-value-of-real-world-evidence-in-drug-approval-and-marketing-processes/2024-07-18T15:11:05+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/dave-nellesen---what-are-dossiers/2024-07-18T15:08:50+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/pro-bono-work-at-analysis-group/2024-07-18T15:11:49+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/discover-analysis-group/2024-07-18T15:08:59+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/the-economic-burden-of-depression-30-year-study/2024-07-18T15:11:30+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/summer-intern-experience---associates/2024-07-18T15:12:23+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/summer-intern-experience---analyst/2024-07-18T15:12:13+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/analyst-experience-at-analysis-group/2024-07-18T15:07:56+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/associate-experience-at-analysis-group/2024-07-23T14:26:57+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/the-business-of-cybersecurity-is-business/2024-07-23T15:18:13+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/determining-the-price-for-one-when-all-you-have-is-the-price-for-many/2024-07-23T15:14:56+00:00weekly0.7https://www.analysisgroup.com/Insights/videos/new-bottles-for-old-wine-a-new-focus-on-antitrust-in-labor-markets/2024-07-23T15:22:33+00:00weekly0.7https://www.analysisgroup.com/people/principals/dave-nellesen/2025-10-07T17:19:27+00:00weekly0.7https://www.analysisgroup.com/people/principals/paul-j--hibbard/2026-01-15T20:51:59+00:00weekly0.7https://www.analysisgroup.com/people/principals/robert-l--vigil/2025-08-07T12:45:10+00:00weekly0.7https://www.analysisgroup.com/people/principals/marnie-a--moore/2025-09-17T14:06:18+00:00weekly0.7https://www.analysisgroup.com/people/principals/juliette-caminade/2026-03-06T17:58:02+00:00weekly0.7https://www.analysisgroup.com/people/principals/na-dawson/2025-11-19T16:36:16+00:00weekly0.7https://www.analysisgroup.com/people/principals/kevin-gold/2024-01-11T10:37:11+00:00weekly0.7https://www.analysisgroup.com/people/principals/brian-ellman/2026-02-10T19:26:20+00:00weekly0.7https://www.analysisgroup.com/people/principals/xinyu-ji/2026-04-02T14:04:12+00:00weekly0.7https://www.analysisgroup.com/people/principals/mark-j--lewis/2024-12-23T16:30:47+00:00weekly0.7https://www.analysisgroup.com/people/principals/rebeccah-weiss-filsoof/2024-06-20T17:02:58+00:00weekly0.7https://www.analysisgroup.com/people/principals/eric-korman/2026-01-28T18:01:20+00:00weekly0.7https://www.analysisgroup.com/people/principals/rene-befurt/2025-09-15T17:33:29+00:00weekly0.7https://www.analysisgroup.com/people/principals/laura-comstock/2025-06-02T18:31:00+00:00weekly0.7https://www.analysisgroup.com/people/principals/laura-o-laughlin/2026-02-12T18:16:31+00:00weekly0.7https://www.analysisgroup.com/people/principals/eric-b-nguyen/2025-09-17T14:06:43+00:00weekly0.7https://www.analysisgroup.com/people/principals/chris-feige/2025-09-26T20:33:33+00:00weekly0.7https://www.analysisgroup.com/people/principals/hristina-bojadzieva-bartlett/2025-12-17T14:40:11+00:00weekly0.7https://www.analysisgroup.com/people/principals/emmanuel-frot/2026-02-03T21:46:38+00:00weekly0.7https://www.analysisgroup.com/people/principals/francois-laliberte/2026-02-04T16:16:06+00:00weekly0.7https://www.analysisgroup.com/people/principals/jimmy-royer/2026-03-09T18:57:48+00:00weekly0.7https://www.analysisgroup.com/people/principals/todd-schatzki/2026-02-26T18:53:10+00:00weekly0.7https://www.analysisgroup.com/people/principals/jessica-resch/2025-11-07T17:35:57+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/elizabeth-a--eccher/2024-12-31T15:51:51+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/george-kosicki/2024-12-31T16:15:29+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/laura-boothman-stamm/2025-05-30T14:47:33+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/robert-s--pindyck/2024-12-31T18:53:56+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/dennis-j--aigner/2024-12-31T15:36:07+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/laurence-c--baker/2026-02-18T15:33:10+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/ray-ball/2024-12-31T18:51:34+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/edward-p--kahn/2024-12-31T15:50:28+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/lawrence-m--benveniste/2024-12-31T17:46:04+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/patricia-chadwick/2024-12-31T18:47:22+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/judith-a--chevalier/2026-01-15T16:40:31+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/francis-x--diebold/2024-12-31T16:12:56+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/mark-s--grinblatt/2024-12-31T17:59:28+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/r--glenn-hubbard/2026-02-03T21:46:41+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/philippe-jorion/2024-12-31T18:49:26+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/k--ramesh/2024-12-31T17:14:48+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/meir-statman/2024-12-31T18:31:27+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/peter-tufano/2024-12-31T18:48:53+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/lawrence-p--weiner/2024-12-31T17:46:32+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/susan-e--woodward/2024-12-31T20:14:51+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/karen-hopper-wruck/2024-12-31T17:15:33+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/robert-a--sherwin/2024-12-31T18:52:18+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/arnold-i--barnett/2025-08-19T14:56:04+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/sebastian-edwards/2024-12-31T20:08:09+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/kathleen-m--eisenhardt/2024-12-31T17:15:54+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/steven-d--eppinger/2025-08-19T14:57:08+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/marshall-l--fisher/2024-12-31T18:00:15+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/pierre-fortin/2024-12-31T18:49:43+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/brian-j--hall/2024-12-31T14:26:13+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/john-r--hauser/2024-12-31T17:04:58+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/luis-m--huete/2024-12-31T17:52:55+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/ronald-c--kessler/2024-12-31T18:57:59+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/william-h--lehr/2024-12-31T20:22:57+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/burton-g--malkiel/2024-12-31T14:26:49+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/john-w--mayo/2024-12-31T17:05:39+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/j--f--philip-merrigan/2024-12-31T16:40:30+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/randolph-bucklin/2024-12-31T18:50:55+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/george-foster/2024-12-31T16:15:11+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/robert-e--hall/2024-12-31T18:53:20+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/barry-m--massarsky/2024-12-31T14:25:34+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/shmuel-s--oren/2024-12-31T20:10:43+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/timothy-j--riddiough/2024-12-31T20:19:16+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/john-a--rizzo/2025-04-16T14:39:43+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/louis-f--rossiter/2024-12-31T17:49:59+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/robert-stavins/2024-12-31T18:55:01+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/ashley-j--stevens/2025-04-16T14:45:35+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/kerry-dean-vandell/2024-12-31T17:17:52+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/lawrence-j--white/2024-12-31T17:45:42+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/john-m--lacey/2024-12-31T17:04:39+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/michael-f--koehn/2024-12-31T18:35:32+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/nicholas-e--piggott/2025-02-21T14:27:36+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/a--mitchell-polinsky/2024-12-31T14:06:12+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/steven-shavell/2024-12-31T20:13:05+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/robert-c--blattberg/2024-12-31T18:52:38+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/michael-w--maher/2024-12-31T18:39:48+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/stephen-g--ryan/2024-12-31T20:11:28+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/walter-n--thurman/2024-12-31T20:21:53+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/marcel-boyer/2024-12-31T17:58:10+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/laura-t--starks/2024-12-31T17:44:58+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/barry-k--goodwin/2024-12-31T14:25:21+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/henry-g--grabowski/2024-12-31T16:17:01+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/frank-sloan/2024-12-31T16:13:22+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/edward-a--snyder/2026-01-07T19:24:52+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/john-chalmers/2024-12-31T17:02:42+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/lucian-a--bebchuk/2024-12-31T17:52:16+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/erik-brynjolfsson/2026-03-19T21:13:41+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/chris-f--kemerer/2025-01-21T16:44:00+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/david-j--denis/2026-04-02T14:04:19+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/michael-k--wohlgenant/2024-12-31T18:36:09+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/roger-ware/2025-05-06T20:31:44+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/joel-h--steckel/2026-01-21T20:14:18+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/james-w--hughes/2024-12-31T16:44:44+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/charlotte-chamberlain/2024-12-31T14:31:06+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/lorraine-eden/2025-03-07T20:24:42+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/oliver-hart/2024-12-31T18:46:38+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/atulya-sarin/2024-12-31T14:23:48+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/robin-cooper/2024-12-31T18:56:34+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/sanjiv-r--das/2025-06-12T16:31:23+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/thomas-lys/2024-12-31T20:18:45+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/william-j--chambers/2024-12-31T20:23:12+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/lee-jen-wei/2024-12-31T17:47:03+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/donna-hitscherich/2024-12-31T15:47:24+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/robert-grien/2025-08-20T14:51:49+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/james-levinsohn/2024-12-31T16:42:26+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/thomas-buchmueller/2025-04-30T16:22:54+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/harold-w--furchtgott-roth/2024-12-31T16:16:43+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/toby-e--stuart/2026-01-23T23:06:30+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/david-s--scharfstein/2024-12-31T15:34:13+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/michael-klausner/2025-03-03T18:14:57+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/michael-s--weisbach/2024-12-31T18:38:19+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/b--espen-eckbo/2024-12-31T14:24:40+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/nabil-n--el-hage/2024-12-31T18:43:53+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/roberto-rigobon/2024-12-31T18:56:07+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/steven-m--shugan/2024-12-31T20:12:51+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/john-j--richard/2025-06-12T16:31:52+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/e--han-kim/2024-12-31T15:47:54+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/gordon-liu/2026-03-25T14:44:31+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/walter-torous/2024-12-31T20:22:34+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/catherine-e--tucker/2026-03-25T17:46:26+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/peter-s--fader/2024-12-31T18:48:36+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jun-s--liu/2024-12-31T17:09:17+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/kathleen-m--sutcliffe/2024-12-31T17:16:17+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/on-amir/2026-03-13T10:49:46+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/shane-frederick/2024-12-31T20:08:23+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/kevin-l--keller/2024-12-31T17:18:16+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jiwoong-shin/2024-12-31T16:49:58+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/olivier-toubia/2024-12-31T18:46:55+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/michael-a--carrier/2024-12-31T18:33:21+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/john-r--minahan/2024-12-31T17:05:15+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/matthew-g--nagler/2024-12-31T18:28:45+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/keith-m--schappert/2024-12-31T17:17:05+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/brendan-sheehy/2024-12-31T14:26:00+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/william-mcgivney/2024-12-31T20:25:01+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/david-j--reibstein/2024-12-31T15:19:56+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/stephen-j--hoch/2024-12-31T20:11:49+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/robert-p--navarro/2024-12-31T18:53:45+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/russell-f--peppet/2024-12-31T18:58:54+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/daniel-o--scharfstein/2024-12-31T14:44:33+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/roberts-w--brokaw-iii/2024-12-31T18:56:19+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/deborah-haas-wilson/2025-08-07T13:50:35+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/myron-s--glucksman/2024-12-31T18:43:30+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/ira-g--kawaller/2024-12-31T16:39:21+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/john-j--mcconnell/2024-12-31T17:04:00+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/claire-tsai/2024-12-31T14:35:44+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/russell-r--wermers/2026-02-13T19:41:33+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/david-gal/2025-02-25T15:53:58+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/rangarajan-k--sundaram/2024-12-31T18:51:12+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/willy-c--shih/2026-03-19T21:25:01+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/paul-b--ginsburg/2024-12-31T18:47:38+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/juanjuan-zhang/2024-12-31T17:08:30+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/daniel-bauer/2025-04-30T13:58:01+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/christopher-r--knittel/2024-12-31T14:34:40+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/steven-k--gissiner/2025-05-28T18:04:16+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/joel-peress/2024-12-31T16:51:39+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/peter-n--golder/2024-12-31T18:48:24+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/michael-siegel/2025-01-21T16:48:38+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/nathan-novemsky/2024-12-31T18:44:49+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/robert-zeithammer/2024-12-31T18:55:46+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/natalie-mizik/2024-12-31T18:44:22+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/john-e--ware/2024-12-31T17:03:36+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/shannon-w--anderson/2024-12-31T20:08:35+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/john-contino/2025-07-14T16:23:35+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/randal-s--milch/2026-03-24T15:36:20+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/paul-oyer/2024-12-31T18:48:06+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/hanming-fang/2024-12-31T16:16:23+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/david-dranove/2025-06-04T14:41:39+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/scott-f--meadow/2024-12-31T20:07:57+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/sylvia-manning/2024-12-31T20:17:09+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jonathan-levav/2024-12-31T17:06:55+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/gary-h--stern/2024-12-31T16:13:40+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/michael-d--mitzenmacher/2026-03-19T21:23:33+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/joseph-willett/2024-12-31T17:08:01+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/alex-edmans/2025-12-12T21:35:55+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jean-pierre-landau/2025-05-12T20:25:47+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jura-liaukonyte/2024-12-31T17:09:38+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/ronald-c--goodstein/2024-12-31T18:57:31+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/kurt-carlson/2024-12-31T17:21:51+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jeffrey-t--prince/2025-05-20T17:37:11+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/shlomo-hershkop/2025-01-21T16:43:29+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/steven-weber/2025-08-19T15:00:48+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/luis-de-la-calle/2025-04-16T14:37:56+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/francis-a--longstaff/2024-12-31T15:56:45+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/william-m--mohl/2024-12-31T20:24:14+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/moshe-buchinsky/2024-12-31T18:42:39+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/lewis-j--allen/2024-12-31T17:47:35+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/fabio-savoldelli/2024-12-31T15:55:19+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/alan-grigoletto/2024-12-31T14:09:06+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/craig-garthwaite/2024-12-31T14:36:36+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/christianna-wood/2024-12-31T14:33:33+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/anupam-b--jena/2025-11-24T14:37:58+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jacques-cremer/2024-12-31T16:42:10+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/tulin-erdem/2025-02-06T21:21:28+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/nina-maar/2024-12-31T18:46:27+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/david-s.-abrams2024-12-31T15:20:30+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/anthony-t.-losasso2025-05-22T14:05:04+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/michael-melvin/2024-12-31T18:37:28+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/marc-zenner/2025-06-02T18:31:03+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/robert-w.-platt2025-02-24T21:44:28+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/andrzej-andy-skrzypacz/2026-02-20T14:43:48+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/esther-mills/2024-12-31T15:55:04+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/keith-hylton/2026-03-13T10:49:48+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/william-m.-zoffer2024-12-31T20:24:40+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/howard-g--birnbaum/2024-12-31T16:18:15+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/james-trautman/2024-12-31T16:43:36+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jeff-bodington/2024-12-31T16:46:21+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/charlotte-wright/2025-02-26T20:06:23+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jonathan-reuter/2025-09-17T14:04:07+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jacob-e.-gersen2024-12-31T16:41:52+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/edward-b.-rock2025-02-05T14:00:00+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/murray-beach/2024-12-31T18:43:03+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/james-r.-hille2025-06-12T16:32:48+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/punam-anand-keller/2024-12-31T18:49:56+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/dina-mayzlin/2026-02-18T16:58:09+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/antoinette-schoar/2024-12-31T14:18:48+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/gary-m.-lawrence2024-12-31T16:13:59+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/daniel-snow/2024-12-31T14:45:43+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/mihir-desai/2025-05-27T19:27:55+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/w.-michael-hanemann2024-12-31T20:21:32+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/micah-officer/2024-12-31T18:32:58+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/keri-pearlson/2026-03-19T21:24:26+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/david-c.-chan-jr2025-03-07T18:49:50+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/bertrand-meyer/2025-01-22T18:32:18+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/stuart-madnick/2025-08-19T14:59:18+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/david-grabowski/2025-07-08T19:05:45+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/angie-graves/2025-08-19T14:57:59+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/merike-kaeo/2025-08-19T14:59:03+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/arun-sundararajan/2025-10-08T18:52:10+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/christopher-f.-noe2024-12-31T14:34:08+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/nathaniel-good/2026-03-19T21:19:45+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/corey-lang/2024-12-31T14:36:03+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/kannan-srinivasan/2024-12-31T17:15:13+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/renee-richardson-gosline/2024-12-31T18:51:51+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/michael-scott-kinch/2024-12-31T18:38:50+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jack-chen/2024-12-31T16:41:10+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/kumar-venkataraman/2024-12-31T17:21:23+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/charles-h.-grice2024-12-31T14:29:25+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/amitabh-chandra/2024-12-31T14:17:09+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/t.-jeffrey-wilks2025-04-30T14:00:40+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/eileen-a.-kamerick2024-12-31T15:50:46+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jennifer-blouin/2024-12-31T16:49:17+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/arthur-b.-laby2025-01-15T16:37:00+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/edward-j-fox/2025-09-23T21:07:49+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/itay-goldstein/2024-12-31T16:40:14+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/barbara-e.-kahn2024-12-31T14:24:54+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/amol-navathe/2025-05-29T15:46:03+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/yael-hochberg/2026-02-03T21:46:40+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/paul-h.-kupiec2024-12-31T18:47:52+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/david-a.-savitz2024-12-31T15:15:29+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/lisa-rotenstein/2024-12-31T17:48:03+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/kevin-r.-powers2024-12-31T17:18:42+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/atheendar-venkataramani/2024-12-31T14:20:50+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/eric-sun/2024-12-31T15:54:10+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/mark-s.-robbins2024-12-31T17:59:49+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/marguerite-brackley/2024-12-31T17:58:36+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/lynne-kiesling/2024-12-31T17:53:16+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/robert-conway/2026-04-02T14:04:18+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/susan-christoffersen/2024-12-31T20:14:37+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jonathan-r.-macey2024-12-31T17:07:17+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/sabrina-howell/2025-09-16T17:04:28+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/steven-case/2024-12-31T20:12:02+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/david-w.-richardson2024-12-31T15:34:59+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/suneal-bedi/2024-12-31T20:14:20+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/simon-blanchard/2024-12-31T20:11:00+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/lou-garrison/2025-07-22T16:55:58+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/james-t-jenson/2026-03-19T21:20:44+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/georgios-zervas/2026-03-19T21:28:44+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/crystal-a.-kolden2024-12-31T14:37:20+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/brian-phelan/2025-10-08T13:51:05+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/j.-michael-mcwilliams2024-12-31T16:40:54+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/d.-scott-showalter2024-12-31T14:38:09+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/kevin-wellenius/2024-12-31T17:20:58+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/erich-muehlegger/2026-01-15T20:21:33+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/david-k-a-mordecai/2025-09-16T19:37:04+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/samantha-kappagoda/2025-09-16T18:24:00+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/christopher-a-bail/2026-03-19T21:12:05+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/darius-palia/2024-12-31T15:15:05+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/stacie-bosley/2024-12-31T20:11:13+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/david-w-larue/2024-12-31T15:34:33+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/ayako-yasuda/2025-07-15T12:59:23+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/daniel-m-fitzpatrick/2024-12-31T14:43:30+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/christopher-m-worsham/2026-02-09T19:39:37+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/l-charles-duke-meythaler/2024-12-31T17:22:49+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/cynthia-steer/2024-12-31T14:37:36+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/amalia-rebecca-miller/2025-03-26T15:52:54+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/laura-happe/2024-12-31T17:44:38+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/amit-bhattacharjee/2026-02-27T16:49:33+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/amanda-starc/2024-12-31T14:10:42+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/wei-jiang/2024-12-31T20:22:44+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/ashish-k-jha/2024-12-31T14:20:20+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/denis-boyle/2024-12-31T15:35:49+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/itamar-simonson/2024-12-31T16:39:55+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/eric-h-sussman/2025-12-19T16:56:35+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/thomas-c-tsai/2024-12-31T20:18:30+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/s-p-kothari/2024-12-31T20:06:00+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/joe-quoyeser/2024-12-31T16:50:48+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jonathan-ketcham/2024-12-31T17:06:33+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/michael-yackira/2024-12-31T18:40:31+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/emma-frejinger/2025-11-19T19:20:03+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/alexander-mackay/2025-04-21T14:37:06+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/henry-klein/2024-12-31T16:17:39+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/chad-syverson/2024-12-31T14:29:04+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/michael-donohoe/2025-12-19T16:56:52+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/genia-long/2024-12-31T16:14:52+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/ruomeng-cui/2025-03-26T15:52:54+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/christopher-whaley/2026-03-25T14:22:39+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/morten-sorensen/2024-12-31T18:42:15+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/abdul-lakhani/2024-12-31T14:08:51+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/alixandra-barasch/2025-05-28T19:40:43+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/paul-godek/2025-05-28T20:25:19+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/ben-johnson/2025-08-19T14:58:37+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/todd-haugh/2025-05-28T20:34:28+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/yesha-yadav/2025-06-26T18:12:27+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/anthony-dukes/2025-06-18T19:58:05+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/john-cawley/2026-02-12T18:13:16+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/marc-siegel/2025-06-17T19:25:08+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/mark-deyong/2025-05-28T20:21:17+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/charles-c-moore/2025-07-15T13:00:12+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/peter-lefkowitz/2025-08-22T16:32:46+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/fabio-moneta/2025-05-28T13:58:49+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/fatima-cody-stanford/2026-02-12T18:12:51+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/alberto-rossi/2025-06-05T17:18:39+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/toni-l-brown/2025-06-09T13:19:17+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/keith-wilcox/2025-07-09T14:29:53+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/srikanth-jagabathula/2025-07-08T19:28:57+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/kevin-m-welsh/2026-03-19T21:27:44+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/eric-cole/2026-03-19T21:18:34+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/paul-clip/2026-03-19T21:17:52+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/steven-puller/2026-01-15T20:47:53+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/charlene-giacin/2025-07-28T14:59:38+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/kelly-hauert/2026-01-15T20:47:54+00:00weekly0.5https://www.analysisgroup.com/people/affiliated-experts/mitchell-l-r-walker-ii/2026-03-19T21:25:56+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/christopher-armstrong/2025-08-28T18:03:07+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/timothy-destefano/2026-03-19T21:19:08+00:00weekly0.5https://www.analysisgroup.com/people/affiliated-experts/thomas-shellhammer/2025-09-04T16:26:07+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/greg-miller/2025-09-04T17:31:13+00:00weekly0.5https://www.analysisgroup.com/people/affiliated-experts/vyacheslav-fos/2025-09-05T16:10:22+00:00weekly0.5https://www.analysisgroup.com/people/affiliated-experts/silke-forbes/2025-09-16T19:40:21+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/jane-summers/2025-10-13T18:02:51+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/seoyoung-kim/2025-10-15T17:26:50+00:00weekly0.5https://www.analysisgroup.com/people/affiliated-experts/martin-beraja/2025-11-04T15:27:16+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/marco-gaboardi/2025-10-30T17:03:44+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/evimaria-terzi/2025-10-30T17:07:47+00:00weekly0.5https://www.analysisgroup.com/people/affiliated-experts/jonathan-fiechter/2025-11-12T16:50:15+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/andrew-metrick/2025-12-15T20:17:51+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/mark-egan/2026-04-02T14:16:22+00:00weekly0.5https://www.analysisgroup.com/people/affiliated-experts/brett-hollenbeck/2026-03-03T19:55:59+00:00weekly0.5https://www.analysisgroup.com/people/affiliated-experts/neil-malhotra/2026-03-12T13:10:04+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/justus-baron/2026-03-31T18:22:34+00:00weekly0.7https://www.analysisgroup.com/people/affiliated-experts/venkatesh-shankar/2026-03-25T17:32:53+00:00weekly0.7https://www.analysisgroup.com/about/locations/boston/2025-03-26T17:40:12+00:00weekly0.7https://www.analysisgroup.com/about/locations/chicago/2025-09-04T19:25:14+00:00weekly0.7https://www.analysisgroup.com/about/locations/dallas/2026-01-07T18:54:02+00:00weekly0.5https://www.analysisgroup.com/about/locations/denver/2025-09-10T17:24:49+00:00weekly0.7https://www.analysisgroup.com/about/locations/los-angeles/2024-07-03T16:45:09+00:00weekly0.7https://www.analysisgroup.com/about/locations/menlo-park/2025-12-09T19:28:16+00:00weekly0.5https://www.analysisgroup.com/about/locations/washington-dc/2025-12-09T19:25:33+00:00weekly0.7https://www.analysisgroup.com/about/locations/new-york/2025-12-09T19:29:12+00:00weekly0.7https://www.analysisgroup.com/about/locations/san-francisco/2024-01-11T10:36:17+00:00weekly0.7https://www.analysisgroup.com/about/locations/beijing/2025-09-04T18:23:35+00:00weekly0.7https://www.analysisgroup.com/about/locations/montreal/2025-08-29T14:50:53+00:00weekly0.7https://www.analysisgroup.com/about/locations/london/2025-02-21T21:22:59+00:00weekly0.7https://www.analysisgroup.com/about/locations/brussels/2025-12-09T19:32:51+00:00weekly0.7https://www.analysisgroup.com/about/locations/paris/2025-03-26T17:46:42+00:00weekly0.7https://www.analysisgroup.com/about/locations/toronto/2025-03-26T17:47:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/webinar--new-landscape-in-ip-damages-discussed-by-vice-president-andrew-clarke/2024-01-11T10:40:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-paul-hibbard-to-join-roundtable-on-electricity-wholesale-market-design/2024-01-11T10:40:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-sponsors-and-presents-at-annual-uscanada-energy-conference/2024-01-11T10:41:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-to-sponsor-and-present-at-new-england-energy-summit/2024-01-11T10:41:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-john-jarosz-to-co-chair-patent-and-trade-secret-remedies-summit/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-platinum-sponsor-of-nysba-antitrust-law-section-annual-meeting/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-juliette-caminade-and-affiliate-christopher-knittel-to-join-aba-webinar-on-self-preferencing-in-digital-platforms/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-to-sponsor-energy-bar-associations-western-chapter-annual-meeting/2024-01-11T10:42:53+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-christopher-llop-to-moderate-digital-innovation-panel-at-the-2023-mit-sloan-healthcare-and-bioinnovations-conference/2024-01-11T10:42:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/first-2023-law-and-economics-symposium-to-discuss-antitrust-in-life-sciences-and-pharmaceuticals/2025-01-07T22:04:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-susan-tierney-to-join-panel-at-new-england-electricity-restructuring-roundtable/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-steve-allen-to-join-transfer-pricing-controversy--litigation-trends-panel-at-tp-minds-americas-2023/2024-01-11T10:42:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jeffrey-kinrich-to-join-panel-at-2023-intellectual-property-institute/2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-yao-lu-to-chair-session-at-the-21st-annual-international-industrial-organization-conference/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-abstract-to-be-featured-as-a-lecture-presentation-at-digestive-disease-week/2026-02-19T17:09:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-and-chief-epidemiologist-dr-mei-sheng-duh-to-join-panel-at-the-annual-milken-institute-global-conference/2024-01-11T10:43:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-samuel-weglein-to-join-aba-webinar-on-app-distribution-and-related-antitrust-considerations/2024-01-11T10:43:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-heor-consultants-to-present-at-ispor-2023/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-joshua-white-to-join-a-panel-at-concurrences-fourth-international-mergers-conference/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-rene-befurt-to-moderate-webinar-on-litigation-around-dark-patterns-in-consent-and-cancellation-processes/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/affiliate-david-c-chan-jr-to-receive-ashecon-medal-at-ashecon-2023/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-to-sponsor-and-participate-in-the-57th-annual-conference-of-the-canadian-economics-association/2026-03-25T14:54:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-affiliates-to-join-aba-panel-on-the-role-of-marketing-experts-in-litigation-moderated-by-manager-kate-schofield-and-organized-by-vice-president-anne-catherine-faye/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/2023-asco-annual-meeting-to-feature-new-outcomes-research-from-analysis-group/2025-02-28T21:54:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-maria-garibotti-to-join-aba-panel-on-two-sided-platforms/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-join-panel-on-cartel-enforcement-in-labor-markets-at-gcr-live-cartels-2023/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-ishita-rajani-to-join-aba-webinar-on-information-sharing-in-the-current-antitrust-landscape/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-to-speak-at-concurrences-new-frontiers-of-antitrust-conference/2024-01-11T10:43:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-rebecca-kirk-fair-to-join-aba-webinar-on-the-pros-and-cons-of-the-us-federal-trade-commissions-proposed-rule-on-non-compete-clauses/2024-01-11T10:43:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-maria-garibotti-to-join-antitrust-and-sports-panel-at-the-first-women-in-antitrust-annual-event/2024-03-28T14:04:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-health-care-consultants-to-present-at-icpe-2023/2025-07-03T15:26:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principals-rebecca-kirk-fair-and-dov-rothman-to-speak-at-aba-antitrust-law-sections-2023-antitrust-merger-guidelines-workshop/2024-01-11T10:43:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-todd-schatzki-to-join-panel-at-the-renewable-energy-markets-2023-conference/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-lisa-pinheiro-to-join-panel-at-lear-competition-festival-2023/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/research-from-analysis-groups-heor-epidemiology-market-access-practice-to-be-featured-at-amcp-nexus-meeting/2024-01-11T10:43:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-join-panel-at-the-new-york-state-bar-associations-department-of-justice-criminal-antitrust-enforcement-program/2024-01-11T10:43:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-anne-catherine-faye-and-new-managing-principal-judy-chang-to-speak-at-aba-antitrust-law-sections-2023-antitrust-and-sustainability-conference/2024-07-12T19:13:54+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-to-join-panel-at-gcr-live-global-merger-control-2023-conference/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-paul-hibbard-to-moderate-panel-at-necbcs-31st-annual-us-canada-executive-energy-conference/2024-01-11T10:43:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-heor-consultants-to-present-at-ispor-europe-2023/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-susan-tierney-to-join-panel-at-fercs-2023-annual-reliability-technical-conference/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-join-panel-at-concurrences-global-antitrust-economics-conference/2024-01-11T10:43:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-marissa-ginn-to-join-cba-and-aba-webinar-on-gender-and-competition/2024-01-11T10:43:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-ishita-rajani-to-moderate-aba-webinar-on-auto-repair-in-the-age-of-telematics/2023-12-18T16:43:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-anne-catherine-faye-to-join-panel-at-nysba-antitrust-law-section-annual-meeting/2024-01-08T16:52:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-and-chief-epidemiologist-dr.-mei-sheng-duh-to-join-panel-at-precision-medicine-world-conference-20242024-01-22T17:36:04+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-anne-catherine-faye-to-speak-at-aba-antitrust-law-sections-2024-next-generation-of-antitrust-data-privacy-and-data-protection-scholars-conference/2024-01-23T14:00:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-kristof-zetenyi-to-join-nycba-merger-guidelines-webinar/2024-02-02T17:42:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-anne-catherine-faye-to-co-chair-2024-sustainability-and-competition-law-conference/2024-02-05T17:27:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-philipp-tillmann-to-moderate-aba-webinar-on-private-enforcement-and-collective-redress-in-europe/2024-02-07T21:00:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-lynn-huynh-to-moderate-clinical-trial-panel-at-2024-mit-sloan-healthcare-and-bioinnovations-conference/2024-02-20T16:47:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/next-law--economics-symposium-to-convene-on-tools-for-assessing-risk-and-value-in-pharmaceutical-and-biotech-investment/2024-02-20T20:12:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/manager-kale-kponee-shovein-to-join-panel-on-addressing-the-double-disease-burden-in-africa-at-harvard-chan-2024-africa-health-conference/2024-02-22T18:43:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-marissa-ginn-to-join-panel-of-judges-at-adam-f-fanaki-competition-law-moot/2024-03-06T16:26:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-to-join-panels-at-aba-antitrust-law-spring-meeting2/2024-03-07T15:19:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-todd-schatzki-to-join-panel-at-energy-bar-associations-annual-meeting-and-conference/2024-03-26T15:13:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-to-sponsor-2024-whoop-it-up-for-women-comedy-night/2024-04-18T18:15:51+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-heor-consultants-to-present-at-ispor-2024/2024-04-29T20:16:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-maureen-chakraborty-to-join-panel-at-securities-litigation-2024-from-investigation-to-trial/2024-04-26T18:04:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-join-aba-webinar-on-ftcs-non-compete-ban/2024-05-02T14:11:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-josh-white-to-join-a-panel-at-concurrences-fifth-international-mergers-conference/2024-05-13T15:14:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/competition-issues-in-the-asia-pacific-region-and-us-west-coast-to-be-discussed-at-usc-gouldag-global-competition-law-thought-leadership-conference/2024-11-15T17:34:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-to-present-new-outcomes-research-at-2024-asco-annual-meeting/2025-03-04T14:36:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-lauren-hunt-to-moderate-webinar-exploring-regulatory-agencies-increased-focus-on-interlocking-directorates/2024-06-06T14:24:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-to-discuss-new-research-at-ashecon-2024/2024-06-10T21:06:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-joshua-white-to-discuss-emerging-tensions-between-antitrust-law-and-efforts-to-promote-carbon-reductions-in-aba-webinar/2024-06-13T19:56:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-speak-at-women-leaders-in-life-sciences-law-conference/2024-07-10T17:20:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-researchers-to-present-at-ispe-2024/2024-08-19T15:19:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-to-join-panel-on-use-of-event-studies-in-international-arbitration/2024-09-05T15:04:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-maria-garibotti-to-moderate-aba-town-hhall-on-legal-issues-with-ai-in-latin-america/2024-09-04T13:03:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-anne-catherine-faye-to-moderate-panel-on-promoting-competition-while-addressing-esg-concerns/2024-09-09T14:08:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-markus-von-wartburg-to-join-panel-on-structural-presumptions-at-cbas-competition-law-fall-conference/2024-09-24T19:26:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/amcp-nexus-meeting-to-feature-research-from-analysis-groups-heor-epidemiology-market-access-practice/2024-09-27T17:51:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jee-yeon-lehmann-to-join-aba-webinar-discussing-the-ftcs-renewed-focus-on-price-discrimination/2024-10-16T19:09:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-to-join-digital-markets-panel-at-concurrences-new-frontiers-of-antitrust-conference/2024-10-08T13:47:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-chris-feige-to-discuss-securities-class-actions-at-annual-symposium/2024-10-17T16:05:49+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-affiliate-simon-blanchard-to-discuss-disclosure-issues-in-the-age-of-ai-and-apis/2024-10-16T13:17:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-presidents-juliette-caminade-and-hitesh-makhija-to-participate-in-2024-golden-state-antitrust-unfair-competition-law-institute/2026-02-18T19:56:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-paul-hibbard-to-moderate-ceo-roundtable-at-us-canada-executive-energy-conference/2024-10-28T14:48:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultant-shannon-seitz-to-discuss-non-competes-in-the-us-at-concurrences-global-antitrust-economics-conference/2024-10-30T15:21:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-ishita-rajani-to-join-panel-on-jobs-outside-of-academia-at-neudc-2024-conference/2024-11-01T16:32:04+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-joshua-white-to-join-panel-on-the-future-of-competition-law-in-pharma-and-tech-at-aba-conference/2024-11-05T18:33:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-heor-consultants-to-present-at-ispor-europe-2024/2024-11-07T14:54:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-catherine-alford-to-discuss-antitrust-and-trade-associations-at-aba-webinar/2024-12-10T18:34:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-joshua-white-to-join-aba-webinar-on-sustainability-trends-in-merger-reviews/2025-01-13T18:22:40+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-ishita-rajani-to-join-aba-webinar-on-eu-facebook-marketplace-decision/2025-01-27T16:41:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-mark-berberian-to-join-expert-witness-cross-examination-panel-at-young-icca-workshop/2025-01-31T18:39:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-yan-song-to-moderate-data-driven-drug-repurposing-panel-at-mit-sloan-conference/2025-02-14T16:09:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-eric-korman-to-moderate-panel-at-eba-western-chapter-meeting/2025-02-25T17:57:40+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-juliette-caminade-to-moderate-aba-webinar-with-oecd-competition-leaders/2025-02-25T21:34:40+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/lauren-hunt-to-provide-commentary-on-controlling-shareholder-transactions-at-byu-law-conference/2025-03-03T18:14:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-marianne-cunnington-to-speak-at-inaugural-european-summit-for-women-leaders-in-life-sciences-law/2025-03-03T21:18:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-jessica-resch-to-join-analysis-groupsignature-litigation-panel-on-assessing-loss-in-emerging-economies-at-paris-arbitration-week/2025-07-21T17:31:48+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-affiliate-lorraine-eden-and-managing-principal-alan-white-to-present-at-usd-school-of-law-transfer-pricing-innovation-symposium/2025-03-07T20:24:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-rebecca-kirk-fair-to-join-mergers-panel-at-winter-antitrust-conference/2025-03-12T14:02:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-and-affiliates-join-panels-in-2025-aba-antitrust-law-spring-meeting/2025-03-26T20:05:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-to-sponsor-2025-whoop-it-up-for-women-comedy-night/2025-03-28T15:45:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-heor-consultants-to-present-at-ispor-2025/2025-04-11T16:06:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-emily-cotton-to-join-webinar-on-structural-presumption/2025-04-18T13:00:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-david-smith-to-join-nabe-webinar-on-forensic-economics-and-damages-experts/2025-04-18T16:31:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-and-affiliates-to-join-23rd-annual-international-industrial-organization-conference/2025-05-21T17:22:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/aua-annual-meeting-to-feature-new-outcomes-research-from-analysis-group/2025-04-22T13:58:51+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-jimmy-royer-to-join-nabe-webinar-on-ai-in-economic-litigation/2025-04-24T18:51:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-to-join-panels-at-2025-patent-enforcement-virtual-summit/2025-04-25T14:35:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-federico-mantovanelli-to-join-aba-webinar-discussing-recent-developments-in-labor-antitrust/2025-05-01T17:53:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/manager-hailey-nguyen-to-present-paper-on-controlling-stockholder-induced-depression-at-aleas-annual-meeting/2025-05-02T19:27:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-jane-choi-to-moderate-aba-panel-on-2025-updates-to-competition-in-the-eu-uk-and-us/2025-05-05T13:24:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-lisa-pinheiro-to-join-panel-at-cryptocurrency-conference/2025-05-08T17:40:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-jessica-resch-to-join-scenario-analysis-panel-at-gar-live/2025-05-14T14:56:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-to-join-trial-training-program/2025-05-19T15:51:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/global-competition-law-conference-to-feature-analysis-group-consultants-and-affiliates/2025-05-20T17:40:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-affiliate-anthony-t-losasso-to-receive-distinguished-service-award-at-ashecon-2025/2025-05-22T14:05:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/at-2025-asco-annual-meeting-analysis-group-to-present-new-outcomes/2026-02-17T22:40:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-marissa-ginn-and-vice-president-nick-dadson-to-lead-panels-at-cea-2025/2025-05-23T20:44:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/chairman-martha-samuelson-to-moderate-aba-webinar-on-industrial-policy-strategies-and-implications/2025-07-08T20:08:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-mei-sheng-duh-to-speak-on-rwe-panel-at-bio-international-convention/2025-06-05T16:51:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-andree-anne-fournier-to-moderate-panel-on-evolving-enforcement-risks-in-life-sciences/2025-07-02T13:35:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/ispe-2025-to-feature-analysis-group-research/2025-08-07T13:05:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/manager-olga-kozlova-guglielmi-to-moderate-aba-panel-on-the-role-of-innovation-in-merger-control-in-technology-markets/2025-08-19T14:38:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-antoine-chapsal-to-speak-on-competition-and-investment-panel-at-new-frontiers-of-antitrust-conference/2025-08-27T14:08:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-paul-hibbard-to-discuss-energy-resource-and-demand-issues-in-new-england/2025-09-04T13:37:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-to-present-on-real-world-evidence-and-ai-applications-at-ispor-rwe-summit/2025-09-05T13:43:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-laura-olaughlin-to-join-panel-on-drip-pricing-and-behavioral-economics/2025-09-15T15:09:48+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-yuan-tian-to-discuss-seps-and-5g-at-northwestern-empirical-research-conference-research-on-standardization/2026-03-19T19:10:49+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-michael-carson-to-join-panel-on-using-experts-in-life-sciences-patent-litigation/2025-10-07T14:11:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-joshua-white-to-discuss-competition-and-growth-at-merger-control-forum/2025-10-08T14:27:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-nori-mehta-to-join-panel-on-drug-pricing/2025-10-08T16:53:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/competition-expert-pierre-regibeau-to-join-panel-at-gcr-live-global-merger-control/2025-10-15T19:31:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-kris-comeaux-to-moderate-panel-on-arbitration-clauses-in-class-actions-and-the-rise-of-mass-arbitration/2025-10-16T14:39:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-heor-consultants-to-present-at-ispor-europe-2025/2025-10-17T13:37:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-presidents-mark-berberian-and-hyun-lee-to-join-crypto-panel-at-seoul-adr-festival/2025-11-10T16:34:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-jessica-resch-to-join-fireside-chat-on-building-a-career-in-arbitration/2025-10-30T16:14:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/manager-cecilia-caliandro-to-join-oecd-roundtable-on-ai-and-innovation/2025-11-04T16:55:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-carletta-wong-to-join-hardtalk-new-york-panel-on-damages-in-arbitration/2025-11-10T19:33:53+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-paul-hibbard-to-moderate-fireside-chat-at-us-canada-executive-energy-conference/2025-11-11T14:02:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/senior-advisor-susan-tierney-to-discuss-energy-resources-and-the-pursuit-of-clean-energy-in-new-england/2025-11-12T16:30:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-hristina-bojadzieva-bartlett-and-affiliated-expert-keri-pearlson-to-join-panel-during-new-york-arbitration-week/2025-11-14T21:14:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/affiliate-emma-frejinger-to-lead-aba-webinar-on-ai-and-antitrust-moderated-by-manager-timothy-j-spittle/2025-11-19T19:20:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-joshua-white-to-join-panel-on-the-implications-of-teva-and-vifor/2025-11-20T14:23:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-ishita-rajani-to-moderate-aba-webinar-on-cartel-enforcement-in-australia-and-new-zealand/2025-11-25T14:10:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-cyril-hariton-to-discuss-competition-in-digital-platforms-and-essential-technologies/2025-12-08T18:04:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-to-join-panels-at-nabe-econ-law-summit/2026-01-05T15:42:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-todd-schatzki-to-discuss-drivers-of-rising-electricity-costs-at-neca-power-markets-conference/2026-01-09T18:56:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-juliette-caminade-to-join-session-at-uscaba-next-generation-of-antitrust-scholars-conference/2026-01-12T17:20:59+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-lisa-pinheiro-to-lead-webinar-on-the-use-of-genai-in-litigation-and-expert-work/2026-01-14T18:53:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/manager-timothy-spittle-to-join-ai-panel-at-georgetown-university-and-world-bank-conference/2026-01-15T19:22:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-lauren-hunt-to-join-panel-on-private-equity-at-byu-law-conference/2026-01-27T20:20:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-managing-principal-mei-sheng-duh-to-speak-at-scope-summit-2026/2026-01-29T18:50:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/principal-juliette-caminade-to-moderate-aba-webinar-on-ai-foundation-models-and-llms/2026-02-04T19:45:49+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-maria-e-garibotti-to-moderate-aba-webinar-on-airline-antitrust/2026-02-17T17:27:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/vice-president-priyanka-bobbili-to-moderate-panel-on-the-next-frontier-of-cardiovascular-innovation/2026-02-20T19:04:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-to-present-heor-research-at-asco-genitourinary-cancers-symposium/2026-03-09T20:03:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/managing-principal-jeff-kinrich-to-join-panel-on-patent-damages-at-usc-ip-institute/2026-03-05T15:58:59+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-principal-juliette-caminade-to-speak-at-antitrust-conference/2026-03-06T17:58:04+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-to-present-on-genai-model-decode-for-asa-webinar/2026-03-09T18:57:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-to-discuss-transfer-pricing-methodologies-at-the-usd-school-of-law-transfer-pricing-innovation-symposium/2026-03-12T17:30:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-experts-to-participate-in-panels-at-the-2026-aba-antitrust-law-spring-meeting/2026-03-13T10:49:49+00:00weekly0.7https://www.analysisgroup.com/news-and-events/events/analysis-group-consultants-to-join-24th-annual-international-industrial-organization-conference/2026-04-01T17:15:48+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/transfer-pricing-expert-steve-allen-joins-analysis-group-as-a-vice-president/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/allergan-wins-summary-judgment-in-securities-fraud-class-action-featuring-expert-reports-from-analysis-group-affiliates/2024-01-11T10:42:51+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/global-competition-review-again-recognizes-analysis-group-among-the-leading-global-economics-consultancies/2025-05-29T13:16:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-survey-gathers-antitrust-practitioner-views-on-us-regulatory-enforcement-trends-in-merger-actions/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/two-papers-coauthored-by-analysis-group-competition-experts-distinguished-with-nominations-for-2023-concurrences-antitrust-writing-awards/2024-01-11T10:42:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/district-court-awards-$0-in-damages-in-trade-secret-and-breach-of-contract-litigation-involving-analysis-group-client-transunion/2024-01-11T10:42:53+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/studies-by-analysis-group-health-care-researchers-recognized-by-the-journal-of-managed-care--specialty-pharmacy/2025-06-30T20:36:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/valuation-testimony-provided-by-analysis-group-in-gramercy-funds-managements-successful-securities-based-international-arbitration-claim/2026-02-05T21:33:47+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/federal-judge-grants-analysis-group-clients-motion-for-summary-judgment-in-panama-electrical-grid-litigation/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-explore-changes-in-grocery-retail-merger-assessment-following-covid-19-pandemic/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-ranked-in-top-10-of-vaults-best-places-to-work/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-michael-schreck-testifies-on-secondary-meaning-in-trademark-infringement-itc-hearing/2024-01-11T10:42:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/amcp-2023-conference-to-feature-new-outcomes-research-from-analysis-group/2026-02-19T20:37:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/paper-on-societal-value-of-covid-19-vaccines-coauthored-by-analysis-group-researchers-earns-top-5-ranking-from-the-journal-of-medical-economics/2024-01-11T10:42:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-clients-gsk-and-teva-win-multiple-class-certification-rulings-in-pharmaceutical-suit/2024-01-11T10:42:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/energy-economists-at-analysis-group-release-independent-study-of-economic-and-environmental-benefits-of-seabrook-nuclear-power-plant/2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/pharmaceutical-manufacturers-win-multiple-class-certification-rulings-in-federal-antitrust-suit-with-support-from-analysis-group-senior-advisor-bruce-strombom/2025-01-28T20:29:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-to-present-at-aba-antitrust-law-spring-meeting2/2024-01-11T10:42:59+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/two-analysis-group-studies-named-editors-choice-by-the-journal-of-medical-economics-and-journal-of-clinical-pathways/2025-12-19T15:25:47+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-webinar-exploring-antitrust-issues-in-the-gig-economy-summarized-by-analysis-groups-nandita-krishnaswamy-and-juliette-thibaud/2025-12-01T14:10:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-win-2023-antitrust-writing-award-for-best-business-article-in-economics/2024-01-11T10:42:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/pro-bono-team-helps-measure-impact-of-shannon-trusts-reading-programs-for-incarcerated-people/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-affiliate-consults-to-new-jersey-in-successful-settlement-of-consumer-fraud-case/2024-01-11T10:43:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-successful-defense-of-challenged-meta-within-unlimited-merger/2024-01-11T10:43:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-coauthors-study-assessing-prevalence-and-incidence-of-alopecia-in-us/2024-01-11T10:43:40+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/challenges-of-detecting-chatgpt-4-discussed-in-law360-article-by-analysis-group-ai-experts/2024-01-11T10:43:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-recognized-by-global-competition-reviews-2023-awards-for-economic-analysis-in-antitrust-litigation/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/american-academy-of-arts-and-sciences-elects-academic-affiliate-amitabh-chandra/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-juliette-caminade-testifies-on-competitive-impacts-of-scope-of-work-restrictions-applied-by-licensing-boards/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/supported-by-analysis-group-accounting-expert-sec-obtains-consent-orders-in-securities-fraud-suit-against-osiris-therapeutics/2024-01-11T10:43:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-heor-consultants-to-present-at-ispor-2023/2024-01-11T10:43:43+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-pro-bono-team-provides-support-in-settlement-reached-on-behalf-of-homeless-families/2025-12-01T14:08:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-assesses-survey-data-for-report-on-smoking-and-vaping-in-quebec/2025-04-08T18:00:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/concurrences-special-issue-on-no-poach-agreements-features-analysis-group-article-recapping-ftc-panels-on-labor-markets/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/rggi-program-continues-to-deliver-economic-benefits-for-northeast-and-mid-atlantic-states-while-advancing-environmental-justice-priorities-according-to-latest-analysis-group-study/2024-04-18T13:00:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-webinar-exploring-antitrust-concerns-with-digital-self-preferencing-behaviors-summarized-by-analysis-groups-juliette-caminade-and-juan-carvajal/2024-01-11T10:43:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-marianne-cunnington-elected-to-ispe-board/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-examine-accounting-guidelines-following-the-collapse-of-silicon-valley-bank/2024-01-11T10:43:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-mourns-the-passing-of-vice-president-anne-larue/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/scotus-review-provides-analysis-group-authors-opportunity-to-examine-survey-methods-for-assessing-trademark-dilution-in-parody-cases/2024-01-11T10:43:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/patent-experts-from-analysis-group-examine-proposed-competence-center-for-standard-essential-patents-seps-in-europe/2024-11-15T17:24:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authored-article-presents-key-considerations-for-merger-review-in-second-score-auctions/2026-02-05T21:32:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-collaborates-with-william-osler-health-system-and-janssen-to-estimate-cost-savings-to-the-canadian-health-care-system-of-using-NGS-testing-in-mNSCLC/2025-02-28T22:00:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/for-2023-edition-of-top-food-and-drug-cases-analysis-group-authors-explore-greenwashing-class-action-claims-against-food-and-beverage-companies/2024-01-11T10:43:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-announces-senior-level-promotions-and-lateral-hires/2026-02-27T16:31:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/report-on-electrification-of-us-heavy-duty-vehicle-fleet-explores-impact-on-electric-utilities-provides-key-takeaways-for-meeting-emission-reduction-goals/2024-04-18T13:01:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-coauthors-study-on-health-care-resource-utilization-and-costs-in-us-patients-with-gerd-barretts-esophagus-and-barretts-esophagus-related-neoplasia/2024-01-11T10:43:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-joshua-white-outlines-critical-considerations-for-pharmaceutical-industry-mergers-at-concurrences-event/2024-01-11T10:43:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/minnesota-state-court-cites-expert-report-and-testimony-of-analysis-group-expert-in-fiduciary-duty-litigation/2024-01-11T10:43:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-economists-again-recognized-as-top-intellectual-property-experts/2026-02-17T19:02:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-assess-clinical-benefits-of-early-initiation-of-long-acting-injectable-antipsychotics-in-patients-with-schizophrenia/2025-02-28T21:59:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-ipwatchdog-article-analysis-group-consultants-detail-use-of-third-party-surveys-in-litigation/2026-02-05T20:39:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-testifies-before-senate-committee-on-impacts-of-climate-change-on-energy-infrastructure/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/summary-judgment-awarded-to-analysis-group-client-in-breach-of-contract-litigation/2025-01-07T22:13:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/antitrust-bulletin-publishes-analysis-group-paper-outlining-alternative-methodology-for-geographic-market-definition-in-health-care-markets/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/dr-anupam-b-jena-an-analysis-group-affiliate-provides-testimony-in-gilead-sciences-successful-defense-of-pay-for-delay-allegations-of-hiv-treatments/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/report-by-senior-advisor-susan-tierney-details-changes-in-coal-fired-power-production-in-the-us/2024-01-11T10:43:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/abas-price-point-publishes-article-with-analysis-group-coauthors-offering-a-practical-guide-to-implementing-the-as-efficient-competitor-aec-test/2026-02-18T20:03:12+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-webinar-exploring-antitrust-considerations-surrounding-app-distribution-summarized-by-analysis-groups-yeseul-hyun-and-lolo-palacios/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-expert-supports-yale-universitys-successful-retirement-plan-defense-in-rare-erisa-jury-trial/2026-01-08T14:08:47+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/study-coauthored-by-analysis-group-authors-explores-impacts-of-californias-surprise-billing-law-on-the-cost-of-anesthesia-care/2024-01-11T10:43:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/ferc-accepts-analysis-group-recommendations-for-revisions-of-inventoried-energy-program-parameters/2024-01-11T10:43:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-client-amazon-canada-defeats-class-certification-in-an-action-brought-by-delivery-drivers/2024-01-11T10:43:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-contribute-to-competition-policy-book/2024-01-11T10:43:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/principal-paul-hibbard-publishes-analysis-of-impact-of-retail-choice-in-the-us-electricity-sector/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/david-j-hutchings-expert-in-economics-and-finance-joins-analysis-group-as-managing-principal/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/electric-utilities-require-regulatory-innovation-capital-investment-to-enable-massachusetts-to-meet-ghg-emission-reduction-targets-according-to-analysis-group-white-paper/2026-03-05T14:54:49+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-research-on-gender-considerations-in-antitrust-analyses-published-in-antitrust-report-and-included-in-oecd-toolkit/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/icpe-2023-featured-presentations-from-analysis-group-consultants/2024-01-11T10:43:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-vice-president-anne-catherine-faye-interviewed-on-our-curious-amalgam-american-bar-association-podcast/2024-01-11T10:43:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/summary-judgment-granted-to-analysis-group-client-in-sec-ponzi-scheme-litigation/2024-01-11T10:36:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-law360-analysis-group-authors-discussed-gender-considerations-in-competition-policy/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/energy-experts-susan-tierney-and-paul-hibbard-contribute-op-ed-on-investment-needed-in-massachusetts-power-grid-to-support-clean-energy-transition/2024-01-11T10:43:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-medical-and-economics-experts-testify-in-celgenes-successful-defense-against-claims-involving-off-label-prescriptions-for-cancer-treatments/2024-01-11T10:43:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/paper-on-asthma-therapy-adherence-and-persistence-coauthored-by-analysis-group-researchers-recognized-by-the-journal-of-allergy-and-clinical-immunology-in-practice/2024-01-11T10:43:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-and-affiliates-contribute-scholarship-to-volume-on-marketing-and-the-law/2025-12-01T14:03:59+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/heor-and-epidemiology-research-from-analysis-group-featured-at-amcp-nexus-meeting/2026-03-03T14:25:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/national-academies-report-on-overcoming-barriers-to-decarbonizing-the-us-coauthored-by-analysis-group-senior-advisor-susan-f-tierney/2024-01-11T10:43:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-webinar-exploring-dark-patterns-summarized-by-analysis-groups-rene-befurt-and-helene-rowland/2024-01-11T10:43:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-rebecca-kirk-fair-discusses-non-competes-on-aba-antitrust-law-section-panel/2024-01-11T10:43:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-explore-the-convergence-of-antitrust-and-sustainability-at-aba-conference/2024-07-12T19:15:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-update-chapter-on-economic-analysis-of-merger-remedies-in-the-fifth-edition-of-global-competition-reviews-merger-remedies-guide/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-again-recognized-as-the-top-women-led-consulting-firm-in-massachusetts/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/epas-proposed-emissions-regulation-will-not-threaten-electric-system-reliability-if-risks-are-addressed-appropriately-according-to-senior-advisor-susan-tierney-in-independent-study/2024-01-11T10:43:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-client-in-securities-fraud-litigation-reaches-settlement/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-the-transition-to-a-decarbonized-economy-nyiso-will-need-to-continue-to-closely-monitor-fuel-and-energy-security-during-cold-winter-conditions-according-to-new-study-by-analysis-group-energy-experts/2026-03-05T14:56:12+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/at-international-aids-society-ias-conference-gheskio-presents-mobile-app-designed-with-analysis-group-to-monitor-patient-visits/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-addresses-electric-system-reliability-concerns-about-epas-proposed-greenhouse-gas-emissions-regulation-at-ferc-conference/2024-01-11T10:43:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-welcomes-new-affiliates-and-announces-senior-level-promotions-and-lateral-hires/2024-07-12T19:18:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-stephen-fink-assesses-pharmaceutical-antitrust-litigation-a-decade-after-us-supreme-courts-actavis-decision/2024-01-11T10:43:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-josh-white-hosts-fireside-chat-and-panel-at-gcr-analysis-group-competition-and-sustainability-2023/2024-01-11T10:43:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-sponsors-38th-annual-meeting-of-the-canadian-econometrics-study-group-and-awards-research-prize/2026-03-25T14:55:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/jury-adopts-analysis-group-principal-robert-vigils-damages-assessment-in-patent-dispute/2024-01-11T10:43:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-to-contribute-18-new-outcomes-research-presentations-at-65th-american-society-of-hematology-annual-meeting-and-exposition/2026-03-30T19:28:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-heor-consultants-present-at-ispor-europe-2023/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/critical-considerations-for-analyses-of-anticompetitive-effects-outlined-by-managing-principal-antoine-chapsal-at-concurrences-conference/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-coauthors-explore-novel-method-for-assessing-real-world-data-on-longitudinal-patient-reported-outcomes/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-lisa-pinheiro-speaks-on-the-role-of-collaboration-in-promoting-esg-goals-at-responsible-investor-usa-2023-conference/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/affiliated-expert-roberts-brokaw-testifies-for-the-irs-in-a-tax-liability-dispute/2024-03-12T14:38:53+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/small--and-medium-sized-businesses-can-drive-growth-through-use-of-third-party-facilitators-according-to-report-by-analysis-group-experts/2024-02-07T16:34:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/antitrust-report-article-authored-by-analysis-group-vice-presidents-discusses-the-as-efficient-competitor-aec-test-explores-antitrust-risk-implications-for-us-courts-and-firms/2026-02-18T20:02:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/article-by-analysis-group-consultants-in-aba-publication-evaluates-merger-review-under-the-biden-administration/2023-12-21T20:46:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-gcrs-digital-markets-guide-analysis-group-authors-contribute-chapter-on-merger-enforcement-in-the-context-of-multi-sided-platforms/2024-11-15T17:32:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-vice-president-philipp-tillmann-publishes-aba-article-summarizing-debate-over-the-role-of-economic-expert-reports-in-german-antitrust-proceedings/2024-01-02T16:42:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/academic-affiliate-joel-steckel-coauthors-trademark-reporter-article-on-addressing-uncertainty-in-survey-responses/2024-01-04T18:15:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/article-coauthored-by-analysis-group-manager-explores-benefits-and-costs-of-wind-production-in-spanish-electricity-market/2024-01-05T16:04:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-vice-president-elyse-swallow-elected-to-the-board-of-ispor-boston/2025-07-24T19:55:40+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-congratulates-authors-of-four-articles-distinguished-with-nominations-for-2024-concurrences-antitrust-writing-awards/2024-11-15T17:32:54+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-study-evaluates-potential-impacts-of-capacity-market-design-changes-for-evolving-energy-grid-in-new-england-region/2024-01-17T14:28:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-analyze-conflicting-conclusions-on-aspartame-safety-in-fdli-article/2024-01-17T15:59:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-named-among-most-highly-regarded-thought-leaders-recommended-experts-and-economists-by-whos-who-legal/2024-01-31T21:41:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-publishes-report-examining-how-vertically-integrated-utilities-could-maximize-return-on-federal-funding-opportunities/2024-01-24T15:40:48+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-heor-research-presented-at-asco-genitourinary-cancers-symposium/2024-04-04T17:51:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/judge-confirms-analysis-group-vice-president-jonathan-borcks-damages-assessment-in-oakland-bulk-oversized-terminal-llc-v-city-of-oakland/2024-01-31T15:38:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/research-by-analysis-group-on-classifying-melanoma-stage-in-a-medicare-population-earns-highest-honor-from-amcp-2024/2024-02-01T18:51:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/non-price-effects-of-mergers-scrutinized-by-analysis-group-consultants/2024-02-12T21:08:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/gcr-antitrust-awards-2024-analysis-group-case-work-and-academic-affiliate-anupam-jena-nominated-for-multiple-competition-awards/2026-02-23T18:11:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-affiliate-opines-on-pushdown-accounting-in-support-of-prevailing-plaintiff-in-contract-dispute-in-transportation-industry/2024-02-29T20:55:32+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-provides-recommendations-for-achieving-net-zero-emissions-in-electrify-this-podcast/2024-02-09T15:11:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-apply-a-scientific-and-drug-development-lens-to-evaluating-killer-acquisition-theories-of-harm-in-biotech-deals/2024-02-12T20:04:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-dr.-mei-sheng-duh-invited-to-speak-at-colloquium-seminar-series-at-harvard-t.h.-chan-school-of-public-health2024-02-14T18:29:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/guide-to-biotech-asset-valuation-methods-coauthored-by-academic-affiliate-amitabh-chandra-and-vice-president-sumon-mazumdar/2024-02-23T17:36:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/studies-by-analysis-group-consultants-among-2023s-most-cited-articles-of-the-journal-of-managed-care-specialty-pharmacy/2024-03-05T21:16:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-expert-testimony-supports-doj-win-in-tax-shelter-case/2025-05-13T21:08:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/senior-advisor-susan-tierney-explores-how-to-accelerate-decarbonization-in-the-energy-transition-show-podcast/2024-03-04T14:41:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/ceo-and-chairman-martha-samuelson-joins-aba-webinar-on-the-meaning-and-impact-of-brown-shoe/2024-03-05T14:30:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-kristof-zetenyi-and-associate-dheeraj-chaudhary-coauthor-article-on-data-in-the-digital-economy-for-cpi-antitrust-chronicle/2025-09-22T19:59:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-to-participate-in-panels-at-2024-aba-antitrust-law-spring-meeting/2026-02-02T14:10:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-webinar-exploring-ftcs-antitrust-lawsuit-against-amazon-summarized-by-managers-jane-choi-and-hailey-nguyen/2024-03-12T14:36:48+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-marissa-ginn-joins-panel-on-gender-and-competition-at-apecs-competition-policy-and-law-group-plenary-meeting/2024-03-11T19:08:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/expert-testimony-from-senior-advisor-keith-ugone-helps-cisco-secure-favorable-settlement-in-antitrust-litigation/2026-02-18T20:01:54+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-energy-harbors-successful-merger-with-vistra/2025-02-19T21:26:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/revised-cdc-guideline-on-opioid-prescribing-analyzed-by-analysis-group-authors/2025-03-26T15:00:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/webinar-on-assessing-risk-and-value-in-pharmaceutical-and-biotech-investment-hosted-by-analysis-group/2024-03-25T13:37:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-joins-new-york-international-arbitration-center-roundtable-discussion-on-event-studies/2024-03-27T15:37:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-webinar-on-right-to-repair-laws-summarized-by-analysis-group-consultants/2024-05-16T17:49:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-announces-senior-level-promotions/2026-02-05T21:32:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-anne-catherine-faye-discusses-the-intersection-between-competition-law-and-sustainability-on-the-competitive-edge-podcast/2024-04-08T19:53:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/pair-of-digital-health-research-papers-coauthored-by-analysis-group-demonstrate-promises-of-wearables-to-generate-reliable-site-less-patient-reported-outcomes-in-rheumatoid-arthritis/2024-04-09T13:19:54+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-win-three-2024-concurrences-antitrust-writing-awards/2024-04-10T13:07:53+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-analyze-public-comments-on-non-compete-ban-in-antitrust-magazine-article/2024-04-10T16:49:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/study-by-analysis-group-consultants-examines-potential-economic-impact-of-legalizing-igaming/2024-04-15T21:12:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/amcp-2024-conference-to-feature-new-outcomes-research-from-analysis-group/2026-03-30T19:27:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/race-and-socioeconomic-treatment-disparities-among-metastatic-castration-sensitive-prostate-cancer-patients-identified-in-study-coauthored-by-analysis-group-researchers/2024-04-22T14:35:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-impinj-in-a-series-of-patent-infringement-litigation-victories/2024-04-17T15:35:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-collision-communications-in-its-successful-breach-of-contract-litigation/2024-04-18T15:04:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/availability-of-modified-cell-therapy-found-to-reduce-health-care-disparities-among-blood-cancer-patients-across-racial-and-ethnic-minority-groups-in-analysis-group-study/2026-02-10T19:17:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-summarize-aba-webinar-on-drip-pricing-and-junk-fees/2026-02-23T18:12:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/principal-eric-korman-appointed-to-energy-bar-associations-board-of-directors/2024-05-02T14:30:32+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/growth-assumptions-in-valuation-models-explored-by-analysis-group-authors-in-aba-publication/2024-05-09T17:38:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-webinar-on-developing-effective-ai-compliance-programs-summarized-by-analysis-group-consultants/2024-05-14T19:40:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-coauthor-article-on-the-role-of-economic-experts-in-criminal-antitrust-litigation-for-cpi-antitrust-chronicle/2024-05-15T20:25:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-john-jarosz-testifies-in-34-million-patent-win-for-analysis-group-client-sight-sciences/2024-05-16T19:35:40+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-develop-a-novel-framework-to-help-clinicians-predict-the-likelihood-of-antibiotic-resistant-bacteria-in-patients-with-uncomplicated-urinary-tract-infections/2024-05-22T13:00:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-pro-bono-team-presents-on-community-wastewater-monitoring-project-at-chelsea-research-festival/2024-05-23T13:32:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-pro-bono-testimony-supports-petconnect-rescues-win-in-trademark-infringement-trial/2026-03-23T15:50:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-lauren-kindler-testifies-in-rokus-successful-patent-infringement-case/2024-05-29T13:40:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/flagship-accounting-conference-renamed-for-analysis-group-academic-affiliate-ray-ball/2024-05-31T13:09:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-kristof-zetenyi-moderates-panel-on-improving-expert-witness-testimony-at-2024-aba-antitrust-law-spring-meeting/2026-02-02T14:09:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-identify-novel-approach-for-assessing-real-world-treatment-effectiveness-in-patients-with-ibs-d/2026-02-19T17:14:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-coauthor-first-large-scale-us-study-on-incidence-of-pneumococcal-disease-in-children-02-years-old/2024-06-06T13:01:34+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/fifteen-analysis-group-consultants-recognized-as-top-economic-experts-in-intellectual-property/2026-02-17T18:58:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-markus-von-wartburg-returns-to-analysis-group-following-secondment-with-competition-bureau-of-canada/2024-06-12T13:03:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-identify-neighborhood-characteristics-that-may-predict-psoriasis-in-quebec-canada/2024-06-18T13:00:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-conducts-discrete-choice-experiment-survey-to-quantify-treatment-preferences-in-patients-with-moderate-to-severe-atopic-dermatitis/2024-06-14T13:42:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/for-2024-edition-of-top-food-and-drug-cases-analysis-group-authors-explore-role-of-marketplace-context-in-assessing-reasonable-consumer-interpretations-of-product-labels/2024-11-05T22:16:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-summarize-aba-webinar-exploring-ex-ante-regulation-of-digital-platforms-across-the-globe/2026-03-25T14:58:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-announces-seven-promotions-to-managing-principal-and-principal/2024-06-20T17:02:59+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-explore-ecosystem-theories-of-harm-in-merger-control-in-journal-of-european-competition-law-article/2026-02-27T16:29:54+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-electric-aircraft-companys-trial-win-in-trade-secret-misappropriation-litigation-against-boeing/2024-06-25T19:08:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/discussion-among-analysis-group-vice-presidents-assesses-the-state-of-trade-secret-disputes/2026-02-17T18:59:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-assess-second-circuit-decisions-in-benchmark-manipulation-cases/2024-07-08T14:50:48+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-present-on-offshore-wind-procurement-at-eba-conference/2024-07-12T19:15:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-joshua-white-explores-the-choice-design-and-implementation-of-merger-remedies-at-concurrences-event/2024-07-11T17:56:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-congratulates-judy-chang-on-appointment-as-commissioner-of-federal-energy-regulatory-commission/2024-07-16T13:00:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aba-panel-on-regulating-gatekeepers-and-ecosystems-summarized-by-analysis-group-consultants/2024-07-18T13:56:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-hosts-2024-health-care-and-life-sciences-litigation-practice-day/2024-07-25T15:44:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-anne-catherine-faye-and-colleagues-assess-intersection-of-antitrust-and-sustainability-in-new-aba-article/2024-07-30T14:59:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-coauthors-examine-the-impact-of-in-office-dispensing-services-on-prostate-cancer-patients/2024-08-05T16:59:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/new-method-for-measurement-of-biopharmaceutical-rd-investment-detailed-by-analysis-group-coauthors-in-nature-reviews-drug-discovery-article/2024-11-21T16:36:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-client-republic-of-cyprus-prevails-in-mass-claims-arbitration/2025-11-12T16:50:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/white-paper-by-analysis-group-consultants-details-walmarts-impact-on-us-economy-and-communities/2024-08-16T14:01:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-and-pfizer-present-final-data-on-covid-19-vaccine-safety-surveillance-program-of-us-veterans-health-administration-patients/2025-07-16T13:19:03+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-team-conducts-one-of-first-studies-to-focus-on-clinical-and-economic-burden-of-us-patients-with-multiple-myeloma-and-renal-impairment/2024-08-27T17:01:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-summarize-aba-webinar-on-the-ftcs-non-compete-ban/2024-08-27T19:29:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/factors-contributing-to-delays-in-blood-thinner-prescriptions-identified-in-analysis-group-study/2024-09-10T17:27:32+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/contribution-of-hyperkalemia-to-risks-of-ckd-progression-and-mortality-explored-in-analysis-group-coauthored-study/2026-03-03T14:05:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/supported-by-analysis-group-energy-traders-reach-favorable-settlement-in-california-gasoline-pricefixing-litigations/2024-10-08T21:31:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-kristof-zetenyi-and-manager-thomas-beckford-examine-logit-demand-model-in-competition-policy-international-article/2024-12-31T21:20:32+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/a-pricing-tool-for-the-masses-analysis-group-authors-explore-the-use-of-llms-for-pricing-design-in-law360-article/2025-04-07T20:32:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-provides-support-for-ranbaxy-and-pfizer-in-defeat-of-lipitor-reverse-payment-litigation/2025-02-20T20:32:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-white-paper-explores-offshore-wind-solicitations-and-procurements-recommends-ideas-for-future-success/2024-09-20T19:48:40+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-publish-report-on-the-impact-of-immigration-on-the-us-economy/2024-09-30T13:20:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/-130-million-award-to-analysis-groups-biopharmaceutical-client-in-breach-of-contract-ruling/2024-10-22T17:25:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-anne-cai-a-panelist-at-california-asian-pacific-american-bar-association-annual-conference/2024-10-07T16:34:33+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-clients-prevail-in-major-publishing-copyright-case/2024-10-08T14:22:49+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-coauthors-explore-economic-aspects-of-biosimilar-entry-in-aba-newsletter/2024-10-24T20:04:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/principal-emmanuel-frot-joins-panel-on-defining-relevant-markets-at-2024-lear-competition-festival/2024-10-14T14:02:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-consumer-financial-protection-bureau-in-navient-case-settlement/2024-11-20T21:53:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-discuss-immigration-report-with-econofact-podcast/2024-10-28T17:35:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/ag-researchers-collaborate-on-investigation-of-novel-therapies-for-rare-autoimmune-disorder/2024-10-29T13:37:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/comparative-efficacy-and-safety-of-anticancer-medication-assessed-by-analysis-group-researchers/2024-10-29T17:12:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-white-paper-explores-market-impacts-of-energy-co-location/2024-10-31T13:15:32+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-partners-highlight-innovative-management-one-firm-framework-at-mit-sloan-event/2024-11-04T19:55:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-coauthor-study-to-quantify-economic-burden-of-cancer-patients-who-relapse-or-are-refractory-to-a-common-targeted-therapy/2024-11-04T17:35:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-summarize-aba-webinar-on-the-regulation-of-interlocking-directorates/2024-11-05T17:28:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-explore-the-future-of-eu-merger-review-policy/2024-11-06T14:59:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/bankruptcy-judge-rules-real-estate-firm-a-ponzi-scheme-after-testimony-by-analysis-group-managing-principal-jeffrey-kinrich/2024-11-07T15:29:54+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-summer-program-in-top-10-of-vaults-best-consulting-internships/2024-11-11T14:09:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/annual-canadian-econometrics-study-group-conference-and-research-prize-sponsored-by-analysis-group/2025-04-08T20:05:11+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/reports-by-managing-principal-john-jarosz-cited-in-grant-of-preliminary-injunction-in-patent-infringement-case/2024-11-12T17:53:49+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-former-unisys-employees-in-successful-litigation-over-legal-fees/2024-11-13T14:31:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/affiliates-peter-tufano-and-christianna-wood-speak-on-esg-disclosures-and-business-collaborations-to-address-climate-change-at-analysis-group-events/2024-11-14T17:40:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/academic-affiliate-sabrina-howell-opines-on-ftxs-digital-asset-values-in-chapter-11-case/2024-11-20T17:40:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-announces-senior-level-promotions-and-welcomes-new-affiliates/2025-04-07T20:31:54+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/article-coauthored-by-analysis-group-vice-president-mickey-ferri-explores-when-how-and-why-to-adjust-license-royalties-for-inflation-in-determining-reasonable-royalty-damages/2024-11-21T14:37:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-recognized-as-2024-top-women-led-consulting-firm-in-massachusetts/2024-11-21T20:10:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/economic-implications-of-health-care-pricing-transparency-regulations-explored-by-analysis-group-coauthors/2024-11-25T14:47:51+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-affiliate-simon-blanchard-explores-data-privacy-considerations-in-cba-webinar/2024-12-04T19:25:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/consultants-present-on-malignancies-cell-disorders-and-more-at-66th-ash-annual-meeting-and-exposition/2026-03-03T14:06:21+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/citing-testimony-of-two-analysis-group-experts-federal-judge-blocks-high-profile-kroger-albertsons-merger/2024-12-16T19:55:40+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/symposium-held-in-recognition-of-blood-disease-research-platforms-fifth-anniversary/2024-12-19T20:17:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/jury-award-in-trade-secret-case-supported-by-damages-testimony-from-analysis-group-managing-principal-justin-mclean/2024-12-20T20:56:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-named-among-thought-leaders-future-leaders-and-recommended-experts-and-economists-by-lexology-index/2024-12-23T16:35:32+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-announces-leadership-transition/2025-01-02T13:57:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-again-recognized-as-an-outstanding-global-economic-consulting-firm-by-global-competition-review/2025-01-02T21:58:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/martha-samuelson-joins-antitrust-magazine-panel-on-the-2023-dojftc-merger-guidelines/2025-01-03T14:57:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/real-world-effectiveness-of-luspatercept-on-transfusion-dependence-examined-by-analysis-group-researchers/2025-01-03T19:59:38+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/testimony-from-analysis-group-affiliate-r-glenn-hubbard-supports-favorable-judgment-in-environmental-liability-case/2025-01-10T15:45:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-congratulates-authors-of-five-articles-distinguished-with-nominations-for-2025-concurrences-antitrust-writing-awards/2025-04-07T20:30:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-competition-experts-examine-global-labor-antitrust-enforcement-efforts/2025-01-16T17:48:14+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/jury-awards-115-million-to-analysis-group-client-in-pharmaceutical-ip-dispute/2025-01-24T14:05:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/citing-analysis-group-expert-catherine-tucker-california-federal-judge-denies-certification-of-user-class-in-high-profile-meta-antitrust-suit/2025-02-03T19:25:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-affiliate-edward-rock-testifies-for-doubleline-capital-in-successful-corporate-governance-arbitration/2025-02-05T14:00:00+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/gcr-antitrust-awards-2025-analysis-group-case-work-and-managing-principal-aaron-yeater-nominated-for-multiple-competition-awards/2026-02-23T17:39:51+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-senior-advisor-keith-ugone-ph-d-supports-samsungs-trial-win-in-patent-infringement-case/2025-02-07T16:31:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-again-ranks-as-a-top-consulting-firm-in-vaults-consulting-50/2025-02-20T15:52:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-strengthens-canadian-presence-with-opening-of-toronto-office/2025-02-14T17:47:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/novel-access-focused-method-for-demonstrating-holistic-value-of-advanced-therapies-with-multiple-approved-indications-co-developed-by-analysis-group/2025-02-21T13:50:53+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/affiliate-edward-fox-and-analysis-group-coauthors-use-kroger-albertsons-ruling-to-explore-drivers-of-supermarket-competition-in-journal-of-retailing-article/2025-03-04T16:11:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-support-fda-bla-approval-of-a-regenerative-medicine-product-using-novel-external-benchmarking-statistical-method/2025-03-06T16:09:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-to-present-new-outcomes-research-at-the-2025-amcp-conference/2026-02-19T17:15:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/economic-considerations-of-rare-disease-treatments-explored-in-analysis-groupcoauthored-article/2025-03-24T14:16:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-announces-promotions-to-vice-president/2025-03-25T16:28:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-steers-walmart-through-ftc-approval-of-vizio-acquisition/2026-02-05T21:30:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-win-2025-antitrust-writing-award-for-best-general-economics-article/2025-04-07T20:29:04+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-aaron-yeater-named-the-2025-economist-of-the-year-by-global-competition-review-for-kroger-albertsons-merger-testimony/2025-04-07T13:57:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/early-alzheimers-disease-diagnosis-and-treatment-patterns-examined-by-analysis-group-researchers/2025-04-08T15:37:53+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-affiliate-alixandra-barasch-presents-on-consumer-perceptions-of-drip-pricing-at-cba-webinar/2025-04-21T15:18:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/far-reaching-nationwide-study-of-treatments-and-outcomes-for-patients-in-china-with-gastric-cancer-conducted-by-analysis-group-researchers/2025-04-22T19:57:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-coauthors-explore-economic-drivers-and-regulatory-changes-for-digital-platform-competition-in-antitrust-magazine/2025-04-30T14:01:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/unlocking-real-world-genomic-insights-analysis-group-leverages-aacr-project-genie-data-for-high-impact-mutation-driven-oncology-research/2025-05-05T16:17:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-ranked-among-top-expert-witness-firms-by-global-arbitration-review/2025-05-16T19:45:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/cardiovascular-benefits-of-weight-loss-drug-assessed-by-analysis-group-researchers/2025-05-19T13:13:12+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/testimony-from-three-analysis-group-experts-helps-client-successfully-defend-erisa-class-action/2025-05-28T18:04:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/iam-recognizes-analysis-group-consultants-as-leading-experts-in-intellectual-property/2026-02-17T18:57:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-co-investigates-the-impact-of-berotralstat-on-health-care-resource-utilization-among-patients-with-hereditary-angioedema-in-jmcp-article/2025-06-03T14:05:48+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-provides-economic-expertise-in-european-commission-investigation-of-csl-vifor/2025-06-03T17:29:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-partner-testifies-in-patent-case-awarding-112-million-in-damages/2025-06-04T13:00:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/federal-jury-adopts-damages-calculation-of-managing-principal-divya-mathur-in-regeneron-pharmaceuticals-antitrust-case-win/2025-06-04T14:52:12+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/30th-european-hematology-association-annual-congress-to-feature-nine-analysis-group-outcomes-research-presentations/2026-02-17T22:38:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-ameren-power-company-in-hearing-before-illinois-commerce-commission/2025-06-10T13:31:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/2025-health-care-and-life-sciences-litigation-practice-day-hosted-by-analysis-group/2025-06-11T17:40:26+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/favorable-copyright-infringement-settlement-supported-by-testimony-from-managing-principal-justin-mclean-and-affiliate-toby-stuart/2026-01-23T23:05:06+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-lisa-pinheiro-and-affiliate-yesha-yadav-joined-crypto-litigation-panel-at-consensus-2025/2025-09-16T17:43:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-cohosts-panel-on-risk-and-loss-assessment-in-emerging-economies-at-paris-arbitration-week/2025-06-27T15:53:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-law360-analysis-group-authors-examine-the-effectiveness-of-the-340b-drug-discount-program/2025-06-27T17:59:40+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/manager-mario-luca-explores-how-mergers-impact-innovation-in-concurrences/2025-06-30T18:09:23+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-assess-bipa-litigation-developments-and-trends/2025-07-02T17:18:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-study-highlights-treatment-patterns-and-resource-use-among-patients-with-advanced-bladder-cancer-pre-enfortumab-vedotin/2026-03-03T14:25:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-examine-the-advancements-in-and-application-of-heor-to-the-evaluation-of-cell-and-gene-therapies-for-rare-diseases/2025-07-22T16:55:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-discuss-regulatory-and-economic-perspectives-on-so-called-surveillance-pricing-in-cpi-antitrust-chronicle/2025-12-22T18:08:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/clinical-burden-of-rare-genetic-disorder-weighed-by-analysis-group-researchers/2025-07-23T17:27:50+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/jury-in-class-action-litigation-returns-favorable-verdict-for-analysis-group-client-first-american-title/2026-01-08T14:04:54+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-used-mass-general-brigham-data-and-natural-language-processing-to-assess-clinical-outcomes-among-patients-with-pulmonary-embolism/2025-07-30T14:01:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/openais-trademark-win-supported-by-rebuttal-expert-joel-steckel-and-analysis-group-team/2025-08-07T12:45:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/learnings-from-aba-panel-on-doj-ftc-labor-antitrust-guidance/2025-08-08T13:30:27+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-evaluate-historical-forecasted-us-electricity-demand/2025-08-21T13:15:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-supports-talen-energy-in-ferc-filing-for-two-maryland-power-plants/2025-08-21T19:59:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/principal-jessica-resch-featured-in-lexologys-arbitration-thought-leader-index/2025-08-22T15:50:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/use-of-loan-covenants-as-a-tool-for-evaluating-borrower-risk-evaluated-by-analysis-group-authors-in-the-accounting-review/2025-08-28T18:03:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/federal-securities-class-action-filings-and-settlements-examined-by-analysis-group-authors-in-law360/2025-09-04T17:08:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-coauthors-recap-aba-webinar-on-competition-developments-across-the-us-and-europe/2025-09-09T18:06:09+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/pro-bono-team-from-analysis-group-assists-massachusetts-in-analyzing-use-of-securitization-to-finance-energy-costs/2025-09-10T16:04:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/for-2025-edition-of-top-food-and-drug-cases-analysis-group-authors-examine-deceptive-advertising-case-involving-natural-claims-on-food-packaging/2025-09-15T18:02:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/testimony-from-analysis-group-managing-principal-rebecca-kirk-fair-and-two-affiliated-experts-helps-natixis-investment-managers-prevail-in-erisa-class-action/2026-01-08T14:04:02+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-discuss-private-equitys-impact-on-innovation/2025-09-18T18:39:07+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/affiliate-michael-mitzenmacher-and-analysis-group-team-support-openais-trademark-win/2025-09-24T15:56:59+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/decode-analysis-groups-genai-model-reveals-long-term-benefits-of-weight-loss-on-cardiometabolic-conditions/2025-10-06T17:27:39+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/federal-judge-grants-summary-judgment-to-analysis-group-client-meta-in-high-profile-antitrust-suit-from-facebook-users-resolving-issues-before-trial/2025-10-01T19:32:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-experts-to-present-heor-and-epidemiology-research-at-amcp-nexus-meeting/2025-12-19T15:20:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/with-nber-sponsorship-analysis-group-strengthens-commitment-to-academic-research/2025-10-08T20:44:53+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-congratulates-2025-nobel-laureate-philippe-aghion/2025-10-17T18:34:01+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-authors-explore-how-data-are-reshaping-health-care-fraud-litigation/2025-10-23T13:59:54+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/reincorporations-away-from-delaware-examined-by-analysis-group/2026-03-06T15:23:49+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-summer-program-again-recognized-as-a-top-consulting-internship/2025-11-04T18:03:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/competition-expert-pierre-regibeau-discusses-eu-merger-control-at-gcr-event-in-brussels/2025-11-05T18:12:10+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/copay-accumulator-and-maximizer-programs-analyzed-by-analysis-group-authors-in-law360/2025-11-05T19:43:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-announces-senior-level-promotion-and-welcomes-new-consultants/2025-11-06T21:00:32+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/lexology-index-names-analysis-group-consultants-as-thought-leaders-and-recommended-experts/2025-11-10T14:47:04+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-michael-carson-discusses-strategic-considerations-for-using-experts-in-life-sciences-patent-litigation-at-aci-forum/2025-11-10T14:31:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-philipp-tillmann-explores-private-enforcement-of-abuse-of-dominance-damages-in-the-eu/2025-11-17T14:54:45+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-celebrates-new-brussels-location-with-competition-expert-pierre-regibeau/2025-11-17T19:23:46+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-contribute-to-award-winning-research-on-real-world-outcomes-in-multiple-myeloma/2025-11-20T21:01:03+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/testimony-by-analysis-group-affiliate-catherine-tucker-cited-in-landmark-antitrust-case-win-by-meta/2026-02-18T20:01:18+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/federal-jury-clears-novo-nordisk-in-false-claims-act-case-that-included-testimony-by-analysis-group-affiliate-anupam-jena/2025-11-24T14:37:56+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-explore-brand-confusion-in-the-era-of-private-labels/2025-11-25T20:10:05+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-forms-partnership-with-distinguished-french-consultancy-ricol-lasteyrie-strengthening-the-reach-of-both-firms/2026-02-02T17:09:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-cohosts-panel-on-cryptocurrency-and-ai-in-shareholder-disputes-at-the-2025-adr-festival-in-seoul/2025-12-01T18:41:19+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-groups-pierre-regibeau-weighs-legal-and-economic-approaches-to-trade-defense-investigation-in-panel-moderated-by-vice-president-pierre-lissot/2025-12-02T15:58:12+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/global-competition-review-recognizes-analysis-group-as-an-outstanding-global-economic-consulting-firm/2025-12-02T18:01:16+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/67th-ash-annual-meeting-and-exposition-to-feature-analysis-group-research-on-malignancies-blood-disorders-and-more/2026-02-19T20:38:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/significant-victory-for-analysis-group-clients-in-libor-antitrust-class-action/2025-12-03T20:30:15+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-joshua-white-discusses-the-interplay-between-uk-merger-control-and-the-pro-growth-agenda/2025-12-10T15:44:25+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/blog-post-by-analysis-group-authors-considers-sustainability-in-eu-merger-review/2025-12-11T16:37:55+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-maria-garibotti-testifies-in-sentencing-phase-of-criminal-antitrust-wage-fixing-case-us-v-lopez/2025-12-12T15:36:20+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/principal-jimmy-royer-and-coauthors-discuss-improving-access-to-ai-inputs-in-management-and-business-review/2025-12-15T16:52:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/principal-hristina-bojadzieva-bartlett-and-affiliate-keri-pearlson-join-analysis-groupcohosted-panel-on-cybersecurity-and-arbitration-during-new-york-arbitration-week/2025-12-17T14:40:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/affiliate-catherine-tucker-and-analysis-group-coauthors-contribute-chapter-on-privacy-competition-and-regulation-to-research-handbook-on-data-privacy-and-competition-law/2025-12-18T15:24:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-joshua-white-considers-role-of-denigration-in-competition-analysis-at-complaw-pharma/2025-12-19T16:35:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-launches-in-house-experiment-to-understand-impact-of-structured-guidance-on-use-of-ai/2026-02-02T20:39:53+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/slam-dunk-settlement-for-racing-teams-owned-by-michael-jordan-denny-hamlin-and-bob-jenkins-in-nascar-antitrust-suit/2026-02-02T20:43:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-congratulates-authors-of-four-articles-distinguished-with-nominations-for-2026-concurrences-antitrust-writing-awards/2026-01-13T17:22:12+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-and-affiliate-judith-chevalier-help-google-defeat-advertiser-class-certification-in-major-antitrust-litigation-on-digital-advertising/2026-01-15T16:40:31+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-examine-potential-risks-and-mitigating-factors-of-acquihires/2026-02-18T15:47:57+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-examine-surrogate-measurements-for-overall-survival-in-bladder-cancer-studies/2026-01-26T16:50:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-two-coauthored-articles-analysis-group-consultants-consider-future-of-eu-merger-review-in-light-of-sustainability-mandates/2026-03-06T16:02:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-helps-client-secure-federal-approval-for-26-6-billion-energy-merger/2026-01-28T16:24:17+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/aditi-mehta-former-doj-antitrust-leader-joins-analysis-group-as-managing-principal/2026-02-02T14:10:44+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/gcr-antitrust-awards-2026-affiliate-catherine-tucker-and-analysis-group-competition-work-nominated-across-several-categories/2026-02-18T20:00:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-researchers-co-investigate-the-real-world-effects-of-berotralstat-on-hereditary-angioedema-attack-rates/2026-03-30T19:26:35+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-use-humira-to-examine-biosimilar-competition-landscape/2026-02-05T17:06:30+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-cyril-hariton-joins-competition-panel-highlights-economic-consideration-related-to-third-party-access-for-digital-infrastructures/2026-02-11T18:40:22+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-earns-top-three-spot-in-vaults-consulting-50/2026-02-12T16:11:24+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/affiliate-russell-wermers-and-analysis-group-coauthors-discuss-the-evaluation-of-target-date-fund-performance-in-the-journal-of-investment-management/2026-03-10T21:24:37+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-consultants-summarize-aba-antitrust-webinar-on-innovation-competition/2026-02-18T15:47:08+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/team-of-analysis-group-consultants-considers-the-costs-and-benefits-of-a-sub-annual-market-for-the-pjm-region/2026-03-06T16:01:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-collaborates-with-research-partners-to-explore-disparities-in-treatment-of-patients-with-chronic-spontaneous-urticaria/2026-03-19T17:49:54+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-experts-support-metas-successful-derivative-securities-settlement/2026-03-24T15:36:28+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-experts-win-two-2026-concurrences-antitrust-writing-awards/2026-03-25T14:30:52+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/global-competition-review-names-ftc-v-meta-behavioural-matter-of-the-year/2026-03-27T13:18:29+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-continues-expansion-of-international-arbitration-expert-bench/2026-03-31T15:23:41+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/pro-bono-testimony-and-report-of-vice-president-kristof-zetenyi-supports-win-for-unhoused-angelenos/2026-03-30T14:35:58+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/vice-president-pierre-lissot-and-colleagues-probe-effective-strategies-for-anti-dumping-complaints/2026-03-31T15:22:49+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/analysis-group-experts-support-hdmi-licensing-administrator-in-favorable-summary-judgment-on-antitrust-claims/2026-03-31T18:22:36+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/managing-principal-rebecca-kirk-fair-moderates-panel-at-antitrust-summit-2026/2026-04-02T14:52:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/sec-voluntarily-dismisses-negligence-claims-against-analysis-group-client-in-accounting-litigation/2026-04-03T15:44:42+00:00weekly0.7https://www.analysisgroup.com/news-and-events/news/in-law360-analysis-group-authors-examine-how-new-fda-guidance-could-reshape-biosimilar-competition/2026-04-03T13:47:13+00:00weekly0.7https://www.analysisgroup.com/news-and-events/press-releases/french/2024-01-11T10:41:23+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/modernization-opportunities-in-new-epa-regulations/2024-04-23T19:50:47+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/sizing-up-the-competition--antitrust-enforcement-and-the-bazaarvoice-ruling/2024-10-07T20:28:08+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/merger-arbitrage-spread---still-shrinking-/2024-04-23T19:55:47+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/the-right-expert-essential-to-bear-stearns-acquittal/2024-10-07T20:34:36+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/academic-perspectives-on-investor-activism/2024-10-07T20:35:00+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/high-frequency-trading-investigations/2024-10-07T20:35:11+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/wolf-pack-activism--a-deeper-look/2024-04-24T15:02:48+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/analysis-group-insights-featured-in-law360/2025-11-14T20:48:04+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/analysis-group-forum/2021-09-17T00:11:28+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/deal-metrics/2020-03-02T17:50:09+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/energy-and-environment/2020-03-02T17:50:29+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/health-care-bulletin/2020-03-02T17:50:23+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/infrastructure/2020-03-02T17:50:41+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/internal/2020-03-02T17:50:57+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/news/2018-10-05T20:23:06+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/q-and-a/2020-03-02T17:51:07+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/settlement-in-microsoft-iowa-litigation/2020-03-02T17:51:17+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/energy-infrastructure/2024-10-07T21:06:29+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/a-diverse-health-care-practice-videos/2024-10-07T21:06:41+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/finding-true-north-in-recent-delaware-appraisal-cases-is-it-the-market-or-the-model/2024-10-07T21:06:49+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/tirole-event-summary---english/2024-04-29T19:49:58+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/tirole-event-summary---french/2024-04-29T19:51:57+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/catherine-tucker-event-summary/2024-04-29T19:52:29+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/a-closer-look-at-appraisal-outcomes/2024-10-07T21:07:09+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/evaluating-the-but-for-world-surveys-experiments-and-market-data/2024-10-07T21:07:20+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/new-amcp-format-for-formulary-submissions/2024-04-24T15:13:19+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/investing-stimulus-dollars-in-advanced-energy-could-boost-post-pandemic-economies/2024-04-29T19:53:48+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/the-intersection-of-law-economics-and-the-environment-in-florida-v.-georgia-a-discussion-with-prof.-robert-stavins2024-04-29T19:54:30+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/economic-analysis-during-the-pandemic/2024-09-26T17:40:11+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/careers-in-antitrust-with-rebecca-kirk-fair/2024-04-29T19:58:27+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/labor-markets-and-antitrust-the-role-of-the-economic-expert-in-us-v.-davita-inc.-and-kent-thiry2025-01-09T20:57:29+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/analysis-group-and-data-science/2024-04-29T19:59:10+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/which-problem-to-solve-assessing-the-complexities-of-drug-pricing-in-the-us/2024-09-26T17:49:15+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/spacs-market-trends-and-litigation-considerations/2024-09-26T17:47:54+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/analysis-group-veterans-share-their-paths-to-economics-consulting/2024-04-29T20:00:54+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/our-partners/2024-04-29T20:01:09+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/highlights-regulatory-rwe/2024-04-29T20:01:28+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/event-summary-how-far-should-the-scope-of-antitrust-be-extended-innovation-environment-privacy/2024-09-26T17:41:02+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/health-care-disparities-measuring-treatment-and-overall-survival-differences-between-white-and-black-patients-with-metastatic-castration-sensitive-prostate-cancer/2026-03-27T14:54:42+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/health-care-disparities-breakthrough-therapy-may-increase-transplant-access-and-improve-outcomes-for-patients-with-blood-cancer-across-racial-and-ethnic-groups/2026-03-27T14:52:31+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/the-economic-impact-of-immigration-on-the-united-states-immigrants-and-the-us-economy/2024-09-30T13:18:32+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/health-care-disparities-in-office-dispensing-could-improve-treatment-access-and-clinical-outcomes-for-nonmetastatic-castration-resistant-prostate-cancer-patients/2026-03-27T14:54:10+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/numerosity-ascertainability-and-causation-navigating-class-claims-of-alleged-delayed-generic-entry/2025-12-02T22:12:05+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/the-future-of-eu-competition-policy-balancing-competitiveness-and-sustainability/2025-03-25T16:02:44+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/biosimilar-litigation-considerations-economic-factors-in-intellectual-property-and-antitrust-cases/2025-12-02T22:11:03+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/health-care-disparities-educating-providers-on-diagnostic-tools-could-improve-alzheimers-care-across-sociodemographic-groups/2026-03-27T14:53:33+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/dexit-trends-tracking-reincorporations-away-from-delaware/2026-03-06T15:21:49+00:00weekly0.7https://www.analysisgroup.com/Insights/ag-feature/health-care-disparities-leveraging-real-world-evidence-to-assess-differences-in-management-of-chronic-spontaneous-urticaria/2026-03-26T16:23:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-rhuepo-in-oncology/2024-06-27T17:42:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/anemia-related-costs-for-cancer-patients/2024-06-06T18:32:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-costs-of-cancer-to-a-major-employer-in-the-united-states--a-case-control-analysis/2024-06-06T18:36:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/understanding-the-pharmacoeconomic-profile-of-cancer/2024-06-06T18:41:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-outpatient-blood-transfusion-in-cancer-patients/2024-06-17T20:08:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-anemia-and-cancer/2024-06-06T18:50:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/depression-and-fibromyalgia--treatment-and-cost-when-diagnosed-separately-or-concurrently/2024-06-17T20:17:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-implications-of-treatment-resistant-depression-among-employees/2024-06-17T20:19:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-depression-in-the-united-states--how-did-it-change-between-1990-and-2000-/2024-06-06T19:03:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economics-of-women-and-depression--an-employer-perspective/2024-06-17T20:26:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-anxiety-and-stress-disorders/2024-06-27T17:47:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-depression--current-assessment-and-future-directions/2024-06-06T19:14:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-economic-impact-of-psychiatric-disorders--where-to-begin-/2024-06-17T20:27:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/management-of-major-depression-in-the-workplace--impact-on-employee-work-loss/2024-06-27T17:50:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-antidepressant-use-on-social-functioning--reboxetine-versus-fluoxetine/2024-06-06T19:28:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-anxiety-disorders-in-the-1990s/2024-06-06T19:32:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economics-of-clinical-depression/2024-06-06T19:37:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-of-rheumatoid-arthritis-to-an-employer/2024-06-06T19:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-depression-in-1990/2024-06-06T19:47:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lower-respiratory-tract-infections--impact-on-the-workplace/2024-06-17T20:32:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-respiratory-infections-in-an-employed-population/2024-06-17T20:35:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-of-asthma-to-an-employer/2024-06-17T20:40:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lack-of-intraocular-pressure-effect-of-budesonide-inhalation-therapy-in-a-mixed-asthmatic-population/2024-06-06T20:03:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-stress-urinary-incontinence--a-claims-data-analysis/2024-06-27T18:01:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-consequences-of-irritable-bowel-syndrome--a-us-employer-perspective/2024-06-17T20:43:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/productivity-and-medical-costs-of-diabetes-in-a-large-employer-population/2024-06-17T20:45:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effects-of-chronic-medical-conditions-on-work-loss-and-work-cutback/2024-06-07T12:54:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/descriptive-epidemiology-of-acute-liver-enzyme-abnormalities-in-the-general-population-of-central-massachusetts/2024-06-07T12:55:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interpretation-of-the-weight-matrix-in-an-artificial-neural-network/2024-06-07T12:56:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/linking-administrative-claims-data-with-archival-productivity-measures-to-inform-employer-decision-making/2024-06-07T12:58:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/administrative-claims-data--a-valuable-tool-in-pharmaceutical-litigation/2024-06-07T13:00:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/using-healthcare-claims-data-for-outcomes-research-and-pharmacoeconomic-analyses/2024-06-07T13:02:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/public-and-private-pharmaceutical-spending-as-determinants-of-health-outcomes-in-canada/2024-06-18T13:47:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-regulatory-perspective-on-productivity-claims--implications-for-future-productivity-research/2024-06-07T13:07:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pharmaceutical-spending-and-health-outcomes-in-the-united-states/2024-06-07T13:09:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/diagnosing-the-illness/2024-06-07T13:10:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-spending-as-determinants-of-health-outcomes/2024-06-07T13:11:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tackling-costs-one-disease-at-a-time/2024-06-07T13:13:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pharmacoeconomics-and-health-policy--current-applications-and-prospects-for-the-future/2024-06-07T13:14:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/calculating-return-on-investment-from-reducing-workplace-costs-of-illness/2024-06-07T13:18:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-next-phase-of-managed-care--targeting-investments-in-employee-health/2024-06-07T13:20:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/price-growth-of-prescription-pharmaceutical-preparations--an-update-and-extension-/2024-06-07T13:21:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consolidation-is-a-tonic-for-health-care-providers--trend-toward-managed-care-and-ascent-of-information-technology-fuel-restructuring-of-an-industry/2024-06-07T13:24:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-consequences-of-illness-in-the-workplace/2024-06-07T13:26:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/your-patent-is-about-to-expire--what-now-/2024-06-18T14:00:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-cost-flexibility-in-the-presence-of-many-outputs--a-public-private-comparison/2024-06-18T14:13:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/product-liability-in-the-pharmaceutical-industry/2024-06-07T13:52:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/omitted-variable-bias-and-hospital-costs/2024-06-07T13:53:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-cost-function-in-a-non-market-health-care-system/2024-06-07T13:54:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-consolidation--optimal-strategy-for-a-two-hospital-town/2024-06-07T13:56:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-depression--societal-and-patient-perspectives/2024-06-07T13:59:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economics-of-anxiety-disorders/2024-06-07T14:22:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/depression-in-the-workplace--effects-on-short-term-disability/2024-06-07T14:25:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-much-does-depression-cost-society-/2024-06-07T14:27:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-cost-and-epidemiological-characteristics-of-patients-with-fibromyalgia-claims/2024-06-27T18:06:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/calculating-the-workplace-cost-of-chronic-disease/2024-06-07T14:31:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consolidation-and-restructuring--the-next-step-in-managed-care/2024-06-07T14:32:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-value-of-cardiovascular-nuclear-medicine/2024-06-07T14:36:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/valuing-a-business-in-a-litigation-context/2024-06-07T14:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/options-as-an-alternative-to-cost-sharing/2024-11-12T21:07:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hedging-long-term-commodity-commitments-with-short-dated-futures-contracts/2024-06-07T14:41:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/stock-option-expense-and-cost-sharing--a-comment/2024-06-07T14:43:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/securities-act-violations--estimation-of-damages/2024-06-07T14:45:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hedge-funds--risk-and-return/2024-06-27T18:11:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/unemployment-insurance-and-job-search-productivity/2024-06-07T14:47:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/canada-unemployment-gap-truly-large--a-labor-flow-analysis/2024-06-27T18:12:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mergers-and-bargaining-in-the-us-airline-industry/2024-06-07T14:54:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/why-strike-insurance-is-unilateral--evidence-from-the-airline-industry-s-mutual-aid-pact/2024-06-07T14:59:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-analysis/2024-06-07T15:02:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-analysis-of-intellectual-property/2025-01-08T16:42:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/discounted-cash-flow-analysis-in-patent-infringement-litigation/2024-06-07T15:06:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-damages-in-patent-infringement-cases/2024-06-07T15:09:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/damage-measures-in-patent-infringement-actions/2024-06-07T15:13:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/analysis-and-measurement-of-damages-in-patent-infringement-actions/2024-06-07T15:18:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/trademark-misuse/2024-06-07T15:20:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/considering-taxes-in-the-computation-of-lost-business-profits/2024-06-27T18:15:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/taxes-and-lost-profits/2024-06-07T15:24:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pre-tax-versus-after-tax-patent-damages--do-the-courts-have-it-right-/2024-06-07T15:28:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-cafc-and-its-patent-damages-awards/2024-06-07T15:29:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-panduit-lost-profits-test-after-bic-leisure-v--windsurfing/2024-06-07T15:30:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/damages-in-patent-and-trademark-infringement/2024-06-07T15:32:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/intellectual-property-valuation-and-hughes-aircraft-v--the-united-states--a-giant-leap-for-mankind-or-lost-in-space-/2024-12-19T17:45:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-of-the-25-per-cent-rule-in-valuing-ip/2024-06-27T18:18:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/book-review--the-lesi-guide-to-licensing-best-practices--strategic-issues-and-contemporary-realities/2024-06-07T15:35:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/boards-of-directors--does-independence-matter-/2024-06-07T15:36:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/preparing-the-financial-expert-or-economist/2024-06-07T15:37:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/challenges-to-the-admissibility-of-financial-expert-witness-testimony/2024-06-07T15:39:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/financial-expert-witness-challenges-and-exclusions--results-and-trends-in-federal-and-state-cases-since-kumho-tire/2024-06-27T18:22:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-cost-of-capital/2024-06-07T15:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/forensic-accounting-and-litigation-consulting-services/2024-06-07T15:42:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-myth-of-the-universal-market/2024-06-07T15:43:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-myth-of-simple-market-solutions/2024-06-07T15:47:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-myths-of-market-prices-and-efficiencies/2024-06-07T15:51:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-better-climate-change-agreement/2024-06-07T15:55:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/markets-can-make-fisheries-sustainable/2024-06-07T15:56:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regulating-by-vintage--let-s-put-a-cork-in-it/2024-06-07T15:56:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/using-market-prices-to-regulate-the-costs-of-a-utility-s-inputs/2024-06-27T18:25:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/datawars--computer-models-in-the-federal-government/2024-06-07T15:58:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-nuclear-waste-controversy/2024-06-07T15:59:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/massachusetts--pre-approval-approach-to-prudence-in-massachusetts/2024-06-10T18:42:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/foreword--using-consensus-building-to-improve-utility-regulation/2024-06-27T18:31:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regional-issues-in-restructuring-the-electric-industry/2024-06-10T18:46:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/research-support-for-the-power-industry/2024-06-27T18:33:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-better-co2-rule/2024-06-27T18:36:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/siting-power-plants-in-the-new-electric-industry-structure--lessons-from-california-and-best-practices-for-other-states/2024-06-27T18:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-political-economy-of-long-term-generation-adequacy--why-an-icap-mechanism-is-needed-as-part-of-standard-market-design/2024-06-27T18:47:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/uncertainty-and-the-distribution-of-benefits-from-utility-conservation-programs/2024-06-27T18:49:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/designing-purpa-power-purchase-auctions--theory-and-practice/2024-06-10T18:55:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-production-simulation-implementations/2024-06-10T18:56:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regional-transmission-groups--how-should-they-be-structured-and-what-should-they-do-/2024-06-27T18:51:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/preparing-for-the-inevitable--the-nationalization-of-the-u-s--nuclear-industry-in-a-competitive-electricity-market/2024-06-10T18:58:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-efficiency-of-market-coordination--evidence-from-wholesale-electric-power-pools/2024-06-10T18:59:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competition-and-institutional-change-in-u-s--electric-power-regulation/2024-06-27T18:53:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/introduction/2024-06-27T18:55:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/binding-constraints-on-electricity-restructuring--an-inventory/2024-06-27T18:57:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-engineering-economic-approach-to-estimating-the-price-elasticity-of-residential-electricity-demand/2024-06-27T18:58:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effects-of-conservation-programs-on-electric-utility-earnings--results-of-two-case-studies/2024-06-27T19:02:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-tax-reform-on-renewable-energy-and-cogeneration-projects/2024-06-28T18:24:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/integrated-analysis-of-demand-side-programs/2024-06-27T20:35:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-integrated-economic-analysis-of-commercial-thermal-energy-storage/2024-11-12T21:26:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/proxy-plant-valuation-methods-for-demand-side-utility-programs/2024-06-27T19:13:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-assessment-of-the-demand-side-management-plans-for-four-new-york-utilities/2024-06-28T18:35:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competitive-bidding-for-electric-power--comparing-evaluation-methods/2024-06-28T18:37:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/auctions-for-purpa-purchases--a-simulation-study/2024-06-28T18:39:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/structural-evolution-in-the-electric-utility-industry/2024-06-28T18:41:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/why-are-vickrey-auctions-rare-/2024-06-28T18:43:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/alternative-approaches-to-competitive-bidding/2024-06-28T18:48:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluation-of-front-loading-in-auctions-for-wholesale-power/2024-06-27T19:16:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/optimization-methods-for-evaluating-competitive-bids-from-private-producers/2024-06-27T19:42:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/auction-markets-for-dispatchable-power--how-to-score-the-bids/2024-06-28T18:52:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risks-in-independent-power-contracts--an-empirical-survey/2024-06-27T19:44:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-dispatchability-features-in-competitive-bidding/2024-06-27T19:47:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/integrating-market-processes-into-utility-resource-planning/2024-06-27T19:51:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/transmission-planning-issues-in-a-competitive-economic-environment/2024-06-28T18:54:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/coordination-in-the-wholesale-market--where-does-it-work-/2024-06-28T18:57:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/coal-gasification-in-a-de-integrated-electricity-industry/2024-06-28T19:01:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reactive-power-is-a-cheap-constraint/2024-06-28T19:06:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regulation-by-simulation--the-role-of-production-cost-models-in-electricity-planning-and-pricing/2024-06-28T19:08:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-linear-model-of-voltage-limited-transmission-interface-constraints/2024-06-27T20:27:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-power-purchases-from-non-utilities-on-the-utility-cost-of-capital/2024-06-27T20:17:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-electricity-industry-in-spain/2024-06-10T20:07:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-performance-of-the-u-s--market-for-independent-electricity-generation/2024-06-28T19:14:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-production-tax-credit-for-wind-turbine-powerplants-is-an-ineffective-incentive/2024-06-27T20:15:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/market-power-in-california-electricity-markets/2024-06-28T19:23:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retail-access-pilot-programs--where-s-the-beef-/2024-06-28T19:25:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-nuclear-power-become-an-ordinary-commercial-asset-/2024-06-28T19:34:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/introducing-competition-to-the-electricity-industry-in-spain--the-role-of-initial-conditions/2024-06-27T20:13:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/numerical-techniques-for-analyzing-market-power-in-electricity/2024-06-27T20:12:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/price-forecasting-in-spot-markets--hidden-risks-in-single-part-bidding/2024-06-10T20:20:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-folklorist-s-guide-to-the-used-power-plant-market/2024-06-27T20:05:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-quantitative-analysis-of-pricing-behavior-in-california-s-wholesale-electricity-market-during-summer-2000/2024-06-28T19:39:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/performance-incentives-for-transmission/2024-06-27T20:04:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electric-utility-planning-and-regulation/2024-06-11T18:35:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/international-comparisons-of-electricity-regulation/2024-06-11T18:38:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-damages-using-forecasting-techniques/2024-06-11T18:40:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dull-witnesses/2024-06-28T19:45:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/damages-on-the-internet/2024-06-11T18:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/conflicting-rulings-about-conflicts/2024-06-11T18:43:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/engagement-letters-for-litigation-services--business-valuation-and-forensic---litigation-services-practice-aid-04-1/2024-06-28T19:48:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/vertical-enclosure--vertical-integration-and-the-reluctance-to-purchase-from-a-competitor/2024-06-28T19:54:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/free-radicals--why-industry-leaders-fail-to-harness-disruptive-technologies/2024-06-11T18:49:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-comprehensive-approach-to-corporate-venturing/2024-06-11T18:50:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-extent-of-the-market/2024-06-11T19:17:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predicting-the-price-effect-of-mergers-with-polynomial-logit-demand/2024-06-28T20:21:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/presenting-economic-expert-testimony-to-a-jury--five-golden-rules/2024-06-11T19:23:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/preparing-for-daubert-challenges-in-antitrust-cases/2024-06-11T19:25:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/network-costs-and-the-regulation-of-wholesale-competition-in-electric-power/2024-06-28T20:24:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hedonic-price-indexes-for-personal-computer-operating-systems-and-productivity-suites/2024-06-28T20:28:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/red-blood-cell-transfusion-and-ventilator-associated-pneumonia--a-potential-link-/2024-06-18T14:19:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effectiveness-of-surgery-on-the-treatment-of-acute-spinal-cord-injury-and-its-relationship-with-pharmacological-treatment/2024-06-11T19:32:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-does-hospice-cost-/2024-06-11T19:33:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-alternative-in-terminal-care--results-of-the-national-advice-on-hospice-care-for-benefits-design/2024-06-11T19:35:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-alternative-in-terminal-care--results-of-the-national-hospice-study/2024-06-11T19:36:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-costs-of-community-acquired-pneumonia-in-an-employed-population/2024-06-11T19:38:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/navigating-the-changing-tides-of-managed-care-and-health-reform/2024-06-11T19:41:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-health-care-system-in-canada/2024-06-11T19:44:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-policy/2024-06-11T19:46:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-minimization-analysis-of-once-weekly-versus-thrice-weekly-epoetin-alfa-for-chemotherapy-related-anemia/2024-06-18T14:22:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/exploring-economic-models-using-excel/2024-06-27T20:02:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/proving-damages--issues-to-consider-in-pursuing-and-defending-the-damages-case/2024-06-11T19:57:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-business-of-economic-consulting/2024-06-11T19:59:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/discussion-of-the-value-relevance-of-intangibles--the-case-of-software-capitalization/2024-07-01T12:53:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fair-value-disclosures-by-bank-holding-companies/2024-06-11T20:04:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-estimation/2024-06-12T13:54:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-baseball-can-teach-policymakers/2024-06-12T13:56:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-clinical-benefits-of-erythropoietic-agents-using-area-under-the-hemoglobin-change-curve/2024-06-18T14:25:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-schizophrenia-in-the-united-states-in-2002/2024-06-18T14:28:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/market-efficiency-versus-behavioral-finance/2024-06-12T14:02:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/energy-and-environmental-policy-in-the-united-states--synergies-and-challenges-in-the-electric-industry/2024-06-27T20:00:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-effects-of-federal-participation-in-terrorism-risk/2024-07-01T12:54:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-importance-of-federal-participation-in-terrorism-risk/2024-06-12T14:09:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/does-econ-analysis-shortchange-future-/2024-06-12T14:10:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/benefits-associated-with-an-early-hemoglobin-response-to-epoetin-alfa-therapy-in-the-treatment-of-chemotherapy-related-anemia/2024-06-12T14:13:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/some-straight-talk-needed-about-csr/2024-06-12T14:15:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-utility-safety-valve-for-cutting-co2/2024-06-12T14:17:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hedge-funds-today--caveat-emptor/2024-06-12T14:19:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-benefit-cost-analysis-helpful-/2024-06-12T14:21:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/application-of-game-theory-to-intellectual-property-royalty-negotiations/2024-06-12T14:40:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pedestrian-and-motor-vehicle-post-stop-data-analysis-report/2024-06-12T14:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-cost-benefit-assessment-of-wholesale-electricity-restructuring-and-competition-in-new-england/2024-06-12T14:48:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/calculating-damages-in-broker-raiding-cases/2024-06-12T14:54:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-and-effects-of-mood-disorders-on-work-performance-in-a-nationally-representative-sample-of-u-s--workers/2024-06-12T14:56:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-analysis--proposition-71---california-stem-cell-research-and-cures-initiative/2024-06-12T14:57:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimated-costs-of-prescription-opioid-analgesic-abuse-in-the-united-states-in-2001--a-societal-perspective-/2024-06-12T14:59:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-market-for-follow-on-biologics--how-will-it-evolve-/2024-06-12T15:02:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dosing-patterns-and-costs-of-erythropoietic-agents-in-patients-with-chronic-kidney-disease-not-on-dialysis-in-managed-care-organizations/2024-06-12T15:04:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/relationship-between-hemoglobin-level-and-quality-of-life-in-anemic-patients-with-chronic-kidney-disease-receiving-epoetin-alfa/2024-06-12T15:06:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-benefits-of-once-weekly-epoetin-alfa-in-anemic-patients-with-colorectal-cancer-receiving-chemotherapy/2024-06-12T15:12:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-role-for-u-s--co2-sequestration-/2024-06-12T15:13:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/live-prices-and-stale-quantities--t-1-accounting-and-mutual-fund-mispricing/2024-06-12T15:16:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/off-label-marketing-investigations-in-the-pharmaceutical-industry/2024-06-12T15:18:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dosing-patterns-and-treatment-costs-of-erythropoietic-agents-in-elderly-patients-with-pre-dialysis-chronic-kidney-disease-in-managed-care-organisations/2024-06-12T15:19:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/roundtable-discussion--importance-of-causation-analysis-in-mass-tort-cases/2024-06-12T15:21:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-value-of-antihypertensive-drugs--a-perspective-on-medical-innovation/2024-11-22T15:47:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/policies-can-work-in-strange-ways/2024-06-12T15:23:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-relative-dosing-of-epoetin-alfa-and-darbepoetin-alfa-in-chronic-kidney-disease/2024-06-12T15:24:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dose-conversion-and-cost-effectiveness-of-erythropoietic-therapies-in-chemotherapy-related-anemia--a-canadian-application/2024-06-12T15:28:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/too-good-to-be-true--an-examination-of-three-economic-assessments-of-california-climate-change-policy/2024-06-12T15:30:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/digital-media-patents-for-profit/2024-06-12T15:32:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-clinical-fractures-after-gonadotropin-releasing-hormone-agonist-therapy-for-prostate-cancer/2024-06-12T15:34:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-cost-benefit-analysis-of-the-new-york-independent-system-operator--the-initial-years/2024-06-18T14:33:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/do-authorized-generic-drugs-deter-paragraph-iv-certifications--recent-evidence/2024-06-12T16:20:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pharmaceutical-spending-and-health-outcomes/2024-11-22T15:46:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competition-between-generic-and-branded-drugs/2024-06-12T16:23:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antihypertensive-drugs--a-perspective-on-the-value-of-improved-blood-pressure-control-in-the-usa/2024-06-12T16:26:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lifetime-and-12-month-prevalence-of-bipolar-spectrum-disorder-in-the-national-comorbidity-survey-replication/2024-06-12T16:27:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lost-earnings-of-persons/2024-06-12T16:28:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economics-of-cost-pass-through-and-damages-in-indirect-purchaser-antitrust-cases/2024-06-12T16:31:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tradable-permits--fly-in-the-ointment-/2024-06-12T16:33:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/free-ghg-cuts--too-good-to-be-true-/2024-06-12T16:35:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mapping-fact-p-and-eortc-qlq-c30-to-the-eq-5d-health-utility-in-metastatic-hormone-refractory-prostate-cancer-patients/2024-06-12T16:38:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/short-term-economic-impact-of-body-weight-change-among-patients-with-type-2-diabetes-treated-with-antidiabetic-agents/2024-06-12T16:39:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-of-inhaled-corticosteroids-and-healthcare-costs-in-mild-persistent-asthma/2024-06-12T16:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-economic-and-outcomes-analysis-using-international-databases--a-review/2024-07-01T12:55:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimated-prevalence-of-peripheral-neuropathy-and-associated-pain-in-adults-with-diabetes-in-france/2024-06-12T16:46:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-cardiometabolic-risk-factor-clusters-on-health-related-quality-of-life-in-the-us/2024-06-18T14:35:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/annual-prevalence-of-diagnosed-schizophrenia-in-the-usa--a-claims-data-analysis-approach/2024-06-18T14:38:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-a-copd-severity-score/2024-06-12T16:56:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-duloxetine-versus-routine-treatment-for-u-s--patients-with-diabetic-peripheral-neuropathic-pain/2024-06-12T16:59:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lifetime-costs-of-patients-with-clinically-detected-uterine-fibroids--an-employer-s-perspective/2024-07-01T12:56:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-stroke-on-health-related-quality-of-life-in-the-noninstitutionalized-population-in-the-united-states/2024-06-12T18:47:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/annual-costs-associated-with-diagnosis-of-uterine-leiomyomata/2024-06-12T18:48:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-and-work-loss-costs-associated-with-persistent-asthma-patients-in-a-privately-insured-population/2024-06-18T14:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/employees-with-overactive-bladder--work-loss-burden/2024-06-18T14:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/china-s-urban-health-insurance-reform-experiment-in-zhenjiang--cost-and-utilization-analyses/2024-06-12T18:54:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/was-the-fairness-doctrine-a--chilling-effect---evidence-from-the-postderegulation-radio-market/2024-06-12T18:57:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regulatory-issues-in-deploying-wireless-voip/2024-06-12T19:00:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/telecom-antitrust-handbook/2024-06-12T19:01:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/look-to-markets-for-next-gen-success/2024-06-12T19:02:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-allowing-local-telephone-companies-to-enter-long-distance-voice-and-data-markets/2024-06-12T19:05:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-evolving-competitive-landscape-in-wireless-internet-markets/2024-06-12T19:06:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/-chilling--the-internet--lessons-from-fcc-regulation-of-radio-broadcasting/2024-05-22T18:36:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effect-on-federal-spending-of-legislation-creating-a-regulatory-framework-for-follow-on-biologics--key-issues-and-assumptions/2024-11-22T15:48:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-is-the-future-of-u-s--coal-/2024-06-12T19:14:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/misconceptions-about-h2o-pricing/2024-06-12T19:15:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-national-perspective-on-allocating-the-costs-of-new-transmission-investment--practice-and-principles/2024-06-12T19:17:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tips-from-the-experts--getting-the-most-out-of-your-experts/2024-06-12T19:19:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-sensible-way-to-cut-co2-emissions/2024-06-12T19:20:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-u-s--cap-and-trade-system-to-address-global-climate-change/2024-06-12T19:21:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-epidemiology-in-drug-safety-litigations/2024-06-12T19:22:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cap-and-trade-or-a-carbon-tax-/2024-06-12T19:24:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-analytic-model-to-determine-the-least-costly-inpatient-erythropoiesis-stimulating-therapy-regimen/2024-06-12T19:26:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/psychometric-validation-of-the-patient-symptom-assessment-in-lung-cancer-instrument-for-small-cell-lung-cancer/2024-06-12T19:27:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dose-and-cost-comparison-of-erythropoietic-agents-in-the-inpatient-hospital-setting/2024-06-12T19:34:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-direct-and-indirect-cost-burden-of-atopic-dermatitis--an-employer-payer-perspective/2024-06-12T19:35:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/linking-a-u-s--cap-and-trade-system-for-greenhouse-gas-emissions/2024-06-12T19:38:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/free-greenhouse-gas-cuts--too-good-to-be-true-/2024-06-27T19:58:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/drug-utilization-and-costs-of-erythropoietic-stimulating-agents-in-chronic-kidney-disease-patients-not-receiving-dialysis/2024-06-12T19:45:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-there-a-difference-in-the-cost-effectiveness-of-erythropoietic-therapies-for-the-treatment-of-anemia-in-patients-receiving-hcv-combination-therapy-/2024-06-12T19:47:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-epoetin-alfa-therapy-on-delaying-time-to-dialysis-in-elderly-patients-with-chronic-kidney-disease/2024-06-12T19:48:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-intravenous-chemotherapy-administration-in-patients-with-small-cell-lung-cancer--a-retrospective-claims-database-analysis/2024-06-12T19:50:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/linking-tradable-permit-systems/2024-06-12T19:51:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/intangible-assets--valuation-and-economic-benefit/2024-06-12T19:54:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/where-does-it-go--spending-by-the-financially-constrained/2024-07-01T12:57:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/drug-safety-and-risk-management-practice--what-drug-companies-can-do/2024-06-12T19:58:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/enviro-justice-and-cap-and-trade/2024-06-12T19:59:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/winning-initiative-campaigns-with-economic-analysis/2024-06-12T20:08:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/csr-through-an-economic-lens/2024-06-12T20:09:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-consequences-of-generic-substitution-for-antiepileptic-drugs-in-a-public-payer-setting--the-case-of-lamotrigine/2024-06-12T20:11:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-consequences-of-generic-substitution-of-lamotrigine-for-patients-with-epilepsy/2024-06-12T20:12:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-generic-substitution-of-lamotrigine--projected-costs-in-the-united-states-using-findings-in-a-canadian-setting/2024-06-12T20:14:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competitive-procurement-of-retail-electricity-supply--recent-trends-in-state-policies-and-utility-practices/2024-06-12T20:18:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-study-on-the-economic-impact-of-bariatric-surgery/2024-06-13T13:10:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/valuation-of-bankrupt-firms/2024-06-13T13:15:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ongoing-drivers-of-wetlands-depletion/2024-06-13T14:48:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-psoriasis-on-health-care-costs-and-patient-work-loss/2024-06-13T14:50:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-importance-of-supply-side-effects-in-antitrust-analyses/2024-06-13T14:52:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/does-generic-substitution-always-make-sense-/2024-06-13T14:54:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ercot-texas-s-competitive-power-experience--a-view-from-the-outside-looking-in/2024-06-13T14:59:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-value-of-formal-quantitative-assessment-of-uncertainty-in-regulatory-analysis/2024-06-13T15:01:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/five-minutes-with----the-economic-impact-of-bariatric-surgery-study-investigators/2024-06-13T15:09:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/data-exclusivity-periods-for-biologics--updating-prior-analyses-and-responding-to-critiques/2024-11-22T15:49:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/land-use-change-and-carbon-sinks/2024-06-13T15:19:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/opportunity-for-a-defining-moment/2024-06-13T15:21:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/anaemia-and-the-risk-of-injurious-falls-in-a-community-dwelling-elderly-population-/2024-06-14T13:50:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/erythropoiesis-stimulating-agents-in-the-treatment-of-anemia-in-myelodysplastic-syndromes--a-meta-analysis-/2024-06-14T13:55:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/management-of-anaemia--a-critical-and-systematic-review-of-the-cost-effectiveness-of-erythropoiesis-stimulating-agents-/2024-06-14T13:56:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-of-pain-therapy-for-osteoarthritis-in-an-insured-population-in-the-united-states-/2024-06-14T13:56:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-claims-data-analysis-of-dosage-adjustment-patterns-of-tnf-antagonists-among-patients-with-rheumatoid-arthritis-/2024-06-14T13:57:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-and-resource-use-of-mild-persistent-asthma-patients-initiated-on-controller-therapy-/2024-06-14T14:00:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/symptom-assessment-in-relapsed-small-cell-lung-cancer--cross-validation-of-the-patient-symptom-assessment-in-lung-cancer-instrument-/2024-06-14T14:02:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-pre-dialysis-epoetin-alfa-on-health-care-and-work-loss-costs-in-chronic-kidney-disease--an-employer-s-perspective/2024-06-14T14:04:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/loss-of-treatment-response-to-infliximab-maintenance-therapy-in-crohn-s-disease--a-payor-perspective/2024-06-14T14:06:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-costs-of-crohn-s-disease-in-the-united-states-and-other-western-countries--a-systematic-review/2024-06-14T14:18:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-escitalopram-versus-citalopram-for-the-treatment-of-major-depressive-disorder-in-a-geriatric-population/2024-06-14T14:22:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-among-employees-with-diabetic-retinopathy-in-the-united-states/2024-06-14T14:25:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/beyond-lifecycle-management---optimizing-performance-following-patent-expiry/2024-06-14T14:27:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-analysis-in-off-label-promotion-cases/2024-06-14T14:29:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/generic-competition-in-the-u-s--pharmaceutical-industry/2024-06-18T14:49:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/simulating-electricity-restructuring-in-california--interactions-with-the-regional-market/2024-06-27T19:55:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/workplace-burden-of-depression--case-study-in-social-functioning-using-employer-claims-data/2024-06-14T14:38:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/depression-in-the-workplace--an-economic-perspective/2024-06-14T14:39:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/depression--a-neglected-major-illness/2024-11-12T20:08:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/institutions-and-individuals/2024-06-14T14:42:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/challenges-in-rif-analyses/2024-06-14T14:43:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-related-and-all-cause-health-care-costs-of-elderly-patients-with-gout/2024-06-14T14:47:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-care-for-patients-with-rheumatoid-arthritis-receiving-tnf-antagonist-therapy-using-claims-data/2024-06-14T14:50:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mapping-fact-p-and-eortc-qlq-c30-to-patient-health-status-measured-by-eq-5d-in-metastatic-hormone-refractory-prostate-cancer-patients/2024-06-14T14:58:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risk-of-renal-impairment-in-hormone-refractory-prostate-cancer-patients-with-bone-metastases-treated-with-zoledronic-acid/2024-06-14T14:59:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/productivity-costs-associated-with-cardiometabolic-risk-factor-clusters-in-the-united-states/2024-06-14T15:05:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comment-on--the-relative-dosing-of-epoetin-alfa-and-darbepoetin-alfa-in-chronic-kidney-disease/2024-06-14T15:07:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-economic-and-outcomes-analyses-using-non-us-databases--a-review/2024-06-14T15:08:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/considering-the-costs-of-bipolar-depression/2024-06-14T15:15:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/compulsory-generic-switching-of-antiepileptic-drugs--high-switchback-rates-to-branded-compounds-compared-with-other-drug-classes/2024-07-01T12:58:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/do-drugs-reduce-utilisation-of-other-healthcare-resources-/2024-06-14T15:18:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/foundations-of-opioid-risk-management/2024-06-14T15:21:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/actual-versus-predicted-first-year-utilization-patterns-of-teriparatide-in-patients-with-employer-sponsored-health-insurance/2024-06-14T15:23:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medical-costs-of-untreated-anemia-in-elderly-patients-with-predialysis-chronic-kidney-disease/2024-06-14T15:26:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dose-conversion-ratio-for-epoetin-alfa-and-darbepoetin-alfa-in-chemotherapy-patients-with-anemia-and-cancer/2024-06-18T14:51:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-and-workloss-costs-associated-with-patients-with-persistent-asthma-in-a-privately-insured-population/2024-06-14T15:29:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-cancer-treatment-associated-bone-loss-and-fractures-among-women-with-breast-cancer-receiving-aromatase-inhibitors/2024-06-14T16:23:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-economic-impact-of-chronic-conditions-in-postmenopausal-women/2024-06-14T16:25:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-illness-for-employees-with-painful-conditions/2024-06-18T14:57:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-and-co-morbidities-of-atrial-fibrillation-in-a-privately-insured-population/2024-06-18T15:00:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-costs-of-opioid-abuse-in-an-insured-population-in-the-united-states/2024-06-18T15:04:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-depression-in-the-us--societal-and-patient-perspectives/2024-06-18T15:06:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dose-conversion-and-cost-effectiveness-of-erythropoietic-therapies-in-chemotherapy-related-anaemia--a-meta-analysis/2024-06-18T15:08:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-cost-effectiveness-of-weekly-epoetin-alfa-relative-to-weekly-darbepoetin-alfa-in-patients-with-chemotherapy-induced-anemia/2024-06-18T15:12:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-epoetin-alfa-and-darbepoetin-alfa-in-patients-with-chemotherapy-related-anemia/2024-06-18T15:14:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/alkaline-phosphatase-predicts-survival-in-patients-with-metastatic-neuroendocrine-tumors/2024-06-14T16:46:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dose-conversion-from-epoetin-alfa-to-darbepoetin-alfa-for-patients-with-chronic-kidney-disease-receiving-hemodialysis/2024-06-18T15:16:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-olanzapine-plus-fluoxetine-combination-therapy-among-patients-treated-for-depression--a-pilot-study/2024-06-18T15:18:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-depression-with-painful-symptoms/2024-06-18T15:19:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-relationship-between-technology-availability-and-health-care-spending/2024-06-18T15:21:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/relationship-between-changes-in-hemoglobin-level-and-quality-of-life-during-chemotherapy-in-anemic-cancer-patients-receiving-epoetin-alfa-therapy/2024-11-12T21:27:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/statistical-explanations-for-a-community-based-study-of-once-weekly-epoetin-alfa-therapy-in-patients-receiving-chemotherapy/2024-06-18T15:23:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-costs-of-cancer--cancer-related-conditions-can-add-dramatically-to-overall-costs-of-care/2024-06-14T17:02:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-technology-in-a-non-market-health-care-system/2024-06-14T17:04:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-of-statistical-sampling-in-litigation/2024-06-14T17:06:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-evaluation-of-the-mccullough-research-report-on-new-york-s-wholesale-power-market/2024-06-18T15:25:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-stimulus-and-green-jobs/2024-06-14T17:09:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-growing-role-of-economic-analysis-in-off-label-promotion-cases/2024-06-14T17:11:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risks-and-costs-of-multiple-generic-substitution-of-topiramate/2024-06-14T17:14:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/proving-patent-damages/2024-06-14T17:15:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-drug-vintage-on-patient-survival--a-patient-level-analysis-using-quebec-s-provincial-health-plan-data/2024-06-14T17:17:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/projected-economic-impact-of-clinical-findings-of-generic-entry-of-topiramate-on-g4-european-countries/2025-02-28T21:53:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/drug-utilization-and-cost-considerations-of-erythropoiesis-stimulating-agents-in-oncology-patients-receiving-chemotherapy/2024-06-18T15:27:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-all-cause-health-care-costs-associated-with-chronic-kidney-disease-in-patients-with-diabetes-and-hypertension--a-managed-care-perspective/2024-06-14T17:22:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-limiting-erythropoiesis-stimulating-agent-use-for-chemotherapy-induced-anemia-on-the-united-states-blood-supply-margin/2024-06-14T17:23:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/erythropoietin-therapy-and-left-ventricular-mass-index-in-ckd-and-esrd-patients--a-meta-analysis/2024-06-14T17:25:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-assessment-of-erythroid-response-to-epoetin-alfa-as-a-single-agent-versus-in-combination-with-granulocyte--or-granulocyte-macrophage-colony-stimulating-factor-in-myelodysplastic-syndromes-using-a-m/2024-06-14T17:31:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/no-free-lunch-at-the-auto-cafe/2024-06-14T17:34:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measuring-the-capacity-impacts-of-demand-response/2024-06-14T17:36:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/determinants-of-direct-cost-differences-among-us-employees-with-major-depressive-disorders-using-antidepressants/2024-06-14T17:37:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/depression-and-work-productivity--the-comparative-costs-of-treatment-versus-nontreatment/2024-06-14T17:40:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identification-of-diabetes-patients-using-claims-data--an-economic-analysis/2024-07-01T13:00:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-illness-and-its-treatment-on-workplace-costs--regulatory-and-measurement-issues/2024-06-14T17:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/actual-and-perceived-impacts-of-tobacco-regulation-on-restaurants-and-firms/2024-06-14T17:44:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measuring-alzheimer-s-disease-progression-with-transition-probabilities--estimates-from-cerad/2024-06-14T17:46:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-pneumonia-in-an-employed-population/2024-06-18T15:28:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-home-infusion-therapy_relative-benefit-index--summary-of-an-analysis-using-insurance-claims-data/2024-06-18T19:30:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/workplace-performance-effects-from-chronic-depression-and-its-treatment/2024-06-14T17:55:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiologic-interpretation-of-artificial-neural-networks/2024-06-14T17:58:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prediction-and-cross-validation-of-neural-networks-versus-logistic-regression--using-hepatic-disorders-as-an-example/2024-06-14T17:59:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/improvement-in-subjective-work-performance-after-treatment-of-chronic-depression--some-preliminary-results/2024-06-14T18:02:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effectiveness-of-surgery-on-the-treatment-of-acute-spinal-cord-injury-and-its-relation-to-pharmacological-treatment/2024-06-14T18:04:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impacts-of-the-new-york-long-term-home-health-care-program/2024-06-14T18:06:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/home-care-in-hospices/2024-06-14T18:08:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/managing-programs-for-the-elderly--design-of-a-social-information-system/2024-06-14T18:10:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-determinants-of-nursing-home-operating-costs-in-new-york-state/2024-06-14T18:35:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medicare-legislation-for-hospice-care--implications-of-national-hospice-study-data/2024-06-14T18:37:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/national-hospice-study-analysis-plan/2024-06-14T18:40:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/why-do-nursing-home-costs-vary--the-determinants-of-nursing-home-costs/2024-06-14T18:42:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/wonderful-politics-of-cap-and-trade/2024-06-14T18:45:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/legal-and-economic-perspectives-concerning-u-s--government-investigations-of-alleged-off-label-promotion-by-drug-manufacturers/2024-06-14T18:47:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effect-of-statutory-indemnity-on-securities-class-action-litigation-settlements--a-first-look/2024-06-27T19:53:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/aba-pharmaceutical-industry-antitrust-handbook/2024-06-18T21:05:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/licensing-in-the-presence-of-technology-standards/2024-11-12T21:30:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/addressing-environmental-justice-concerns-in-the-design-of-california-s-climate-policy/2024-06-14T18:52:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evolving-ghg-trading-systems-outside-its-borders--how-should-california-respond--6442447901/2024-11-12T21:34:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/strategic-options-for-investment-in-transmission-in-support-of-offshore-wind-development-in-massachusetts/2024-11-12T21:35:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/worried-about-competitiveness--6442447033/2024-11-12T21:36:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competition-and-title-insurance-rates-in-california/2024-11-12T21:37:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/angel-finance--the-other-venture-capital/2024-11-12T21:38:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-relationship-between-compliance-with-antidepressant-therapy-and-employer-costs-among-employees-in-the-united-states/2024-11-12T21:40:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/combating-stat-abuse/2024-11-12T21:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patent-auctions--how-far-have-we-come-/2024-11-12T21:44:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-shrinking-merger-arbitrage-spread--reasons-and-implications/2024-11-12T21:50:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/voluntary-agreements-with-industries--participation-incentives-with-industry-wide-targets/2024-11-12T21:52:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-new-york-independent-system-operator--a-ten-year-review/2024-11-12T21:53:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/next-steps-for-california-climate-policy-ii--moving-ahead-under-uncertain-circumstances/2024-11-12T21:54:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-mutual-fund-industry--competition-and-investor-welfare/2024-11-12T21:55:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/left-behind--latin-america-and-the-false-promise-of-populism/2024-11-12T21:57:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-of-transfusional-iron-overload-in-patients-with-myelodysplastic-syndrome-or-severe-anemia--data-from-multicenter-clinical-practices/2024-11-12T21:58:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-implications-of-iv-versus-oral-anti-angiogenesis-therapies-in-patients-with-advanced-renal-cell-carcinoma--retrospective-claims-database-analysis/2024-11-12T22:01:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-consequences-of-not-recognizing-bipolar-disorder-patients--a-cross-sectional-descriptive-analysis/2024-11-13T15:23:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/proof-of-common-impact-in-antitrust-litigation--the-value-of-regression-analysis/2024-11-13T15:23:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/securities-class-action-doesn-t-suit-us/2024-11-13T15:24:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-exacerbations-of-chronic-obstructive-pulmonary-disease-and-exacerbation-definition--a-review/2024-11-13T15:25:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-proton-pump-inhibitor-compliance-on-health-care-resource-utilization-and-costs-in-patients-with-gastroesophageal-reflux-disease/2024-11-13T15:26:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-new-approach-to-antitrust-class-certification/2024-11-13T15:27:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-cost-of-disability-and-medically-related-absenteeism-among-employees-with-multiple-sclerosis-in-the-us/2024-11-13T15:38:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-compliance-with-proton-pump-inhibitors-on-nsaid-treatment/2024-11-13T15:44:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-a-budget-impact-model-to-quantify-potential-cost-savings-from-prescription-opioids-designed-to-deter-abuse-or-ease-of-extraction/2024-11-13T15:43:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-utility-of-adalimumab-versus-infliximab-maintenance-therapies-in-the-united-states-for-moderately-to-severely-active-crohn-s-disease/2024-11-13T15:58:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-renal-impairment-after-treatment-with-ibandronate-versus-zoledronic-acid--a-retrospective-medical-records-review/2024-11-13T15:59:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/resource-utilization-and-costs-of-schizophrenia-patients-treated-with-olanzapine-versus-quetiapine-in-a-medicaid-population/2024-11-13T16:07:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparing-the-treatment-patterns-of-patients-with-schizophrenia-treated-with-olanzapine-and-quetiapine-in-the-pennsylvania-medicaid-population/2024-11-13T16:08:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/workplace-impacts-of-anti-tnf-therapies-in-rheumatoid-arthritis--review-of-the-literature/2024-11-13T16:08:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antidepressant-treatment-patterns-and-costs-among-us-employees/2024-11-13T16:09:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-nonadherence-to-antiepileptic-drugs-on-health-care-utilization-and-costs--findings-from-the-ransom-study/2024-11-13T16:10:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-multiple-sclerosis-disease-modifying-drugs-in-an-employed-population--direct-and-indirect-costs/2024-11-13T16:14:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-two-adalimumab-treatment-schedule-strategies-for-moderate-to-severe-crohn-s-disease--results-from-the-charm-trial/2024-11-13T16:37:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-health-care-use-and-costs-in-newly-diagnosed-and-established-patients-with-fibromyalgia/2024-11-13T16:39:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-psoriasis-compared-to-the-general-population-and-stratified-by-disease-severity/2024-11-13T16:40:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-associated-with-epileptic-partial-onset-seizures-among-the-privately-insured-in-the-united-states/2024-11-13T16:54:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-utilization-and-costs-incurred-by-patients-with-major-depression-after-being-switched-from-escitalopram-to-another-ssri-for-non-medical-reasons/2024-11-13T16:56:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-adalimumab-on-symptoms-of-psoriatic-arthritis-in-patients-with-moderate-to-severe-psoriasis--a-pooled-analysis-of-randomized-clinical-trials/2024-11-13T16:58:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effect-of-adalimumab-on-reducing-depression-symptoms-in-patients-with-moderate-to-severe-psoriasis--a-randomized-clinical-trial/2024-11-13T18:26:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/coronary-heart-disease-and-stroke-risk-in-patients-with-psoriasis--retrospective-analysis/2024-11-13T18:29:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/high-prevalence-of-potential-drug-drug-interactions-for-psoriasis-patients-prescribed-methotrexate-or-cyclosporine-for-psoriasis/2024-11-13T18:30:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/societal-cost-of-rheumatoid-athritis-patients-in-the-us/2024-11-13T18:33:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-costs-associated-with-initiating-nph-insulin-versus-glargine-in-patients-with-type-2-diabetes--a-retrospective-database-analysis/2024-11-13T18:35:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/inhaled-corticosteroids-or-long-acting-beta-agonists-alone-or-in-fixed-dose-combinations-in-asthma-treatment--a-systematic-review-of-fluticasone-budesonide-and-formoterol-salmeterol/2024-11-13T18:36:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/analytic-models-to-identify-patients-at-risk-for-prescription-opioid-abuse/2024-11-13T18:38:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/age-differences-in-the-prevalence-and-co-morbidity-of-dsm-iv-major-depressive-episodes--results-from-the-who-world-mental-health-survey-initiative/2024-11-13T18:41:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cardiovascular-and-economic-outcomes-after-initiation-of-lipid-lowering-therapy-with-atorvastatin-vs-simvastatin-in-an-employed-population/2024-11-13T18:49:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-adalimumab-for-the-maintenance-of-remission-in-patients-with-crohn-s-disease/2024-11-13T18:50:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/employer-model-of-workplace-impacts-of-anti-tnf-therapy-for-rheumatoid-arthritis/2024-11-13T19:10:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-implications-of-generic-substitution-of-antiepileptic-drugs--a-review-of-recent-evidence/2024-11-13T19:13:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/do-electric-cars-make-economic-sense-for-the-mass-market-/2024-11-13T19:15:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-u-s--electric-car-race--what-do-consumers-really-want-/2024-11-13T19:16:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-uneasy-case-for-product-liability/2024-11-13T19:16:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-angiogenesis-inhibitor-therapies-for-metastatic-renal-cell-carcinoma-in-clinical-practice--results-from-a-medical-chart-review-study/2024-11-13T19:22:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-of-response-to-sequential-sunitinib-and-the-impact-of-prior-vegf-targeted-drug-washout-in-patients-with-metastatic-clear-cell-renal-cell-carcinoma/2024-11-13T19:24:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/renal-toxicity-in-patients-with-multiple-myeloma-receiving-zoledronic-acid-vs--ibandronate--a-retrospective-medical-records-review/2024-11-13T19:27:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-epilepsy-among-the-privately-insured-in-the-us/2024-11-13T19:30:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/taming-a-whale-lurking-in-pension-financing/2024-11-13T19:30:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-we-afford-to-cut-carbon-/2024-11-13T19:32:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-path-forward-for-climate-talks/2024-11-13T19:34:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/two-countries-key-to-progress-in-2010/2024-11-13T19:40:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/state-eyes-on-the-climate-policy-prize/2024-11-13T19:40:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/beware-scorched-earth-strategies/2024-11-13T19:43:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-investors-really-want/2024-11-13T19:44:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-non-adherence-to-imatinib-treatment-in-chronic-myeloid-leukemia-patients/2024-11-13T19:45:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-25-percent-rule-lives-on/2024-11-13T19:47:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-hepatotoxicity-related-hospitalizations-among-patients-treated-with-opioid-acetaminophen-combination-prescription-pain-medications/2025-02-28T21:51:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/introducing-perspectives-on-comparative-effectiveness-research/2024-11-13T19:54:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perspectives-on-comparative-effectiveness-research--views-from-diverse-constituencies/2024-11-13T19:55:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-experts-in-antitrust-class-certification/2024-11-13T19:56:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-the-clinical-benefits-of-bariatric-surgery-in-diabetes-patients-with-bmi-is-great-than-equal-35-kg-per-m2/2024-11-13T19:56:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/generic-antiepileptic-drugs-and-associated-medical-resource-utilization-in-the-united-states/2025-02-28T21:52:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-changing-landscape-for-credit-ratings/2024-12-19T17:46:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-fruits-of-comparative-effectiveness/2025-07-01T20:09:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/in-defense-of-pollution-markets/2024-11-13T20:33:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/wind-integration-studies--optimization-vs--simulation/2024-11-13T20:34:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-price-isn-t-right--event-studies-in-m-a-suits/2024-11-13T20:36:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/data-exclusivity-for-biologics/2024-11-13T20:38:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-effective-way-to-quantify-the-safety-profile-of-a-drug-or-device-when-background-toxicity-rates-are-low/2024-11-13T20:39:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-public-sector-research-in-the-discovery-of-drugs-and-vaccines/2024-11-13T20:41:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fcc-media-ownership-study--5--station-ownership-and-programming-in-radio/2024-11-13T20:42:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-firm-size-in-bilateral-bargaining--a-study-of-the-cable-television-industry/2024-11-13T20:43:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/horizontal-integration-for-bargaining-power--evidence-from-the-cable-television-industry/2024-11-13T20:44:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consumption-inequality-and-intra-household-allocations/2024-11-13T20:49:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pros-and-cons-of-statistical-sampling/2024-11-13T20:50:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-guide-to-economic-and-policy-analysis-of-epa-s-transport-rule/2024-11-13T20:51:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-a-reasonable-royalty-ever-be-zero-/2024-11-13T20:52:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cardiovascular-and-economic-outcomes-after-initiation-of-atorvastatin-versus-simvastatin-in-an-employed-population-stratified-by-cardiovascular-risk/2024-11-13T20:55:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/removal-of-opioid-acetaminophen-combination-prescription-pain-medications--assessing-the-evidence-for-hepatotoxicity-and-consequences-of-removal/2024-11-13T20:56:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/managing-care-and-costs--the-sustained-cost-impact-of-reduced-hospitalizations-in-a-partnership-measurement-model-of-disease-management/2024-11-13T21:00:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-benefit-analysis-of-adalimumab-versus-traditional-non-biologic-therapies-for-patients-with-crohn-s-disease/2024-11-13T21:03:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/methodological-issues-in-a-meta-analysis/2024-11-13T21:07:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-of-employees-with-treatment-resistant-and-non-treatment-resistant-major-depressive-disorder/2024-11-13T21:08:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/descriptive-analysis-of-medicaid-patients-with-postherpetic-neuralgia-treated-with-lidocaine-patch-5-percent/2024-11-13T21:10:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-without-head-to-head-trials--a-method-for-matching-adjusted-indirect-comparisons-applied-to-psoriasis-treatment/2024-11-13T21:11:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluation-of-compliance-and-health-care-utilization-in-patients-treated-with-single-pill-vs--free-combination-antihypertensives/2024-11-13T21:12:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/chart-review-of-patients-on-valsartan-based-single-pill-combinations-vs--arb-based-free-combinations-for-bp-goal-achievement/2024-11-13T21:14:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/benefit-risk-analysis-of-adalimumab-vs-methotrexate-and-placebo-in-the-treatment-of-moderate-to-severe-psoriasis/2024-11-13T21:16:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-bariatric-surgery-on-comorbidities-and-medication-use-among-obese-patients/2024-11-13T21:17:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comment--the-impact-of-methodological-approach-on-cost-findings-in-comparison-of-epoetin-alfa-with-darbepoetin-alfa/2024-11-13T21:19:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-and-medical-care-costs-among-medicare-beneficiaries-receiving-therapy-for-peripheral-arterial-disease/2024-11-14T18:57:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/generation-fleet-turnover-in-new-england--modeling-energy-market-impacts/2024-11-14T19:01:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retirement-is-coming--preparing-for-new-england-s-capacity-transition/2024-11-14T19:03:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/resale-price-maintenance-following-leegin--u-s--and-canadian-perspectives/2024-11-14T19:21:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-initiation-timing-of-ssri-or-snri-on-depressed-adolescent-health-care-utilization-and-costs/2024-11-14T19:25:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-economic-framework-for-analyzing-covenants-not-to-compete/2024-11-14T21:35:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/does-the-route-of-administration-for-estrogen-hormone-therapy-impact-the-risk-of-venous-thromboembolism-/2024-11-14T21:37:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/anemia-and-the-risk-of-injurious-falls-in-a-community-dwelling-elderly-population/2024-11-14T21:43:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-switching-from-valsartan-to-other-angiotensin-receptor-blockers-in-patients-with-hypertension/2024-11-14T21:49:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-cardiovascular-events-in-patients-with-hypertension-in-u-s--managed-care-settings/2024-11-15T17:23:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effects-of-adalimumab-treatment-and-psoriasis-severity-on-self-reported-work-productivity-and-activity-impairment-for-patients-with-moderate-severe-psoriasis/2024-11-15T17:34:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-and-safety-of-adalimumab-among-patients-with-moderate-to-severe-psoriasis-with-co-morbidities/2024-11-15T18:21:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-adalimumab-versus-placebo-on-risk-of-symptom-worsening-in-psoriasis-and-subsequent-impacts-on-health-related-quality-of-life/2024-12-19T16:56:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-comorbidities-in-patients-with-psoriasis-is-substantial/2024-11-15T18:33:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-survey-based-assessment-of-the-prevalence-and-severity-of-chronic-hand-dermatitis-in-a-managed-care-organization/2024-11-15T18:36:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-vildagliptin-and-sitagliptin-in-japanese-patients-with-type-2-diabetes--a-matching-adjusted-indirect-comparison-of-randomized-trials/2024-12-19T16:57:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/achieving-glycemic-goal-with-initial-versus-sequential-combination-therapy-using-metformin-and-pioglitazone-in-type-2-diabetes-mellitus/2024-11-15T18:48:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/systematic-review--the-costs-of-ulcerative-colitis-in-western-countries/2024-11-15T18:51:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-adalimumab-therapy-on-incidence-of-hospitalization-and-surgery-in-crohn-s-disease--results-from-the-charm-study/2024-11-15T18:52:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-outcomes-of-switching-treatment-in-major-depressive-disorder-patients/2024-11-15T19:01:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/savings-estimate-for-a-medicare-insured-group/2024-11-15T19:29:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/red-blood-cell-transfusions-and-the-risk-of-ards-among-critically-ill--a-cohort-study/2024-11-15T19:30:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/remission-of-major-depressive-disorder-without-adverse-events--a-comparison-of-escitalopram-versus-serotonin-norepinephrine-reuptake-inhibitors/2024-11-15T19:52:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-therapeutic-substitution-of-a-brand-selective-serotonin-reuptake-inhibitor-with-an-alternative-generic-selective-serotonin-reuptake-inhibitor/2024-11-15T19:53:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-of-antipsychotic-drugs-in-patients-with-alzheimer-s-disease-treated-with-rivastigmine-versus-donepezil/2024-11-15T19:55:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medical-and-work-loss-burden-of-pre-dialysis-chronic-kidney-disease-and-related-anemia--an-employer-s-perspective/2024-11-15T20:06:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-risk-of-clinical-fracture-in-men-with-non-metastatic-prostate-cancer-receiving-gonadotropin-releasing-hormone-agonist-therapy/2024-11-15T20:10:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prediction-and-cross-validation-in-modeling-incident-cases-of-hepatic-disorders-using-automated-medical-data/2024-11-15T20:11:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-nilotinib-and-dasatinib-in-newly-diagnosed-chronic-myeloid-leukemia--a-matching-adjusted-indirect-comparison-of-randomized-trials/2024-11-15T20:17:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/safety-and-treatment-patterns-of-multikinase-inhibitors-in-patients-with-metastatic-renal-cell-carcinoma-at-a-tertiary-oncology-center-in-italy/2024-11-15T20:18:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-benefits-of-timely-intervention-with-zoledronic-acid-in-patients-with-metastatic-prostate-cancer-to-bones--a-retrospective-study-of-us-veterans/2024-11-15T20:41:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-visits-and-costs-following-outpatient-treatment-of-cap-with-levofloxacin-or-moxifloxacin/2024-11-15T20:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/private-sector-investment-and-employment-impacts-of-reassigning-spectrum-to-mobile-broadband-in-the-united-states/2024-11-15T20:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mortality-and-nonadherence-to-aeds/2024-11-15T21:06:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/running-the-numbers/2024-11-15T21:09:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-ten-northeast-and-mid-atlantic-states/2024-11-15T21:13:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-ten-northeast-and-mid-atlantic-states--appendix/2024-11-15T21:14:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-ten-northeast-and-mid-atlantic-states--methodological-note/2024-11-15T21:23:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/early-retirement-and-income-loss-in-patients-with-early-and-advanced-parkinson-s-disease/2024-11-15T21:24:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/integrated-telehealth-and-care-management-program-for-medicare-beneficiaries-with-chronic-disease-linked-to-savings/2024-11-15T21:28:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-ten-northeast-and-mid-atlantic-states--fact-sheet/2024-11-15T21:29:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-evaluation-of-denosumab-compared-with-zoledronic-acid-in-hormone-refractory-prostate-cancer-patients-with-bone-metastases/2024-11-15T21:30:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-applicability-of-the-epa-market-forces-study-to-the-scrap-metal-recycling-industry/2024-11-15T21:31:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evolving-brand-name-and-generic-drug-competition-may-warrant-a-revision-of-the-hatch-waxman-act/2024-11-15T21:32:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/carbon-control-and-the-economy--economic-impacts-of-rggi-s-first-three-years/2024-11-18T22:02:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/book-review--monopsony-in-law-and-economics/2024-11-18T22:03:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/why-coal-plants-retire--power-market-fundamentals-as-of-2012/2024-11-18T22:04:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/did-the-durban-meeting-succeed-/2024-11-18T22:05:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/labor-costs-and-the-rate-case/2024-11-18T22:05:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pay-as-bid-vs--uniform-pricing--discriminatory-auctions-promote-strategic-bidding-and-market-manipulation/2024-11-18T22:06:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/options-for-addressing-leakage-in-california-s-climate-policy/2024-11-18T22:07:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-hazard-rate-analysis-of-mirant-s-generating-plant-outages-in-california/2024-11-18T22:07:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/california-s-cap-and-trade-decisions/2024-11-18T22:08:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/next-steps-for-california-with-federal-cap-and-trade-policy-on-the-horizon/2024-11-18T22:09:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/implementation-of-the-biosimilar-pathway--economic-and-policy-issues/2024-11-18T22:10:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recently-released-fda-guidance-and-biosimilar-development--implications-for-the-litigation-environment/2024-11-18T22:11:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-effects-of-most-favored-nation-clauses/2024-11-18T22:12:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-great-patent-purchase/2024-11-18T22:13:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/expert-analysis-of-plan-losses-in-erisa-class-action-litigation/2024-11-18T22:13:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/some-economics-of-royalty-bundling/2024-11-18T22:14:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-interdependence-of-electricity-and-natural-gas--current-factors-and-future-prospects/2024-11-18T22:15:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-evolving-standards-for-class-certification-in-antitrust-cases/2024-11-18T22:16:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prioritizing-safety-versus-budget--fda-and-cms-adopt-different-stances/2024-11-19T18:53:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-positive-outlook-for-cleaner-air-and-reliable-electric-service/2024-11-19T18:54:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/persistence-and-compliance-of-deferoxamine-versus-deferasirox-in-medicaid-patients-with-sickle-cell-disease/2024-11-19T18:55:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/concomitant-asthma-medication-use-in-patients-receiving-omalizumab--results-from-three-large-insurance-claims-databases/2024-11-19T18:56:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economics-of-the-hematopoietic-growth-factors/2024-12-19T16:59:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lifetime-costs-to-medicare-of-providing-care-to-patients-with-chronic-lymphocytic-leukemia/2025-02-28T21:50:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-skeletal-complications-and-treatment-patterns-associated-with-early-vs--delayed-zoledronic-acid-therapy-in-multiple-myeloma/2024-11-19T19:03:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-related-quality-of-life-in-patients-with-advanced-renal-cell-carcinoma-receiving-pazopanib-or-placebo-in-a-randomised-phase-iii-trial/2024-11-19T19:04:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/safety-and-treatment-patterns-of-angiogenesis-inhibitors-in-patients-with-metastatic-renal-cell-carcinoma--evidence-from-u-s--community-oncology-clinics/2024-11-19T19:04:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/increased-risks-of-developing-anxiety-and-depression-in-young-patients-with-crohn-s-disease/2024-11-19T19:05:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-post-traumatic-stress-disorder-vs-major-depressive-disorder-among-patients-covered-by-medicaid-or-private-insurance/2024-11-19T19:06:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interprofessional-education-about-decision-support-for-patients-across-cultures/2024-11-19T19:07:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-of-patients-treated-with-extended-release-oxymorphone-hcl-or-controlled-release-oxycodone-hcl/2024-11-19T19:08:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-role-of-tricyclic-antidepressants-in-the-treatment-of-fibromyalgia/2024-11-19T19:08:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-costs-and-survival-of-medicare-beneficiaries-with-early-and-advanced-parkinson-s-disease/2024-11-19T19:15:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/utilization-and-cost-comparison-of-erythropoiesis-stimulating-agents-in-inpatient-and-outpatient-hospital-settings/2025-02-28T21:51:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-impact-of-vagus-nerve-stimulation-therapy-in-patients-with-drug-resistant-epilepsy/2024-11-19T19:17:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risks-and-cost-burden-of-venous-thromboembolism-and-bleeding-for-patients-undergoing-total-hip-or-knee-replacement-in-a-managed-care-population/2024-11-19T19:18:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risks-of-developing-psychiatric-disorders-in-pediatric-patients-with-psoriasis/2024-11-19T19:19:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reduced-mortality-in-cystic-fibrosis-patients-treated-with-tobramycin-inhalation-solution/2024-11-19T19:20:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-outcomes-of-multiple-versus-single-long-acting-inhalers-in-copd/2024-11-19T19:21:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/excess-costs-associated-with-patients-with-chronic-thromboembolic-pulmonary-hypertension-in-a-u-s--privately-insured-population/2024-11-19T19:22:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tiotropium-therapy-versus-tiotropium-monotherapy-for-treating-severe-to-very-severe-copd/2024-11-19T19:23:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-pulmonary-arterial-hypertension-and-chronic-thromboembolic-pulmonary-hypertension-in-the-united-states/2024-11-19T19:23:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/excess-costs-associated-with-patients-with-pulmonary-arterial-hypertension-in-a-u-s--privately-insured-population/2024-11-19T19:24:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/therapy-persistence-and-adherence-in-patients-with-chronic-obstructive-pulmonary-disease--multiple-versus-single-long-acting-maintenance-inhalers/2024-11-19T19:25:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-costs-associated-with-dupuytren-s-contracture/2024-11-19T19:26:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-and-economic-damages--theoretical-and-practical-issues/2024-11-19T19:27:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-single-center-experience-with-low-dose-warfarin-in-patients-undergoing-total-hip-or-knee-replacement-surgery/2024-11-19T19:42:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-metastatic-breast-cancer--a-u-s--managed-care-perspective/2024-11-19T19:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-to-use-clinical-trial-data-in-court/2024-11-19T19:45:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/climate-policy--a-breath-of-fresh-air/2024-11-19T19:46:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/shut-up-and-stand-still--understanding-the-role-of-standstill-provisions-in-m-a-disputes/2024-11-19T19:46:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reliability-and-emission-impacts-of-stationary-engine-backed-demand-response-in-regional-power-markets/2024-11-19T19:49:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/promotional-reviews--an-empirical-investigation-of-online-review-manipulation/2024-11-19T19:50:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-options-for-cost-containment-raise-costs-/2024-11-19T19:51:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/implications-of-policy-interactions-for-california-s-climate-policy/2024-11-25T19:16:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/using-the-value-of-allowances-from-california-s-ghg-cap-and-trade-system/2024-11-25T19:17:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/data-exclusivity-periods-and-next-generation-improvements-to-innovator-biologics--key-issues/2024-11-25T19:17:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tools-for-handling-mortgage-based-fca-claims/2024-11-25T19:18:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/terrorism-and-the-electric-power-delivery-system/2024-11-25T19:19:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rising-rates-for-rent-a-bees/2024-11-25T19:20:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lost-in-the-clouds--the-impact-of-copyright-scope-on-investment-in-cloud-computing-ventures/2024-11-25T19:21:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/doj-s-recent-workshop-on-most-favored-nation-clauses/2025-01-08T16:41:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/personalized-medicine--trends-in-clinical-studies-based-on-national-registry-data/2025-06-30T21:00:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/summary-of-quantifiable-benefits-and-costs-related-to-select-targeted-infrastructure-replacement-programs/2024-11-25T19:24:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-direct-and-indirect-costs-among-u-s--privately-insured-employees-with-hypogonadism/2024-11-25T19:25:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/duloxetine-use-in-chronic-low-back-pain--treatment-patterns-and-costs/2024-11-25T19:25:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effect-of-asthma-exacerbations-on-health-care-costs-among-asthmatic-patients-with-moderate-and-severe-persistent-asthma/2024-11-25T19:26:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/physicians--decisions-to-prescribe-antidepressant-therapy-in-older-patients-with-depression-in-a-u-s--managed-care-plan/2024-11-25T19:27:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/asthma-severity-categorization-using-a-claims-based-algorithm-or-pulmonary-function-testing/2024-11-25T19:28:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-inhaled-corticosteroid-use-and-local-adverse-events-in-persistent-asthma/2024-11-25T19:28:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/three-lingering-design-issues-affecting-market-performance-in-california-s-ghg-cap-and-trade-program/2024-11-25T19:33:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hypoglycaemia-and-accident-risk-in-people-with-type-2-diabetes-mellitus-treated-with-non-insulin-antidiabetes-drugs/2024-11-25T19:34:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/food-safety-concerns--impact-on-prices-and-producers/2024-11-25T19:35:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-the-regulatory-environment-on-it-entrepreneurship-in-the-u-s--and-eu/2024-11-25T19:36:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/brief-of-antitrust-economists-as-amici-curiae-in-support-of-respondents/2024-11-25T19:37:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/california-s-advanced-energy-economy--advanced-energy-business-leaders--perspectives-and-recommendations-on-california-s-energy-policies/2024-11-25T19:38:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-it-worth-anything--using-surveys-in-intellectual-property-cases/2024-11-25T19:39:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/caution-required-when-using-managerial-accounting-data-in-court/2024-11-25T19:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-regulators-and-grid-operators-in-meeting-natural-gas-and-electric-coordination-challenges/2024-11-25T19:42:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-economic-perspective-on-building-labeling-policies/2024-11-25T19:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-economic-model-of-parkinson-s-disease--implications-for-slowing-progression-in-the-united-states/2024-11-25T19:44:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-the-data-protection-regulation-in-the-eu/2024-11-25T19:44:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/on-market-pricing-strategies/2024-11-25T19:45:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reflections-on-a-personal-milestone/2024-11-25T19:46:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/planning-for-offshore-energy-development/2024-11-25T19:47:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/planning-for-offshore-energy-development---summary-and-report/2024-11-25T19:47:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/planning-for-offshore-energy-development---complete/2024-11-25T19:48:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-and-validation-of-a-claims-based-prediction-model-for-copd-severity/2024-05-17T20:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-guanfacine-extended-release-as-an-adjunctive-therapy-to-a-stimulant-compared-with-stimulant-monotherapy-for-the-treatment-of-adhd/2024-11-25T19:49:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-the-right-model-for-auto-defect-suits/2024-11-25T19:50:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/vertical-practices-and-the-exclusion-of-rivals-post-eaton/2024-11-25T19:51:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/spectrum-auctions-around-the-world--an-assesment-of-international-experiences-with-auction-restrictions/2024-11-25T19:52:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-hypothetical-negotiation-and-reasonable-royalty-damages--the-tail-wagging-the-dog/2024-11-25T19:53:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/little-guidance-for-lower-courts-in-ftc-v--actavis/2024-11-25T19:54:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-the-impact-of-iso-ne-s-proposed-forward-capacity-market-performance-incentives/2024-11-25T19:55:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/problems-with-hypothesizing-reasonable-royalty-negotiation/2024-11-25T19:56:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/monday-morning-quarterbacking-and-antitrust-damages/2024-11-25T19:56:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/report-of-the-independent-advisory-panel-regarding-integration-of-renewable-energy-into-california-s-electric-system/2024-11-25T19:57:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/beyond-ab-32--post-2020-climate-policy-for-california/2024-11-25T19:58:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-attorneys-should-know-about-fda-s-medwatch-data/2024-11-25T19:58:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/opportunities-for-improving-attainment-of-quality-measures-in-patients-with-type-2-diabetes-mellitus/2025-02-28T21:49:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recent-trends-in-brand-name-and-generic-drug-competition/2024-11-25T20:00:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/project-vigilance--functional-feasibility-study-for-the-installation-of-ambri-energy-storage-batteries-at-joint-base-cape-cod/2024-11-25T20:01:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impacts-of-the-green-communities-act-on-the-massachusetts-economy--a-review-of-the-first-six-years-of-the-act-s-implementation/2024-11-25T20:02:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impacts-of-the-green-communities-act-on-the-massachusetts-economy--a-review-of-the-first-six-years-of-the-act-s-implementation--faq/2024-11-25T20:03:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/greenhouse-gas-emission-reductions-from-existing-power-plants--options-to-ensure-electric-system-reliability--report/2024-11-25T20:04:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/greenhouse-gas-emission-reductions-from-existing-power-plants--options-to-ensure-electric-system-reliability--q-and-a/2024-11-25T20:04:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/presentation-of-econometric-analyses/2024-11-25T20:05:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/applying-econometrics-to-address-class-certification/2024-06-03T13:10:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/crediting-greenhouse-gas-emission-reductions-from-energy-efficiency-investments/2024-11-25T20:06:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epa-s-clean-power-plan---states--tools-for-reducing-costs-and--increasing-benefits-to-consumers/2024-11-25T20:06:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/expert-analysis--using-simulation-to-assist-courts-in-assessing-the-prudence-of-retirement-plan-investment-decisions/2024-11-25T20:07:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/big-data-can-yield-big-insights-on-promotional-practices/2024-11-25T20:07:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/meta-analysis-of-the-efficacy-and-safety-of-bortezomib-re-treatment-in-patients-with-multiple-myeloma/2024-11-25T20:08:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-vancouver-energy-socioeconomic-impacts--primary-economic-impacts/2024-11-25T20:09:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-systematic-review-of-the-economic-and-humanistic-burden-of-illness-in-irritable-bowel-syndrome-and-chronic-constipation/2025-06-30T20:58:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comorbidities-in-patients-with-irritable-bowel-syndrome-with-constipation-or-chronic-idiopathic-constipation/2025-06-30T20:59:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incremental-direct-and-indirect-costs-of-untreated-vasomotor-symptoms/2025-02-28T21:49:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/early-evidence-suggests-gigabit-broadband-drives-gdp/2024-11-25T20:25:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-fallacy-of-inferring-collusion-from-countercyclical-prices/2024-11-25T20:28:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/random-selection-is-best-for-mdl-bellwether-trials/2024-11-25T20:29:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-epa-s-clean-power-plan--evaluation-of-energy-efficiency-program-ramp-rates-and-savings-levels/2024-05-17T20:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/gastrointestinal-comorbidities-associated-with-atrial-fibrillation/2024-11-25T20:32:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prasugrel-vs--clopidogrel-in-acute-coronary-syndrome-patients-treated-with-prasugrel/2024-11-25T20:33:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-length-of-stay-of-nonvalvular-atrial-fibrillation/2024-11-25T20:34:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-rivaroxaban-associated-with-lower-inpatient-costs-compared-to-warfarin-among-patients-with-non-valvular-atrial-fibrillation-/2024-11-25T20:35:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/weekly-risk-of-venous-thromboembolism-recurrence-in-patients-receiving-oral-anticoagulants/2024-11-25T20:36:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-comparative-effectiveness-and-safety-of-rivaroxaban-and-warfarin-in-nonvalvular-atrial-fibrillation-patients/2024-11-25T20:36:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medicaid-spending-on-contraceptive-coverage-and-pregnancy-related-care/2024-11-25T20:38:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-early-versus-late-systemic-lupus-erythematosus-diagnosis-on-clinical-and-economic-outcomes/2024-11-25T20:38:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-length-of-stay--is-rivaroxaban-associated-with-shorter-inpatient-stay-compared-to-warfarin-among-patients-with-non-valvular-atrial-fibrillation-/2024-11-25T20:40:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-factors-associated-with-myocardial-infarction-in-venous-thromboembolism-patients/2024-11-25T20:42:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/all-cause-and-disease-related-health-care-costs-associated-with-recurrent-venous-thromboembolism/2024-11-25T20:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-once-daily-versus-twice-daily-dosing-frequency-on-adherence-to-chronic-medications-among-patients-with-venous-thromboembolism/2024-11-25T20:43:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-cost-burden-associated-with-multiple-sclerosis-relapses--excess-costs-of-persons-with-ms-and-their-spouse-caregivers/2024-11-25T20:44:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-potential-of-energy-efficiency--a-resource-potentially-unlocked-by-the-clean-power-plan/2024-11-25T20:45:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/towards-understanding-the-role-of-price-in-residential-electricity-choices--evidence-from-a-natural-experiment/2024-11-25T20:46:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effect-of-patent-litigation-and-patent-assertion-entities-on-entrepreneurial-activity/2024-11-25T20:46:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electric-system-reliability-and-epa-s-clean-power-plan--tools-and-practices/2024-11-25T20:47:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-growing-economic-burden-of-depression-in-the-u-s-/2024-11-25T20:48:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electric-system-reliability-and-epa-s-clean-power-plan--the-case-of-pjm/2024-11-25T20:48:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-outcomes-among-medicare-patients-receiving-bioengineered-cellular-technologies-for-treatment-of-diabetic-foot-ulcers/2024-11-25T20:49:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-epidemiology-of-herpes-zoster-and-its-complications-in-medicare-cancer-patients/2024-11-25T20:51:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tax-shelters-or-efficient-tax-planning--a-theory-of-the-firm-perspective-on-the-economic-substance-doctrine/2025-12-10T17:19:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/nyiso-capacity-market--evaluation-of-options/2024-11-25T20:53:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/forecasting-corporate-failure--understanding-statistical-and-theoretical-approaches-to-bankruptcy-prediction/2024-05-17T20:42:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-note-on-the-economics-of-pass-through-with-two-part-tariff-pricing/2024-11-25T20:54:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/3-questions-to-ask-when-using-surveys-in-litigation/2024-08-15T19:54:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-analysis-of-dose-titration-and-serum-testosterone-level-assessments-in-patients-treated-with-topical-testosterone/2024-11-25T20:55:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/duloxetine-use-in-employees-with-low-back-pain--treatment-patterns-and-direct-and-indirect-costs/2024-11-25T20:56:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-intravenous-cancer-therapy-administration-in-patients-with-metastatic-soft-tissue-sarcoma-in-a-us-population/2024-11-25T20:57:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-prevalence-and-economic-impact-of-prescription-opioid-related-side-effects-among-patients-with-chronic-noncancer-pain/2024-11-25T20:58:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-comparative-analysis-of-medicaid-long-term-care-policies-and-their-effects-on-elderly-dual-enrollees/2024-11-25T20:59:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-burden-of-undiagnosed-opioid-abuse-among-commercially-insured-individuals/2024-11-25T21:02:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-diabetic-foot-ulcers-for-medicare-and-private-insurers/2024-11-25T21:03:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/sources-of-prescription-opioids-among-diagnosed-opioid-abusers/2024-11-25T21:07:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-diagnosed-opioid-abuse-among-commercially-insured-individuals/2024-11-25T21:08:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-costs-of-opioid-abuse-and-dependence-from-an-employer-perspective--a-retrospective-analysis-using-administrative-claims-data/2024-11-25T21:09:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/refractory-hodgkin-lymphoma-post-asct--median-overall-survival-meta-analysis/2024-11-25T21:10:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/refractory-hodgkin-lymphoma-post-autologous-transplant--meta-analysis-versus-historical-data/2024-11-25T21:11:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-direct-and-indirect-costs-of-uterine-fibroid-tumors--a-systematic-review-of-the-literature-between-2000-and-2013/2024-11-25T21:11:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-epidemiology-and-targeted-therapies-for-relapsed-and-refractory-cd30--lymphomas/2024-11-25T21:12:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-utilization-and-costs-in-women-diagnosed-with-endometriosis-before-and-after-diagnosis--a-longitudinal-analysis-of-claims-databases/2024-11-25T21:13:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-adverse-events-during-treatment-with-everolimus-plus-exemestane-or-single-agent-chemotherapy-in-patients-with-advanced-breast-cancer-in-western-europe/2024-11-25T21:14:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-analysis-of-liposomal-amphotericin-b-and-amphotericin-b-lipid-complex-in-the-treatment-of-invasive-fungal-infections-in-the-united-states/2024-11-25T21:15:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identifying-patient-subgroups-who-benefit-most-from-a-treatment--using-administrative-claims-data-to-uncover-treatment-heterogeneity/2024-11-25T21:15:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-economic-burden-of-metastatic-and-recurrent-locally-advanced-head-and-neck-cancer-patients/2024-11-25T21:16:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-costs-associated-with-bevacizumab-and-cetuximab-in-second-line-treatment-of-metastatic-colorectal-cancer/2024-11-25T21:18:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incremental-third-party-costs-associated-with-copd-exacerbations--a-retrospective-claims-analysis/2024-11-25T21:19:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-assessment-of-the-economic-and-industry-reasonableness-of-sprint-s-offer-for-clearwire/2024-11-25T21:20:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/new-ec-competition-policy-brief/2024-11-25T21:20:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/exploring-key-european-issues-that-have-significant-ramifications-for-u-s--interests/2024-11-25T21:21:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-the-prospects-for-convergence-in-collective-redress-remedies-in-the-european-union/2024-11-25T21:21:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-comparative-analysis-of-uk--and-eu--proposed-collective-action-regimes/2024-11-25T21:22:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/societal-economic-benefits-associated-with-an-extended-release-opioid-with-abuse-deterrent-technology-in-the-united-states/2024-11-25T21:23:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/outlet-types-and-the-canadian-consumer-price-index/2024-11-25T21:24:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measurement-biases-in-consumer-price-indexes/2024-11-25T21:25:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-healthcare-resource-utilization-and-costs-associated-with-ulcerative-colitis-in-a-privately-insured-employed-population-in-the-us/2024-11-25T21:26:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-effectiveness-of-pasireotide-on-health-related-quality-of-life-in-patients-with-cushing-s-disease/2024-11-25T21:27:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-health-related-quality-of-life-study-comparing-vitala-continence-control-device-versus-traditional-pouch-system-only-in-patients-with-end-colostomy/2024-11-25T21:28:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pain-relief-and-tolerability-balance-of-immediate-release-tapentadol-or-oxycodone-treatment-for-patients-with-moderate-to-severe-osteoarthritis-or-low-back-pain/2024-11-25T21:29:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/validating-migraine-specific-quality-of-life-questionnaire-v2-1-in-episodic-and-chronic-migraine/2024-11-25T21:32:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-qualitative-study-on-feasibility-of-a-web-based-women-s-health-portal-and-information-system/2024-11-25T21:33:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-novel-approach-to-estimate-the-minimally-important-difference-for-the-fatigue-impact-scale-in-multiple-sclerosis-patients/2024-11-25T21:33:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interpreting-premenstrual-symptoms-impact-survey-scores-using-outcomes-in-health-related-quality-of-life-and-sexual-drive-impact/2024-11-25T21:34:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-treatments-for-premenstrual-dysphoric-disorder/2024-11-25T21:35:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interpreting-score-differences-in-the-insomnia-severity-index--using-health-related-outcomes-to-define-the-minimally-important-difference/2024-11-25T21:43:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparability-of-the-asthma-control-test-telephone-interview-administration-format-with-self-administered-mail-out-mail-back-format/2024-12-02T03:08:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antipsychotic-medication-utilization-trends-among-texas-veterans--1997-2002/2024-12-02T03:10:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-premenstrual-dysphoric-disorder-on-health-related-quality-of-life/2024-12-02T03:11:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/factors-related-to-antipsychotic-oversupply-among-central-texas-veterans/2024-12-02T03:12:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mapping-mos-sleep-scale-scores-to-sf-6d-utility-index/2024-12-02T03:25:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/frequency-of-new-onset-diabetes-mellitus-and-use-of-antipsychotic-drugs-among-central-texas-veterans/2024-12-02T03:27:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/provision-of-pharmacy-services-in-community-health-centers-and-migrant-health-centers/2024-12-02T03:28:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rights-issues-and-creeping-acquisitions-in-india/2024-12-02T03:29:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/carbon-control-and-competitive-wholesale-electricity-markets--compliance-paths-for-efficient-market-outcomes/2024-12-02T03:30:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/average-overcharge-models-and-determining-individual-harm-in-collective-actions/2024-12-02T03:32:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ohio-s-electricity-future--assessment-of-context-and-options/2024-12-02T03:32:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electric-system-reliability-and-epa-s-clean-power-plan--the-case-of-miso/2024-12-02T03:33:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/positive-subjective-measures-in-abuse-liability-studies-and-real-world-nonmedical-use/2024-12-02T03:35:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-outcomes-in-braf-v600e-mutant-melanoma-patients-with-brain-metastases-receiving-vemurafenib-in-the-real-world-setting/2024-12-02T03:35:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/alk-rearrangement-testing-and-treatment-patterns-for-patients-with-alk-positive-non-small-cell-lung-cancer/2024-12-02T03:37:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/psoriasis-and-risk-of-diabetes-associated-microvascular-and-macrovascular-complications/2024-12-02T03:38:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-survival-and-hospitalization-rates-between-medicare-patients-with-advanced-nsclc-treated-with-bevacizumab-carboplatin-paclitaxel-and-carboplatin-paclitaxel--a-retrospective-cohort-study/2024-12-02T03:39:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/investigation-of-adverse-event-related-costs-for-patients-with-metastatic-breast-cancer-in-a-real-world-setting/2024-12-02T03:40:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-moderate-to-severe-crohn-s-disease-on-employees--salary-growth/2024-12-02T03:42:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-low-grade-adverse-events-on-health-related-quality-of-life-in-adult-patients-receiving-imatinib-or-nilotinib-for-newly-diagnosed-philadelphia-chromosome-positive-chronic-myelogenous-leukemia/2024-12-02T03:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/distribution-and-drivers-of-costs-in-type-2-diabetes-mellitus-treated-with-oral-hypoglycemic-agents--a-retrospective-claims-data-analysis/2024-12-02T03:44:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-developing-colorectal-cancer-and-benign-colorectal-neoplasm-in-patients-with-chronic-constipation/2024-12-02T03:45:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-regular-molecular-monitoring-and-tyrosine-kinase-inhibitor-therapy-adherence-in-chronic-myelogenous-leukemia-in-the-chronic-phase/2024-12-02T03:46:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-benefits-of-adequate-molecular-monitoring-in-patients-with-chronic-myelogenous-leukemia/2024-12-02T03:48:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-molecular-monitoring-and-long-term-outcomes-in-chronic-myelogenous-leukemia-patients-treated-with-first-line-imatinib/2024-12-02T03:50:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-longitudinal-analysis-of-costs-associated-with-change-in-disease-activity-in-systemic-lupus-erythematosus/2024-12-02T03:53:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-the-long-term-risk-of-recurrence-and-other-clinical-outcomes-in-gist-patients-receiving-imatinib-as-adjuvant-therapy--a-retrospective-chart-extract-based-approach/2024-12-02T03:54:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/outcomes-in-atrial-fibrillation-patients-on-combined-warfarin---antiarrhythmic-therapy/2024-12-02T03:55:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-second-line-targeted-therapies-for-metastatic-renal-cell-carcinoma--a-systematic-review-and-meta-analysis-of-real-world-observational-studies/2024-12-02T03:56:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/everolimus-and-sunitinib-for-advanced-pancreatic-neuroendocrine-tumors--a-matching-adjusted-indirect-comparison/2024-12-02T03:56:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-pulmonary-exacerbation-risk-score-among-cystic-fibrosis-patients-not-receiving-recommended-care/2024-12-02T03:57:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-treatment-patterns-and-economic-outcomes-in-metastatic-breast-cancer-patients-initiated-on-trastuzumab-versus-lapatinib--a-retrospective-analysis/2024-12-02T03:58:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hyperactivity-disorder--a-retrospective-analysis-of-patients-initiated-on-lisdexamfetamine-vs-other-medications/2024-12-02T03:59:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-therapy-augmentation-and-deviation-rates-from-the-recommended-once-daily-dosing-regimen-between-ldx-and-commonly-prescribed-long-acting-stimulants-for-the-treatment-of-adhd-in-youth-and/2024-12-02T04:00:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hyperactivity-disorder--a-retrospective-analysis/2024-12-02T04:01:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/net-metering-in-the-commonwealth-of-massachusetts--a-framework-for-evaluation/2024-12-02T04:01:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-analysis-in-fiduciary-monitoring-disputes-following-the-supreme-court-s--tibble--ruling/2026-01-16T16:18:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-and-resource-utilization-associated-with-anemia-and-rash-in-chronic-hepatitis-c-patients-treated-with-direct-acting-antiviral-agents-in-the-united-states/2024-12-02T04:03:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/don-t-let-nuke-plants-go-too-fast/2024-12-02T04:03:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-modified-approach-to-random-selection-of-bellwether-cases/2024-12-02T04:04:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/nomenclature-and-traceability-debate-for-biosimilars--small-molecule-surrogates-lend-support-for-distinguishable-nonproprietary-names/2024-12-02T04:05:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-a-telehealth-and-care-management-program-for-patients-with-chronic-obstructive-pulmonary-disease/2024-12-02T04:06:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-adherence-and-persistence-associated-with-nebivolol-or-hydrochlorothiazide-as-add-on-treatment-for-hypertension/2024-12-02T04:07:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-care-management-and-telehealth--a-longitudinal-analysis-using-medicare-data/2024-12-02T04:08:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/appraisal-arbitrage----is-there-a-delaware-advantage-/2024-12-02T04:09:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rebuttal-it-s-not-an-inappropriate-reasonable-royalty-rule/2024-12-02T04:10:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-commercial-success-at-the-u-s--patent-trial-and-appeal-board/2024-12-02T04:12:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-analysis-of-investment-and-drawdown-strategies-over-a-long-retirement-horizon/2024-12-02T04:13:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-backdating-executive-stock-options-always-costly-to-shareholders-/2024-12-02T04:14:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/power-system-reliability-in-new-england--meeting-electric-resource-needs-in-an-era-of-growing-dependence-on-natural-gas/2024-12-02T04:14:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-redemption-option--discussion-and-valuation-considerations-from-the-abi-commission-s--proposed-chapter-11-reform/2024-12-02T04:15:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-global-economic-impacts-associated-with-virtual-and-augmented-reality/2024-12-02T04:17:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/global-economic-impacts-associated-with-artificial-intelligence/2024-12-02T04:18:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-enforcement-in-two-sided-markets/2026-03-12T17:02:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ferc-revises-market-based-rate-procedures/2024-05-17T20:42:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-paris-agreement-lays-a-good-foundation-for-climate-progress/2024-12-02T04:21:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-liability-in-the-context-of-corporate-misconduct/2024-12-02T04:21:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-schizophrenia-in-the-united-states-in-2013/2024-12-02T04:23:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/4-considerations-for-residential-mass-appraisal-valuation/2024-12-02T04:23:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-the-life-sciences-industry-bank-on-biosimilars-/2024-12-02T04:24:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/correlation-or-cause--brand-name-drug-prescription-rates/2024-12-02T04:24:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/donning-and-doffing-damages--tyson-takeaways-for-antitrust/2024-12-02T04:25:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/machine-learning-algorithms-can-help-health-care-litigation/2024-12-03T16:16:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/response-to-rejoinder--clearing-up-the-confusion/2024-12-03T16:16:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-myth-of--price-disconnects--in-us-pharma-markets/2024-12-03T16:17:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/viewing-recent-opioid-regulations-in-context/2024-12-03T16:19:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-and-abuse--the-myth-of-divided-antitrust-economics/2024-12-03T16:19:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economics-of-pass-through-with-production-constraints/2024-12-03T16:21:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-value-of-der-to-d/2024-12-03T16:22:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rggi-and-co2-emissions-trading-under-the-clean-power-plan--options-for-trading-among-generating-unit/2024-12-03T16:23:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/stock-prices-aren-t-enough-for--rule-of-reason--analysis/2024-12-03T16:25:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pay-for-delay-and-stock-prices---smoking-gun-or-damp-squib/2024-12-03T16:26:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-potential-for-litigation-in-new-era-of-biosimilars/2024-12-03T16:26:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/will-expanded-eeo-1-data-collection-yield-new-insights-/2024-05-17T20:44:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-u-s--coal-industry--challenging-transitions-in-the-21st-century/2024-12-03T16:27:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/does-the-clean-power-plan-go-too-far--no-/2024-12-03T16:28:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/practical-uses-for-machine-learning-in-health-care-cases/2024-05-17T20:43:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-evaluation-of-timely-versus-delayed-use-of-tumor-necrosis-factor-inhibitors-for-treatment-of-psoriatic-arthritis-in-the-us/2024-12-03T16:28:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-systemic-glucocorticoid-related-complications-in-severe-asthma/2025-02-28T21:45:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-social-media-data-lead-to-earlier-detection-of-drug-related-adverse-events/2024-11-21T20:52:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-common-adverse-events-associated-with-metastatic-colorectal-cancer-treatment-in-the-united-states/2024-05-17T20:44:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-healthcare-costs-among-newly-diagnosed-patients-with-chronic-myeloid-leukemia-receiving-dasatinib-or-nilotinib-as-first-line-therapy-in-the-united-states/2024-05-17T20:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/systematic-literature-review-of-dpp-4-inhibitors-in-patients-with-type-2-diabetes-mellitus-and-renal-impairment/2024-12-03T16:31:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-paliperidone-palmitate-versus-oral-atypical-antipsychotics-on-health-care-resource-use-and-costs-in-veterans-with-schizophrenia/2024-12-03T16:32:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-time-to-progression-and-subsequent-survival-inceritinib-treated-patients-with-advanced-alk-positive-non-small-cell-lung-cancer/2024-12-03T16:33:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/categorizing-natural-history-trajectories-of-ambulatory-function-measured-by-the-6-minute-walk-distance-in-patients-with-duchenne-muscular-dystrophy/2024-12-03T18:08:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/excess-costs-associated-with-possible-misdiagnosis-of-alzheimer-s-disease-among-patients-with-vascular-dementia-in-a-uk-cprd-population/2024-12-03T18:09:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ledipasvir-for-hepatitis-c-genotype-1-in-japanese-patients--an-indirect-comparison/2024-12-03T18:09:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/delay-in-initiation-of-adjuvant-trastuzumab-therapy-leads-to-decreased-overall-survival-and-relapse-free-survival-in-patients-with-her2-positive-non-metastatic-breast-cancer/2024-12-03T20:14:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-and-treatment-patterns-of-cycling-between-conventional-synthetic-disease-modifying-antirheumatic-drugs-among-biologic-treated-patients-with-rheumatoid-arthritis/2024-12-03T20:15:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-brain-metastasis-among-lung-cancer-patients-in-the-united-states/2024-12-03T20:18:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-switching-to-a-non-tumor-necrosis-factor-inhibitor-versus-a-tumor-necrosis-factor-inhibitor-biologic-therapy-among-patients-with-rheumatoid-arthritis/2024-12-03T20:18:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-dosing-and-drug-costs-with-everolimus-or-axitinib-as-second-targeted-therapies-for-advanced-renal-cell-carcinoma--a-retrospective-chart-review-in-the-us/2024-12-03T20:20:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hyperactivity-disorder-treated-with-lisdexamfetamine-dimesylate-or-atomoxetine/2024-12-03T20:21:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-rejection-principle-for-sequential-tests-of-multiple-hypotheses-controlling-familywise-error-rates/2024-12-03T20:22:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-iron-chelation-therapy-and-associated-healthcare-resource-utilization-and-costs-in-medicaid-patients-with-sickle-cell-disease-and-thalassemia/2024-12-03T20:27:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/daclatasvir---sofosbuvir-versus-standard-of-care-for-hepatitis-c-genotype-3--a-matching-adjusted-indirect-comparison/2024-12-03T20:34:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/drug-drug-interaction-associated-with-mold-active-triazoles-among-hospitalized-patients/2024-12-03T20:40:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer-receiving-everolimus-based-therapy-or-chemotherapy/2024-12-03T20:44:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer--a-retrospective-us-claims-study/2024-12-03T20:45:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-and-incremental-cost-per-responder-of-methotrexate-versus-apremilast-for-methotrexate-naive-patients-with-psoriasis/2024-12-03T20:46:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/network-meta-analysis-and-cost-per-responder-of-tumor-necrosis-factor-alpha-and-interleukin-inhibitors-in-the-treatment-of-active-ankylosing-spondylitis/2024-12-03T20:46:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-work-loss-in-dermatomyositis-and-polymyositis-patients-in-a-privately-insured-us-population/2024-12-03T20:48:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-happens-after-a-single-surgical-intervention-for-hidradenitis-suppurativa--a-retrospective-claims-based-analysis/2024-12-03T20:54:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/management-of-epidermal-growth-factor-receptor-inhibitor-associated-rash--a-systematic-review/2024-12-03T20:55:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/daclatasvir-and-sofosbuvir-versus-sofosbuvir-and-ribavirin-in-patients-with-chronic-hepatitis-c-coinfected-with-hiv--a-matching-adjusted-indirect-comparison/2024-12-03T20:56:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer-in-the-united-states--a-physician-survey/2024-12-03T20:58:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/relationship-between-brain-volume-loss-and-cognitive-outcomes-among-patients-with-multiple-sclerosis--a-systematic-literature-review/2024-12-05T15:57:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-evaluation-of-treatment-patterns-and-outcomes-in-elderly-patients-newly-diagnosed-with-acute-myeloid-leukemia--a-retrospective-analysis-of-electronic-medical-records-from-us-community-oncology-prac/2025-06-30T20:57:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/updated-trends-in-us-brand-name-and-generic-drug-competition/2024-12-06T16:25:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/validation-of-a-new-risk-measure-for-chronic-obstructive-pulmonary-disease-exacerbation-using-health-insurance-claims-data/2024-12-06T16:27:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-everolimus-and-axitinib-as-second-targeted-therapies-for-metastatic-renal-cell-carcinoma-in-the-us--a-retrospective-chart-review/2024-12-06T16:28:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-medicaid-spending-in-schizoaffective-patients-treated-with-once-monthly-paliperidone-palmitate-or-oral-atypical-antipsychotics/2025-02-28T21:48:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer-receiving-everolimus-based-therapy-or-chemotherapy--a-retrospective-cla/2024-12-06T16:31:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-and-validation-of-an-algorithm-for-identifying-urinary-retention-in-a-cohort-of-patients-with-epilepsy-in-a-large-us-administrative-claims-database/2024-12-06T16:38:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-direct-and-indirect-costs-associated-with-endometriosis--a-systematic-literature-review/2024-12-06T16:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--mbc-patients-with-multiple-metastatic-sites/2024-12-06T19:24:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/venous-thromboembolism-and-cardiovascular-disease-complications-in-menopausal-women-using-transdermal-versus-oral-estrogen-therapy/2024-12-06T19:30:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/human-epidermal-growth-factor-receptor-2-negative-metastatic-breast-cancer--a-retrospective-c/2024-12-06T19:31:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/changes-in-practice-patterns-of-clopidogrel-in-combination-with-proton-pump-inhibitors-after-an-fda-safety-communication/2024-12-06T20:02:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparisons-of-efficacy-of-bay-81-8973-vs-two-recombinant-factor-viii-for-the-prophylactic-treatment-of-severe-hemophilia-a/2024-12-09T21:46:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/public-health-impact-of-complete-and-incomplete-rotavirus-vaccination-among-commercially-and-medicaid-insured-children-in-the-united-states/2024-12-09T21:47:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-analysis-of-the-impact-of-increasing-access-to-long-acting-reversible-contraceptives-in-a-commercially-insured-population/2024-12-09T21:48:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ml-compared-with-other-basal-insulin-therapies-in-patients-with-type-2-diabetes-mellitus--a-network-meta-analysis/2024-12-09T21:51:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survival-in-patients-with-non-metastatic-breast-cancer-treated-with-adjuvant-trastuzumab-in-clinical-practice/2024-12-09T21:52:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/variation-in-care-for-patients-with-irritable-bowel-syndrome-in-the-united-states/2024-12-09T21:53:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reliable-analysis-is-key-to-addressing-ascertainability/2024-05-17T20:44:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-bad-data-analyses-can-sabotage-discrimination-cases/2024-05-17T20:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/millstone-power-station---providing-support-for-achieving-connecticut-s-clean-energy-goals/2024-05-17T20:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/challenges-for-empirical-research-on-rpm/2024-05-17T20:41:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-benefit-based-conjoint-analysis-benefit-product-design-/2024-05-17T20:41:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-proposed-northern-pass-transmission-project--assessing-its-impacts-on-new-hampshire/2024-05-17T20:44:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-comparison-of-residential-water-bills--cal-water-oroville-and-south-feather-water---power-agency/2024-07-01T18:15:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-early-origins-of-birth-order-differences-in-children-s-outcomes-and-parental-behavior/2024-05-17T20:44:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/racial-discrimination-in-the-labor-market--theory-and-empirics/2024-05-17T20:43:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-dose-ratio-of-subcutaneous-to-intravenous-immunoglobulin-therapy-among-patients-with-primary-immunodeficiency-disease-switching-to-20--subcutaneous-immunoglobulin-therapy/2024-05-17T20:42:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/study-to-establish-new-york-electricity-market-icap-demand-curve-parameters/2024-05-17T20:44:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/murky-markets--a-review-of-ferc-s-determination-of-submarkets-in-wholesale-electric-power-mergers/2024-05-17T20:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/asunaprevir-versus-ifn-based-regimens-in-genotype-1b-hepatitis-c-virus-infection/2024-05-17T20:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-biological-treatments-for-moderate-to-severe-psoriasis--a-network-meta-analysis-adjusting-for-cross-trial-differences-in-reference-arm-response/2024-05-17T20:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/new-technologies-and-obsolete-analyses--internet-search-and-the-analysis-of-market-definition/2024-06-11T15:12:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-consequences-of-contested-government-takeovers-of-investor-owned-water-utilities/2024-07-01T18:18:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-consumers-really-think-about-reference-price-labels/2024-05-17T20:44:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ensuring-validity-and-admissibility-of-consumer-surveys/2024-05-17T20:42:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patterns-of-disease-monitoring-and-treatment-among-patients-with-tuberous-sclerosis-complex-related-angiomyolipomas/2024-05-17T20:43:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-lifetimes-of-hydrophobic-amino-acid-pairs-measured-directly-from-molecular-dynamics-simulations/2024-05-17T20:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tracing-the-path-to-health-care-investigation-settlements/2024-05-17T20:44:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/proliferation-and-apoptosis-of-smooth-muscle-cells-in-benign-prostate-hyperplasia/2024-05-17T20:43:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/certain-and-progressive-methylation-of-histone-h4-at-lysine-20-during-the-cell-cycle/2024-05-17T20:41:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-risk-score-for-fluconazole-failure-among-patients-with-candidemia/2024-05-17T20:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-isavuconazole-vs--voriconazole-as-first-line-treatment-for-invasive-aspergillosis/2024-05-17T20:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/domains-of-heterochromatin-protein-1-required-for-drosophila-melanogaster-heterochromatin-spreading/2024-05-17T20:42:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-multiple-facets-of-histone-h4-lysine-20-methylation/2024-05-17T20:44:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/preferential-dimethylation-of-histone-h4-lysine-20-by-suv4-20/2024-05-17T20:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/expert-analysis-of-class-certification-issues/2024-05-17T20:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-analysis-of-nonpatent-intellectual-property-rights-and-damages-measures/2024-05-17T20:42:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/federal-securities-acts-and-areas-of-expert-analysis/2024-05-17T20:42:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/phase-ii-assessment-of-the-competitive-effects-associated-with-the-new-gtld-program/2024-05-17T20:43:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/enforcement-of-anticollusion-laws-against-domestic-and-foreign-firms/2025-01-10T16:10:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rggi-and-emissions-allowance-trading--options-for-voluntary-cooperation-among-rggi-and-non-rggi-states/2024-05-17T20:44:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survey-and-real-world-data--a-winning-combination/2024-05-17T20:44:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/enhancing-the-resilience-of-the-nation-s-electricity-system/2024-05-17T20:42:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/over-declaration-of-standard-essential-patents-and-determinants-of-essentiality/2024-05-17T20:43:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/decision-making-in-a-world-of-comparative-effectiveness-research/2024-05-17T20:42:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/introducing-decision-making-in-a-world-of-comparative-effectiveness-research/2024-05-17T20:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perspectives-of-comparative-effectiveness-research-from-the-world-of-decision-making/2024-05-17T20:43:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perspectives-on-the-use-of-comparative-effectiveness-research-by-life-sciences-executives--an-interview-with-a-senior-executive-at-an-international-life-science-company/2024-05-17T20:43:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perspectives-on-the-common-drug-review-process-at-the-canadian-agency-for-drugs-and-technologies-in-health/2024-05-17T20:43:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-non-pharmaceutical-technologies-at-the-canadian-agency-for-drugs-and-technologies-in-health/2024-05-17T20:42:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/legal-considerations-in-a-world-of-comparative-effectiveness-research/2024-05-17T20:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparisons--a-brief-history-and-a-practical-look-forward/2024-05-17T20:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perspectives-on-the-use-of-comparative-effectiveness-research-by-life-sciences-executives--an-interview-with-mike-bonney/2024-05-17T20:43:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/managing-multiple-expert-witnesses--best-practices-and-pitfalls/2024-05-17T20:43:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-new-standard-for-suspicious-order-monitoring/2024-05-17T20:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-ocrelizumab-versus-subcutaneous-interferon-beta-1a-for-the-treatment-of-relapsing-multiple-sclerosis/2024-05-17T20:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/insights-on-provider-consolidation-and-narrow-networks/2024-05-17T20:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/marijuana-legalization-implications-for-massachusetts/2024-05-17T20:43:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consider-value-vs--budget-impact-in-mass--drug-prices/2024-05-17T20:42:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-related-quality-of-life-and-work-productivity-associated-with-hiscr-and-nrs30-response-among-patients-with-moderate-to-severe-hidradenitis-suppurativa/2024-10-21T15:18:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/natural-gas-pipeline-certification--policy-considerations-for-a-changing-industry/2026-03-05T14:52:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/united-states--economics/2024-05-17T20:44:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/capacity-resource-performance-in-nyiso-markets--an-assessment-of-wholesale-market-options/2024-05-17T20:41:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/apolipoprotein-c-iii-and-high-density-lipoprotein-subspecies-defined-by-apolipoprotein-c-iii-in-relation-to-diabetes-risk/2024-05-17T20:41:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-early-outcomes-of-alk-positive-non-small-cell-lung-cancer-patients-receiving-ceritinib--a-chart-review-study/2024-05-17T20:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/monitoring-for-and-characterizing-crizotinib-progression--a-chart-review-of-alk-positive-non-small-cell-lung-cancer-patients/2024-05-17T20:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-of-acute-ischemic-stroke-treatment-with-intravenous-recombinant-tissue-plasminogen-activator/2024-05-17T20:43:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/readmission-risk-in-chronic-obstructive-pulmonary-disease-patients--comparative-study-of-nebulized-beta2-agonists/2024-05-17T20:43:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-services-utilization-among-fee-for-service-medicare-and-medicaid-patients-under-age-65-with-behavioral-health-illness-at-an-urban-safety-net-hospital/2024-05-17T20:42:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/achievement-of-glycated-hemoglobin-goals-in-the-us-remains-unchanged-through-2014/2024-05-17T20:41:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-among-patients-with-advanced-gastric-cancer-in-south-korea/2024-05-17T20:43:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-bipolar-i-disorder-in-the-united-states-in-2015/2024-05-17T20:44:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/importance-of-balancing-follow-up-time-and-impact-of-oral-anticoagulant-users--selection-when-evaluating-medication-adherence-in-atrial-fibrillation-patients-treated-with-rivaroxaban-and-apixaban/2024-05-17T20:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/maintenance-of-weight-loss-or-stability-in-subjects-with-obesity--a-retrospective-longitudinal-analysis-of-a-real-world-population/2024-05-17T20:43:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/functional-limitations-and-health-care-resource-utilization-for-individuals-with-cognitive-impairment-without-dementia--findings-from-a-united-states-population-based-survey/2024-05-17T20:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-long-acting-beta2-agonists-as-monotherapy-for-chronic-obstructive-pulmonary-disease--a-network-meta-analysis/2024-05-17T20:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/age-and-outcomes-of-primary-prevention-implantable-cardioverter-defibrillators-in-patients-with-nonischemic-systolic-heart-failure/2024-05-17T20:41:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-before-and-after-perampanel-initiation-among-patients-with-epilepsy-in-the-united-states/2024-05-17T20:42:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/access-to-cancer-specialist-care-and-treatment-in-patients-with-advanced-stage-lung-cancer/2024-05-17T20:41:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/poor-early-response-to-methotrexate-portends-inadequate-long-term-outcomes-in-patients-with-moderate-to-severe-psoriasis--evidence-from-2-phase-3-clinical-trials/2024-05-17T20:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/inpatient-admissions-and-costs-associated-with-persistent-use-of-dalfampridine-extended-release-in-multiple-sclerosis--a-claims-database-analysis/2024-05-17T20:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-in-advanced-pancreatic-neuroendocrine-tumors-in-the-era-of-targeted-therapy--perspectives-from-an-academic-tertiary-center-and-community-oncology-practices/2024-05-17T20:44:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/benefit-risk-trade-offs-for-treatment-decisions-in-moderate-to-severe-rheumatoid-arthritis--focus-on-the-patient-perspective/2024-05-17T20:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/improvement-of-carcinoid-syndrome-symptoms-following-treatment-with-above-standard-dose-of-octreotide-lar/2024-05-17T20:42:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-and-costs-per-responder-among-biologic-treatments-for-moderate-to-severe-plaque-psoriasis-in-japan/2024-05-17T20:43:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-effectiveness-among-patients-with-metastatic-colorectal-cancer-treated-with-ziv-aflibercept-in-community-oncology-practices-in-the-usa/2024-05-17T20:44:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overall-survival-in-patients-with-glioblastoma-before-and-after-bevacizumab-approval/2024-05-17T20:43:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/baseline-characteristics-and-treatment-patterns-of-patients-with-schizophrenia-initiated-on-once-every-three-months-paliperidone-palmitate-in-a-real-world-setting/2025-02-28T21:41:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/out-of-pocket-medical-costs-and-third-party-healthcare-costs-for-children-with-down-syndrome/2024-05-17T20:43:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-for-venous-thromboembolism-recurrence-among-rivaroxaban-treated-patients-who-continued-versus-discontinued-therapy--analyses-among-patients-with-vte/2024-05-17T20:44:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-opioid-abuse--updated-findings/2024-05-17T20:44:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/same-day-hiv-testing-with-initiation-of-antiretroviral-therapy-versus-standard-care-for-persons-living-with-hiv--a-randomized-unblinded-trial/2024-05-17T20:44:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/public-health-impact-of-rotarix-vaccination-among-commercially-insured-children-in-the-united-states/2024-05-17T20:43:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-costs-in-patients-with-chronic-myeloid-leukemia-with-better-adherence-to-tyrosine-kinase-inhibitors-and-increased-molecular-monitoring-frequency/2024-07-12T17:32:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-paliperidone-palmitate-versus-oral-atypical-antipsychotics-on-health-care-resource-use-and-costs-in-veterans-with-schizophrenia-and-comorbid-substance-abuse/2024-05-17T20:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/attributes-of-nuclear-imaging-centers-impacting-physician-referrals-for-single-photon-emission-computed-tomography-myocardial-perfusion-imaging-tests/2024-05-17T20:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/nilotinib-versus-dasatinib-as-second-line-therapy-in-patients-with-philadelphia-chromosome-positive-chronic-myeloid-leukemia-in-chronic-phase-who-are-resistant-or-intolerant-to-imatinib--a-cost-effect/2024-05-17T20:43:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-and-outcomes-of-alk--non-small-cell-lung-cancer-patients-in-korea/2024-05-17T20:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-and-associated-incremental-costs-of-treatment-with-enzalutamide-versus-abiraterone-acetate-plus-prednisone-in-chemotherapy-naive-patients-with-metastatic-castration-resistant-pr/2024-05-17T20:43:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-following-allogeneic-hematopoietic-stem-cell-transplant-in-patients-with-diffuse-large-b-cell-lymphoma/2024-05-17T20:42:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-symptomatic-skeletal-events-on-health-care-resource-utilization-and-quality-of-life-among-patients-with-castration-resistant-prostate-cancer-and-bone-metastases/2024-05-17T20:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-costs-of-ischemic-stroke-by-discharge-status/2024-05-17T20:43:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/outcomes-based-contracting-experience--research-findings-from-u-s--and-european-stakeholders/2024-05-17T20:43:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/stroke-risk-reduction-outweighed-bleeding-risk-increase-from-vitamin-k-antagonist-treatment-among-nonvalvular-atrial-fibrillation-patients-with-high-stroke-risk-and-low-bleeding-risk/2024-05-17T20:44:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overall-survival-with-ponatinib-versus-allogeneic-stem-cell-transplantation-in-philadelphia-chromosome-positive-leukemias-with-the-t315i-mutation/2024-05-17T20:43:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-characteristics-and-overall-survival-in-patients-with-post-docetaxel-metastatic-castration-resistant-prostate-cancer-in-the-community-setting/2024-05-17T20:43:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-characteristics-and-outcomes-of-patients-wth-metastatic-castration-resistant-prostate-cancer-receiving-chemotherapy-versus-androgen-receptor-targeted-therapy-after-failure-of-first-line-and/2024-05-17T20:43:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-survival-outcomes-and-prognostic-factors-among-patients-receiving-first-targeted-therapy-for-advanced-renal-cell-carcinoma--a-seer-medicare-database-analysis/2024-05-17T20:43:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patterns-of-care-among-patients-receiving-sequential-targeted-therapies-for-advanced-renal-cell-carcinoma--a-retrospective-chart-review-in-the-usa/2024-05-17T20:43:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/basal-insulin-initiation-use-and-experience-among-people-with-type-2-diabetes-mellitus-with-different-patterns-of-persistence--results-from-a-multi-national-survey/2024-05-17T20:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-persistence-and-hospitalization-rates-among-patients-with-schizophrenia--a-quasi-experiment-to-evaluate-a-patient-information-program/2025-02-28T21:41:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/duration-of-treatment-in-prostate-cancer-patients-treated-with-abiraterone-acetate-or-enzalutamide/2024-05-17T20:42:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-in-medicaid-patients-with-schizophrenia-initiated-on-a-first--or-second-generation-long-acting-injectable-versus-oral-antipsychotic/2024-05-17T20:44:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-treatment-patterns-and-healthcare-costs-associated-with-probable-lennox-gastaut-syndrome/2024-05-17T20:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-sarcoidosis-in-a-commercially-insured-population-in-the-united-states/2024-05-17T20:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/high-cost-sarcoidosis-patients-in-the-united-states--patient-characteristics-and-patterns-of-health-care-resource-utilization/2024-05-17T20:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-burden-of-hepatorenal-syndrome-among-commercially-insured-and-medicare-patients-in-the-united-states/2024-05-17T20:44:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-systemic-corticosteroid-exposure--a-systematic-literature-review/2024-05-17T20:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/diagnostic-yield-of-active-case-finding-for-tuberculosis-and-hiv-at-the-household-level-in-slums-in-haiti/2024-05-17T20:42:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/opioid-abuse--a-detailed-examination-of-cost-drivers-over-a-24-month-follow-up-period--journal-of-managed-care-and-specialty-pharmacy/2024-05-17T20:43:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/drivers-of-excess-costs-of-opioid-abuse-among-a-commercially-insured-population/2024-05-17T20:42:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retreatment-rates-among-endometriosis-patients-undergoing-hysterectomy-or-laparoscopy/2024-05-17T20:44:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-adalimumab-versus-secukinumab-for-the-treatment-of-psoriatic-arthritis--a-matching-adjusted-indirect-comparison/2024-05-17T20:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/can-matching-adjusted-indirect-comparison-methods-mitigate-placebo-response-differences-among-patient-populations-in-adjunctive-trials-of-brivaracetam-and-levetiracetam-/2024-05-17T20:41:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-outcomes-in-elderly-advanced-renal-cell-carcinoma-patients-starting-pazopanib-or-sunitinib-treatment--a-retrospective-medicare-claims-analysis/2024-05-17T20:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-renal-function-on-ischemic-stroke-and-major-bleeding-rates-in-nonvalvular-atrial-fibrillation-patients-treated-with-warfarin-or-rivaroxaban--a-retrospective-cohort-study-using-real-world-evi/2024-05-17T20:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-associated-with-switching-or-discontinuation-from-anti-tnf-inhibitors-for-nonmedical-reasons/2024-05-17T20:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cardiovascular-event-risk-assessment-in-psoriasis-patients-treated-with-tumor-necrosis-factor-alpha-inhibitors-versus-methotrexate/2024-05-17T20:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/quality-measure-and-weight-loss-assessment-in-patients-with-type-2-diabetes-mellitus-treated-with-canagliflozin-or-dipeptidyl-peptidase-4-inhibitors/2025-02-28T21:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/relationship-between-patient-copayments-in-medicare-part-d-and-vaccination-claim-status-for-herpes-zoster-and-tetanus-diphtheria-acellular-pertussis/2024-05-17T20:44:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effectiveness-and-healthcare-costs-among-stabilised-rheumatoid-arthritis-patients-with-dose-reduction-of-adalimumab-or-etanercept-in-real-world/2024-05-17T20:42:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--advanced-breast-cancer-/2024-05-17T20:44:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hyperactivity-disorder-in-a-commercially-insured-population-in-the-united-states/2024-05-17T20:43:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hyperactivity-disorder-in-the-uk/2024-05-17T20:41:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/introduction-to-lost-profits/2024-05-17T20:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/analysis-of-cost-behavior/2024-05-17T20:41:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/using-net-cash-flow-versus-accrual-net-income/2024-05-17T20:44:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-ability-to-achieve-lost-sales-as-a-consideration-in-damages-analyses/2024-05-17T20:44:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fiscal-state-aid--are-us-companies-being-unfairly-targeted-/2025-01-10T16:08:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prejudice-and-racial-matches-in-employment/2024-05-17T20:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/avoiding-bias--ensuring-validity-and-admissibility-of-survey-evidence-in-litigations/2024-05-17T20:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consumer-surveys-in-trademark-infringement-litigation--fiji-vs--viti-case-study/2025-12-10T17:19:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recent-developments-in-litigation-and-regulation-related-to-no-hire-and-employee-non-compete-agreements--implications-for-franchise-systems/2024-05-17T20:44:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-department-of-justice-and-federal-trade-commission-guidance-for-human-resources-professionals-and-recent-comments-by-enforcement-officials-related-to-no-poaching-agreements/2025-07-07T13:51:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/are-workers-willing-to-pay-to-join-a-better-team-/2024-05-17T20:41:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competition-drives-rapid-growth-in-california-communications-market/2024-07-01T18:18:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/proactive-pay-equity-studies-can-shield-mass--employers/2024-05-17T20:43:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/music-consumption-and-marketing-science--does-spotify-change-users--music-consumption-/2024-05-17T20:43:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-primer-on-bargaining--how-mergers-may-affect-negotiated-prices/2024-05-17T20:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/claims-based-risk-model-for-first-severe-copd-exacerbation/2024-05-17T20:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/spontaneous-urticaria-in-the-united-states/2024-05-17T20:44:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-characteristics-and-outcomes-associated-with-receiving-an-earlier-versus-later-diagnosis-of-probable-alzheimer-s-disease/2024-05-17T20:43:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-analysis-of-braf-gene-mutation-testing-in-real-world-practice-using-claims-data/2024-05-17T20:42:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/implications-of-stroke-and-bleeding-risk-scores-and-comorbidities-on-episode-based-bundled-payments-for-patients-with-nonvalvular-atrial-fibrillation/2024-05-17T20:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-prevalence-of-hyperkalemia-in-the-united-states/2024-05-17T20:44:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-utilization-of-molecular-diagnostic-testing-and-matched-drug-therapies-in-the-treatment-of-metastatic-cancers/2025-06-30T20:51:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-cost-burden-and-change-of-employment-status-in-treatment-resistant-depression--a-matched-cohort-study-using-a-us-commercial-claims-database/2024-05-17T20:42:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-patients-with-inadequate-response-to-targeted-immunomodulators-for-rheumatoid-arthritis/2024-05-17T20:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/increased-prevalence-of-cancer-in-adult-patients-with-psoriasis-in-the-united-states--a-claims-based-analysis/2024-05-17T20:43:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-costs-associated-with-adverse-events-in-patients-with-cancer/2024-05-17T20:41:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-psoriasis-in-children-and-adolescents-in-the-united-states--a-claims-based-analysis/2024-05-17T20:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer-in-us-community-oncology-practices--an-observational-study/2024-05-17T20:42:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-comparison-of-continued-anticoagulation-with-rivaroxaban-versus-placebo-based-on-the-1-year-einstein-extension-trial-efficacy-and-safety-results/2024-05-17T20:42:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/one-year-effect-of-the-medicare-annual-wellness-visit-on-detection-of-cognitive-impairment--a-cohort-study/2024-05-17T20:43:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hba1c-control-and-cost-effectiveness-in-patients-with-type-2-diabetes-mellitus-initiated-on-canagliflozin-or-a-glucagon-like-peptide-1-receptor-agonist-in-a-real-world-setting/2025-02-28T21:35:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/quality-goal-attainment-and-maintenance-in-patients-with-type-ii-diabetes-mellitus-initiated-on-canagliflozin-or-a-glucagon-like-peptide-1-receptor-agonist-in-an-actual-practice-setting/2025-02-28T21:36:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/insurance-switching-and-mismatch-between-the-costs-and-benefits-of-new-technologies/2024-11-22T15:43:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-ceritinib-in-previously-untreated-anaplastic-lymphoma-kinase-positive-metastatic-non-small-cell-lung-cancer-in-the-united-states/2024-05-17T20:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-medicaid-spending-in-comorbid-schizophrenia-populations--once-monthly-paliperidone-palmitate-versus-oral-atypical-antipsychotics/2024-05-17T20:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-adalimumab-and-etanercept-for-the-treatment-of-moderate-to-severe-psoriasis--an-indirect-comparison-using-individual-patient-data-from-randomized-trials/2024-05-17T20:42:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-treatment-failure-in-chronic-lymphocytic-leukemia-patients/2025-02-28T21:36:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-iron-chelation-therapy-patients-switched-deferasirox-dispersible-tablets-to-deferasirox-film-coated/2024-05-17T20:41:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/procalcitonin-guidance-in-patients-with-lower-respiratory-tract-infections--a-systematic-review-and-meta-analysis/2024-05-17T20:43:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effectiveness-and-safety-of-anticoagulants-for-the-treatment-of-venous-thromboembolism-in-patients-with-cancer/2024-05-17T20:42:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/severe-adverse-events-impact-overall-survival-and-costs-in-elderly-patients-with-advanced-non-small-cell-lung-cancer-on-second-line-therapy/2024-05-17T20:44:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer--a-network-meta-analysis/2024-05-17T20:43:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-persistence-with-fingolimod-for-the-treatment-of-multiple-sclerosis--a-systematic-review-and-meta-analysis/2024-05-17T20:43:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-and-costs-per-responder-among-biologic-treatments-for-moderate-to-severe-psoriasis--a-network-meta-analysis/2024-05-17T20:43:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/her2--metastatic-breast-cancer-among-adult-premenopausal-women/2024-05-17T20:42:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-cost-of-hyperkalemia-in-the-united-states/2024-05-17T20:44:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-use-and-cost-associated-with-varying-dosages-of-extended-corticosteroid-exposure-in-a-us-population/2024-05-17T20:42:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/quantitative-characterization-of-the-relationship-between-levels-of-extended-corticosteroid-use-and-related-adverse-events-in-a-us-population/2024-05-17T20:43:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-of-ponatinib-versus-earlier-generation-tyrosine-kinase-inhibitors-for-front-line-treatment-of-newly-diagnosed-philadelphia-positive-acute-lymphoblastic-leukemia/2024-05-17T20:42:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-and-costs-per-responder-among-biologic-treatments-for-moderate-to-severe-psoriasis/2024-05-17T20:43:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/role-of-cost-sharing-subsidies-on-the-initiation-of-and-adherence-to-tyrosine-kinase-inhibitor-therapy-by-medicare-beneficiaries-with-chronic-myeloid-leukemia/2024-05-17T20:44:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/systematic-literature-review-and-meta-analysis-of-tumor-necrosis-factor-alpha-experienced-rheumatoid-arthritis/2024-05-17T20:44:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retention-in-care-among-patients-with-early-hiv-disease-in-haiti/2024-05-17T20:44:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/understanding-the-gap-between-efficacy-in-randomized-controlled-trials-and-effectiveness-in-real-world-use-of-glp-1-ra-and-dpp-4-therapies-in-patients-with-type-2-diabetes/2024-05-17T20:44:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-in-patients-with-advanced-gastric-cancer-in-taiwan/2024-05-17T20:44:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparing-the-cost-of-treatment-with-octreotide-long-acting-release-versus-lanreotide-in-patients-with-metastatic-gastrointestinal-neuroendocrine-tumors/2024-05-17T20:42:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-and-safety-of-procalcitonin-guidance-in-patients-with-suspected-or-confirmed-sepsis--a-systematic-review-and-meta-analysis/2024-05-17T20:42:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/keeping-covenants--getting-debt-ratios-right/2024-05-17T20:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/are-payers-ready-to-address-the-financial-challenges-associated-with-gene-therapy-/2024-11-22T15:45:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/vehicle-fuel-economy-and-air-pollution-standards--a-literature-review-of-the-rebound-effect/2024-05-17T20:44:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-expanding-carbon-cap-and-trade-regime--a-decade-of-experience-with-rggi-charts-a-path-forward/2024-05-17T20:41:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-tyranny-of-market-shares--incorporating-survey-based-evidence-into-merger-analysis/2024-05-17T20:44:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/we-need-to-improve-medicare-s-annual-wellness-visit-to-better-detect-early-dementia/2024-05-17T20:44:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/b-vaccination-series-completion-among-us-adults--a-claims-based-analysis/2024-05-17T20:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-and-costs-of-accidents-among-attention-deficit-hyperactivity-disorder-patients/2024-12-09T21:55:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/whats-so-different-about-anxiety-disorders-such-as-phobias-/2024-12-19T17:06:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/money-cant-buy-happiness/2024-12-09T22:00:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/attention-deficit-hyperactivity-disorder--increased-costs-for-patients-and-their-families/2024-12-09T22:01:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-workplace-burden-of-depression--underlying-causes-recent-empirical-findings-and-future-directions/2024-12-19T17:08:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/savings-in-direct-medical-costs-from-the-use-of-tobi-tobramycin-solution-for-inhalation-in-patients-with-cystic-fibrosis/2024-12-09T22:03:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lifetime-medical-costs-for-women--cardiovascular-disease-diabetes-and-stress-urinary-incontinence/2024-12-09T22:08:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/productivity-loss-due-to-irritable-bowel-syndromereply/2024-12-09T22:08:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/l-evolution-du-regime-d-assurance-medicament-changes-in-the-drug-prescription-coverage-in-quebec/2024-12-19T17:11:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/when-can-a-medicare-insured-group-mig-succeed-/2024-12-19T17:47:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/la-performance-des-clsc-au-quebec-local-health-clinic-performance-in-quebec/2024-12-09T22:19:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measuring-hospital-efficiency-in-the-presence-of-quasi-fixed-inputs--an-analysis-of-quebec-hospitals/2024-12-09T22:21:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-unemployment-insurance-on-job-search-productivity-the-reservation-wage-the-probability-of-re-employment-and-the-post-displacement-wage/2024-12-19T17:16:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effect-of-deregulation-on-employee-earnings--pilots-flight-attendants-and-mechanics-1959-1992/2024-12-09T22:32:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-tale-of-two-taxes-a-challenge-to-hill/2024-12-09T22:33:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/using-existing-tools-to-pry-open-transmissiona-new-england-proposal/2024-12-09T22:35:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/needed--broad-perspective-fresh-ideas/2024-12-19T17:30:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-equity-capital-estimation--methodology-measurement-issues-data-and-regression-results/2024-12-09T22:37:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/power-asset-valuation--real-options-ancillary-services-and-environmental-risks/2024-12-19T17:34:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/at-the-electricity-resource-bazaar-lessons-from-case-studies-of-integrated-bidding-in-new-york/2024-12-19T17:36:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/contract-paths-phase-shifters-and-efficient-electricity-trade/2024-12-09T22:46:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-of-attention-deficit-hyperactivity-disorder-adhd-in-the-us--excess-costs-of-persons-with-adhd-and-their-family-members-in-2000/2024-12-09T22:47:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-analysis-of-the-diffusion-of-new-antidepressants--variety-quality-and-marketing-efforts/2024-12-09T22:47:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-conflict-impact-and-common-methods-of-proof-in-intermediate-indirect-purchaser-class-action-litigation/2024-12-09T22:48:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-prevalence-and-effects-of-adult-attention-deficit-hyperactivity-disorder-on-work-performance-in-a-nationally-representative-sample-of-workers/2024-12-09T22:49:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-prevalence-and-correlates-of-nonaffective-psychosis-in-the-national-comorbidity-survey-replication-ncs-r/2024-12-09T22:50:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-antihypertensive-drugs-on-the-number-and-risk-of-death-stroke-and-myocardial-infarction-in-the-united-states/2024-12-09T22:52:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dosing-patterns-treatment-costs-and-frequency-of-physician-visits-in-adults-with-cancer-receiving-erythropoietic-agents-in-managed-care-organizations/2024-12-09T22:52:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact--and-treatment-of-anemia-in-the-elderly---clinical-epidemiological-and-economic-perspectives/2024-12-09T22:53:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/as-reservoirs-fall-prices-should-rise/2024-12-09T22:54:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/authorized-generic-drugs-price-competition-and-consumers-welfare/2024-12-09T22:57:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-costs-of-adults-treated-for-attention-deficit-hyperactivity-disorder-who-received-alternative-drug-therapies/2024-12-09T22:57:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-retrospective-claims-database-analysis-to-assess-patterns-of-interstitial-cystitis--ic-diagnosis/2024-12-10T14:51:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/decoding-developments-in-todays-electric-industry--ten-points-in-the-prism/2024-12-10T14:54:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hpv-prevalence-e6-sequence-variation-and-physical-state-of-hpv16-isolates-from-patients-with-cervical-cancer-in-sichuan-china/2024-12-10T14:55:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/employees-with-fibromyalgia--medical-comorbidity-healthcare-costs-and-work-loss/2024-12-10T14:55:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/sensation-seeking-overconfidence-and-trading-activity/2024-12-10T14:58:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/linking-tradable-permit-systems-for-greenhouse-gas-emissions--opportunities-implications-and-challenges/2024-12-10T14:59:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-quality-of-life-and-treatment-compliance-associated-with-antibiotic-therapies-in-patients-with-cystic-fibrosis--a-review-of-the-literature/2024-12-10T15:00:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-implications-and-uncertainties-of-obtaining-permanent-injunctive-relief-after-ebay-v.-mercexchange2024-12-19T17:40:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-treatment-persistence-hospital-utilization-costs-among-major-depressive-disorder-geriatric-patients-treated-with-escitalopram/2024-12-10T15:02:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-chronic-hand-dermatitis-on-quality-of-life-work-productivity-activity-impairment-and-medical-costs/2024-12-10T15:27:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-21st-century-interstate-electric-highway-system--connecting-consumers-and-domestic-clean-power-supplies/2024-12-10T15:30:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-single-photon-emission-computed-tomography-spect-use-after-acute-myocardial-infarction-ami-on-cardiac-procedure-rates-and-hospital-length-of-stay/2024-12-19T17:41:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-referral-patterns-testing-and-surgery-in-aortic-valve-disease--leaving-women-and-elderly-patients-behind-/2024-12-10T15:33:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-a-partnership-measurement-model-of-disease-management--improving-cardiovascular-outcomes-in-nova-scotia-icons/2024-12-10T15:51:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interstitial-cystitis--cost-treatment-and-co-morbidities-in-an-employed-population/2024-12-10T15:53:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/algorithms-to-identify-colonic-ischemia-complications-of-constipation-and-irritable-bowel-syndrome-in-medical-claims-data--development-and-validation/2024-12-10T15:54:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-crit-study--anemia-and-blood-transfusion-in-the-critically-ill--current-clinical-practice-in-the-united-states/2024-12-10T15:55:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-osteoporosis-breast-cancer-and-cardiovascular-disease-among-postmenopausal-women-in-an-employed-population/2024-12-18T22:10:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identification-of-a-claims-data-signature-and-economic-consequences-for-treatment-resistant-depression/2024-12-18T22:11:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/switching-costs-price-sensitivity-and-health-plan-choice/2024-05-17T20:44:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/levaluation-de-lefficience-budgetaire-des-clsc-au-quebec-a-partir-de-la-methode-dea/2024-12-18T22:12:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-quality-adjusted-life-years-and-supportive-care.-recombinant-human-erythropoietin-as-a-treatment-of-cancer-associated-anemia2024-12-18T22:13:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/une-analyse-du-contexte-budgetaire-de-lactivite-medicale-au-quebec-an-analysis-of-the-budgetary-context-of-medical-activity-in-quebec/2024-12-18T22:14:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/etude-dimpact-du-projet-de-loi-sur-le-tabac-impact-report-on-the-proposed-tobacco-law/2024-12-18T22:14:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/implementing-communitybased-longterm-care--experience-of-the-longterm-home-health-care-program/2024-12-18T22:17:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-does-the-nursing-home-sector-behave--a-multiequation-model-of-nursing-home-behavior/2024-12-18T22:18:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/angel-finance--the-other-venture-capital-in-companion-to-venture-capital/2024-12-18T22:20:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/discount-rate-risk-and--economic-damages--practical-considerations/2024-12-18T22:21:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-the-immigrant-investor-program-in-canada-english/2024-12-18T22:21:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-the-immigrant-investor-program-in-canada-francais/2024-12-18T22:22:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-hospitalization-risk-and-associated-costs-among-patients-receiving-sargramostim-filgrastim-and-pegfilgrastim-for-chemotherapy-induced-neutropenia/2024-12-18T22:23:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/modeling-for-health-care-and-other-policy-decisions--uses-roles-and-validity/2024-12-18T22:23:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/employer-burden-of-mild-moderate-and-severe-major-depressive-disorder--mental-health-services-utilization-and-costs-and-work-performance/2024-12-18T22:27:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/angiogenesis-inhibitor-therapies-for-metastatic-renal-cell-carcinoma--effectiveness-safety-and-treatment-patterns-in-clinical-practice-based-on-medical-chart-review/2024-12-19T14:41:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ensuring-a-clean-modern-electric-generating-fleet-while-maintaining-electric-system-reliability/2024-12-19T14:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perceptions-and-prescribing-considerations-among-us-psychiatrists-regarding-drugdrug-interactions-associated-with-oral-atypical-antipsychotics/2024-12-19T14:42:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-real-world-comparison-of-medical-visits-costs-and-adherence-between-nilotinib-and-dasatinib-in-chronic-myeloid-leukemia/2024-12-19T14:43:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tolerability-efficacy-and-safety-of-pegylated-liposomal-doxorubicin-in-combination-with-carboplatin-vs-gemcitabine-carboplatin-for-the-treatment-of-platinum-sensitive-recurrent-ovarian-cancer--review/2024-12-19T14:44:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-consequence-of-switching-to-citalopram-after-its-generic-entry-for-adult-patients-with-major-depressive-disorder-mdd-treated-with-escitalopram/2024-12-19T14:47:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparing-healthcare-costs-of-medicaid-patients-with-postherpetic-neuralgia-phn-treated-with-lidocaine-patch-5-percent-versus-gabapentin-or-pregabalin/2024-12-19T14:47:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-of-copd--relationships-between-daily-dosing-frequency-adherence-resource-use-and-costs/2024-12-19T14:48:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/seventh-circuit-creates-uncertainty-about-401k-provider-rfps/2024-12-19T14:49:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/societal-costs-of-prescription-opioid-abuse-dependence-and-misuse-in-the-united-states/2024-12-19T14:53:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/copayment-level-treatment-persistence-and-health-care-utilization-in-hypertension-patients-treated-with-single-pill-combination-therapy/2024-12-19T14:54:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiologic-evaluation-of-cardiovascular-risk-in-patients-receiving-milnacipran-venlafaxine-or-amitriptyline--evidence-from-french-health-data/2024-12-19T14:55:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/compliance-persistence-healthcare-resource-use-and-treatment-costs-associated-with-aliskiren-plus-arb-versus-ace-inhibitor-plus-arb-combination-therapy/2024-12-19T14:56:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-choice-trial--adalimumab-demonstrates-safety-fistula-healing-improved-quality-of-life-and-increased-work-productivity-in-patients-w-crohn-s/2024-12-19T14:57:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/computerized-algorithms-for-the-identification-of-irritable-bowel-syndrome-colonic-ischemia-and-complications-of-constipation/2024-12-19T14:58:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-persistence-healthcare-utilization-and-costs-in-adult-patients-with-major-depressive-disorder--a-comparison-between-escitalopram/2024-12-19T14:58:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comorbidity-burden-healthcare-resource-utilization-and-costs-in-chronic-gout-patients-refractory-to-conventional-urate-lowering-therapy/2024-12-19T14:59:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/average-wholesale-price--efficient-benchmark-or-conspiratorial-instrument-/2024-12-19T15:00:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ensuring-a-clean-modern-electric-generating-fleet-while-maintaining-electric-system-reliability--summer-2011-update/2024-12-19T15:01:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ensuring-a-clean-modern-electric-generating-fleet-while-maintaining-electric-system-reliability--fall-2011-update/2024-12-19T15:04:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/solar-development-incentives--status-of-colorados-solar-pv-program-practices-in-other-states-and-suggestions-for-next-steps/2024-12-19T15:10:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/exact-and-efficient-inference-procedure-for-meta-analysis-and-its-application-to-the-analysis-of-independent-2--2-tables/2024-12-19T15:11:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/americas-bright-future--cleaner-air-and-affordable-reliable-electricity/2024-12-19T15:11:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/all-cause-and-potentially-disease-related-health-care-costs-associated-with-venous-thromboembolism-in-commercial-medicare-and-medicaid-beneficiaries/2024-12-19T15:12:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-analysis-of-everolimus-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-advanced-breast-cancer/2024-12-19T15:13:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-dermatologic-adverse-drug-reactions-in-the-treatment-of-colorectal-non-small-cell-lung-and-head-and-neck-cancers/2024-12-19T15:14:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/demand-response-in-capacity-markets--reliability-dispatch-and-emission-outcomes/2024-12-19T15:16:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/re--stopeck-a-rader-m-henry-d-et-al.-cost-effectiveness-of-denosumab-vs.-zoledronic-acid-for-prevention-of-skeletal-related-events2024-12-19T15:16:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-medication-adherence-to-disease-modifying-drugs-on-severe-relapse-and-direct-and-indirect-costs-among-employees-with-multiple-sclerosis-in-u.s2024-12-19T15:17:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-practice-patterns-health-care-utilization-and-costs-in-patients-with-low-back-pain--the-long-road-to-guideline-concordant-care/2024-12-19T15:18:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disjunctions-of-conjunctions-cognitive-simplicity-and-consideration-sets/2024-12-19T15:20:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recent-average-price-trends-for-implantable-medical-devices-2007-2011/2024-12-19T15:22:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-incremental-net-health-benet-of-requirements-for-cardiovascular-risk-evaluation-for-diabetes-therapies/2025-06-30T20:57:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-of-pasireotide-for-the-treatment-of-cushing-s-disease-a-rare-endocrine-disorder-associated-with-considerable-comorbidities/2024-12-19T15:23:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-quality-of-life-and-costs-associated-with-implantation-of-vagus-nerve-stimulation-therapy/2024-12-19T15:24:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/advanced-diagnostics--innovation-reimbursement-and-coverage-challenges/2024-12-19T15:24:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-completing-chronic-hepatitis-c-chc-treatment-on-post-therapy-healthcare-cost/2024-12-19T15:25:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-adults-with-major-depressive-disorder-in-the-united-states-2005-and-2010/2024-12-19T15:25:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-implementing-a-multiple-inflammatory-biomarker-based-approach-to-identify-treat-and-reduce-cardiovascular-risk/2024-12-19T15:26:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-use-and-costs-of-privately-insured-patients-who-switch-discontinue-or-persist-on-anti-muscarinic-therapy-for-overactive-bladder/2024-12-19T15:27:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-the-utility-of-existing-patient-reported-outcome-scales-in-novel-patient-populations-with-pancreatic-cancer-lung-cancer-and-myeloproliferative-neoplasms-using-medicare-current-beneficiary/2024-12-19T15:28:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-model-to-identify-patients-at-risk-for-prescription-opioid-abuse-dependence-and-misuse/2024-12-19T15:29:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-resource-use-and-economic-outcomes-associated-with-atypical-antipsychotic-prescriptions-in-children-and-adolescents-with-attention-deficit-hyperactivity-disorder-in-quebec/2024-12-19T15:30:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-outcomes-of-everolimus-temsirolimus-and-sorafenib-as-second-targeted-therapies-for-metastatic-renal-cell-carcinoma--a-us-medical-record-review/2024-12-19T15:31:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-analysis-of-everolimus-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-her2--advanced-breast-cancer-in-the-united-states/2024-12-19T15:32:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/sleep-quality-and-other-patient-reported-outcomes-improve-after-patients-with-psoriasis-with-suboptimal-response-to-other-systemic-therapies-are-switched-to-adalimumab--results-from-progress-an-open-/2024-12-19T15:33:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hypoglycemia-treatment-discontinuation-and-costs-in-patients-with-type-2-diabetes-mellitus-on-oral-antidiabetic-drugs/2024-12-19T15:34:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/deutsche-bahn-files-suit-in-german-court-seeking-1.8-billion-in-damages2024-12-19T15:34:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-time-to-clinical-response-a-proxy-for-discharge-readiness-among-hospitalized-patients-with-community-acquired-pneumonia-who-received-either-ceftaroline-fosamil-or-ceftriaxone-in-two-ph/2024-12-19T15:35:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-validity-responsiveness-and-meaningfulness-of-the-hidradenitis-suppurativa-clinical-response-hiscr-as-the-clinical-endpoint-for-hidradenitis-suppurativa-treatment/2024-12-19T15:36:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-the-efficacy-of-sequential-biologic-therapies-for-rheumatoid-arthritis-patients-with-an-inadequate-response-to-tumor-necrosis-factor--inhibitors/2024-12-19T15:36:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/validation-of-the-headache-impact-test-hit-6-across-episodic-and-chronic-migraine/2024-12-19T15:37:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measuring-the-health-status-burden-in-hemodialysis-patients-using-the-sf-36-health-survey/2024-12-19T15:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-evaluation-of-the-effects-of-an-angiotensin-receptor-blocker-on-health-related-quality-of-life-in-patients-with-high-normal-blood-pressure-prehypertension-in-the-trial-of-preventing-hypertension/2024-12-19T15:40:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-prescribing-decision-drivers-and-predictors-of-complete-response-following-disease-recurrence-in-gastrointestinal-stromal-tumor-patients-a-chart-extract-based-approach/2024-12-19T15:41:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-patterns-of-endocrine-therapy-for-metastatic-hormone-receptor-positive-hrhuman-epidermal-growth-factor-receptor-2-negative-her2--breast-cancer-patients-in-the-united-states--2002-2012/2024-12-19T15:42:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-gastrointestinal-stromal-tumor-gist-recurrence-in-patients-who-have-received-adjuvant-imatinib-therapy/2024-12-19T15:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/confound-it-revisiting-the-special-case-of---overdisclosure---in-the-context-of-halliburtons-price-impact-test/2024-12-19T15:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-health-care-resource-utilization-and-costs-in-u.s.-patients-diagnosed-with-chronic-hepatitis-c-infection-who-received-telaprevir-or-boceprevir2024-12-19T15:44:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-economics-outcomes-epidemiology-published-research-and-presentations/2025-11-10T13:40:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economists-perspective-on-the-efficiency-defense-in-provider-consolidations--what-works-what-doesnt-work-and-what-we-still-dont-know/2024-12-19T15:45:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-index-of-intergenerational-equity--2016/2024-12-19T15:45:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-private-damages-actions-in-the-united-states-canada-and-the-european-union/2024-12-19T15:46:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-healthcare-costs-and-dose-escalation-in-psoriasis-patients-initiated-on-ustekinumab-versus-adalimumab--a-retrospective-claim-study/2024-12-19T15:47:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-ceritinib-in-patients-previously-treated-with-crizotinib-in-anaplastic-lymphoma-kinase-positive-alk-non-small-cell-lung-cancer-in-canada/2024-12-19T15:48:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rotavirus-vaccination-in-a-medicaid-infant-population-from-four-us-states--compliance-vaccination-completion-rate-and-predictors-of-compliance/2024-12-19T15:50:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-overall-survival-healthcare-resource-use-and-costs-in-elderly-medicare-beneficiaries-with-chronic-myeloid-leukemia-using-second-generation-tyrosine-kinase-inhibitors-as-second-lin/2024-12-19T15:57:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-illness-among-patients-with-fragile-x-syndrome-fxs--a-medicaid-perspective/2024-12-19T15:58:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-ocular-complications-in-patients-with-noninfectious-intermediate-uveitis-posterior-uveitis-or-panuveitis/2024-12-19T15:58:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-glycemic-blood-pressure-and-weight-control-in-patients-with-type-2-diabetes-mellitus-treated-with-canagliflozin-an-electronic-health-record-based-study/2025-02-28T21:48:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-expanded-use-of-biologic-therapy-for-the-treatment-of-rheumatoid-arthritis-and-crohn-s-disease-in-argentina-brazil-colombia-and-mexico/2024-12-19T16:00:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/asas40-and-asdas-clinical-responses-in-the-ability-1-clinical-trial-translate-to-meaningful-improvements-in-physical-function-health-related-quality-of-life-and-work-productivity-in-patients-with-non/2024-12-19T16:04:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-treatment-patterns-and-survival-among-alk-non-small-cell-lung-cancer-nsclc-patients-treated-with-crizotinib--a-chart-review-study/2024-12-19T16:06:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/basal-insulin-persistence-associated-factors-and-outcomes-after-treatment-initiation-among-people-with-type-2-diabetes-mellitus-in-the-us/2024-12-19T16:08:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-analysis-model-of-colonoscopy-preparation-using-split-dose-reduced-volume-oral-sulfate-solution-oss-and-polyethylene-glycol-with-electrolytes-solution-peg-els/2024-12-19T16:15:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-indirect-comparison-and-cost-per-responder-analysis-of-adalimumab-methotrexate-and-apremilast-in-the-treatment-of-methotrexate-naive-patients-with-psoriatic-arthritis/2024-12-19T16:16:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-outcomes-health-care-resource-utilization-and-costs-of-bortezomib-and-dexamethasone-with-cyclophosphamide-or-lenalidomide-in-newly-diagnosed-multiple-myeloma/2024-12-19T16:17:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-and-associated-incremental-costs-of-treatment-with-enzalutamide-versus-abiraterone-acetate-plus-prednisone-in-chemotherapy-naive-patients-with-metastatic-castration-resistant-pr2/2024-12-19T16:18:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/individualized-prediction-of-changes-in-6-minute-walk-distance-for-patients-with-duchenne-muscular-d1/2024-05-17T20:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/asas40-and-asdas-clinical-responses-in-the-ability-1-clinical-trial-translate-to-meaningful-improvem1/2024-05-17T20:41:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-comparison-of-damage-theories-in-price-fixing-cases-in-the-united-states-canada-and-the-european-union/2025-05-01T18:33:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-clinical-and-economic-burden-of-mucormycosis-related-hospitalizations-in-the-united-states--a-retrospective-study/2024-05-17T20:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/calculating-damages-in-price-fixing-cases-in-the-united-states-canada-and-the-european-union/2025-05-01T18:33:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-of-statistical-sampling-in-litigation1/2024-07-01T12:59:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-cost-of-capital1/2024-05-17T20:42:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electricity-markets-reliability-and-the-evolving-u.s.-power-system2024-05-17T20:42:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-research--a-pharmaceutical-industry-perspective-on-outlook-dilemmas-and-controversies/2024-05-17T20:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/decision-making-with-machine-learning-in-our-modern-data-rich-health-care-industry/2024-05-17T20:42:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hedge-funds--the-good-the-bad-and-the-lucky/2024-05-17T20:42:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-weight-change-among-patients-treated-with-glucagon-like-peptide-1-receptor-agonist-dipeptidyl-peptidase-4-inhibitor-and-sulfonylureas/2024-05-17T20:44:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-healthcare-resource-utilization-and-costs-following-first-line-antidepressant-treatment-in-major-depressive-disorder--a-retrospective-us-claims-database-analysis/2024-05-17T20:44:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/basal-insulin-persistence-associated-factors-and-outcomes-after-treatment-initiation--a-retrospective-database-study-among-people-with-type-2-diabetes-mellitus-in-japan/2024-05-17T20:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-isavuconazole-vs.-voriconazole-as-first-line-treatment-for-invasive-a12024-05-17T20:42:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-reduction-from-resolutionimprovement-of-carcinoid-syndrome-symptoms-following-treatment-with-a1/2024-05-17T20:42:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-and-safety-of-attention-deficithyperactivity-disorder-pharmacotherapies-including-guanfacine-extended-release--a-mixed-treatment-comparison/2024-05-17T20:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-common-adverse-events-associated-with-metastatic-colorectal-cancer-treatment-1/2024-05-17T20:44:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-healthcare-costs-among-newly-diagnosed-patients-with-chronic-myeloid-leukemia1/2024-05-17T20:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-biologic-disease-modifying-antirheumatic-drugs-for-the-treatment-of-rheumatoid-arthritis-after-etanercept-discontinuation-in-the-united-kingdom-france-and-germany/2024-05-17T20:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antibiotic-treatment-patterns-costs-and-resource-utilization-among-patients-with-community-acquired-pneumonia--a-us-cohort-study/2024-05-17T20:41:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-retrospective-study-to-assess-clinical-characteristics-and-time-to-initiation-of-open-triple-therapy-among-patients-with-chronic-obstructive-pulmonary-disease-newly-established-on-longacting-mono-/2024-05-17T20:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-persistence-and-inpatient-utilization-among-adult-schizophrenia-patients-using-once-monthly-versus-twice-monthly-long-acting-atypical-antipsychotics/2024-05-17T20:41:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-real-world-central-nervous-system-events-in-patients-with-advanced-prostate-cancer-using-abiraterone-acetate-bicalutamide-enzalutamide-or-chemotherapy/2024-05-17T20:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-health-care-resource-utilization-and-spending-in-medicaid-beneficiaries-initiating-second-generation-long-acting-injectable-agents-versus-oral-atypical-antipsychotics/2025-02-28T21:46:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-of-everolimus-for-the-treatment-of-progressive-well-differentiated-non-functional-neuroendocrine-tumors-of-gastrointestinal-or-lung-origin-that-are-advanced-or-metastatic/2024-05-17T20:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effect-of-adalimumab-on-visual-functioning-in-patients-with-noninfectious-intermediate-uveitis-posterior-uveitis-and-panuveitis-in-the-visual-1-and-visual-2-trials/2024-05-17T20:42:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/corticosteroid-related-adverse-events-systematically-increase-with-corticosteroid-dose-in-noninfectious-intermediate-posterior-or-panuveitis--post-hoc-analyses-from-the-visual-1-and-visual-2-trials/2024-05-17T20:42:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-complications-and-health-care-utilization-among-endometriosis-patients-undergoing-a-laparoscopy-or-a-hysterectomy--a-retrospective-claims-analysis/2024-05-17T20:44:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patterns-of-disease-monitoring-and-treatment-among-patients-with-tuberous-sclerosis-complex-related-1/2024-05-17T20:43:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-healthcare-costs-and-dose-escalation-in-psoriasis-patients-initiated-on-ustekinumab-versus-adalimumab--a-retrospective-claim-study2/2024-05-17T20:42:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-ocrelizumab-versus-subcutaneous-interferon-beta-1a-for-the-treatment-1/2024-05-17T20:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/projecting-the-cost-utilization-and-patient-care-impact-of-prescribing-extended-release-non-abuse-deterrent-opioids-to-chronic-pain-patients/2024-05-17T20:43:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-use-costs-and-disease-progression-associated-with-diabetic-nephropathy-in-adults-with-type-2-diabetes--a-retrospective-observational-study/2024-05-17T20:42:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lost-profits-damages--principles-methods-and-applications/2024-05-17T20:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comment-on-the-flaws-in-using-the-hypothetical-monopolist-test-from-the-payor-perspective-in-health-care-merger-cases-by-field-fisher-and-coglianese/2024-05-17T20:41:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/joint-ventures-group-boycotts-and-volume-discounts/2024-05-17T20:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/united-states-v.-energy-solutionsperspectives-on-litigating-antitrust-merger-challenges2024-05-17T20:44:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survey-evidence-to-evaluate-a-marketing-claim--skye-astiana-plaintiff-v.-ben-and--jerry-s-homemade-inc.-defendant2024-05-17T20:44:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/government-takeovers-of-water-systems-are-costly-dont-deliver-results/2024-07-01T18:19:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-nine-northeast-and-mid-atlantic-states--review-of-rggis-third-three-year-compliance-period-2015-2017/2024-05-17T20:44:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/back-to-school--a-primer-on-university-403b-plan-litigation/2024-05-17T20:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-healthcare-resource-utilization-and-costs-in-patients-with-acute-myeloid-leukemia-in-commercially-insured-and-medicare-populations/2024-05-17T20:44:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-evaluation-of-hba1c-blood-pressure-and-weight-loss-among-patients-with-type-2-diabetes-mellitus-treated-with-canagliflozin/2025-02-28T21:37:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/factors-associated-with-the-number-and-size-of-renal-angiomyolipomas-in-sporadic-angiomyolipoma-saml--a-study-of-adult-patients-with-saml-managed-in-a-dutch-tertiary-referral-center/2024-05-17T20:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/asthma-control-lung-function-symptoms-and-corticosteroid-sparing-after-omalizumab-initiation-in-patients-with-allergic-asthma/2024-05-17T20:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-trajectories-healthcare-resource-use-and-costs-of-diabetic-nephropathy-among-patients-with-type-2-diabetes--a-latent-class-analysis/2024-05-17T20:41:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reimbursement-landscape-for-molecular-testing-in-non-small-cell-lung-cancer-nsclc/2024-05-17T20:44:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-additional-costs-per-month-of-progression-free-survival-and-overall-survival--an-economic-model-comparing-everolimus-with-cabozantinib-nivolumab-and-axitinib-for-second-line-treatment-of-metasta/2024-05-17T20:44:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reliability-of-coded-data-to-identify-earliest-indications-of-cognitive-decline-cognitive-evaluation-and-alzheimer-s-disease-diagnosis--a-pilot-study-in-england/2024-05-17T20:44:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-treatment-patterns-and-economic-outcomes-of-patients-initiating-injectable-medications-for-management-of-type-2-diabetes-mellitus-in-japan/2024-05-17T20:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluation-of-clinical-outcomes-among-nonvalvular-atrial-fibrillation-patients-treated-with-rivaroxaban-or-warfarin-stratified-by-renal-function/2024-05-17T20:42:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/value-of-transfusion-independence-in-severe-aplastic-anemia-from-patients-perspectives--a-discrete-choice-experiment/2024-05-17T20:44:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-clinical-and-economic-outcomes-of-patients-with-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-receiving-ceritinib--a-retrospective-observational-claims-analysis/2024-05-17T20:44:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risk-of-cardiovascular-events-in-psoriasis-patients-treated-with-tumor-necrosis-factor--inhibitors-versus-phototherapy--an-observational-cohort-study/2024-05-17T20:44:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/singleton-v.-fifth-generation-inc2024-05-17T20:44:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-outcomes-with-subcutaneous-bortezomib-in-patients-with-relapsed-mantle-cell-lymphoma--a-retrospective-observational-study-of-patient-medical-records-from-us-community-oncology/2025-02-28T21:47:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dosing-patterns-and-economic-burden-of-palbociclib-drug-wastage-in-hrher2--metastatic-breast-cancer/2024-05-17T20:42:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/occupational-licensing-in-healthcare-and-beyond--recent-developments-in-case-law-enforcement-legislation-and-research/2025-10-10T15:11:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economics--overview/2024-06-18T21:07:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economics-of-biosimilar-drugs-and-new-considerations-in-intellectual-property-and-antitrust-litigation/2025-07-01T15:15:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/resource-adequacy-and-wholesale-market-structure-for-a-future-low-carbon-power-system-in-california/2024-05-17T20:44:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comments-on-certification-of-new-interstate-natural-gas-pipeline-facilities/2024-05-17T20:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/online-and-offline-retail-distribution--introduction/2024-05-17T20:43:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-assessment-of-mergers-in-online-and-offline-retail-sales--are-new-tools-needed-for-the-economists-toolbox-/2024-05-17T20:44:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competitive-assessment-of-digital-comparison-platforms--in-search-of-consensus/2024-05-17T20:42:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cryptocurrencies-demystified-and-the-secs-regulatory-stance/2024-05-17T20:42:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-rise-of-biosimilars-and-the-future-of-healthcare-intellectual-property/2024-05-17T20:44:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patent-damages-in-us-courts--overview-of-current-state-of-play/2024-05-17T20:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/smart-contracts-and--their-potential-tax-implications/2024-05-17T20:44:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimated-cost-of-anticancer-therapy-directed-by-comprehensive-genomic-profiling-in-a-single-center-study/2025-06-30T20:53:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-ability-to-achieve-lost-sales-as-a-consideration-in-damages-analyses-under-different-legal-frameworks/2024-05-17T20:44:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/political-advertising-and-election-results/2024-05-17T20:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-effect-of-mergers-on-labor-markets/2024-05-17T20:41:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-cost-impact-of-continued-anticoagulation-with-rivaroxaban-vs-aspirin-for-prevention-of-recurrent-symptomatic-vte-in-the-einstein-choice-trial-population/2024-05-17T20:42:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-utility-values-for-treatment-related-health-states-of-acute-myeloid-leukemia-in-the-united-states/2024-10-21T15:16:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-ischemic-stroke-in-patients-newly-diagnosed-with-heart-failure-focus-on-patients-without-atrial-fibrillation/2024-05-17T20:44:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effectiveness-and-safety-of-anticoagulants-for-the-treatment-of-venous-thromboembolism-in-patients-with-cancer2/2024-12-19T16:43:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/european-union--two-sided-markets-platforms-and-network-effects/2024-05-17T20:42:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/united-states--e-commerce-economics-market-power-and-enforcement-in-vertical-markets/2025-06-13T19:57:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/3-aspects-of-value-preservation-for-restructuring-cos/2024-05-17T20:41:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identifying-solutions-to-psychological-insulin-resistance-an-international-study/2024-05-17T20:42:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-of-patients-with-psoriatic-arthritis-receiving-secukinumab-and-reasons-for-initiation-a-us-retrospective-medical-chart-review/2024-05-17T20:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/factors-associated-with-more-frequent-diagnostic-tests-and-procedures-in-patients-with-irritable-bowel-syndrome/2024-05-17T20:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-clinical-outcomes-in-advanced-gastrointestinal-neuroendocrine-tumors-gi-net-a-multicenter-retrospective-chart-review-study/2024-05-17T20:44:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characterization-of-patients-with-ankylosing-spondylitis-receiving-secukinumab-and-reasons-for-initiating-treatment-a-us-physician-survey-and-retrospective-medical-chart-review/2024-05-17T20:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-post-transition-to-once-every-3-months-paliperidone-palmitate-in-patients-with-schizophrenia-within-us-commercial-plans/2024-05-17T20:43:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-clinical-outcomes-in-advanced-lung-neuroendocrine-tumors-in-real-world-settings-a-multicenter-retrospective-chart-review-study/2024-05-17T20:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/observational-study-of-characteristics-and-clinical-outcomes-of-dutch-patients-with-tuberous-sclerosis-complex-and-renal-angiomyolipoma-treated-with-everolimus/2024-05-17T20:43:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-among-adults-with-adhd-receiving-long-acting-therapy/2024-05-17T20:44:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/concomitant-use-of-psychotropic-medication-with-stimulants-for-the-treatment-of-adhd-in-children-and-adolescents-a-retrospective-insurance-claims-study-in-the-united-states/2024-05-17T20:42:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-predictive-risk-models-for-major-adverse-cardiovascular-events-among-patients-with-type-2-diabetes-mellitus-using-health-insurance-claims-data/2025-02-28T21:37:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-catheter-related-complications-among-japanese-patients-with-central-venous-catheters-as-well-as-patients-with-short-bowel-syndrome/2024-05-17T20:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/causation-and-harm-in-data-breach-litigation/2024-05-17T20:41:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-burden-and-treatment-patterns-in-commercially-insured-children-with-chronic-idiopathicspontaneous-urticaria-a-real-world-study-in-the-united-states2/2024-05-17T20:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/removal-of-ineligible-outcome-cases-reduces-confounding/2024-05-17T20:44:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-economic-outcomes-during-time-on-treatment-among-patients-who-initiated-sunitinib-or-pazopanib-as-first-targeted-therapy-for-advanced-renal-cell-carcinoma-a-retrospective-analysis-of-medicare-claims-data/2024-05-17T20:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-cohort-study-comparing-the-risk-of-severe-hepatotoxicity-in-hospitalized-patients-treated-with-echinocandins-for-invasive-candidiasis-in-the-presence-of-confounding-by-indication/2024-05-17T20:44:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-hidradenitis-suppurativa-on-work-loss-indirect-costs-and-income/2024-05-17T20:42:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/postsurgical-treatment-landscape-and-economic-burden-of-locoregional-and-distant-recurrence-in-patients-with-operable-nonmetastatic-melanoma/2024-05-17T20:43:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/stage-iii-melanoma-incidence-and-impact-of-transitioning-to-the-8th-ajcc-staging-system-a-us-population-based-study/2024-05-17T20:44:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-midostaurin-in-the-treatment-of-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-in-the-united-states/2024-05-17T20:42:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epilepsy-treatment-patterns-among-patients-with-tuberous-sclerosis-complex/2024-05-17T20:42:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-of-antiepileptic-drugs-in-the-adjunctive-treatment-of-refractory-partial-onset-seizures-meta-analysis-of-pivotal-trials/2024-05-17T20:42:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-analysis-of-comprehensive-genomic-profiling-in-patients-with-advanced-non-small-cell-lung-cancer/2025-06-30T20:47:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-infections-among-chronic-myeloid-leukemia-patients-receiving-dasatinib-or-nilotinib/2024-05-17T20:41:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-analysis-of-clinical-progression-in-patients-with-metastatic-castration-resistant-prostate-cancer-in-the-strive-and-terrain-trials/2024-05-17T20:43:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-duration-healthcare-resource-utilization-and-costs-among-chemotherapy-naive-patients/2024-05-17T20:44:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-burden-of-non-infectious-intraocular-inflammatory-eye-diseases-a-systematic-literature-review/2024-05-17T20:44:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-abuse-of-prescription-opioids/2024-05-17T20:44:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-psoriasis-with-high-comorbidity-among-privately-insured-patients-in-the-united-states/2024-05-17T20:44:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/short-term-rehospitalizations-in-young-adults-with-schizophrenia-treated-with-once-monthly-paliperidone-palmitate-or-oral-atypical-antipsychotics-a-retrospective-analysis/2024-05-17T20:44:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-among-patients-with-colorectal-cancer-treated-with-trifluridinetipiracil-and-regorafenib/2024-05-17T20:43:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-disease-associated-with-a-copd-eosinophilic-phenotype/2025-02-28T21:38:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-systemic-corticosteroids-on-blood-eosinophil-counts-in-asthma-real-world-data/2025-02-28T21:39:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-in-labor-markets-insights-from-the-ftc-hearings-on-competition-and-consumer-protection-in-the-21st-century/2024-05-17T20:41:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-in-patients-with-metastatic-castration-resistant-prostate-cancer/2024-05-17T20:43:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-rivaroxaban-versus-apixaban-among-patients-with-non-valvular-atrial-fibrillation/2024-05-17T20:41:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-long-term-direct-and-indirect-economic-burden-among-parkinsons-disease-caregivers-in-the-united-states/2024-05-17T20:44:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-characteristics-of-patients-with-asthma-copd-and-asthma-copd-overlap-in-the-nhanes-database/2025-02-28T21:39:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-treatments-for-previously-treated-advanced-or-metastatic-non-small-cell-lung-cancer/2024-05-17T20:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-time-to-progression-associated-with-post-progression-survival-in-previously-treated-metastatic-non-small-cell-lung-cancer-with-braf-v600e-mutation/2024-05-17T20:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-first-line-ceritinib-and-crizotinib-in-advanced-or-metastatic-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer/2024-05-17T20:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cms-hospital-readmission-reduction-program-and-anticoagulants-received-following-a-total-hip-and-knee-arthroplasty-discharge/2024-05-17T20:41:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-comorbidity-burden-of-hidradenitis-suppurativa-in-the-united-states-/2024-05-17T20:44:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-nab-paclitaxel-plus-gemcitabine-vs-folfirinox-in-metastatic-pancreatic-cancer/2024-05-17T20:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medicaid-spending-burden-among-beneficiaries-with-treatment-resistant-depression/2024-05-17T20:43:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-workplace-disparities-may-arise-an-economic-outline/2026-01-04T22:04:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risk-of-recurrent-vte-and-major-bleeding-in-a-commercially-insured-population-of-cancer-patients-treated-with-anticoagulation/2024-05-17T20:44:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/changes-health-related-quality-of-life-long-term-eltrombopag-treatment-adults-persistentchronic-immune-thrombocytopenia/2024-05-17T20:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/description-of-baseline-characteristics-of-pediatric-allergic-asthma-patients-including-those-initiated-on-omalizumab/2024-05-17T20:42:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-and-clinical-outcomes-of-treatment-intensification-in-patients-with-type-2-diabetes-uncontrolled-on-basal-insulin-in-a-real-world-setting/2024-05-17T20:43:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/genotype-and-lifetime-burden-of-disease-in-hypertrophic-cardiomyopathy-insights-from-the-sarcomeric-human-cardiomyopathy-registry-share/2024-05-17T20:42:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-carcinoid-syndrome-symptoms-and-long-term-use-of-somatostatin-analogs-on-quality-of-life-in-patients-with-carcinoid-syndrome/2024-05-17T20:42:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/monitoring-of-hematologic-cardiac-and-hepatic-function-in-post-menopausal-women-with-hrher2--metastatic-breast-cancer/2024-05-17T20:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-healthcare-resource-utilization-in-patients-with-flt3-mutated-and-wild-type-acute-myeloid-leukemia/2024-05-17T20:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/short-term-costs-associated-with-non-medical-switching-in-autoimmune-conditions/2024-05-17T20:44:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-in-patients-with-metastatic-melanoma/2024-05-17T20:42:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patterns-of-treatment-and-braf-testing-with-immune-checkpoint-inhibitors-and-targeted-therapy/2024-05-17T20:43:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economics-of-excessive-pricing-an-application-to-the-pharmaceutical-industry/2024-05-17T20:42:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antiepileptic-drug-titration-and-related-health-care-resource-use-and-costs/2024-05-17T20:41:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-prospective-economic-impact-of-once-monthly-paliperidone-palmitate-versus-oral-atypical-antipsychotics-in-medicaid-patients-with-schizophrenia/2024-05-17T20:44:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-use-of-omalizumab-in-patients-with-chronic-idiopathicspontaneous-urticaria-in-the-united-states/2024-05-17T20:44:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-factors-health-care-resource-utilization-and-costs-associated-with-nonadherence-to-antiretrovirals-in-medicaid-insured-patients-with-hiv/2025-02-28T21:40:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/elotuzumab-plus-lenalidomide-and-dexamethasone-in-relapsedrefractory-multiple-myeloma/2024-05-17T20:42:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/time-to-treatment-intensification-after-monotherapy-failure-and-its-association-with-subsequent-glycemic-control-among-93515-patients-with-type-2-diabetes/2024-05-17T20:44:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-costs-associated-with-transitioning-to-3-month-paliperidone-palmitate/2025-02-28T21:40:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reliability-of-coded-data-to-identify-earliest-indications-of-cognitive-decline-cognitive-evaluation-and-alzheimers-disease-diagnosis/2024-05-17T20:44:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comorbidities-and-prescribed-medications-in-patients-with-or-without-dry-eye-disease-a-population-based-study/2024-05-17T20:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-and-monitoring-patterns-among-premenopausal-women-with-hrher2--advanced-breast-cancer/2024-05-17T20:44:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-analysis-healthcare-costs-relative-risk-hyperprolactinemia-associated-antipsychotic-treatments-united-states/2024-05-17T20:41:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identifying-subpopulation-higher-likelihoods-early-response-treatment-heterogeneous-rare-disease/2024-05-17T20:42:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-of-prolonged-anticoagulation-with-rivaroxaban-after-unprovoked-venous-thromboembolism/2024-12-19T16:44:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-study-tolerability-effectiveness-adjunctive-antihypertensive-drugs-patients-inadequate-response-initial-treatment/2024-05-17T20:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/progression-free-survival-with-endocrine-based-therapies-progression-non-steroidal-aromatase-inhibitor/2024-05-17T20:43:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-much-is-data-security-worth/2024-06-11T14:51:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/combining-the-power-of-artificial-intelligence-with-the-richness-of-healthcare-claims-data-opportunities-and-challenges/2024-05-17T20:41:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/challenges-and-pitfalls-in-cartel-fining/2024-05-17T20:41:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-and-oncologist-preferences-for-the-treatment-of-adults-with-advanced-soft-tissue-sarcoma/2024-05-17T20:43:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/granite-bridge-environmental-benefits-of-system-expansion/2026-03-05T14:49:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risk-of-recurrent-vte-and-major-bleeding-in-a-commerciallyinsured-population-of-cancer-patients-treated-with-anticoagulation/2024-05-17T20:44:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-reallocating-spectrum-to-5g/2024-07-01T18:15:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/online-advertising-and-antitrust-network-effects-switching-costs-and-data-as-an-essential-facility/2024-05-17T20:43:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/scarcity-market-power-and-prices-at-slot-constrained-airports-evidence-from-mexico-city/2024-06-11T14:51:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/authors-contribution-effect-of-delayed-treatment-intensification-on-glycemic-control-in-the-real-world/2024-05-17T20:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/erisa-litigation-involving-target-date-funds/2024-05-17T20:42:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/returning-back-to-school-an-update-on-university-retirement-plan-litigation/2024-05-17T20:44:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/up-or-down-the-price-effects-of-mergers-of-intermediaries/2024-05-17T20:44:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hilsley-v.-ocean-spray-cranberries-inc2024-05-17T20:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-delaware-s-antitakeover-statute-unconstitutional--further-analysis-and-a-reply-to-symposium-participants/2024-12-19T16:44:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-delaware-s-antitakeover-statute-unconstitutional--evidence-from-1988-2008/2024-12-19T16:45:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/occupational-license-laws-may-hurt-health-care-competition/2025-10-10T15:10:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fuel-mix-and-greenhouse-gas-emissions-of-municipal-electric-light-plants-in-massachusetts/2024-05-17T20:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economics-overview-2019/2024-06-18T21:00:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/summary-of-the-federal-trade-commission-workshop/2024-12-19T16:46:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/guiding-principles-in-setting-cartel-sanctions/2024-05-17T20:42:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clean-energy-in-new-york-state-the-role-and-economic-impacts-of-a-carbon-price-in-nyisos-wholesale-electricity-markets/2024-05-17T20:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-womens-health-clinic-closures-on-fertility/2024-05-17T20:44:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/gao-report-illuminates-insurer-influence-on-drug-discounts/2024-05-17T20:42:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-purchase-probability-scales-can-shed-light-on-consumer-purchase-intentions/2024-05-17T20:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/appraisal-challenges-and-benefits-to-target-shareholders-through-narrowing-arbitrage-spread/2025-01-03T17:57:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/data-pinpoints-expert-valuation-differences-in-del.-appraisals2024-05-17T20:42:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/categorising-trajectories-individual-item-changes-north-star-ambulatory-assessment/2024-05-17T20:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/competition-scale-and-hedge-fund-performance-evidence-from-merger-arbitrage/2024-05-17T20:42:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/why-does-the-consumer-welfare-standard-work-matching-methods-to-markets/2024-05-17T20:44:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fercs-certification-of-new-interstate-natural-gas-facilities-revising-the-1999-policy-statement-for-21st-century-conditions/2024-05-17T20:42:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/employed-for-higher-pay-how-medicare-payment-rules-affect-hospital-employment-of-physicians/2024-05-17T20:42:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fuel-and-energy-security-in-new-york-state-an-assessment-of-winter-operational-risks-for-a-power-system-in-transition/2024-05-17T20:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-development-of-health-technology-assessment-in-asia-current-status-and-future-trends/2024-05-17T20:44:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/temporal-and-geographic-variation-in-the-incidence-of-alzheimers-disease-diagnosis-in-the-us-between-2007-and-2014/2024-05-17T20:44:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/analyzing-country-risk-premium-in-icsid-awards/2024-05-17T20:41:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/time-to-move-away-from-old-precedents-in-ferc-pipeline-reviews/2024-05-17T20:44:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-and-indirect-cost-of-obesity-among-the-privately-insured-in-the-united-states-a-focus-on-the-impact-by-type-of-industry/2024-05-17T20:42:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/in-all-probability-an-economic-reading-of-damages-under-factory-at-chorzow/2026-01-23T20:33:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/energy-security-improvements-impact-assessment/2024-05-17T20:42:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-societal-economic-burden-of-autosomal-dominant-polycystic-kidney-disease-in-the-united-states/2024-05-17T20:44:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/implications-of-energy-ratings-for-residential-real-estate-markets2/2024-05-17T20:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evidence-based-assessment-of-current-and-emerging-bladder-sparing-therapies-for-non-muscle-invasive-bladder-cancer-after-bacillus-calmette-guerin-therapy-a-systematic-review-and-meta-analysis/2024-10-21T15:11:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/powering-through--and-beyond--the-crisis/2024-05-17T20:43:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/vertical-relationships-horizontal-effects-the-evolving-debate-on-vertical-labor-market-restraints/2024-05-17T20:44:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/great-recession-holds-mortgage-crisis-lessons-for-today/2025-05-01T18:07:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/covid-19s-strain-on-hospitals-may-necessitate-more-relief/2026-02-02T14:56:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/5g-infrastructure-buildout-and-the-economic-impact-of-faster-clearing-of-c-band-spectrum-in-the-united-states/2024-07-01T18:14:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/remember-stacker-another-look-at-killer-acquisitions-in-the-digital-economy/2024-05-17T20:44:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/valuing-firms-in-a-world-of-pandemic-induced-bankruptcies/2024-12-05T16:16:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/carbon-pricing-for-new-england-context-key-factors-and-impacts/2024-05-17T20:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/qualified-renters-need-not-apply-race-and-voucher-discrimination-in-the-metro-boston-rental-housing-market/2024-05-17T20:43:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survey-says-tips-on-getting-over-the-daubert-hurdle/2024-05-17T20:44:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/calif.-pay-for-delay-law-lacks-nuance2024-05-17T20:41:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/suicidal-ideation-and-attempts-in-the-united-states-of-america-among-stimulant-treated-non-stimulant-treated-and-untreated-patients-with-a-diagnosis-of-attention-deficithyperactivity-disorder/2025-01-03T23:40:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economics--overview-measurement-error-bias-in-overcharge-calculations-global-competition-review-europe-middle-east-and-africa-antitrust-review-2021-july-2020/2024-05-17T20:42:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/accounting-for-the-coronavirus/2024-05-17T20:41:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/expediting-ma-deal-processes-via-negotiations-vs.-auctions2025-01-03T17:55:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/utility-energy-efficiency-program-performance-from-a-climate-change-perspective-a-comparison-of-structural-and-behavioral-programs/2024-05-17T20:44:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/model-of-short--and-long-term-outcomes-of-emicizumab-prophylaxis-treatment-for-persons-with-hemophilia-a/2025-12-19T15:11:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-treatment-resistant-depression-in-privately-insured-u.s.-patients-with-physical-conditions2024-05-17T20:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/innovation-competition-assessment-by-competition-authorities/2024-06-11T14:43:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-review-of-two-regulatory-approved-anti-cd19-car-t-cell-therapies-in-diffuse-large-b-cell-lymphoma-why-are-indirect-treatment-comparisons-not-feasible/2024-05-17T20:41:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimation-of-total-costs-in-pediatric-and-young-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-receiving-tisagenlecleucel-from-a-u.s.-hospitals-perspective2024-11-13T15:07:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimation-of-total-costs-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-receiving-tisagenlecleucel-from-a-us-hospitals-perspective/2024-11-13T15:11:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/successful-health-care-provider-strategies-to-overcome-psychological-insulin-resistance-in-united-states-and-canada/2024-05-17T20:44:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-safety-and-efficacy-of-ozanimod-versus-fingolimod-for-relapsing-multiple-sclerosis/2024-05-17T20:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-heart-failure-management-medications-following-cardiac-resynchronization-therapy/2024-05-17T20:41:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/grading-and-management-of-cytokine-release-syndrome-in-patients-treated-with-tisagenlecleucel-in-the-juliet-trial/2024-05-17T20:42:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-assessment-of-clinical-outcomes-among-first-line-sunitinib-patients-with-clear-cell-metastatic-renal-cell-carcinoma-mrcc-by-the-international-mrcc-database-consortium-risk-group/2024-05-17T20:43:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/new-survey-methods-may-assess-tm-dilution-with-more-detail/2024-05-17T20:43:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-based-analysis-can-be-useful-in-calif.-contract-disputes2024-05-17T20:42:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/weighing-the-benefits-how-much-weight-will-your-survey-have-in-court/2024-05-17T20:44:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-economic-evaluation-of-risankizumab-versus-other-biologic-treatments-of-moderate-to-severe-plaque-psoriasis-in-japan/2024-05-17T20:41:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-jak-inhibitors-for-moderate-to-severe-rheumatoid-arthritis-a-network-meta-analysis/2024-05-17T20:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/achieving-western-states-greenhouse-gas-ghg-reduction-objectives--least-cost-compliance-in-a-constantly-evolving-policy-environment/2024-05-17T20:41:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/erisa-litigation-involving-health-and-welfare-plans/2024-05-17T20:42:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/back-to-school--three-years-later-an-update-on-university-retirement-plan-litigation/2024-05-17T20:41:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/use-of-home-health-and-other-healthcare-delivery-pathways-among-privately-insured-patients-with-and-without-treatment-resistant-depression/2024-05-17T20:44:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-simultaneous-versus-sequential-initiation-of-basal-insulin-and-glucagon-like-peptide-1-receptor-agonists-on-hba1c-in-type-2-diabetes-a-retrospective-observational-study/2024-05-17T20:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-illness-among-patients-with-severe-aplastic-anemia-who-have-had-insufficient-response-to-immunosuppressive-therapy-a-multicenter-retrospective-chart-review-study/2024-05-17T20:41:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-and-economic-burden-of-hyperkalemia-in-the-united-states-medicare-population/2024-05-17T20:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antiproliferative-effects-of-telotristat-ethyl-in-patients-with-neuroendocrine-tumors-the-teleace-real-world-chart-review-study/2024-05-17T20:41:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-of-long-term-prednisone-and-deflazacort-use-in-patients-with-duchenne-muscular-dystrophy-experience-at-a-single-large-care-center/2024-05-17T20:43:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-renal-and-cardiovascular-events-among-patients-with-type-2-diabetes-mellitus-and-nephropathy-a-cost-model-based-on-the-credence-clinical-trial/2025-02-28T21:28:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-crohns-disease-in-the-united-states-long-term-healthcare-and-work-loss-related-costs/2025-02-28T21:28:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-inflammatory-bowel-disease-among-patients-with-chronic-inflammatory-diseases-a-retrospective-cohort-study/2024-05-17T20:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/in-hospital-therapy-for-heart-failure-with-reduced-ejection-fraction-in-the-united-states/2024-05-17T20:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prognostic-factors-for-changes-in-the-timed-4-stair-climb-in-patients-with-duchenne-muscular-dystrophy-and-implications-for-measuring-drug-efficacy-a-multi-institutional-collaboration/2024-05-17T20:43:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/suitability-of-external-controls-for-drug-evaluation-in-duchenne-muscular-dystrophy/2024-05-17T20:44:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-longitudinal-assessment-of-the-impact-of-endometriosis-on-patients-salary-growth-and-risk-of-leaving-the-workforce/2024-05-17T20:41:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-postpartum-depression-among-commercially-insured-households/2025-06-30T20:44:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/projecting-the-long-term-economic-impact-of-once-monthly-paliperidone-palmitate-versus-oral-atypical-antipsychotics-in-medicaid-patients-with-schizophrenia/2024-05-17T20:43:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-and-treatment-patterns-among-patients-with-atopic-dermatitis-using-advanced-therapies-in-the-united-states-analysis-of-a-retrospective-claims-database/2025-02-28T21:29:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-analysis-of-comorbidities-and-treatment-burden-among-patients-with-hiv-infection-in-a-us-medicaid-population/2024-05-17T20:44:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/financing-drug-innovation-in-the-us-current-framework-and-emerging-challenges/2024-10-28T19:00:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparison-of-the-efficacy-of-apalutamide-and-enzalutamide-with-adt-in-the-treatment-of-non-metastatic-castration-resistant-prostate-cancer/2024-05-17T20:43:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-assessment-of-weight-change-associated-with-the-initiation-of-a-protease-or-integrase-strand-transfer-inhibitor-in-patients-with-human-immunodeficiency-virus/2025-02-28T21:29:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/egfr-mutation-testing-and-treatment-decisions-in-patients-progressing-on-first--or-second-generation-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors/2024-05-17T20:42:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospital-utilization-rates-following-antipsychotic-dose-reduction-in-mood-disorders-implications-for-treatment-of-tardive-dyskinesia/2024-05-17T20:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-clinical-outcomes-of-pazopanib-immediately-after-discontinuation-of-immunotherapy-for-advanced-renal-cell-carcinoma/2024-05-17T20:43:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-of-chemoradiotherapy-versus-single-modality-therapy-and-overall-survival-among-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer/2024-05-17T20:43:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-national-comprehensive-cancer-network-guidelines-for-brca-testing-among-high-risk-breast-cancer-patients-a-retrospective-chart-review-study/2024-05-17T20:41:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-economic-evaluation-of-pembrolizumab-versus-other-adjuvant-treatment-strategies-for-resected-high-risk-stage-iii-melanoma-in-the-usa/2024-05-17T20:41:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-pembrolizumab-with-axitinib-as-first-line-treatment-for-advanced-renal-cell-carcinoma/2024-05-17T20:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/individual-contribution-in-team-contests/2024-05-17T20:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/key-strategies-for-overcoming-psychological-insulin-resistance-in-adults-with-type-2-diabetes-the-uk-subgroup-in-the-emotion-study/2024-05-17T20:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-illness-among-commercially-insured-patients-with-systemic-sclerosis-with-interstitial-lung-disease-in-the-usa-a-claims-data-analysis/2024-05-17T20:42:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-among-commercially-insured-patients-with-systemic-sclerosis-in-the-united-states/2024-05-17T20:42:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/modeling-the-potential-impact-of-abuse-deterrent-opioids-on-medical-resource-utilization/2024-05-17T20:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/which-method-is-for-you-not-all-surveys-are-made-the-same/2026-03-13T18:36:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-pharma-cos.-can-evaluate-alliance-agreements-validity2024-05-17T20:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cardiac-arrhythmia-detection-outcomes-among-patients-monitored-with-the-zio-patch-system-a-systematic-literature-review/2024-05-17T20:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burden-of-patients-with-chronic-hepatitis-c-with-versus-without-antiviral-treatment-in-japan-an-observational-cohort-study-using-hospital-claims-data/2024-05-17T20:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-investigation-into-the-durability-of-glycemic-control-in-patients-with-type-ii-diabetes-initiated-on-canagliflozin-or-sitagliptin-a-real-world-analysis-of-electronic-medical-records/2025-02-28T21:32:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-risk-models-for-major-adverse-chronic-renal-outcomes-among-patients-with-type-2-diabetes-mellitus-using-insurance-claims-a-retrospective-observational-study/2024-05-17T20:42:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/transparency-in-health-economic-modeling-options-issues-and-potential-solutions/2024-05-17T20:44:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-work-loss-associated-with-prescription-related-opioid-use-disorder-a-retrospective-analysis-of-claims-data/2024-05-17T20:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy/2024-05-17T20:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-patient-preferences-for-treatment-decisions-for-new-direct-acting-antiviral-daa-therapies-for-chronic-hepatitis-c-virus-infections/2024-05-17T20:41:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-of-first-line-sunitinib-followed-by-immuno-oncology-checkpoint-inhibitors-in-patients-with-metastatic-renal-cell-carcinoma/2024-05-17T20:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-healthcare-resource-utilization-related-to-migraine-treatment-failure-a-panel-based-chart-review-in-france-germany-italy-and-spain/2024-05-17T20:43:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/migraine-related-healthcare-resource-use-in-the-emergency-department-setting-a-panel-based-chart-review-in-france-germany-italy-and-spain/2024-05-17T20:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epilepsy-impaired-functioning-and-quality-of-life-in-patients-with-tuberous-sclerosis-complex/2024-05-17T20:42:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-a-classifier-to-identify-patients-with-probable-lennox-gastaut-syndrome-in-health-insurance-claims-databases-via-random-forest-methodology/2024-05-17T20:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/postdischarge-health-care-costs-and-readmission-in-patients-with-hyperkalemia-related-hospitalizations/2024-05-17T20:43:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/validation-of-an-ambient-measurement-system-ams-for-physical-activities-in-a-paediatric-population/2024-05-17T20:44:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-non-cisplatin-first-line-therapies-for-metastatic-urothelial-carcinoma-phase-2-imvigor210-study-versus-us-patients-treated-in-the-veterans-health-administration/2024-05-17T20:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/number-needed-to-treat-and-cost-per-remitter-for-biologic-treatments-of-crohns-disease-in-japan/2024-12-19T16:46:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-commissioners-history-of-cartel-enforcement-in-europe-multidimensional-comparison-of-administrations2/2025-01-10T16:07:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-among-patients-with-advanced-gastric-cancer-in-russia-a-chart-review-study/2024-05-17T20:43:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regulatory-considerations-for-cost-effective-integration-of-electric-vehicle-charging-infrastructure/2024-05-17T20:44:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-of-metastatic-castration-resistant-prostate-cancer-with-radium-223-a-retrospective-study-at-a-us-tertiary-oncology-center/2025-07-16T13:21:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/state-vs.-local-management-of-pension-assets-effects-of-the-massachusetts-chapter-68-public-pension-reform2025-03-04T16:29:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/allowances-for-loan-losses-under-the-transition-to-cecl-during-the-pandemic/2024-05-17T20:41:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/climate-change-impact-and-resilience-study--phase-ii-an-assessment-of-climate-change-impacts-on-power-system-reliability-in-new-york-state/2024-05-17T20:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparisons-of-the-efficacy-and-safety-of-acalabrutinib-versus-other-targeted-therapies-in-relapsedrefractory-mantle-cell-lymphoma/2024-05-17T20:43:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/influence-of-patient-reported-outcomes-on-the-treatment-effect-of-deferasirox-film-coated-and-dispersible-tablet-formulations-in-the-eclipse-trial-a-post-hoc-mediation-analysis/2024-05-17T20:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-rate-of-occurrence-healthcare-resource-use-and-costs-of-adverse-events-among-metastatic-non-small-cell-lung-cancer-patients-treated-with-first--and-second-generation-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors/2024-05-17T20:44:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/key-factors-for-overcoming-psychological-insulin-resistance-an-examination-of-patient-perspectives-through-content-analysis/2024-05-17T20:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/paper-trail-working-papers-and-recent-scholarship/2025-04-30T16:51:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/when-the-wind-doesnt-blow-the-limits-of-intermittent-resources-and-battery-storage-in-the-decarbonization-of-new-englands-power-system-under-increased-electrification/2024-05-17T20:44:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-venous-thromboembolism-in-cancer-patients-treated-with-anticoagulants/2024-05-17T20:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-upadacitinib-on-patient-reported-outcomes-results-from-select-beyond/2024-05-17T20:42:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/upadacitinib-improves-patient-reported-outcomes-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-conventional-synthetic-disease-modifying-antirheumatic-drugs-results-from-select-next/2024-05-17T20:44:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-and-quality-of-life-burden-of-anemia-on-patients-with-ckd-on-dialysis-a-systematic-review/2024-05-17T20:42:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-switching-to-different-biologic-therapies-among-tumor-necrosis-factor-inhibitor-experienced-patients-with-psoriatic-arthritis/2024-05-17T20:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparison-of-blinatumomab-vs.-inotuzumab-ozogamicin-for-adults-with-relapsedrefractory-acute-lymphoblastic-leukemia2024-05-17T20:43:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/validation-of-the-atopic-dermatitis-control-tool-adct-using-a-longitudinal-survey-of-biologic-treated-patients-with-atopic-dermatitis/2024-05-17T20:44:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-costs-associated-with-corticosteroid-use-in-patients-with-castration-resistant-prostate-cancer-an-administrative-claims-analysis/2024-05-17T20:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adverse-events-associated-with-cumulative-corticosteroid-use-in-patients-with-castration-resistant-prostate-cancer-an-administrative-claims-analysis/2024-05-17T20:41:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-costs-of-stroke-and-major-bleeding-in-patients-with-atrial-fibrillation-treated-with-non-vitamin-k-antagonist-oral-anticoagulants/2024-05-17T20:42:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-effect-of-implantable-cardioverter-defibrillator-in-patients-with-diabetes-and-non-ischaemic-systolic-heart-failure/2024-05-17T20:44:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tyrosine-kinase-inhibitor-therapy-treatment-and-discontinuation-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-in-the-united-states-a-clinical-practice-perspective/2024-05-17T20:44:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-absenteeism-and-disability-cost-burden-of-obesity-among-privately-insured-employees-a-comparison-of-healthcare-industry-versus-other-major-industries-in-the-united-states/2024-05-17T20:42:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-and-tolerability-of-pazopanib-as-first-targeted-therapy-in-metastatic-renal-cell-carcinoma-a-retrospective-chart-review-in-latin-america/2024-05-17T20:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/us-integrated-delivery-networks-perspective-on-economic-burden-of-patients-with-treatment-resistant-depression-a-retrospective-matched-cohort-study/2024-05-17T20:44:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-clinician-impression-of-depression-symptom-severity-associated-with-incremental-economic-burden-in-privately-insured-us-patients-with-treatment-resistant-depression/2024-05-17T20:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-treatment-resistant-depression-in-medicare-a-retrospective-claims-database-analysis/2024-05-17T20:41:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consideration-of-potential-drug-drug-interactions-in-selection-of-fda-approved-drugs-indicated-for-prostate-cancer/2024-05-17T20:42:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/are-medicaid-coverage-gaps-associated-with-higher-health-care-resource-utilization-and-costs-in-patients-with-schizophrenia/2024-05-17T20:41:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-and-health-related-quality-of-life-associated-with-current-treatments-for-anaemia-in-patients-with-ckd-not-on-dialysis-a-systematic-review/2024-05-17T20:42:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mild-traumatic-brain-injury-in-the-united-states-demographics-brain-imaging-procedures-health-care-utilization-and-costs/2024-05-17T20:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/systematic-literature-review-of-clinical-trials-of-endocrine-therapies-for-premenopausal-women-with-metastatic-hr-her2--breast-cancer/2024-05-17T20:44:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-assessment-and-prediction-of-td-incidence-in-psychiatric-patients-taking-concomitant-antipsychotics-a-retrospective-data-analysis/2024-05-17T20:44:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-analysis-of-switching-patients-with-schizophrenia-from-oral-risperidone-or-oral-paliperidone-to-once-monthly-paliperidone-palmitate/2025-02-28T21:30:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-adherence-in-patients-with-metastatic-colorectal-cancer-treated-with-trifluridine-plus-tipiracil-or-regorafenib/2024-05-17T20:43:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-of-high-cost-patients-with-noninfectious-inflammatory-eye-diseases/2024-05-17T20:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-burden-of-bronchopulmonary-dysplasia-among-extremely-preterm-infants/2024-05-17T20:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adjuvant-therapy-versus-watch-and-wait-post-surgery-for-stage-iii-melanoma-a-multicountry-retrospective-chart-review/2024-05-17T20:41:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/modeling-the-impact-of-real-world-adherence-to-once-daily-qd-versus-twice-daily-bid-non-vitamin-k-antagonist-oral-anticoagulants-on-stroke-and-major-bleeding-events-among-non-valvular-atrial-fibrillation-patient/2024-05-17T20:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-burden-of-tardive-dyskinesia-secondary-to-antipsychotic-medication-use-among-patients-with-mental-disorders/2024-05-17T20:44:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-non-medical-switching-from-originator-biologics-to-biosimilars-a-systematic-literature-review/2024-05-17T20:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/factors-that-impact-a-patients-experience-when-undergoing-single-photon-emission-computed-tomography-myocardial-perfusion-imaging-spect-mpi-in-the-us-a-survey-of-patients-imaging-center-staff-and-physicians/2024-05-17T20:42:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-first-line-ceritinib-and-crizotinib-in-advanced-or-metastatic-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-an-adjusted-indirect-comparison-with-external-controls/2024-05-17T20:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effectiveness-of-first-line-treatments-in-metastatic-squamous-non-small-cell-lung-cancer/2024-05-17T20:42:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-models-for-prediction-of-implantable-cardioverter-defibrillator-benefit-insights-from-the-danish-trial/2024-05-17T20:44:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-implications-of-anticoagulation-strategies-after-percutaneous-coronary-intervention-among-patients-with-atrial-fibrillation-a-pioneer-af-pci-analysis/2024-05-17T20:42:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-venous-thromboembolism-recurrence-in-patients-with-cancer/2024-05-17T20:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-study-on-the-association-of-biomarkers-with-real-world-outcomes-of-omalizumab-treated-patients-with-allergic-asthma/2024-05-17T20:44:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measuring-the-impact-of-air-pollution-on-health-care-costs/2026-01-02T18:48:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-omalizumab-outcomes-in-chronic-idiopathic-urticaria-a-real-world-study/2024-05-17T20:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-modelling-of-costs-associated-with-outcomes-reported-for-type-2-diabetes-mellitus-t2dm-patients-in-the-canvas-and-empa-reg-cardiovascular-outcomes-trials/2025-02-28T21:32:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-nocturia-on-the-u.s.-health-care-system-and-society-a-national-health-and-nutrition-examination-survey-analysis2024-05-17T20:44:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/second-line-rituximab-bendamustine-versus-rituximab-gemcitabine-oxaliplatin-in-diffuse-large-b-cell-lymphoma-in-the-real-world/2024-05-17T20:44:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/analysis-of-real-world-treatment-patterns-healthcare-resource-utilization-and-costs-between-octreotide-and-lanreotide-among-patients-with-neuroendocrine-tumors/2024-05-17T20:41:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/insights-into-the-natural-history-of-metachromatic-leukodystrophy-from-interviews-with-caregivers/2024-05-17T20:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-change-in-quality-of-life-carcinoid-syndrome-symptoms-and-healthcare-resource-utilization-in-patients-with-carcinoid-syndrome/2024-05-17T20:41:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-of-adverse-events-among-patients-with-metastatic-urothelial-cancer-in-usa/2024-05-17T20:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-relapse-after-hematopoietic-stem-cell-transplantation-hsct-in-patients-with-acute-myeloid-leukemia-aml-a-retrospective-claims-based-analysis/2024-05-17T20:43:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/suitability-of-natural-history-data-for-external-controls-in-duchenne-muscular-dystrophy/2024-05-17T20:44:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-provider-characteristics-on-the-hepatitis-a-and-b-vaccination-status-of-adults-in-the-united-states-during-2007-2015/2024-05-17T20:44:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-relapserecurrence-in-patients-with-major-depressive-disorder/2024-05-17T20:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-treatment-comparison-of-nivolumab-versus-observation-or-ipilimumab-as-adjuvant-therapy-in-resected-melanoma-using-pooled-clinical-trial-data/2024-05-17T20:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-durability-of-relapse-rate-reduction-in-patients-with-multiple-sclerosis-receiving-fingolimod-for-up-to-3years-a-retrospective-us-claims-database-analysis/2024-05-17T20:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-time-to-next-treatment-health-care-resource-utilization-and-costs-in-patients-with-chronic-lymphocytic-leukemia-initiated-on-front-line-ibrutinib-or-chemoimmunotherapy/2024-05-17T20:42:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-healthcare-resource-utilization-and-costs-in-medicaid-beneficiaries-with-schizophrenia-transitioning-from-once-monthly-to-once-every-3-months-paliperidone-palmitate/2025-02-28T21:33:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-incidence-of-inflammatory-bowel-disease-among-patients-with-other-chronic-inflammatory-diseases-treated-with-interleukin-17a-or-phosphodiesterase-4-inhibitors/2024-05-17T20:43:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/right-ventricular-dysfunction-and-the-effect-of-defibrillator-implantation-in-patients-with-nonischemic-systolic-heart-failure/2024-05-17T20:44:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/myocardial-fibrosis-and-the-effect-of-primary-prophylactic-defibrillator-implantation-in-patients-with-non-ischemic-systolic-heart-failuredanish-mri/2024-05-17T20:43:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-spinal-muscular-atrophy-in-the-united-states-a-contemporary-assessment/2024-05-17T20:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/covid-19-and-bottom-line-impacts-in-trademark-litigation/2024-05-17T20:42:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--florida/2024-05-17T20:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--arizona/2024-05-17T20:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--pennsylvania/2024-05-17T20:42:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--nevada/2024-05-17T20:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--illinois/2024-05-17T20:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--colorado/2024-05-17T20:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/trends-in-health-service-use-and-potentially-avoidable-hospitalizations-before-alzheimers-disease-diagnosis-a-matched-retrospective-study-of-us-medicare-beneficiaries/2024-05-17T20:44:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimated-prevalence-and-incidence-of-dry-eye-disease-based-on-coding-analysis-of-a-large-all-age-united-states-health-care-system/2024-05-17T20:42:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survival-motor-function-and-motor-milestones-comparison-of-avxs-101-relative-to-nusinersen-for-the-treatment-of-infants-with-spinal-muscular-atrophy-type-1/2024-05-17T20:44:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-the-real-world-safety-profile-of-vedolizumab-using-the-united-states-food-and-drug-administration-adverse-event-reporting-system/2024-05-17T20:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-deep-molecular-response-in-chronic-phase---chronic-myeloid-leukemia-patients-treated-with-second-line-nilotinib-or-dasatinib-a-multi-country-retrospective-chart-review-study/2024-05-17T20:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-biochemical-control-and-comorbidities-in-patients-with-acromegaly-an-italian-longitudinal-retrospective-chart-review-study/2024-05-17T20:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/institutionalization-risk-and-costs-associated-with-agitation-in-alzheimers-disease/2024-05-17T20:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparison-of-health-related-quality-of-life-and-adverse-events-of-apalutamide-versus-enzalutamide-in-non-metastatic-castration-resistant-prostate-cancer/2024-05-17T20:43:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/determinants-of-meningococcal-acwy-vaccination-in-adolescents-in-the-us-completion-and-compliance-with-the-cdc-recommendations/2024-05-17T20:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/beyond-multidrug-resistance-leveraging-rare-variants-with-machine-and-statistical-learning-models-in-mycobacterium-tuberculosis-resistance-prediction/2024-05-17T20:41:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-teduglutide-on-quality-of-life-among-patients-with-short-bowel-syndrome-and-intestinal-failure/2024-05-17T20:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-impact-of-glycated-hemoglobin-reduction-on-treatment-intensification-and-glycated-hemoglobin-goal-attainment-in-type-2-diabetes-mellitus-patients/2025-02-28T21:33:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dry-eye-disease-ranking-among-common-reasons-for-seeking-eye-care-in-a-large-us-claims-database/2024-05-17T20:42:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medication-adherence-and-persistence-in-chronic-obstructive-pulmonary-disease-patients-receiving-triple-therapy-in-a-usa-commercially-insured-population/2024-05-17T20:43:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-overall-survival-among-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer/2024-05-17T20:44:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/calcipotriol-plus-betamethasone-dipropionate-aerosol-foam-vs.-apremilast-methotrexate-acitretin-or-fumaric-acid-esters-for-the-treatment-of-plaque-psoriasis-a-matching-adjusted-indirect-comparison2024-05-17T20:41:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-and-clinical-benefits-of-early-identification-of-acute-kidney-injury-using-a-urinary-biomarker/2024-05-17T20:42:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-benefits-of-rapid-antiretroviral-therapy-initiation-in-reducing-medical-and-overall-health-care-costs-among-medicaid-covered-patients-with-human-immunodeficiency-virus/2024-05-17T20:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rapid-initiation-of-antiretroviral-therapy-following-diagnosis-of-human-immunodeficiency-virus-among-patients-with-commercial-insurance-coverage/2025-02-28T21:34:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-pembrolizumab-for-the-adjuvant-treatment-of-resected-high-risk-stage-iii-melanoma-in-the-united-states/2024-05-17T20:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparisons-of-annualized-bleeding-rate-and-utilization-of-bay-94-9027-versus-three-recombinant-factor-viii-agents-for-prophylaxis-in-patients-with-severe-hemophilia-a/2024-05-17T20:43:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--texas/2024-05-17T20:42:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--michigan/2024-05-17T20:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-of-antipsychotic-treatment-switching-in-patients-with-schizophrenia-bipolar-and-major-depressive-disorders/2024-05-17T20:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medication-adherence-in-patients-with-asthma-using-once-daily-versus-twice-daily-icslabas/2024-05-17T20:43:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characterizing-real-world-use-of-tiotropium-in-asthma-in-the-usa/2024-05-17T20:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dupilumab-versus-cyclosporine-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-adults-indirect-comparison-using-the-eczema-area-and-severity-index/2024-05-17T20:42:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-budget-impact-analysis-of-the-introduction-of-copanlisib-for-treatment-of-relapsed-follicular-lymphoma-in-the-united-states/2024-05-17T20:41:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy2/2024-05-17T20:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-severity-and-minimal-clinically-important-differences-in-clinical-outcome-assessments-for-alzheimers-disease-clinical-trials/2024-05-17T20:42:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-non-infectious-inflammatory-eye-disease-niied-in-a-commercially-insured-population-in-the-united-states/2024-05-17T20:42:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comorbidities-and-survival-in-patients-with-lipodystrophy-an-international-chart-review-study/2024-05-17T20:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/racial-disparities-in-treatment-patterns-and-outcomes-among-patients-with-multiple-myeloma-a-seer-medicare-analysis/2024-05-17T20:43:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-offsets-in-the-treatment-journeys-of-patients-with-relapsedrefractory-multiple-myeloma/2025-02-28T21:35:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-costs-associated-with-premature-mortality-among-those-with-veno-occlusive-diseasesinusoidal-obstruction-syndrome-with-multiorgan-dysfunction-post-hematopoietic-stem-cell-transplant/2024-05-17T20:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adverse-medical-conditions-across-treatment-options-in-patients-with-psoriasis-a-claims-based-analysis/2024-05-17T20:41:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/apportioning-value-in-patent-portfolio-license-and-sale-agreements/2024-05-17T20:41:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effect-of-risankizumab-on-patient-reported-outcomes-in-moderate-to-severe-psoriasis-the-ultimma-1-and-ultimma-2-randomized-clinical-trials/2024-10-21T15:12:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/accelerating-job-growth-and-an-equitable-low-carbon-energy-transition-the-role-of-the-clean-energy-accelerator/2024-05-17T20:41:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/wholesale-power-market-design-in-a-future-low-carbon-electric-system/2024-05-17T20:44:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--minnesota/2024-12-19T16:47:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-potential-drug-drug-interactions-and-pre-existing-conditions-for-adverse-events-in-augmentation-therapies-among-patients-with-treatment-resistant-depression/2025-01-03T23:19:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/making-the-right-call-in-revenue-recognition/2024-05-17T20:43:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-biologics-and-oral-treatments-for-plaque-psoriasis-a-meta-analysis/2024-05-17T20:42:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-overview-of-patients-with-haemophilia-a-in-china-epidemiology-disease-severity-and-treatment-strategies/2024-05-17T20:41:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/realworld-analysis-of-haemophilia-patients-in-china-a-single-centres-experience/2024-05-17T20:44:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interim-measures-in-antitrust-investigations-an-economic-discussion/2025-04-30T16:52:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/accelerating-decarbonization-of-the-u.s.-energy-system2024-05-17T20:41:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-in-patients-with-myelodysplastic-syndromes-treated-with-hypomethylating-agents-a-seer-medicare-analysis/2024-05-17T20:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/network-meta-analysis-of-nivolumab-plus-ipilimumab-in-the-second-line-setting-for-advanced-hepatocellular-carcinoma/2024-05-17T20:43:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-income-growth-in-patients-with-rheumatoid-arthritis-treated-with-anti-tumor-necrosis-factor-therapy/2024-05-17T20:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-peanut-allergy-in-pediatric-patients-with-evidence-of-reactions-to-peanuts-in-the-united-states/2024-05-17T20:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/shareholder-distributions-vs.-reinvestment-the-gap-grows2024-05-17T20:44:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consequences-of-insurance-denials-among-u.s.-patients-prescribed-repository-corticotropin-injection-for-acute-exacerbations-of-multiple-sclerosis2024-05-17T20:42:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tyrosine-kinase-inhibitor-therapy-discontinuation-in-patients-with-chronic-myeloid-leukemia-in-chronic-phase-in-the-united-states-after-clinical-practice-guideline-updates/2024-05-17T20:44:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/five-year-estimated-glomerular-filtration-rate-in-patients-with-hypoparathyroidism-treated-with-and-without-rhpth1-84/2024-05-17T20:42:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-research-using-matching-adjusted-indirect-comparison-an-application-to-treatment-with-guanfacine-extended-release-or-atomoxetine-in-children-with-attention-deficit/2024-05-17T20:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/quality-measure-attainment-in-patients-with-type-2-diabetes-mellitus/2025-02-28T21:50:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/drug-utilization-and-cost-for-erythropoiesis-stimulating-agents-in-a-long-term-care-resident-population-with-chronic-kidney-disease/2025-02-28T21:52:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-of-survival-healthcare-resource-utilization-and-healthcare-costs-in-veterans-with-non-metastatic-castration-resistant-prostate-cancer/2024-05-17T20:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mitigating-antitrust-concerns-when-competitors-share-data-using-blockchain-technology/2024-06-11T14:39:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-cos.-can-reduce-fca-risk-by-leveraging-data2024-05-17T20:42:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/upadacitinib-monotherapy-improves-patient-reported-outcomes-in-rheumatoid-arthritis-results-from-select-early-and-select-monotherapy/2024-05-17T20:44:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-of-capmatinib-for-adults-with-metastatic-non-small-cell-lung-cancer-harboring-a-met-exon-14-skipping-mutation-in-the-united-states/2024-11-05T19:40:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-in-patients-with-heart-failure-hospitalized-with-covid-19/2024-05-17T20:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-predictors-of-adherence-in-hiv-patients-receiving-single--or-multiple-tablet-darunavir-cobicistat-emtricitabine-and-tenofovir-alafenamide/2025-02-28T21:30:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-of-patients-with-locally-advanced-or-metastatic-epithelioid-sarcoma/2024-05-24T17:41:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-healthcare-resource-utilization-in-patients-with-classical-hodgkin-lymphoma-treated-with-pembrolizumab-and-nivolumab-in-the-usa/2024-05-17T20:43:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-recurrent-pericarditis-on-health-related-quality-of-life/2024-05-24T17:33:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-effect-of-elagolix-treatment-for-endometriosis-on-postmenopausal-bone-outcomes-a-model-bridging-phase-iii-trials-to-an-older-real-world-population/2024-05-17T20:42:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-and-health-care-resource-use-associated-with-reslizumab-treatment-in-adults-with-severe-eosinophilic-asthma-in-real-world-practice/2024-05-17T20:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-ceritinib-vs.-crizotinib-in-previously-untreated-anaplastic-lymphoma-kinase-alk-positive-non-small-cell-lung-cancer-nsclc-in-hong-kong2024-05-17T20:42:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-evidence-and-modern-antitrust/2024-05-17T20:42:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-budget-impact-analysis-of-gilteritinib-for-the-treatment-of-relapsed-or-refractory-flt3-mut-acute-myeloid-leukemia-in-a-us-health-plan/2024-05-17T20:41:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/do-appraisal-challenges-benefit-target-shareholders-through-narrowing-arbitrage-spread/2025-01-03T17:53:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-challenges-of-using-return-on-capital-as-an-indicator-of-monopoly-power/2024-05-17T20:44:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-cost-effectiveness-of-low-dose-budesonide-as-a-step-2-treatment-for-pediatric-asthma-in-china/2025-12-19T15:10:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-treatment-comparison-of-the-efficacy-of-patisiran-and-inotersen-for-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy/2024-05-17T20:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-matching-adjusted-indirect-comparison-of-upadacitinib-versus-tofacitinib-in-adults-with-moderate-to-severe-rheumatoid-arthritis/2024-05-17T20:41:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-chronic-respiratory-morbidity-length-of-stay-inpatient-readmissions-and-costs-among-extremely-preterm-infants-with-bronchopulmonary-dysplasia/2024-05-17T20:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-economic-burden-among-patients-with-and-without-heart-failure-worsening-after-cardiac-resynchronization-therapy/2026-03-03T14:23:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/initiation-of-antidepressant-medication-and-risk-of-incident-stroke-using-the-adult-changes-in-thought-cohort-to-address-time-varying-confounding/2024-05-17T20:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-associated-with-tuberous-sclerosis-complex-in-patients-with-epilepsy/2024-05-17T20:42:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survival-and-clinical-outcomes-with-telotristat-ethyl-in-patients-with-carcinoid-syndrome/2024-05-17T20:44:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-first-line-ibrutinib-compared-to-chemoimmunotherapy-treatment-among-medicare-beneficiaries-with-chronic-lymphocytic-leukemia/2025-02-28T21:31:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-treatment-resistant-depression-in-privately-insured-us-patients-with-co-occurring-anxiety-disorder-andor-substance-use-disorder/2024-05-17T20:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/independent-consultant-study-to-establish-new-york-icap-demand-curve-parameters-for-the-20212022-through-20242025-capability-years--final-report/2024-05-17T20:43:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/us-costeffectiveness-of-polatuzumab-vedotin-bendamustine-and-rituximab-in-diffuse-large-b-cell-lymphoma/2024-05-17T20:44:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/causal-inference-and-adjustment-for-reference-arm-risk-in-indirect-treatment-comparison-meta-analysis/2024-05-17T20:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-double-low-dose-budesonide-and-low-dose-budesonide-plus-montelukast-among-pediatric-patients-with-persistent-asthma-receiving-step-3-treatment-in-china/2025-12-19T15:09:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-characteristics-among-patients-with-agitation-and-dementia-in-the-united-states-findings-from-a-large-observational-retrospective-chart-review/2024-05-17T20:44:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-outcomes-of-erythropoiesis-stimulating-agent-hyporesponsiveness-in-the-post-bundling-era/2024-05-17T20:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cancer-associated-thrombosis-and-mortality-in-patients-with-cancer-stratified-by-khorana-score-risk-levels/2024-05-17T20:41:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-olaparib-as-a-maintenance-treatment-for-women-with-newly-diagnosed-advanced-ovarian-cancer-and-brca12-mutations-in-the-united-states/2024-05-17T20:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/access-to-big-data-as-a-remedy-in-big-tech/2024-05-17T20:41:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-severity-at-the-time-of-initial-cognitive-assessment-is-related-to-prior-health-care-resource-use-burden/2024-05-17T20:42:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/grading-of-neurological-toxicity-in-patients-treated-with-tisagenlecleucel-in-the-juliet-trial/2024-05-17T20:42:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/deflazacort-versus-prednisone-treatment-for-duchenne-muscular-dystrophy-a-meta-analysis-of-disease-progression-rates-in-recent-multicenter-clinical-trials/2024-05-17T20:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/vaso-occlusive-crises-and-costs-of-sickle-cell-disease-in-patients-with-commercial-medicaid-and-medicare-insurance---the-perspective-of-private-and-public-payers/2024-05-17T20:44:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/major-depressive-disorders-have-an-enormous-economic-impact/2024-05-17T20:43:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-adults-with-major-depressive-disorder-in-the-united-states-2010-and-2018/2024-10-18T18:50:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/monitoring-and-switching-patterns-of-patients-with-chronic-myeloid-leukemia-treated-with-imatinib-in-community-settings-a-chart-review-analysis/2024-05-17T20:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparing-nilotinib-with-dasatinib-as-second-line-therapies-in-patients-with-chronic-myelogenous-leukemia-resistant-or-intolerant-to-imatinib--a-retrospective-chart-review-analysis/2024-05-17T20:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-timely-switching-from-imatinib-to-a-second-generation-tyrosine-kinase-inhibitor-after-12-month-complete-cytogenetic-response-failure-a-chart-review-analysis/2024-05-17T20:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-of-gout-patients-treated-with-colchicine-or-other-common-treatments-for-gout-in-acute-care-settings-a-retrospective-chart-review-study/2024-05-17T20:44:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-critical-appraisal-and-recommendations-for-cost-effectiveness-studies-of-polyadp-ribose-polymerase-inhibitors-in-advanced-ovarian-cancer/2024-05-17T20:41:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/procommunity-procalcitonin-use-in-real-world-us-community-hospital-settings/2024-05-17T20:43:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-effectiveness-of-second-line-sunitinib-following-immuno-oncology-therapy-in-patients-with-metastatic-renal-cell-carcinoma-a-real-world-study/2024-05-24T17:38:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-model-to-quantify-potential-medical-events-avoided-and-cost-savings-from-abuse-deterrent-opioids/2024-05-17T20:41:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-growing-burden-of-major-depressive-disorders-mdd-implications-for-researchers-and-policy-makers/2024-05-17T20:44:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cluster-analysis-of-care-pathways-in-adults-with-major-depressive-disorder-with-acute-suicidal-ideation-or-behavior-in-the-usa/2025-01-03T23:15:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-prevalence-and-national-burden-of-treatment-resistant-depression-and-major-depressive-disorder-in-the-united-states/2025-01-03T23:16:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/introduction-to-the-special-issue-of-pharmacoeconomics-on-major-depressive-disorders/2025-01-03T23:18:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lessons-from-recent-banking-litigation/2025-01-03T23:33:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/telehealth-growth-trends-highlight-emerging-risks/2024-05-17T20:44:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy-for-america/2024-05-17T20:42:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-transportation-electrification/2024-05-17T20:42:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-data-based-look-at-covids-commercial-real-estate-impact/2024-05-17T20:41:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/inpatient-management-and-post-discharge-outcomes-of-hyperkalemia/2024-05-24T17:27:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cigar-association-of-america-et-al.-v.-united-states-food-and-drug-administration-et-al2024-05-17T20:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/rolling-disclosure-cap-method-may-lead-to-lower-damages/2025-01-03T23:51:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-overall-survival-of-patients-with-metastatic-castration-resistant-prostate-cancer-in-the-us-prior-to-parp-inhibitors/2024-05-17T20:44:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-bridge-over-troubled-waters-the-role-of-due-diligence-in-mitigating-spac-litigation-risks/2024-05-17T20:41:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-chronic-kidney-disease-in-adult-patients-with-chronic-hypoparathyroidism-treated-with-rhpth1-84-compared-with-a-historical-control-cohort/2024-05-17T20:44:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-and-timing-of-response-to-teduglutide-in-patients-with-short-bowel-syndrome-dependent-on-parenteral-support/2024-05-24T17:29:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/umeclidiniumvilanterol-compared-with-fluticasone-propionatesalmeterol-budesonideformoterol-and-tiotropium-as-initial-maintenance-therapy-in-patients-with-copd-who-have-high-costs-and-comorbidities/2024-05-24T17:30:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-characteristics-treatment-patterns-health-care-resource-use-and-costs-of-patients-with-diffuse-large-b-cell-lymphoma-in-the-u.s2024-05-24T17:32:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-genetic-testing-patterns-in-metastatic-castration-resistant-prostate-cancer/2024-05-24T17:35:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-impact-of-antiepileptic-drug-combinations-with-versus-without-perampanel-on-healthcare-resource-utilization-in-patients-with-epilepsy-in-the-united-states/2024-05-24T17:36:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-sequencing-and-healthcare-costs-among-cllsll-patients-treated-with-venetoclax/2025-02-28T21:20:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/regional-variations-in-prevalence-and-severity-of-autosomal-dominant-polycystic-kidney-disease-in-the-united-states/2024-05-17T20:44:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disruption-of-pharmacotherapy-during-the-transition-from-adolescence-to-early-adulthood-in-patients-with-attention-deficithyperactivity-disorder-a-claims-database-analysis-across-the-usa/2024-05-17T20:42:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-per-remitter-with-esketamine-nasal-spray-versus-standard-of-care-for-treatment-resistant-depression/2024-05-17T20:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/confirmed-disability-progression-provides-limited-predictive-information-regarding-future-disease-progression-in-multiple-sclerosis/2024-05-17T20:42:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparison-of-darolutamide-versus-apalutamide-and-enzalutamide-for-nonmetastatic-castration-resistant-prostate-cancer/2024-05-17T20:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-of-major-atherothrombotic-vascular-events-among-patients-with-peripheral-artery-disease-after-revascularization/2024-05-17T20:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-major-atherothrombotic-vascular-events-among-patients-with-peripheral-artery-disease-after-revascularization/2024-05-17T20:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-profiles-clinical-outcomes-and-healthcare-resource-utilization-of-patients-with-migraine-prescribed-erenumab-a-multicenter-chart-review-study-of-us-headache-centers/2024-05-17T20:44:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-and-relative-ranking-of-biologics-and-oral-therapies-for-moderate-to-severe-plaque-psoriasis-a-network-meta-analysis/2024-05-17T20:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overcoming-psychological-insulin-resistance-a-practical-guide-for-healthcare-professionals/2024-05-17T20:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-cost-burden-of-hemophilia-b-in-the-united-states/2024-05-17T20:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-utilization-and-safety-of-daratumumab-iv-rapid-infusions-administered-in-a-community-setting-a-retrospective-observational-study/2025-02-28T21:21:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/outcomes-and-resource-use-of-patients-with-large-hemispheric-infarction-and-cerebral-edema-analysis-of-real-world-data/2024-05-17T20:43:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/persistence-to-hypomethylating-agents-and-clinical-and-economic-outcomes-among-patients-with-myelodysplastic-syndromes/2024-05-17T20:43:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/upadacitinib-improves-patient-reported-outcomes-vs-placebo-or-adalimumab-in-patients-with-rheumatoid-arthritis-results-from-select-compare/2024-05-17T20:44:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medication-patterns-of-abiraterone-acetate-plus-prednisone-or-enzalutamide-and-psa-progression-in-veterans-with-metastatic-castration-resistant-prostate-cancer/2024-05-17T20:43:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--virginia/2024-05-17T20:42:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--west-virginia/2024-05-17T20:42:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--new-mexico/2024-05-17T20:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-stimulus-investment-in-advanced-energy--ohio/2024-05-17T20:42:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-management-and-outcomes-in-patients-hospitalized-for-acute-heart-failure-in-japan/2024-05-17T20:42:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-safety-and-benefit-risk-profile-of-biologics-and-oral-treatment-for-moderate-to-severe-plaque-psoriasis-a-network-meta-analysis-of-clinical-trial-data/2024-05-17T20:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-the-use-of-pharmacological-stress-agents-during-single-photon-emission-computed-tomography-myocardial-perfusion-imaging-tests-after-inadequate-exercise-stress-test/2024-05-17T20:42:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/integrating-real-world-data-and-modeling-to-project-changes-in-femoral-neck-bone-mineral-density-and-fracture-risk-in-premenopausal-women/2024-05-17T20:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-among-adults-with-attention-deficithyperactivity-disorder-in-the-united-states-a-retrospective-claims-study/2026-02-19T17:18:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-a-clean-electricity-payment-program/2024-05-17T20:42:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/when-it-comes-to-the-price-transparency-rule-not-all-data-is-created-equal/2025-04-30T16:34:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-recent-case-law-tells-us-about-the-importance-of-consumer-surveys-in-trademark-cases/2024-05-17T20:44:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/new-survey-methods-address-consumer-uncertainty-in-trademark-law/2024-05-17T20:43:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/gender-considerations-in-the-analysis-of-market-definition-and-competitive-effects-a-practical-framework-and-illustrative-example/2025-05-01T16:08:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-evidence-in-support-of-oncology-product-registration-a-systematic-review-of-new-drug-application-and-biologics-license-application-approvals-from-2015-2020/2024-05-17T20:43:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/youtubes-violative-view-rate-methodology-a-statistical-assessment/2024-05-17T20:44:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-analysis-of-merger-remedies/2025-10-10T15:21:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/algorithmic-pricing-what-every-antititrust-lawyer-needs-to-know/2026-03-16T13:02:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/united-states-platform-economics-and-mergers/2025-04-30T16:50:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-importance-of-exit-via-acquisition-to-venture-capital-entrepreneurship-and-innovation/2026-02-27T16:39:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/no-exit-a-threat-to-venture-capital-entrepreneurship-and-innovation/2026-02-27T16:44:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/why-exit-via-acquisition-is-essential-to-entrepreneurial-investment/2026-02-27T16:46:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-and-repeat-how-the-venture-capital-ecosystem-drives-entrepreneurship-and-innovation/2026-02-27T16:37:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-outcomes-associated-with-dupilumab-use-in-patients-with-atopic-dermatitis-1-year-results-from-the-relieve-ad-study/2024-10-21T15:10:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lost-profits-damages-principles-methods-and-applications-second-edition/2025-01-28T20:28:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-ability-to-achieve-lost-sales-as-a-consideration-in-damages-analyses2/2024-05-17T20:44:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/industry-and-economic-research/2024-05-17T20:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/modifications-to-the-bsm-construct-in-the-nyiso-capacity-market-analysis-of-potential-capacity-market-competitiveness-and-reliability-outcomes/2024-05-17T20:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-use-of-surveys-in-lost-profits-analyses/2024-05-17T20:44:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-data-for-healthcare-research-in-china-call-for-actions/2024-05-17T20:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-to-interpret-a-contract-ask-those-whod-sign-it/2024-08-28T15:50:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-benralizumab-results-from-the-zephyr-1-study/2024-05-17T20:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-commercially-insured-patients-with-major-depressive-disorder-and-acute-suicidal-ideation-or-behavior-in-the-united-states/2025-01-03T23:14:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pathways-study-evaluation-of-pathways-to-a-future-grid/2024-05-17T20:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-potential-global-economic-impact-of-the-metaverse/2025-10-10T15:09:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/methane-reduction-technology-electricity-and-abatement-costs/2024-05-17T20:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fercs-acceptance-of-2-capacity-accreditation-methods-will-complicate-renewables-development/2024-05-17T20:42:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-intersection-of-self-preferencing-and-pricing-practices-in-the-digital-world/2025-04-30T16:49:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/direct-health-care-costs-associated-with-covid-19-in-the-united-states/2024-05-17T20:42:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interim-measures-in-antitrust-investigations-an-economic-discussion-oecd-note/2025-04-30T16:49:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/determining-the-price-for-one-when-all-you-have-is-the-price-for-many/2024-05-17T20:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reading-new-and-old-tea-leaves-u.s.-agencies-request-for-information-may-give-insights-into-the-future-of-merger-review2024-05-17T20:43:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/moore-v.-trader-joes-co2024-05-17T20:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/update-on-the-commentary-on-the-doj-bank-merger-guidelines/2025-09-19T13:29:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/update-on-financial-benchmark-manipulation-litigation/2026-02-04T16:39:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/criminal-antitrust-the-discovery-process-and-the-role-of-economic-experts/2024-05-17T20:42:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-of-avapritinib-versus-best-available-therapy-in-the-treatment-of-advanced-systemic-mastocytosis/2024-05-17T20:42:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/academia-in-court-how-marketing-scholarship-informs-the-law/2024-05-17T20:41:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-choice-of-inhalers-for-asthma-care-on-global-carbon-footprint-and-societal-costs-a-long-term-economic-evaluation/2025-01-03T23:41:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prejudgment-interest-w.d.-texas-got-it-right-in-the-vlsi-v.-intel-patent-suit2024-05-17T20:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-ongoing-tale-of-two-sided-markets/2024-05-17T20:44:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-progression-on-healthcare-resource-utilization-and-costs-among-patients-with-high-grade-non-muscle-invasive-bladder-cancer-after-bacillus-calmette-guerin-therapy-a-retrospective-seer-medicare-analysis/2024-05-17T20:44:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-medication-adherence-on-healthcare-resource-utilization-work-loss-and-associated-costs-in-a-privately-insured-employed-population-treated-with-adalimumab-in-the-united-states/2024-05-17T20:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-benefit-from-improvements-in-health-related-quality-of-life-with-upadacitinib-comparisons-with-tofacitinib-and-methotrexate-in-patients-with-rheumatoid-arthritis/2024-05-17T20:42:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/systematic-literature-review-of-clinical-and-economic-evidence-for-spinal-muscular-atrophy/2024-05-17T20:44:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/discontinuation-and-switchback-after-non-medical-switching-from-originator-tumor-necrosis-factor-alpha-tnf-inhibitors-biologics-to-biosimilars-a-meta-analysis-of-real-world-studies-from-2012-to-2018/2024-05-17T20:42:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-adjuvant-therapy-in-patients-with-resected-melanoma-an-application-of-the-theory-of-planned-behavior/2024-05-17T20:41:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-treatment-effects-of-inotersen-on-health-related-quality-of-life-in-patients-with-hattr-amyloidosis-with-polyneuropathy-analysis-of-the-open-label-extension-of-the-neuro-ttr-trial/2026-03-03T14:23:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/factors-associated-with-increased-health-related-quality-of-life-benefits-in-hereditary-transthyretin-amyloidosis-polyneuropathy-patients-treated-with-inotersen/2024-05-17T20:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-preferences-for-attributes-of-biologic-treatments-in-moderate-to-severe-asthma-a-discrete-choice-experiment-study/2024-05-28T20:08:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cll-492-real-world-adherence-to-first-line-ibrutinib-and-acalabrutinib-single-agent-among-patients-with-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma/2025-02-28T20:54:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cml-475-real-world-treatment-patterns-among-patients-with-chronic-myeloid-leukemia-in-chronic-phase-cml-cp-cycling-through-multiple-tyrosine-kinase-inhibitors-tkis-in-the-united-states-us/2024-05-17T20:41:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/maralixibat-treatment-response-in-alagille-syndrome-is-associated-with-improved-health-related-quality-of-life/2024-05-17T20:43:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/symptoms-associated-with-adhdtreatment-related-adverse-side-effects-and-their-impact-on-quality-of-life-and-work-productivity-in-adults-with-adhd/2026-02-19T17:18:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-dosing-and-discontinuation-patterns-among-patients-treated-with-pegvaliase-for-phenylketonuria-evidence-from-dispensing-data/2024-05-17T20:44:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/physician-perceptions-of-drug-utilization-management-results-of-a-national-survey/2024-05-17T20:43:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identifying-individuals-with-undiagnosed-post-traumatic-stress-disorder-in-a-large-united-states-civilian-population--a-machine-learning-approach/2024-05-17T20:42:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mpn-435-overall-survival-in-patients-with-systemic-mastocytosis-with-associated-hematologic-neoplasm-treated-with-avapritinib-versus-best-available-therapy/2024-05-17T20:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-reported-outcomes-of-upadacitinib-versus-abatacept-in-patients-with-rheumatoid-arthritis-and-an-inadequate-response-to-biologic-disease-modifying-antirheumatic-drugs-12--and-24-week-results-of-a-phase-3-trial/2024-05-17T20:43:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/early-prostate-specific-antigen-response-among-black-and-non-black-patients-with-advanced-prostate-cancer-treated-with-apalutamide/2024-05-17T20:42:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-achieving-and-maintaining-near-complete-or-complete-skin-clearance-on-patient-quality-of-life-in-moderate-to-severe-psoriasis2/2024-05-17T20:44:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/nivolumab-versus-placebo-as-adjuvant-therapy-for-resected-stage-iii-melanoma-a-propensity-weighted-indirect-treatment-comparison-and-number-needed-to-treat-analysis-for-recurrence-free-survival-and-overall-survival/2024-05-17T20:43:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-experts-in-criminal-antitrust-price-fixing-litigation-discovery-and-scope/2024-05-17T20:42:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/what-can-covid-tell-us-about-market-definition-in-air-travel/2025-12-22T18:14:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-economic-analysis-of-the-self-preferencing-debate/2025-04-30T16:50:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fraud-on-the-market-and-the-economics-of-securities-litigation-claims-in-europe/2024-05-28T18:14:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-effectiveness-and-safety-of-dutasteride-versus-finasteride-in-patients-with-male-androgenic-alopecia-in-south-korea-a-multicentre-chart-review-study/2024-05-17T20:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/five-year-estimated-glomerular-filtration-rate-in-adults-with-chronic-hypoparathyroidism-treated-with-rhpth1-84-a-retrospective-cohort-study/2025-02-06T22:41:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treating-anemic-patients-with-myelofibrosis-in-the-new-janus-kinase-inhibitor-era-current-evidence-and-real-world-implications/2024-05-17T20:44:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-of-real-world-commercially-insured-patients-with-treatment-resistant-depression-initiated-on-esketamine-nasal-spray-or-conventional-therapies-in-the-united-states/2024-05-17T20:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/united-states-platform-economics-and-mergers2/2025-09-19T13:31:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-mergers-and-regulatory-uncertainty/2025-05-01T16:05:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/perceptions-of-regulatory-uncertainty-in-antitrust-practices/2025-05-01T15:45:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-societal-economic-value-of-covid-19-vaccines-in-the-united-states/2024-05-17T20:44:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-costs-among-adult-patients-with-hemophilia-a-on-factor-viii-prophylaxis-an-administrative-claims-analysis/2025-06-30T20:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-semaglutide-2.4-mg-for-the-treatment-of-adult-patients-with-overweight-and-obesity-in-the-united-states2024-05-17T20:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pik3ca-mutation-status-progression-and-survival-in-advanced-hr--her2--breast-cancer-a-meta-analysis-of-published-clinical-trials/2024-05-28T20:28:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-persistence-and-time-to-next-treatment-with-ibrutinib-in-patients-with-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-including-patients-at-high-risk-for-atrial-fibrillation-or-stroke/2025-02-28T20:54:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-related-quality-of-life-following-allogeneic-hematopoietic-cell-transplantation-with-omidubicel-versus-umbilical-cord-blood/2024-05-17T20:42:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-the-relative-effectiveness-of-erenumab-compared-with-onabotulinumtoxina-for-the-prevention-of-chronic-migraine/2024-05-17T20:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/post-transplant-maintenance-therapy-in-patients-with-flt3-mutated-acute-myeloid-leukemia-real-world-treatment-patterns-and-outcomes/2024-05-17T20:43:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/advancing-the-development-of-real-world-data-for-healthcare-research-in-china-challenges-and-opportunities/2025-12-19T15:07:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risk-reduction-of-accidental-exposure-related-systemic-allergic-reactions-extrapolated-based-on-food-challenge-data-after-1-year-of-peanut-oral-immunotherapy/2024-11-13T15:12:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-eosinophilic-gastritis-and-eosinophilic-enteritis-in-the-united-states/2024-05-17T20:44:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-migraine-related-healthcare-resource-utilization-and-costs-associated-with-improved-vs.-worsenedstable-migraine-a-panel-based-chart-review-in-france-germany-italy-and-spain2024-05-17T20:43:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/determinants-of-hyperkalemia-progression-among-patients-with-mild-hyperkalemia/2024-05-17T20:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hemophilia-gene-therapy-value-assessment-methodological-challenges-and-recommendations/2024-05-17T20:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-metabolic-acidosis-among-patients-with-chronic-kidney-disease-and-hyperkalemia/2024-05-17T20:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-use-and-costs-associated-with-diabetic-and-idiopathic-gastroparesis-a-claims-analysis-of-the-first-3-years-following-the-diagnosis-of-gastroparesis/2024-05-17T20:42:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/chronic-myeloid-leukemia-part-i-real-world-treatment-patterns-healthcare-resource-utilization-and-associated-costs-in-later-lines-of-therapy-in-the-united-states/2024-05-17T20:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burdens-of-recurrence-following-nephrectomy-for-intermediate-high--or-high-risk-renal-cell-carcinoma-a-retrospective-analysis-of-surveillance-epidemiology-and-end-results-medicare-data/2024-05-17T20:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-invasive-pneumococcal-disease-in-children-with-commercial-insurance-or-medicaid-coverage-in-the-united-states-before-and-after/2024-05-17T20:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adalimumab-is-associated-with-lower-healthcare-resource-and-steroid-use-versus-vedolizumab-in-biologic-naive-crohns-disease-a-retrospective-claims-database-analysis/2024-05-17T20:41:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/increasing-covid-19-vaccination-in-the-united-states-projected-impact-on-cases-hospitalizations-and-deaths-by-age-and-racial-group/2024-05-17T20:43:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burden-of-tumor-lysis-syndrome-among-patients-with-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-a-real-world-us-retrospective-study/2025-02-28T20:55:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-utilization-and-outcomes-of-systemic-therapy-among-patients-with-advanced-or-recurrent-endometrial-cancer-in-the-united-states/2025-02-28T20:55:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-adherence-to-treatment-with-inhaled-corticosteroidslong-acting-agonists-on-asthma-outcomes-in-the-united-states/2024-05-17T20:42:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-hospitalization-related-costs-of-adverse-events-for-novel-androgen-receptor-inhibitors-in-non-metastatic-castration-resistant-prostate-cancer-an-indirect-comparison/2024-05-17T20:44:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-per-patient-achieving-remission-with-venetoclax-based-combinations-in-newly-diagnosed-patients-with-acute-myeloid-leukemia-ineligible-for-intensive-induction-chemotherapy/2024-11-13T15:11:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-the-impact-of-a-meningitisencephalitis-panel-on-hospital-length-of-stay-a-systematic-review-and-meta-analysis/2024-05-17T20:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-utilization-and-costs-among-us-adolescents-with-alopecia-areata/2024-05-17T20:42:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-real-world-health-resource-use-and-costs-of-misdiagnosing-bipolar-i-disorder/2024-05-17T20:44:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/chronic-myeloid-leukemia-part-ii-cost-of-care-among-patients-in-advanced-phases-or-later-lines-of-therapy-in-chronic-phase-in-the-united-states-from-a-commercial-perspective/2024-05-17T20:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retail-landscape-changes-may-affect-kroger-albertsons-deal/2024-05-17T20:44:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-among-children-and-adolescents-with-attention-deficithyperactivity-disorder-in-the-united-states---a-retrospective-claims-analysis/2024-05-17T20:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-attention-deficithyperactivity-disorder-among-children-and-adolescents-in-the-united-states-a-societal-perspective/2024-05-17T20:42:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-risk-of-chronic-kidney-disease-development-in-adult-patients-with-chronic-hypoparathyroidism-treated-with-rhpth1-84-a-retrospective-cohort-study/2025-02-06T22:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-weight-gain-and-the-incidence-of-cardiometabolic-conditions-among-people-living-with-hiv-1-at-high-risk-of-weight-gain-initiated-on-antiretroviral-therapy/2025-02-28T20:56:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-and-persistence-to-single-inhaler-versus-multiple-inhaler-triple-therapy-for-asthma-management/2024-05-17T20:41:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-physician-and-administrator-reported-cost-of-drug-utilization-management-to-physician-practices-a-cross-sectional-survey/2024-05-17T20:44:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/symptom-control-in-patients-with-asthma-using-inhaled-corticosteroidslong-acting-2-agonists-fluticasone-furoatevilanterol-or-budesonideformoterol-in-the-us-a-retrospective-matched-cohort-study/2024-05-17T20:44:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/understanding-the-health-system-conditions-affecting-the-use-of-long-acting-injectable-antipsychotics-in-the-treatment-of-schizophrenia-in-clinical-practice-a-us-healthcare-provider-survey/2024-05-17T20:44:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lower-risk-of-cardiovascular-events-in-adult-patients-with-chronic-hypoparathyroidism-treated-with-rhpth1-84-a-retrospective-cohort-study/2024-05-17T20:43:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-characteristics-treatment-patterns-and-outcomes-among-black-and-white-patients-with-multiple-myeloma-initiating-daratumumab-a-real-world-chart-review-study/2025-02-28T20:57:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-burden-of-respiratory-complications-associated-with-extreme-prematurity-an-analysis-of-us-medicaid-claims/2024-05-17T20:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-newly-initiated-systemic-therapy-for-atopic-dermatitis-in-the-united-states-a-claims-database-analysis/2025-02-28T20:57:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-and-environmental-benefits-to-massachusetts-from-the-operation-of-the-seabrook-nuclear-plant/2024-05-17T20:42:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-treatment-sequences-for-chronic-lymphocytic-leukemia-in-the-united-states-a-cost-of-care-and-budget-impact-model-of-venetoclax-plus-obinutuzumab-sequences/2025-12-19T15:08:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/webinar-recap-antitrust-questions-in-new-labor-markets/2025-12-01T14:07:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/delays-in-pulmonary-decline-in-eteplirsen-treated-patients-with-duchenne-muscular-dystrophy/2024-05-17T20:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-pembrolizumab-plus-chemotherapy-as-first-line-treatment-in-pd-l1-positive-metastatic-triple-negative-breast-cancer/2024-05-17T20:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interdisciplinary-model-informed-drug-development-for-extending-duration-of-elagolix-treatment-in-patients-with-uterine-fibroids/2024-05-17T20:43:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/temporal-trends-in-grade-34-adverse-events-and-associated-costs-of-nivolumab-plus-cabozantinib-versus-sunitinib-for-previously-untreated-advanced-renal-cell-carcinoma/2024-05-17T20:44:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-venetoclax-in-combination-with-azacitidine-versus-azacitidine-monotherapy-in-patients-with-acute-myeloid-leukemia/2024-11-13T15:13:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-illness-for-patients-with-cholangiocarcinoma-in-the-united-states-a-retrospective-claims-analysis/2024-05-17T20:41:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-among-caregivers-of-pediatric-patients-with-neurofibromatosis-type-1-nf1-and-plexiform-neurofibroma-pn-in-the-united-states-a-cross-sectional-study/2024-05-17T20:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-progression-stages-and-burden-in-patients-with-duchenne-muscular-dystrophy-using-administrative-claims-supplemented-by-electronic-medical-records/2024-06-03T20:40:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comprehensive-genomic-profiling-in-advancedmetastatic-colorectal-cancer-number-needed-to-test-and-budget-impact-of-expanded-first-line-use/2024-05-17T20:42:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/national-and-regional-description-of-healthcare-measures-among-adult-medicaid-beneficiaries-with-schizophrenia-within-the-united-states/2025-02-28T20:58:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/contemporary-outpatient-management-of-patients-with-worsening-heart-failure-with-reduced-ejection-fraction-rationale-and-design-of-the-chart-hf-study/2024-05-17T20:42:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-humanistic-burden-among-pediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibroma-in-the-usa/2024-05-17T20:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-experience-of-a-severe-hypoglycaemic-event-from-the-perspective-of-people-with-diabetes-and-their-caregivers-what-am-i-going-to-do/2024-05-17T20:44:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-and-understanding-combination-therapy-decision-drivers-for-the-treatment-of-overactive-bladder-in-the-united-states/2024-05-17T20:42:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/excess-healthcare-resource-utilization-and-healthcare-costs-among-privately-and-publicly-insured-patients-with-major-depressive-disorder-and-acute-suicidal-ideation-or-behavior-in-the-united-states/2024-05-17T20:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reasons-for-treatment-changes-in-adults-with-attention-deficithyperactivity-disorder-a-chart-review-study/2024-05-17T20:44:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-posttraumatic-stress-disorder-in-the-united-states-from-a-societal-perspective/2024-05-17T20:44:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/trends-in-prevalence-and-incidence-of-alopecia-areata-alopecia-totalis-and-alopecia-universalis-among-adults-and-children-in-a-us-employer-sponsored-insured-population/2024-05-17T20:44:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-acute-effects-of-azithromycin-use-on-cardiovascular-mortality-as-compared-with-amoxicillin-clavulanate-in-us-veterans/2025-07-16T13:29:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-combined-prospective-and-retrospective-comparison-of-long-term-functional-outcomes-suggests-delayed-loss-of-ambulation-and-pulmonary-decline-with-long-term-eteplirsen-treatment/2024-05-17T20:41:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparison-of-the-efficacy-of-loncastuximab-tesirine-versus-treatment-in-the-chemoimmunotherapy-era-for-relapsedrefractory-diffuse-large-b-cell-lymphoma/2024-05-17T20:43:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-and-economic-burden-of-respiratory-syncytial-virus-among-adults-in-the-united-states-a-retrospective-analysis-using-2-insurance-claims-databases/2025-02-28T20:58:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-after-initiating-fremanezumab-treatment-in-us-patients-with-episodic-and-chronic-migraine-or-difficult-to-treat-migraine/2024-05-17T20:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-clinical-pathways-on-treatment-patterns-and-outcomes-for-patients-with-non-small-cell-lung-cancer-real-world-evidence-from-a-community-oncology-practice/2024-05-17T20:42:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-impact-of-antipsychotic-dose-reduction-on-clinical-outcomes-and-health-care-resource-use-among-medicare-patients-with-schizophrenia/2024-05-17T20:44:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-associated-with-nasal-polyposis-recurrence-among-commercially-insured-patients-in-the-united-states/2024-05-17T20:42:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-pre-existing-conditions-relevant-for-adverse-events-and-potential-drug-drug-interactions-associated-with-augmentation-therapies-among-patients-with-treatment-resistant-depression/2024-05-17T20:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/gilteritinib-vs-salvage-chemotherapy-in-flt3-mutated-acute-myeloid-leukemia-number-needed-to-treat-for-clinical-outcomes-per-a-secondary-analysis-of-the-admiral-trial/2024-05-17T20:42:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-among-patients-with-metastatic-pancreatic-ductal-adenocarcinoma-treated-with-liposomal-irinotecan/2024-05-17T20:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/difficulty-of-detecting-ai-content-poses-legal-challenges/2024-12-19T16:48:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-healthcare-resource-utilization-and-costs-of-patients-diagnosed-with-primary-mediastinal-b-cell-lymphoma-in-the-united-states/2024-05-17T20:44:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-and-treatment-patterns-of-relapsedrefractory-diffuse-large-b-cell-lymphoma-in-patients-receiving-3-therapy-lines-in-post-car-t-era/2024-05-17T20:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-health-related-quality-of-life-in-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-eq-5d-based-utilities-in-the-explorer-hcm-trial/2024-05-17T20:41:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant-single-agent-pembrolizumab-for-high-risk-early-stage-triple-negative-breast-cancer-in-the-united-states/2025-07-07T18:07:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/conceptual-framework-and-methodological-challenges-for-modeling-effectiveness-in-oncology-treatment-sequence-models/2024-05-17T20:42:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dynamics-of-improvement-in-health-related-quality-of-life-hrqol-with-long-term-eltrombopag-treatment-in-adults-with-chronic-immune-thrombocytopenia-itp-in-extend/2024-05-17T20:42:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/multicenter-compact-study-of-complications-in-patients-with-sickle-cell-disease-and-utilization-of-iron-chelation-therapy/2024-05-17T20:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impacts-of-the-regional-greenhouse-gas-initiative-on-ten-northeast-and-mid-atlantic-states2/2024-05-17T20:44:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/webinar-recap-self-preferencing-is-tech-different-than-brick-and-mortar/2025-04-30T16:48:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/primary-hyperoxaluria-type-1-disease-manifestations-and-healthcare-utilization-a-multi-country-online-chart-review-study/2024-05-17T20:43:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-tisagenlecleucel-for-the-treatment-of-pediatric-and-young-adult-patients-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia-in-japan/2024-11-13T15:13:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-tisagenlecleucel-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-japan/2024-11-13T15:10:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/report-on-the-implications-of-ubers-paying-the-national-living-wage-on-p1-time/2024-05-17T20:44:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hospitalizations-and-healthcare-costs-associated-with-rifaximin-versus-lactulose-treatment-among-commercially-insured-patients-with-hepatic-encephalopathy-in-the-united-states/2024-05-17T20:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparison-of-tisagenlecleucel-and-blinatumomab-in-pediatric-relapsedrefractory-acute-lymphoblastic-leukemia/2024-05-17T20:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/total-cost-of-testing-for-genomic-alterations-associated-with-next-generation-sequencing-versus-polymerase-chain-reaction-testing-strategies-among-patients-with-metastatic-non-small-cell-lung-cancer/2025-02-28T20:59:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparison-of-apomorphine-sublingual-film-and-levodopa-inhalation-powder-for-parkinsons-disease-off-episodes/2024-05-17T20:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-apomorphine-sublingual-film-as-an-on-demand-treatment-for-off-episodes-in-patients-with-parkinsons-disease/2024-05-17T20:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-outcomes-in-patients-with-myelodysplastic-syndromes-treated-with-hypomethylating-agents-a-seer-medicare-analysis/2024-05-17T20:44:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/time-to-first-exacerbation-adherence-and-medical-costs-among-us-patients-receiving-umeclidiniumvilanterol-or-tiotropium-as-initial-maintenance-therapy-for-chronic-obstructive-pulmonary-disease/2024-05-17T20:44:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overall-survival-in-the-real-world-and-clinical-trials-a-case-study-validating-external-controls-in-advanced-melanoma/2024-05-17T20:43:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/svb-collapse-reinvigorates-bank-accounting-debate/2024-05-17T20:44:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-recurrence-in-triple-negative-breast-cancer-among-working-age-patients-in-the-united-states/2024-05-17T20:44:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-overall-survival-of-patients-with-metastatic-castration-resistant-prostate-cancer-in-the-us-prior-to-parp-inhibitors2/2024-05-17T20:44:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/beyond-frontline-therapy-with-abiraterone-and-enzalutamide-in-metastatic-castration-resistant-prostate-cancer-a-real-world-us-study/2024-05-17T20:41:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/compliance-with-cannabis-act-regulations-regarding-online-promotion-among-canadian-commercial-cannabis-licensed-firms/2024-05-17T20:42:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/parody-and-tarnishment-how-empirical-methods-can-aid-triers-of-fact/2024-05-17T20:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/global-issues-in-eus-licensing-plans-for-essential-patents/2024-11-15T17:44:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-thromboembolic-events-and-associated-healthcare-costs-in-patients-with-inflammatory-bowel-disease/2024-05-17T20:44:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-thromboembolic-events-and-associated-risk-factors-including-treatments-in-patients-with-immune-mediated-diseases/2024-05-17T20:44:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-thromboembolic-events-among-patients-with-immune-mediated-diseases/2024-05-17T20:44:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-tisagenlecleucel-and-lisocabtagene-maraleucel-among-adults-with-relapsedrefractory-large-b-cell-lymphomas-an-indirect-treatment-comparison/2024-05-17T20:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-post-traumatic-stress-disorder-in-the-united-states-a-systematic-literature-review/2024-05-17T20:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-attention-deficithyperactivity-disorder-among-adults-in-the-united-states-a-societal-perspective/2024-05-17T20:42:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-the-covid-19-pandemic-on-adolescent-vaccinations-projected-time-to-reverse-deficits-in-routine-adolescent-vaccination-in-the-united-states/2025-10-14T13:42:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficiencies-in-the-second-score-auction-model/2026-02-05T21:27:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/management-of-patients-with-metastatic-castration-sensitive-prostate-cancer-in-the-real-world-setting-in-the-united-states/2025-02-28T21:22:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparison-of-isatuximab-plus-carfilzomib-and-dexamethasone-with-daratumumab-plus-lenalidomide-and-dexamethasone-in-relapsed-multiple-myeloma/2024-05-17T20:43:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consequences-of-insurance-denials-among-u-s-patients-prescribed-repository-corticotropin-injection-acthar-gel-for-nephrotic-syndrome/2024-05-17T20:42:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-savings-of-expedited-care-with-upfront-next-generation-sequencing-testing-versus-single-gene-testing-among-patients-with-metastatic-non-small-cell-lung-cancer-based-on-current-canadian-practices/2025-02-28T22:05:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-tisagenlecleucel-for-the-treatment-of-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-the-united-states/2024-05-17T20:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-matching-adjusted-indirect-comparison-of-single-arm-trials-in-patients-with-relapsed-or-refractory-follicular-lymphoma-who-received-at-least-two-prior-systemic-treatments/2024-06-03T20:47:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-analysis-of-adherence-to-hiv-treatment-and-healthcare-utilization-in-a-commercially-insured-population/2024-05-17T20:44:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-in-medicaid-beneficiaries-with-recently-relapsed-schizophrenia-or-with-uncontrolled-symptoms-of-schizophrenia-not-adherent-to-antipsychotics/2025-02-28T21:22:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-incidence-and-economic-burden-of-schizophrenia-among-medicaid-beneficiaries/2025-02-28T21:24:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recent-cases-on-green-messaging-in-food-and-beverage-company-advertising/2024-05-17T20:44:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-use-short-term-disability-days-and-costs-associated-with-states-of-persistence-on-antidepressant-lines-of-therapy/2024-05-17T20:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/opioid-induced-constipation-cost-impact-of-approved-medications-in-the-emergency-department/2024-05-17T20:43:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-minimization-analysis-comparing-eltrombopag-vs-romiplostim-for-adults-with-chronic-immune-thrombocytopenia/2024-05-17T20:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/trifluridinetipiracil-and-regorafenib-in-patients-with-metastatic-colorectal-cancer-a-retrospective-study-at-a-tertiary-oncology-center/2024-05-17T20:44:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/-deterioration-of-health-related-quality-of-life-after-withdrawal-of-risankizumab-treatment-in-patients-with-moderate-to-severe-plaque-psoriasis-a-machine-learning-predictive-model/2024-05-17T20:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-of-gilteritinib-for-relapsedrefractory-flt3mut-acute-myeloid-leukemia/2024-05-17T20:42:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patterns-of-daily-motor-symptom-control-with-carbidopalevodopa-enteral-suspension-versus-oral-carbidopalevodopa-therapy-in-advanced-parkinsons-disease-clinical-trial-post-hoc-analyses/2024-05-17T20:43:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-changes-healthcare-resource-utilization-and-costs-among-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-a-claims-database-study/2024-05-17T20:44:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/value-of-remission-in-patients-with-rheumatoid-arthritis-a-targeted-review/2024-05-17T20:44:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/all-cause-health-care-resource-utilization-and-costs-among-adults-with-alopecia-areata-a-retrospective-claims-database-study-in-the-united-states/2024-05-17T20:41:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mental-health-and-health-related-quality-of-life-among-nephrology-nurses-a-survey-based-cross-sectional-study/2024-05-17T20:43:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-and-care-partner-burden-in-ckd-patients-with-and-without-anemia-a-us-based-survey/2026-02-19T17:31:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-associated-with-peanut-allergy-management-under-allergen-avoidance-among-commercially-insured-individuals/2024-05-17T20:42:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparison-of-tisagenlecleucel-and-historical-treatments-for-relapsedrefractory-diffuse-large-b-cell-lymphoma/2024-11-13T15:09:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-healthcare-resource-utilization-and-costs-associated-with-tisagenlecleucel-and-axicabtagene-ciloleucel-among-patients-with-diffuse-large-b-cell-lymphoma-an-analysis-of-hospital-data-in-the-united-states/2024-05-17T20:43:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/steroid-switching-in-dystrophinopathy-treatment-a-us-chart-review-of-patient-characteristics-and-clinical-outcomes/2024-05-17T20:44:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-and-validation-of-a-healthcare-utilization-based-algorithm-to-identify-acute-exacerbations-of-chronic-obstructive-pulmonary-disease/2024-05-17T20:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/benefit-of-prompt-versus-delayed-use-of-single-inhaler-fluticasone-furoateumeclidiniumvilanterol-ffumecvi-following-a-copd-exacerbation/2024-05-17T20:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-us-pericarditis-prevalence-using-national-health-encounter-surveillance-databases/2024-05-17T20:42:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-prostate-specific-antigen-response-and-treatment-adherence-of-apalutamide-in-patients-with-non-metastatic-castration-resistant-prostate-cancer/2024-05-17T20:43:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-switching-to-infliximab-biosimilars-on-treatment-patterns-among-us-veterans-receiving-innovator-infliximab/2025-02-06T22:38:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-tenosynovial-giant-cell-tumors-among-employed-workforce-in-the-united-states/2024-05-17T20:44:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-evidence-of-the-clinical-and-economic-impact-of-long-acting-injectable-versus-oral-antipsychotics-among-patients-with-schizophrenia-in-the-united-states-a-systematic-review-and-meta-analysis/2025-02-28T21:24:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-and-economic-burden-associated-with-recurrent-pericarditis-in-a-privately-insured-united-states-population/2024-05-17T20:42:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-central-nervous-system-complications-in-sickle-cell-disease-a-systematic-review-and-meta-analysis/2024-05-17T20:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-risankizumab-on-pasi90-and-dlqi01-duration-in-moderate-to-severe-psoriasis-a-post-hoc-analysis-of-four-phase-3-clinical-trials/2024-05-17T20:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-pasi-response-on-work-productivity-and-the-effect-of-risankizumab-on-indirect-costs-using-machine-learning-in-patients-with-moderate-to-severe-psoriasis/2024-05-17T20:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-rivaroxaban-and-warfarin-among-nonvalvular-atrial-fibrillation-patients-with-obesity-and-polypharmacy/2024-05-17T20:42:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/literature-review-of-fatigue-scales-and-association-with-clinically-meaningful-improvements-in-outcomes-among-patients-with-and-without-paroxysmal-nocturnal-hemoglobinuria/2024-05-17T20:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/carbon-footprint-and-associated-costs-of-asthma-exacerbation-care-among-uk-adults/2024-05-17T20:41:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-nephrolithiasis-and-nephrocalcinosis-in-patients-with-chronic-hypoparathyroidism-a-retrospective-cohort-study/2024-05-17T20:44:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-and-validation-of-a-claims-based-model-to-identify-patients-at-risk-of-chronic-thromboembolic-pulmonary-hypertension-following-acute-pulmonary-embolism/2024-05-17T20:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/daratumumab-improves-depth-of-response-and-progression-free-survival-in-transplant-ineligible-high-risk-newly-diagnosed-multiple-myeloma/2025-02-28T21:16:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burden-of-obstructive-hypertrophic-cardiomyopathy-in-the-united-states/2024-05-17T20:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-acute-otitis-media-in-children-in-the-united-states-before-and-after-the-introduction-of-7-and-13-valent-pneumococcal-conjugate-vaccines-during-1998-2018/2024-05-17T20:43:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-transition-from-intravenous-to-subcutaneous-delivery-of-rituximab-benefits-for-payers-health-care-professionals-and-patients-with-lymphoma/2025-06-30T20:40:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-costs-among-patients-with-macular-oedema-associated-with-non-infectious-uveitis-a-us-commercial-payers-perspective/2024-05-17T20:42:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/continuing-trends-in-u-s-brand-name-and-generic-drug-competition/2024-10-28T19:01:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-chronic-kidney-disease-and-estimated-glomerular-filtration-rate-decline-in-patients-with-chronic-hypoparathyroidism-a-retrospective-cohort-study/2024-05-17T20:44:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-cardiovascular-conditions-in-patients-with-chronic-hypoparathyroidism-a-retrospective-cohort-study/2024-05-17T20:44:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimating-the-drivers-of-urban-economic-complexity-and-their-connection-to-economic-performance/2025-10-14T13:41:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-among-patients-with-mantle-cell-lymphoma-and-comparison-of-healthcare-resource-utilization-and-costs-among-relapsedrefractory-patients/2025-02-28T21:26:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/increased-health-care-resource-utilization-and-costs-associated-with-herpes-zoster-among-patients-aged-50-years-with-chronic-obstructive-pulmonary-disease-in-the-united-states/2024-05-17T20:43:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/heavy-duty-vehicle-electrification-planning-for-and-development-of-needed-power-system-infrastructure/2024-05-17T20:42:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/temporal-trends-of-adverse-events-and-costs-of-nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/2024-05-17T20:44:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-and-evaluation-of-a-predictive-algorithm-for-unsatisfactory-response-among-patients-with-pulmonary-arterial-hypertension-using-health-insurance-claims-data/2024-05-17T20:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-the-administration-of-erythropoiesis-stimulating-agents-for-the-treatment-of-anemia-in-patients-with-non-dialysis-dependent-chronic-kidney-disease-a-us-societal-perspective/2026-02-19T17:30:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/nusinersen-for-spinal-muscular-atrophy-in-the-united-states-findings-from-a-retrospective-claims-database-analysis/2024-05-17T20:43:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-treatment-comparison-of-larotrectinib-versus-entrectinib-in-treating-patients-with-trk-gene-fusion-cancers/2024-05-28T20:29:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/excess-healthcare-costs-in-patients-with-autosomal-dominant-polycystic-kidney-disease-by-renal-dysfunction-stage/2024-05-17T20:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identification-of-patients-with-metastatic-castration-sensitive-or-metastatic-castration-resistant-prostate-cancer-using-administrative-health-claims-and-laboratory-data/2025-02-28T21:25:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-agitation-in-long-term-care-residents-with-dementia-in-the-united-states/2024-05-17T20:42:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/higher-medication-adherence-and-lower-opioid-use-among-individuals-with-autoimmune-disease-enrolled-in-an-adalimumab-patient-support-program-in-the-united-states/2024-05-17T20:42:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-analysis-of-weight-gain-and-body-mass-index-increase-among-patients-with-hiv-1-using-antiretroviral-regimen-containing-tenofovir-alafenamide-tenofovir-disoproxil-fumarate-or-neither-in-the-united-states/2025-02-28T21:18:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/weight-change-and-predictors-of-weight-change-among-patients-initiated-on-darunavircobicistatemtricitabinetenofovir-alafenamide-or-bictegraviremtricitabinetenofovir-alafenamide-a-real-world-retrospective-study/2025-02-28T21:27:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/body-mass-index-increase-and-weight-gain-among-people-living-with-hiv-1-initiated-on-single-tablet-darunavircobicistatemtricitabinetenofovir-alafenamide/2025-02-28T21:18:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-fremanezumab-in-migraine-patients-initiating-treatment-in-the-united-states-results-from-a-retrospective-chart-study/2024-05-17T20:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/decreased-antibiotic-exposure-using-a-procalcitonin-protocol-for-respiratory-infections-and-sepsis-in-us-community-hospitals-procommunity/2024-05-17T20:42:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiology-and-economic-burden-of-lewy-body-dementia-in-the-united-states/2024-05-17T20:42:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/projecting-the-long-term-clinical-value-of-mavacamten-for-the-treatment-of-obstructive-hypertrophic-cardiomyopathy-in-the-united-states-an-assessment-of-net-health-benefit/2024-05-17T20:43:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-management-of-hyperkalemia-in-the-emergency-department-an-electronic-medical-record-analysis/2024-05-17T20:43:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/modeling-the-health-and-economic-implications-of-adopting-a-1-dose-9-valent-human-papillomavirus-vaccination-regimen-in-a-high-income-country-setting-an-analysis-in-the-united-kingdom/2025-10-14T13:48:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-metreleptin-on-patient-outcomes-and-quality-of-life-in-generalized-and-partial-lipodystrophy/2024-05-17T20:42:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/benefit-risk-analysis-of-upadacitinib-compared-with-adalimumab-in-the-treatment-of-patients-with-moderate-to-severe-rheumatoid-arthritis/2024-05-17T20:41:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/defining-utility-values-for-chorea-health-states-in-patients-with-huntingtons-disease/2024-05-17T20:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-adherence-to-tetrabenazine-or-deutetrabenazine-among-patients-with-huntingtons-disease-a-retrospective-database-analysis/2024-05-17T20:43:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-among-patients-with-gastroesophageal-reflux-disease-barretts-esophagus-and-barretts-esophagus-related-neoplasia-in-the-united-states/2024-05-17T20:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-outcomes-and-healthcare-resource-utilization-in-newly-treated-korean-patients-with-asthma-a-retrospective-cohort-study/2024-05-17T20:44:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-healthcare-resource-utilization-hru-and-costs-of-patients-with-paroxysmal-nocturnal-hemoglobinuria-pnh-receiving-eculizumab-in-a-us-population/2024-05-17T20:43:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluation-of-treatment-patterns-healthcare-resource-utilization-and-costs-among-patients-receiving-treatment-for-cytomegalovirus-following-allogeneic-hematopoietic-cell-or-solid-organ-transplantation/2024-05-17T20:42:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-pegcetacoplan-versus-ravulizumab-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-previously-treated-with-eculizumab-a-matching-adjusted-indirect-comparison/2024-05-17T20:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-and-safety-of-rivaroxaban-and-warfarin-among-nonvalvular-atrial-fibrillation-nvaf-patients-with-obesity-and-polypharmacy-in-the-united-states-us/2024-05-17T20:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-and-safety-of-rivaroxaban-versus-warfarin-among-non-valvular-atrial-fibrillation-patients-with-obesity-in-a-us-population/2024-05-17T20:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-of-rivaroxaban-versus-warfarin-among-non-valvular-atrial-fibrillation-nvaf-patients-with-obesity-in-a-us-population/2024-05-17T20:42:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-healthcare-resource-utilization-and-costs-of-patients-with-hrher2-advanced-breast-cancer-treated-with-ribociclib-versus-other-cdk46-inhibitors/2026-02-19T17:19:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/defining-utility-values-for-patients-with-tardive-dyskinesia/2024-05-17T20:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-burden-and-treatment-adherence-among-children-and-adolescent-patients-with-asthma/2024-05-17T20:42:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-effectiveness-of-patients-with-multiple-myeloma-initiating-daratumumab-across-different-lines-of-therapy-a-real-world-chart-review-study/2025-02-28T21:26:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-benefit-risk-profiles-of-treatments-for-moderate-to-severe-plaque-psoriasis-a-network-meta-analysis/2024-05-17T20:43:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hcv-reinfection-rates-after-cure-or-spontaneous-clearance-among-hiv-infected-and-uninfected-men-who-have-sex-with-men/2024-05-17T20:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-metreleptin-in-patients-with-lipodystrophy-with-and-without-baseline-concomitant-medication-use/2024-06-03T20:45:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-modifications-of-renin-angiotensin-aldosterone-system-inhibitors-in-patients-with-hyperkalemia-initiating-sodium-zirconium-cyclosilicate-therapy-the-optimize-i-study/2024-05-17T20:43:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ischemic-stroke-and-systemic-embolism-among-one-and-done-direct-oral-anticoagulant-users-with-non-valvular-atrial-fibrillation/2024-05-17T20:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/venous-thromboembolism-recurrence-among-one-and-done-direct-oral-anticoagulant-users-a-retrospective-longitudinal-study/2024-05-17T20:44:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-study-to-examine-prognostic-value-of-c-reactive-protein-in-patients-with-surgically-resectable-non-small-cell-lung-cancer/2024-05-17T20:44:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-5-year-retrospective-observational-study-assessing-rheumatoid-arthritis-disease-outcome-measures-to-characterize-systemic-lupus-erythematosus-burden-in-the-usa/2024-05-17T20:41:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/elucidating-the-real-world-burden-of-chronic-rhinosinusitis-with-nasal-polyps-in-patients-in-the-usa/2024-05-17T20:42:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/profiling-disease-and-economic-burden-in-crswnp-using-machine-learning/2025-07-16T13:24:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-progression-and-longitudinal-clinical-outcomes-of-lewy-body-dementia-in-the-nacc-database/2024-05-17T20:42:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/on-the-double-robustness-and-semiparametric-efficiency-of-matching-adjusted-indirect-comparisons/2024-05-17T20:43:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-clinical-outcomes-in-patients-with-schizophrenia-following-different-long-acting-injectable-event-driven-initiation-strategies/2025-02-28T20:44:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/respiratory-syncytial-virus-related-complications-and-healthcare-costs-among-a-medicare-insured-population-in-the-united-states/2025-02-28T20:45:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/network-meta-analysis-of-efficacy-of-ixazomib-lenalidomide-and-dexamethasone-in-relapsedrefractory-multiple-myeloma/2025-07-16T13:23:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burden-in-patients-with-systemic-lupus-erythematosus-during-the-first-year-after-initiating-oral-corticosteroids-a-retrospective-us-database-study/2024-05-17T20:41:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-resource-utilization-and-treatment-over-the-disease-course-of-symptomatic-obstructive-hypertrophic-cardiomyopathy-in-the-united-states/2024-05-17T20:41:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-upper-endoscopy-utilization-patterns-among-patients-with-gastroesophageal-reflux-disease-barrett-esophagus-and-barrett-esophagus-related-esophageal-neoplasia-in-the-united-states/2024-05-17T20:44:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-weight-changes-in-people-with-hiv-1-at-risk-of-weight-gain-female-black-or-hispanic-switching-from-integrase-strand-transfer-inhibitors/2025-02-28T20:46:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/same-day-testing-with-initiation-of-antiretroviral-therapy-or-tuberculosis-treatment-versus-standard-care-for-persons-presenting-with-tuberculosis-symptoms-at-hiv-diagnosis-a-randomized-open-label-trial-from-haiti/2024-05-17T20:44:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-by-patients-with-alagille-syndrome/2024-05-17T20:42:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-racial-variation-in-treatment-and-outcomes-among-patients-with-peripheral-artery-disease/2024-05-17T20:43:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-hyperphagia-and-obesity-in-bardet-biedl-syndrome-a-multicountry-survey/2026-03-03T14:20:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/caregiver-burden-in-bardet-biedl-syndrome-findings-from-the-care-bbs-study/2026-03-03T14:22:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-characteristics-associated-with-all-cause-healthcare-costs-of-alopecia-areata-in-the-united-states/2024-05-17T20:43:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-cost-benefits-of-anti-obesity-medication-for-us-veterans-participating-in-the-move-weight-management-program/2025-07-16T13:26:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-treatment-patterns-and-clinical-outcomes-of-chronic-hepatitis-b-across-3-continents-retrospective-database-study/2024-05-17T20:41:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-of-calcium-and-phosphate-levels-with-incident-chronic-kidney-disease-in-patients-with-hypoparathyroidism-a-retrospective-case-control-study/2024-05-17T20:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-free-survival-as-a-predictor-of-overall-survival-in-localized-renal-cell-carcinoma-following-initial-nephrectomy-a-retrospective-analysis-of-surveillance-epidemiology-and-end-results-medicare-data/2024-05-17T20:42:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparison-of-darolutamide-versus-apalutamide-and-enzalutamide-for-nonmetastatic-castration-resistant-prostate-cancer2/2024-05-17T20:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-associated-with-vonoprazan-based-versus-proton-pump-inhibitor-based-therapy-for-helicobacter-pylori-infection-in-japan/2024-05-17T20:43:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-non-invasive-all-cause-pneumonia-in-children-in-the-united-states-before-and-after-the-introduction-of-pneumococcal-conjugate-vaccines-a-retrospective-claims-database-analysis/2024-05-17T20:43:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-acute-otitis-media-pneumonia-and-invasive-pneumococcal-disease-in-children-in-the-united-states-after-the-introduction-of-13-valent-pneumococcal-conjugate-vaccines-during-2014-2018/2024-05-17T20:42:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prolonged-oral-corticosteroid-treatment-in-patients-with-systemic-lupus-erythematosus-an-evaluation-of-12-month-economic-and-clinical-burden/2024-05-17T20:43:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/surgical-treatment-patterns-healthcare-resource-utilization-and-economic-burden-in-patients-with-tenosynovial-giant-cell-tumor-who-underwent-joint-surgery-in-the-united-states/2024-05-17T20:42:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-physician-preferences-for-biologics-in-moderate-to-severe-inflammatory-bowel-disease-retrospective-chart-review-in-europe/2025-07-16T13:27:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hypereosinophilic-syndrome-in-europe-retrospective-study-of-treatment-patterns-clinical-manifestations-and-healthcare-resource-utilization/2024-05-17T20:42:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-of-potential-drug-drug-interactions-with-ritonavir-containing-covid-19-therapy/2024-05-17T20:43:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-tardive-dyskinesia-on-physical-psychological-social-and-professional-domains-of-patient-lives-a-survey-of-patients-in-the-united-states/2024-05-17T20:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-the-preds-score-to-predict-in-hospital-mortality-of-patients-with-ebola-virus-disease-under-advanced-supportive-care-results-from-the-evista-cohort-in-the-democratic-republic-of-the-congo/2024-05-17T20:42:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiology-and-economic-burden-of-von-hippel-lindau-disease-associated-renal-cell-carcinoma-in-the-united-states/2024-05-17T20:42:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-healthcare-utilization-and-costs-of-patients-with-treatment-resistant-depression-initiated-on-esketamine-intranasal-spray-and-covered-by-us-commercial-health-plans/2024-05-17T20:44:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-schizophrenia-in-the-united-states/2025-09-12T14:52:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-per-relapse-avoided-for-ozanimod-versus-other-selected-disease-modifying-therapies-for-relapsing-remitting-multiple-sclerosis-in-the-united-states/2024-05-17T20:42:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-of-serum-calcium-and-phosphate-with-incident-cardiovascular-disease-in-patients-with-hypoparathyroidism/2024-05-17T20:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-barriers-to-access-and-equity-for-covid-19-vaccination-in-the-us/2025-03-27T17:02:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-pembrolizumab-as-an-adjuvant-treatment-of-renal-cell-carcinoma-post-nephrectomy-in-the-united-states/2024-05-17T20:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/surgical-treatment-patterns-healthcare-resource-utilization-and-economic-burden-in-patients-with-tenosynovial-giant-cell-tumor-who-underwent-joint-surgery-in-the-united-states2/2024-05-17T20:44:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/budget-impact-analysis-of-rebyota-fecal-microbiota-live-jslm-fmbl-or-preventing-recurrent-clostridioides-difficile-infection-in-the-us/2024-05-17T20:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-rebyota-fecal-microbiota-live-jslm-fmbl-versus-standard-of-care-for-the-prevention-of-recurrent-clostridioides-difficile-infection-in-the-usa/2024-05-17T20:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-omadacycline-and-impact-of-unapproved-omadacycline-prescription-claims-among-adult-outpatients-with-community-acquired-bacterial-pneumonia/2024-05-17T20:43:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-impact-of-open-label-designs-in-patient-reported-outcomes-investigation-in-oncology-clinical-trials/2024-05-17T20:41:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/attainment-of-early-deep-prostate-specific-antigen-response-in-metastatic-castration-sensitive-prostate-cancer-a-comparison-of-patients-initiated-on-apalutamide-or-enzalutamide/2024-05-17T20:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-prostate-specific-antigen-response-in-patients-with-metastatic-castration-sensitive-prostate-cancer-initiated-on-apalutamide-or-abiraterone-acetate-a-retrospective-cohort-study/2024-05-17T20:42:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiology-and-patient-journey-of-rett-syndrome-in-the-united-states-a-real-world-evidence-study/2024-05-17T20:42:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-progression-rates-in-ambulatory-duchenne-muscular-dystrophy-by-steroid-type-patient-age-and-functional-status/2024-05-17T20:42:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/functional-and-clinical-outcomes-associated-with-steroid-treatment-among-non-ambulatory-patients-with-duchenne-muscular-dystrophy1/2024-05-17T20:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-matching-adjusted-indirect-comparison-of-nivolumab-plus-cabozantinib-versus-pembrolizumab-plus-axitinib-in-patients-with-advanced-renal-cell-carcinoma/2024-05-17T20:41:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-multicenter-chart-review-of-patient-characteristics-treatment-and-outcomes-in-hereditary-angioedema-unmet-need-for-more-effective-long-term-prophylaxis/2024-05-17T20:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-treatment-comparison-itc-of-the-efficacy-of-vutrisiran-and-tafamidis-for-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy/2024-05-17T20:43:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/benefits-of-autoantibody-enrichment-in-early-rheumatoid-arthritis-analysis-of-efficacy-outcomes-in-four-pooled-abatacept-trials/2024-05-28T20:27:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-of-pediatric-liver-transplantation-among-commercially-and-medicaid-insured-patients-with-cholestasis-in-the-united-states/2024-05-17T20:42:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/projecting-the-economic-outcomes-of-switching-patients-with-schizophrenia-from-oral-atypical-antipsychotics-to-once-monthly-once-every-3-months-and-once-every-6-months-paliperidone-palmitate/2024-05-17T20:43:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-comorbidities-and-healthcare-resource-utilization-among-medicaid-enrolled-extremely-premature-infants/2024-05-17T20:41:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ckd-progression-and-economic-burden-in-individuals-with-ckd-associated-with-type-2-diabetes/2024-05-17T20:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dmd-genotypes-and-motor-function-in-duchenne-muscular-dystrophy-a-multi-institution-meta-analysis-with-implications-for-clinical-trials/2024-05-17T20:42:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/frequency-and-clinicoeconomic-impact-of-delays-to-definitive-diagnosis-of-obstructive-hypertrophic-cardiomyopathy-in-the-united-states/2024-05-17T20:42:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-results-of-carbidopalevodopa-enteral-suspension-across-the-day-in-advanced-parkinsons-disease-post-hoc-analyses-from-a-large-54-week-trial/2024-05-17T20:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/time-and-personnel-costs-associated-with-adverse-event-ae-management-among-patients-with-chronic-lymphocytic-leukemia-cll/2024-05-17T20:44:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indicators-of-suboptimal-treatment-and-associated-healthcare-costs-among-patients-with-crohns-disease-initiated-on-biologic-or-conventional-agents/2025-02-28T21:19:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predicting-clinical-remission-of-chronic-urticaria-using-random-survival-forests-machine-learning-applied-to-real-world-data/2024-05-17T20:43:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-on-hospitalizations-of-long-term-versus-short-term-therapy-with-sodium-zirconium-cyclosilicate-during-routine-outpatient-care-of-patients-with-hyperkalemia-the-recognize-i-study/2024-05-17T20:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-experience-of-pediatric-patients-treated-with-peanut-arachis-hypogaea-allergen-powder-dnfp/2026-02-19T17:30:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-cardiometabolic-outcomes-among-people-living-with-hiv-1-initiated-on-integrase-strand-transfer-inhibitor-versus-non-integrase-strand-transfer-inhibitor-antiretroviral-therapies/2025-02-28T20:48:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-recurrent-clostridioides-difficile-infection-in-the-usa-a-systematic-literature-review-and-cost-synthesis/2024-05-17T20:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/diagnostic-yield-of-active-case-finding-for-tuberculosis-at-human-immunodeficiency-virus-testing-in-haiti/2024-05-17T20:42:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/superior-outcomes-and-lower-outpatient-costs-with-scale-up-of-antiretroviral-therapy-at-the-gheskio-clinic-in-port-au-prince-haiti/2024-05-17T20:44:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-related-quality-of-life-instruments-for-clinical-trials-in-al-amyloidosis-report-from-the-amyloidosis-forum-hrqol-working-group/2024-05-17T20:42:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-comparative-effectiveness-of-acalabrutinib-and-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia/2024-05-17T20:43:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-among-patients-with-attention-deficithyperactivity-disorder-and-comorbid-anxiety-andor-depression-in-the-united-states-a-retrospective-claims-analysis/2024-05-17T20:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reasons-for-treatment-changes-in-children-and-adolescents-with-attention-deficithyperactivity-disorder-a-chart-review-study/2026-02-19T17:29:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prescription-opioid-utilization-patterns-and-associated-outcomes-among-privately-insured-patients-prescribed-opioids-to-manage-pain-associated-with-osteoarthritis/2024-05-17T20:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-discontinuation-patterns-for-patients-with-chronic-lymphocytic-leukemia-in-real-world-settings-results-from-a-multi-center-international-study/2024-05-17T20:44:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/safety-differences-across-androgen-receptor-inhibitors-in-nonmetastatic-castration-resistant-prostate-cancer/2024-05-17T20:44:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/matching-adjusted-indirect-comparison-maic-results-confirmed-by-head-to-head-trials-a-case-study-in-psoriasis/2024-05-17T20:43:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-mepolizumab-in-severe-asthma-and-chronic-rhinosinusitis-in-the-us-impact-of-comorbidity-and-sinus-surgery/2024-05-17T20:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-and-risk-of-herpes-zoster-in-patients-with-ulcerative-colitis-and-crohns-disease-in-the-usa/2024-06-03T20:39:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-herpes-zoster-in-patients-with-rheumatoid-arthritis-in-the-united-states-a-retrospective-cohort-study/2024-06-03T20:42:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burden-of-herpes-zoster-in-patients-with-rheumatoid-arthritis-a-retrospective-cohort-study-using-administrative-claims/2024-06-03T20:46:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-illness-and-treatment-patterns-among-patients-with-von-willebrand-disease-in-us-clinical-practice/2024-05-17T20:41:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-and-safety-of-ozanimod-and-ponesimod-for-relapsing-multiple-sclerosis-a-matching-adjusted-indirect-comparison/2025-10-14T13:47:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-clinical-outcomes-health-care-resource-utilization-and-costs-in-older-patients-with-metastatic-castration-resistant-prostate-cancer-in-the-united-states-an-analysis-of-seer-medicare-data/2024-05-17T20:44:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-and-comorbidity-burden-amonpeople-living-with-hiv-a-review-of-systematic-literature-reviews/2025-02-28T21:20:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/chronic-obstructive-pulmonary-disease-is-associated-with-an-increased-risk-of-herpes-zoster-a-retrospective-united-states-claims-database-analysis/2024-05-17T20:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-illness-among-patients-with-pulmonary-arterial-hypertension-pah-associated-with-connective-tissue-disorders-ctd/2024-05-17T20:42:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/longitudinal-assessment-of-creatine-kinase-creatinecreatinineratio-and-myostatin-as-monitoring-biomarkers-in-becker-muscular-dystrophy/2024-05-17T20:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-in-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer-receiving-first-line-treatment-in-the-united-states-an-insurance-claims-based-descriptive-analysis/2025-02-28T20:47:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/improved-outcomes-with-high-dose-isoniazid-in-multidrug-resistant-tuberculosis-treatment-in-haiti/2024-05-17T20:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-overall-survival-of-patients-with-double-class-and-triple-class-refractory-multiple-myeloma-a-us-electronic-health-record-database-study/2024-05-17T20:44:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluation-of-disease-free-survival-as-a-predictor-of-overall-survival-and-assessment-of-real-world-burden-of-disease-recurrence-in-resected-early-stage-non-small-cell-lung-cancer/2024-05-17T20:42:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-outcomes-in-resected-early-stage-non-small-cell-lung-cancer-an-analysis-of-the-seer-medicare-data/2024-05-17T20:44:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-pegcetacoplan-versus-ravulizumab-and-eculizumab-in-complement-inhibitor-naive-patients-with-paroxysmal-nocturnal-hemoglobinuria-a-matching-adjusted-indirect-comparison/2024-05-17T20:42:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-use-and-reimbursement-amount-by-site-of-care-in-patients-with-diffuse-large-b-cell-lymphoma-receiving-chimeric-antigen-receptor-t-cell-car-t-therapy/2025-02-06T22:37:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-therapy-management-on-axitinib-related-adverse-events-in-patients-with-advanced-renal-cell-carcinoma-receiving-first-line-axitinib-checkpoint-inhibitor/2024-05-17T20:43:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-pembrolizumab-as-an-adjuvant-treatment-of-resected-stage-iib-or-iic-melanoma-in-the-united-states/2026-03-03T14:22:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-persistence-among-bio-naive-patients-with-crohns-disease-initiated-on-ustekinumab-or-adalimumab/2025-02-28T20:49:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/esketamine-nasal-spray-for-major-depressive-disorder-with-acute-suicidal-ideation-or-behavior-description-of-treatment-access-utilization-and-claims-based-outcomes-in-the-united-states/2024-05-17T20:42:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-use-of-third-party-surveys-in-litigation/2026-02-05T20:38:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/geographic-market-definition-in-commercial-health-insurer-matters-a-unified-approach-for-merger-review-monopolization-claims-and-monopsonization-claims/2024-05-17T20:42:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/u-s-coal-fired-power-generation-market-fundamentals-as-of-2023-and-transitions-ahead/2024-05-17T20:44:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/preliminary-injunctive-relief-in-patent-cases-repairing-irreparable-harm/2024-05-17T20:43:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-practical-guide-to-the-implementation-of-the-as-efficient-competitor-aec-test/2026-02-18T19:52:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recap-of-distribution-essentials-app-distribution-and-related-antitrust-considerations/2026-01-02T18:54:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-balance-billing-legislation-and-anesthesia-payments-in-california-a-retrospective-analysis/2024-05-17T20:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mergers-and-monopsony-the-anthem-cigna-merger/2024-05-17T20:43:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/at-the-crossroads-improving-customer-choice-for-products-in-the-u-s-electricity-sector/2024-05-17T20:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/massachusetts-energy-transition-innovation-for-electric-utility-regulation/2026-03-05T14:51:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/gender-considerations-in-the-analysis-of-market-definition-and-competitive-effects-a-practical-framework-and-illustrative-example2/2025-05-01T15:47:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/oecd-gender-inclusive-toolkit-may-inform-competition-policy/2025-05-01T16:03:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/power-grid-most-important-piece-of-climate-puzzle/2024-05-17T20:43:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-cambridge-handbook-of-marketing-and-the-law/2025-12-01T14:00:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/accelerating-decarbonization-in-the-united-states-technology-policy-and-societal-dimensions/2024-05-17T20:41:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/consent-flows-and-cancellation-processes-how-to-spot-dark-patterns/2024-05-17T20:42:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-use-of-conjoint-analysis-in-high-stakes-litigation/2025-01-03T23:54:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/escherichia-coli-resistance-treatment-patterns-and-clinical-outcomes-among-females-with-uuti-in-germany-a-retrospective-physician-based-chart-review-study/2025-09-12T14:51:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electric-system-reliability-and-epa-regulation-of-ghg-emissions-from-power-plants-2023/2024-05-17T20:42:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-and-clinical-burden-of-herpes-zoster-among-patients-with-inflammatory-bowel-disease-in-the-united-states/2024-06-03T20:41:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-time-to-discontinuation-of-first-line-venetoclaxobinutuzumab-in-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma/2025-02-28T20:52:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-invasive-escherichia-coli-disease-among-older-adult-patients-treated-in-hospitals-in-the-united-states/2026-02-19T17:28:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-switching-following-moderatesevere-chronic-obstructive-pulmonary-disease-exacerbation-in-patients-with-commercial-or-medicare-insurance-in-the-united-states/2024-05-17T20:44:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fuel-and-energy-security-in-new-york-state-an-assessment-of-winter-operational-risks-for-a-power-system-in-transition2/2026-03-05T14:48:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/federal-energy-regulatory-commissions-reliability-technical-conference-prepared-statement-of-susan-f-tierney-ph-d-senior-advisor-analysis-group/2024-05-17T20:42:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ten-years-post-actavis-lessons-learned-and-the-future-of-reverse-payment-antitrust-cases/2024-05-17T20:44:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-womens-treatment-preferences-for-vasomotor-symptoms-due-to-menopause/2024-05-17T20:41:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-persistence-and-other-treatment-patterns-among-bio-naive-patients-with-crohns-disease-treated-with-ustekinumab-or-adalimumab/2024-05-17T20:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-and-caregiver-outcomes-after-onasemnogene-abeparvovec-treatment-findings-from-the-cure-sma-2021-membership-survey/2024-05-17T20:43:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-incidence-of-adverse-clinical-outcomes-among-people-with-coronary-artery-disease-andor-peripheral-artery-disease-in-relation-to-vascular-risk-in-the-united-states/2024-05-17T20:43:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-centric-assessment-of-rheumatoid-arthritis-using-a-smartwatch-and-bespoke-mobile-app-in-a-clinical-setting/2024-05-17T20:43:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-effectiveness-of-cladribine-tablets-in-patients-with-relapsing-forms-of-multiple-sclerosis-in-the-united-states/2024-05-17T20:44:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/progression-free-survival-of-daratumumab-versus-bortezomib-triplet-combination-with-lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-newly-diagnosed-multiple-myeloma-taurus-chart-review-study/2025-02-28T20:52:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-journey-before-and-after-a-formal-post-traumatic-stress-disorder-diagnosis-in-adults-in-the-united-states-a-retrospective-claims-study/2024-05-17T20:43:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-health-care-costs-and-resource-utilization-for-commonly-used-proteasome-inhibitor-immunomodulatory-drug-based-triplet-regimens-for-the-management-of-patients-with-relapsedrefractory-multiple-myeloma-in-the-united-states/2025-07-16T13:16:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-herpes-zoster-among-patients-with-psoriasis-in-the-united-states/2024-06-03T20:43:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-rifaximin-use-following-an-initial-overt-hepatic-encephalopathy-hospitalization-on-rehospitalization-and-costs/2026-02-19T17:28:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/nivolumab-plus-chemotherapy-for-advanced-gastric-gastroesophageal-junction-and-esophageal-adenocarcinoma-analysis-of-number-needed-to-treat-and-number-needed-to-harm/2024-05-17T20:43:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/corticosteroid-use-and-adherence-in-patients-treated-with-acthar-gel-for-advanced-sarcoidosis/2024-05-17T20:42:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-among-patients-with-connective-tissue-disorder-related-pulmonary-arterial-hypertension-in-the-united-states-a-retrospective-claims-based-analysis/2024-05-17T20:44:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-burden-of-invasive-escherichia-coli-disease-among-older-adult-patients-treated-in-hospitals-in-the-united-states/2026-02-19T17:27:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-comparison-of-first-line-treatment-adherence-between-single-agent-ibrutinib-and-acalabrutinib-in-patients-with-chronic-lymphocytic-leukemia/2025-02-28T20:51:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-adults-with-major-depressive-disorder-in-the-united-states-2019/2024-05-17T20:44:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-costs-for-patients-with-spinal-muscular-atrophy-findings-from-a-retrospective-us-claims-database-analysis/2024-05-17T20:42:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/unintended-consequences-of-increased-out-of-pocket-costs-during-medicare-coverage-gap-on-anticoagulant-discontinuation-and-stroke/2026-03-03T14:18:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-among-patients-with-alopecia-areata-in-the-usa-a-retrospective-claims-analysis/2024-05-17T20:43:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-adverse-event-related-hospitalization-among-patients-with-epidermal-growth-factor-receptor-egfr-mutated-metastatic-non-small-cell-lung-cancer-after-treatment-with-egfr-tyrosine-kinase-inhibitor-and-platinum-based-chemotherapy-regi/2024-05-17T20:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/persistence-and-dose-escalation-during-maintenance-phase-and-use-of-nonbiologic-medications-among-patients-with-ulcerative-colitis-initiated-on-ustekinumab-in-the-united-states/2024-05-17T20:43:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/enhancement-and-external-validation-of-algorithms-using-diagnosis-codes-to-identify-invasive-escherichia-coli-disease/2024-05-17T20:42:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-evidence-of-eteplirsen-treatment-effects-in-patients-with-duchenne-muscular-dystrophy-in-the-usa/2024-06-03T20:38:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-multicenter-retrospective-chart-review-study-of-treatment-and-disease-patterns-and-clinical-outcomes-of-patients-with-chronic-phase-chronic-myeloid-leukemia-in-third-line-treatment-or-with-t315i-mutation/2024-05-17T20:41:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-of-menopausal-vasomotor-symptom-severity-with-sleep-and-work-impairments-a-us-survey/2024-05-17T20:41:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ischemic-stroke-and-systemic-embolism-among-patients-with-non-valvular-atrial-fibrillation-who-abandon-oral-anticoagulant-therapy/2024-05-17T20:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-event-free-survival-and-overall-survival-in-early-stage-triple-negative-breast-cancer/2024-05-23T19:20:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effect-of-fecal-microbiota-live-jslm-rebyota-rbl-on-health-related-quality-of-life-in-patients-with-recurrent-clostridioides-difficile-infection-results-from-the-punch-cd3-clinical-trial/2024-05-28T20:09:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/access-and-real-world-use-patterns-of-esketamine-nasal-spray-among-patients-with-treatment-resistant-depression-covered-by-private-or-public-insurance/2024-05-17T20:41:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/persistence-and-other-treatment-patterns-among-bio-experienced-patients-with-crohns-disease-initiated-on-ustekinumab-or-adalimumab/2024-05-17T20:43:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-burden-treatment-patterns-and-economic-impact-of-rectovaginal-fistulas-in-patients-with-crohns-disease-findings-from-a-retrospective-observational-longitudinal-study-based-on-us-claims-databases/2024-05-17T20:42:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-healthcare-resource-use-in-medicare-beneficiaries-with-parkinsons-disease/2024-05-17T20:44:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparing-real-world-healthcare-costs-associated-with-single-tablet-regimens-for-hiv-1-the-2-drug-regimen-dolutegravirlamivudine-vs-standard-3-or-4-drug-regimens/2024-05-17T20:42:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/weight-and-bmi-changes-following-initiation-of-emtricitabinetenofovir-alafenamide-co-formulated-with-darunavir-or-co-administered-with-dolutegravir-in-overweight-or-obese-art-naive-people-living-with-hiv-1/2025-02-28T20:53:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-effectiveness-of-dupilumab-in-patients-with-atopic-dermatitis-results-up-to-3-years-from-the-relieve-ad-study2/2026-01-04T22:00:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/digital-tools-offering-channels-for-success-facilitating-a-small--and-medium-sized-business-renaissance/2024-05-17T20:42:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-practical-guide-to-using-the-as-efficient-competitor-aec-test-to-manage-and-monitor-antitrust-risk/2026-02-18T19:54:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-mergers-and-regulatory-uncertainty2/2025-05-01T16:07:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-the-debate-about-multi-sided-platform-regulation-is-shaping-merger-enforcement/2025-04-30T16:48:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/german-antitrust-community-debates-how-to-most-effectively-consider-economic-expert-reports-in-follow-on-cartel-damage-proceedings/2024-05-17T20:42:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incorporating-uncertainty-in-trademark-surveys-do-respondents-really-know-what-they-are-talking-about/2024-05-17T20:43:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/measuring-the-impact-of-wind-power-and-intermittency/2024-05-17T20:43:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/capacity-market-alternatives-for-a-decarbonized-grid-prompt-and-seasonal-markets/2024-05-17T20:41:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-curious-case-of-aspartame-how-the-same-evidence-can-yield-seemingly-different-conclusions/2024-05-17T20:44:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/electric-utilities-and-the-iraiija-ensuring-maximum-benefits-for-consumers-from-new-federal-funding-opportunities/2024-05-17T20:42:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/is-data-the-new-oil-non-price-effects-of-mergers-in-data-intensive-industries/2024-05-17T20:43:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/avatrombopag-treatment-response-in-patients-with-immune-thrombocytopenia-the-real-ava-1.0-study2024-05-17T20:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/continuity-of-care-among-patients-newly-initiated-on-second-generation-oral-or-long-acting-injectable-antipsychotics-during-a-schizophrenia-related-inpatient-stay/2025-02-28T20:50:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-benralizumab-on-asthma-exacerbation-related-medical-healthcare-resource-utilization-and-medical-costs-results-from-the-zephyr-2-study/2024-05-17T20:42:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/time-to-next-treatment-in-patients-with-chronic-lymphocytic-leukemia-initiating-first-line-ibrutinib-or-acalabrutinib/2025-02-28T20:50:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/persistence-among-patients-with-crohn-disease-previously-treated-with-an-anti-tumor-necrosis-factor-inhibitor-and-switching-or-cycling-to-another-biologic-agent/2024-05-17T20:43:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-biotech-deals-may-help-competition-despite-ftc-view/2024-05-17T20:42:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/chronic-corticosteroid-use-is-associated-with-substantial-clinical-and-economic-burden-in-patients-with-crohns-disease-initiated-on-biologic-or-conventional-therapies-in-the-us-a-retrospective-study/2024-05-17T20:41:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mortality-among-us-veterans-with-a-physician-documented-diagnosis-of-pyruvate-kinase-deficiency/2024-05-17T20:43:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-modeling-of-prostate-specific-membrane-antigen-positron-emission-tomography-with-piflufolastat-f-18-for-the-initial-diagnosis-of-patients-with-prostate-cancer-in-the-united-states/2024-05-17T20:42:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-burden-and-predictors-associated-with-non-response-to-antihistamine-based-therapy-in-chronic-spontaneous-urticaria/2024-05-17T20:42:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-factors-associated-with-newly-diagnosed-attention-deficithyperactivity-disorder-in-adults-a-retrospective-case-control-study/2026-02-19T17:23:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-and-physician-preferences-for-acute-myeloid-leukemia-maintenance-treatments-following-hematopoietic-stem-cell-transplantation/2024-05-17T20:43:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-outcomes-on-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-hif-phis-in-anaemia-associated-with-chronic-kidney-disease-network-meta-analyses-in-dialysis-and-non-dialysis-dependent-populations/2024-05-17T20:42:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/systematic-review-and-network-meta-analysis-comparing-the-efficacy-of-fezolinetant-with-hormone-and-nonhormone-therapies-for-treatment-of-vasomotor-symptoms-due-to-menopause/2024-05-17T20:44:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-costs-among-patients-with-hematologic-malignancies-receiving-allogeneic-transplants-a-us-payer-perspective/2024-05-17T20:42:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-clinical-management-of-individuals-with-rett-syndrome-a-physician-survey/2024-05-17T20:43:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/gastrointestinal-manifestations-in-pediatric-and-adult-patients-with-rett-syndrome-an-analysis-of-us-claims-and-physician-survey-data/2024-05-17T20:42:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-of-venetoclax-based-combination-therapies-and-other-therapies-in-treatment-naive-patients-with-acute-myeloid-leukemia-ineligible-for-intensive-chemotherapy-a-network-meta-analysis/2024-05-17T20:42:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/biotech-asset-valuation-methods-a-practitioners-guide/2024-05-17T20:41:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-of-otx-101-ophthalmic-solution-cyclosporine-ophthalmic-emulsion-and-lifitegrast-ophthalmic-solution-in-patients-with-dry-eye-disease-a-retrospective-analysis/2024-05-17T20:44:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-tardive-dyskinesia-on-patients-and-caregivers-a-survey-of-caregivers-in-the-united-states/2024-05-17T20:43:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-real-world-assessment-of-healthcare-costs-associated-with-agitation-in-alzheimers-dementia/2026-02-19T17:24:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-living-with-an-adult-with-depressive-symptoms-among-households-in-the-united-states/2024-05-17T20:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/potential-utility-of-c-reactive-protein-for-tuberculosis-risk-stratification-among-patients-with-non-meningitic-symptoms-at-hiv-diagnosis-in-low-and-middle-income-countries/2024-05-17T20:43:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-delayed-diagnosis-in-patients-with-pulmonary-arterial-hypertension-pah/2024-12-19T16:49:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/event-free-survival-as-a-predictor-of-overall-survival-and-recurrence-burden-of-patients-with-non-small-cell-lung-cancer-receiving-neoadjuvant-therapy/2024-05-17T20:42:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-journey-of-civilian-adults-diagnosed-with-posttraumatic-stress-disordera-chart-review-study/2024-05-17T20:43:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dosing-patterns-of-patients-with-paroxysmal-nocturnal-hemoglobinuria-treated-with-ravulizumab-in-the-united-states-a-retrospective-claims-based-analysis/2024-05-17T20:42:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-study-of-single-inhaler-triple-therapy-with-fluticasone-furoateumeclidiniumvilanterol-on-asthma-control-in-the-us/2024-05-17T20:43:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-dupilumab-in-patients-with-asthma-findings-from-the-united-states-advantage-study/2024-05-17T20:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/kidney-failure-attributed-to-immunoglobulin-a-nephropathy-a-usrds-retrospective-cohort-study-of-epidemiology-treatment-modalities-and-economic-burden/2024-05-17T20:43:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-invasive-escherichia-coli-disease-on-clinical-outcomes-and-medical-resource-utilization-among-asian-patients-in-the-united-states/2024-05-17T20:43:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-healthcare-resource-utilization-and-costs-of-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-in-the-us/2024-05-17T20:44:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/safety-of-upadacitinib-in-immune-mediated-inflammatory-diseases-systematic-literature-review-of-indirect-and-direct-treatment-comparisons-of-randomized-controlled-trials/2024-05-17T20:44:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-erenumab-versus-rimegepant-for-migraine-prevention-using-matching-adjusted-indirect-comparison/2024-05-17T20:42:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-economic-burden-of-metastatic-castration-resistant-prostate-cancer-before-and-after-first-line-therapy-initiation/2024-05-17T20:43:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-and-health-related-quality-of-life-impact-of-fecal-microbiota-live-jslm-a-post-hoc-analysis-of-punch-cd3-patients-at-first-recurrence-of-clostridioides-difficile-infection/2024-05-17T20:42:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-efficacy-and-safety-of-tisagenlecleucel-and-axicabtagene-ciloleucel-among-adults-with-rr-follicular-lymphoma/2024-11-13T15:08:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-differential-rates-of-disease-progression-in-amyloid-positive-early-alzheimers-disease-findings-from-a-longitudinal-cohort-analysis/2025-10-14T13:48:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/potential-implications-of-slowing-disease-progression-in-amyloid-positive-early-alzheimers-disease-estimates-from-real-world-data/2025-10-14T13:45:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-safety-of-first-line-immuno-oncology-combination-therapies-for-advanced-non-small-cell-lung-cancer/2024-05-17T20:43:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-of-trilaciclib-among-patients-with-extensive-stage-small-cell-lung-cancer-receiving-chemotherapy/2024-05-17T20:43:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-during-remission-and-after-relapse-among-older-patients-with-newly-diagnosed-acute-myeloid-leukemia-without-hematopoietic-stem-cell-transplant-a-retrospective-study-using-the-seer-medicare-database/2024-05-17T20:42:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/data-in-the-digital-economy-the-anti-hero-of-antitrust-or-just-bad-reputation/2025-09-22T20:00:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/webinar-recap-breaking-news-amazon-and-ftc/2025-01-03T23:57:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-cdcs-revised-guideline-on-opioid-prescriptions/2025-03-26T14:59:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/auto-repair-in-the-age-of-telematics-recap/2024-05-17T20:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/anatomy-of-public-comments-an-empirical-analysis-of-comments-on-ftcs-proposed-ban-of-employee-non-competes/2026-01-02T18:52:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-potential-economic-impact-of-legalizing-igaming-on-casino-revenues-in-five-states-new-york-illinois-louisiana-maryland-and-virginia/2024-05-17T20:44:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/emerging-racial-disparities-among-medicare-beneficiaries-and-veterans-with-metastatic-castration-sensitive-prostate-cancer/2024-05-17T20:42:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/projected-impact-of-omidubicel-onlv-on-racialethnic-disparities-in-allogeneic-hematopoietic-cell-transplantation-allo-hct-outcomes-in-hematologic-malignancies/2026-02-10T19:15:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/webinar-recap-drip-pricing-junk-fees-all-wet-or-a-serious-antitrust-consumer-protection-issue/2026-03-16T13:05:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/delaware-appraisal-rulings-spotlight-growth-assumptions-in-expert-valuation-models/2024-05-17T20:42:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tree-based-machine-learning-to-identify-predictors-of-psoriasis-incidence-at-the-neighborhood-level-a-populational-study-from-quebec-canada/2024-10-24T15:13:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-clinical-outcomes-and-healthcare-costs-in-patients-with-crohns-disease-treated-with-vedolizumab-versus-ustekinumab-in-the-united-states/2026-02-19T17:17:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/webinar-recap-designing-effective-ai-compliance-programs/2024-05-17T20:44:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-comparative-efficacy-and-safety-of-risdiplam-and-nusinersen-in-children-with-type-1-spinal-muscular-atrophy/2024-05-17T20:43:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-patterns-and-sequences-of-targeted-therapy-use-in-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-in-the-united-states-a-longitudinal-study/2025-09-12T14:46:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/navigating-economic-expert-work-in-criminal-antitrust-litigation/2024-05-17T20:43:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evolving-evidence-based-value-assessment-of-one-time-therapies-tisagenlecleucel-as-a-case-study/2024-05-17T20:42:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-neoadjuvant-treatment-patterns-and-outcomes-in-resected-non-small-cell-lung-cancer/2024-05-17T20:43:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pathway-for-development-and-validation-of-multi-domain-endpoints-for-amyloid-light-chain-al-amyloidosis/2024-05-17T20:44:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-of-predictive-models-to-inform-a-novel-risk-categorization-framework-for-antibiotic-resistance-in-e-coli-causing-uncomplicated-urinary-tract-infection/2025-01-03T23:42:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/stratified-patient-profiling-for-vedolizumab-effectiveness-in-crohns-disease-identifying-optimal-subgroups-for-enhanced-treatment-response-in-the-evolve-study2/2024-05-23T15:13:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-clinical-outcomes-among-patients-with-metastatic-prostate-cancer-harboring-homologous-recombination-repair-mutations/2024-05-23T15:57:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluating-the-real-world-effectiveness-of-belimumab-in-patients-with-sle-using-sle-related-laboratory-values-and-rheumatoid-arthritis-derived-disease-activity-measures-rapid3-swollen-joint-count-and-tender-joint-count/2024-05-23T16:20:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-of-patients-with-worsening-heart-failure-with-reduced-ejection-fraction/2024-05-23T16:50:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/tolvaptan-and-number-needed-to-harm-in-autosomal-dominant-polycystic-kidney-disease/2024-05-23T17:20:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/development-and-validation-of-a-claims-based-algorithm-to-identify-moderate-exacerbations-in-patients-with-asthma-treated-in-the-us/2026-03-03T14:16:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-maintenance-phase-persistence-on-ustekinumab-and-adalimumab-in-ulcerative-colitis/2024-05-23T18:28:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/structured-literature-review-to-identify-human-papillomaviruss-natural-history-parameters-for-dynamic-population-models-of-vaccine-impacts/2025-10-14T13:44:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-associated-with-adverse-events-during-treatment-episodes-for-adult-attention-deficithyperactivity-disorder/2026-02-19T17:22:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/frequency-and-economic-burden-of-exacerbations-in-inhaled-corticosteroidlong-acting-beta-agonist-treated-patients-with-asthma-a-retrospective-us-claims-study/2026-03-03T14:15:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-lenalidomidedexamethasone-based-triplet-regimens-for-treatment-of-relapsed-andor-refractory-multiple-myeloma-in-the-united-states-an-analysis-of-real-world-electronic-health-records-data/2025-07-16T13:28:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/likelihood-of-antimicrobial-resistance-in-urinary-e-coli-isolates-among-us-female-patients-with-recurrent-vs-non-recurrent-uncomplicated-urinary-tract-infection/2024-05-30T16:46:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-use-of-anti-pd1-monotherapy-as-adjuvant-therapy-and-determinants-of-treatment-choice-in-stage-iii-cutaneous-melanoma-in-the-us/2024-05-30T20:38:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-free-interval-a-novel-approach-to-assessing-real-world-treatment-effectiveness-and-economic-impact-among-patients-with-irritable-bowel-syndrome-with-diarrhea/2026-02-19T17:11:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/new-vaccine-platforms-novel-dimensions-of-economic-and-societal-value-and-their-measurement/2024-06-03T20:56:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-overall-survival-with-abiraterone-acetate-versus-enzalutamide-in-chemotherapy-naive-patients-with-metastatic-castration-resistant-prostate-cancer/2026-03-03T14:21:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/incidence-of-pneumococcal-disease-in-children-48-months-old-in-the-united-states-19982019/2024-06-06T13:02:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-association-between-systemic-corticosteroid-exposure-and-complications-in-us-patients-with-severe-asthma/2024-06-05T17:24:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-clinical-outcomes-after-platinum-doublet-chemotherapy-and-immunotherapy-in-metastatic-non-small-cell-lung-cancer-a-multiregional-chart-review-in-the-united-states-europe-and-japan/2024-06-05T17:40:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cytochrome-p450-inhibitorinducer-treatment-patterns-among-patients-in-the-united-states-with-advanced-ovarian-cancer-who-were-prescribed-or-were-eligible-for-polyadenosine-diphosphate-adp-ribose-polymerase-inhibitors-in-the-first-line-maintenance-set/2024-06-05T17:59:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/survival-among-patients-receiving-eteplirsen-for-up-to-8-years-for-the-treatment-of-duchenne-muscular-dystrophy-and-contextualization-with-natural-history-controls/2024-06-05T18:14:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiology-and-economic-burden-of-von-hippel-lindau-disease-associated-central-nervous-system-hemangioblastomas-and-pancreatic-neuroendocrine-tumors-in-the-united-states/2024-06-05T18:35:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-of-genetic-testing-delayed-care-and-suboptimal-treatment-associated-with-polymerase-chain-reaction-versus-next-generation-sequencing-biomarker-testing-for-genomic-alterations-in-metastatic-non-small-cell-lung-cancer/2025-02-28T14:46:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-evidence-of-pressure-enabled-drug-delivery-for-trans-arterial-chemoembolization-and-radioembolization-among-patients-with-hepatocellular-carcinoma-and-liver-metastases/2024-06-12T16:28:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characterizing-the-real-world-economic-burden-of-metastatic-castration-sensitive-prostate-cancer-in-the-united-states/2024-06-12T16:57:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-use-and-clinical-impact-of-an-electronic-patient-reported-outcome-tool-in-patients-with-solid-tumors-treated-with-immuno-oncology-therapy/2024-06-12T16:55:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-sotrovimab-for-the-early-treatment-of-covid-19-evidence-from-the-us-national-covid-cohort-collaborative-n3c/2024-06-12T17:10:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-users-of-triple-therapy-for-asthma-in-the-us/2024-06-12T17:23:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-formulary-related-pharmacy-claim-rejections-of-cariprazine-on-health-care-utilization-and-treatment-patterns-among-patients-with-bipolar-i-disorder/2024-06-12T17:42:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-chronic-corticosteroid-use-among-patients-with-ulcerative-colitis-initiated-on-targeted-treatment-or-conventional-therapy-in-the-united-states/2024-06-12T17:55:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-flt3-mutation-testing-among-patients-with-acute-myeloid-leukemia-in-china-a-retrospective-observational-study/2024-06-12T18:05:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-before-and-after-prucalopride-treatment-an-observational-study-in-patients-with-chronic-idiopathic-constipation-in-the-united-states/2024-06-12T18:14:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/delayed-treatment-initiation-of-oral-anticoagulants-among-medicare-patients-with-atrial-fibrillation/2024-06-12T18:21:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/implications-of-delayed-testosterone-recovery-in-patients-with-prostate-cancer/2024-06-12T18:32:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-preferences-for-treatment-attributes-in-moderate-to-severe-atopic-dermatitis-a-discrete-choice-experiment/2024-09-24T19:53:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/top-food-and-drug-cases-2023-cases-to-watch-2024/2024-07-08T18:11:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/webinar-recap-digital-ex-ante-regulation-goes-global/2026-03-25T14:57:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/ecosystem-theories-of-harm-in-merger-enforcement-current-direction-and-open-questions/2026-02-27T16:37:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/trade-secret-disputes-quantifying-damages/2026-02-17T19:29:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/second-circuit-weighs-in-on-several-benchmark-manipulation-cases/2025-01-03T23:52:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-spring-meeting-2024-panel-recap-reining-in-gatekeepers-and-ecosystems/2026-01-02T17:48:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antitrust-and-sustainability-what-actions-should-firms-take-in-a-world-without-clear-rules/2024-07-30T14:59:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/psa-outcomes-and-clinical-surveillance-among-patients-with-nonmetastatic-castration-resistant-prostate-cancer-treated-with-a-next-generation-androgen-receptor-inhibitor-in-urology-practices-with-or-without-in-office-dispensing/2024-08-05T16:59:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comprehensive-measurement-of-biopharmaceutical-rd-investment/2024-11-21T16:36:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/understanding-walmarts-impact-on-the-us-economy-and-communities/2025-04-30T16:46:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-burden-of-medicare-beneficiaries-with-multiple-myeloma-and-renal-impairment-an-observational-study/2024-08-27T16:56:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-ftcs-non-compete-ban-what-lies-ahead/2024-08-27T19:29:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/delayed-treatment-initiation-of-oral-anticoagulants-among-medicare-patients-with-atrial-fibrillation2/2024-09-10T17:27:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hyperkalemia-and-risk-of-chronic-kidney-disease-progression-a-propensity-score-matched-analysis/2026-03-03T14:04:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/logit-or-leave-it/2024-12-31T21:19:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-algorithmic-versus-generative-ai-pricing-tools/2025-04-07T20:37:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/offshore-wind-procurement-the-driver-of-economy-wide-decarbonization/2024-09-20T19:48:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/contemporary-outpatient-management-of-patients-with-worsening-heart-failure-with-reduced-ejection-fraction-clinical-outcome-results-from-the-chart-hf-study/2024-09-25T15:40:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-age-at-ivacaftor-initiation-on-pulmonary-outcomes-among-people-with-cystic-fibrosis/2024-09-25T18:05:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-patterns-and-economic-burden-associated-with-treatment-failure-with-advanced-therapies-in-patients-with-moderate-to-severe-ulcerative-colitis/2024-09-25T18:25:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-generalized-myasthenia-gravis-mg-in-the-united-states-and-the-impact-of-common-comorbidities-and-acute-mg-events/2026-02-19T20:31:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-analysis-of-persistence-and-remission-with-guselkumab-versus-secukinumab-and-ixekizumab-in-the-united-states/2024-09-25T18:47:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/functional-trajectories-before-and-after-loss-of-ambulation-in-duchenne-muscular-dystrophy-and-implications-for-clinical-trials/2024-09-25T19:02:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-and-safety-of-ozanimod-versus-other-oral-dmts-in-relapsing-remitting-multiple-sclerosis-a-synthesis-of-matching-adjusted-indirect-comparisons/2025-10-14T13:45:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/herpes-zoster-burden-in-patients-with-asthma-real-world-incidence-healthcare-resource-utilisation-and-cost/2024-09-25T19:36:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-clinical-outcomes-among-patients-with-metastatic-castration-sensitive-prostate-cancer-initiating-apalutamide/2024-09-25T20:05:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-immigration-on-the-united-states/2024-09-30T13:19:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-psychiatric-comorbidities-in-pediatric-patients-with-attention-deficithyperactivity-disorder-a-claims-based-case-cohort-study/2026-02-19T17:21:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-costs-associated-with-psychiatric-comorbidities-in-adult-patients-with-attention-deficithyperactivity-disorder/2026-02-19T17:21:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-impact-of-ivacaftor-on-mortality-rate-and-health-outcomes-in-people-with-cystic-fibrosis/2024-10-04T18:15:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-centanafadine-in-adults-with-adhd-a-matching-adjusted-indirect-comparison-versus-methylphenidate-hydrochloride-extended-release-concerta/2025-09-12T14:48:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-impact-of-suboptimal-treatment-and-treatment-switch-among-patients-with-crohns-disease-treated-with-a-first-line-biologic-a-us-retrospective-claims-database-study/2024-10-07T19:01:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/vertical-arrangements-and-restrictions-in-europe/2025-12-17T15:12:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/aba-panel-recap-the-pe-effect-antitrust-scrutiny-abounds/2025-01-03T23:55:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-economic-burden-associated-with-disease-progression-from-metastatic-castration-sensitive-to-castration-resistant-prostate-cancer-on-treatment-in-the-united-states/2024-10-07T20:02:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/improved-health-outcomes-in-patients-with-systemic-lupus-erythematosus-following-early-belimumab-initiation-without-prior-immunosuppressant-use-a-real-world-descriptive-study/2024-10-07T20:19:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-anti-seizure-treatment-and-adverse-events-among-individuals-living-with-drug-resistant-focal-epilepsy-in-the-united-states/2025-07-16T13:24:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-acute-healthcare-resource-use-and-costs-of-patients-with-treatment-resistant-depression-completing-induction-phase-of-esketamine-in-the-united-states/2024-10-08T17:23:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/meaningful-changes-in-motor-function-in-duchenne-muscular-dystrophy-dmd-a-multi-center-study/2024-10-07T20:55:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-long-term-implications-of-age-9-initiation-of-hpv-vaccination-on-series-completion-by-age-13-15-in-the-us-projections-from-an-age-structured-vaccination-model/2025-10-14T13:43:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-cardiovascular-events-following-intermittent-and-continuous-androgen-deprivation-therapy-in-patients-with-nonmetastatic-prostate-cancer/2024-10-08T16:55:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/igg-testing-immunoglobulin-replacement-therapy-and-infection-outcomes-in-patients-with-cll-or-nhl-real-world-evidence/2024-10-08T17:06:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/understanding-profiles-of-patients-with-treatment-resistant-depression-by-stringency-of-health-plan-prior-authorization-criteria-for-approval-of-esketamine-nasal-spray/2024-10-08T17:21:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-dupilumab-versus-benralizumab-and-mepolizumab/2024-10-08T17:45:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-of-high-healthcare-cost-among-patients-with-generalized-myasthenia-gravis-a-combined-machine-learning-and-regression-approach-from-a-us-payer-perspective/2026-02-19T20:32:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effectiveness-of-patisiran-after-switching-from-tafamidis-for-the-treatment-of-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy/2024-10-08T18:45:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characterizing-the-journey-of-rett-syndrome-among-females-in-the-united-states-a-real-world-evidence-study-using-the-rett-syndrome-natural-history-study-database/2024-10-08T18:53:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-herpes-zoster-among-patients-with-psoriatic-arthritis-in-the-united-states/2024-10-09T17:55:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-eosinophilic-granulomatosis-with-polyangiitis-in-europe/2024-10-09T18:22:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-real-world-healthcare-resource-utilization-among-advanced-therapy-naive-and-advanced-therapy-experienced-patients-with-ulcerative-colitis-initiated-on-ustekinumab-or-vedolizumab/2026-02-19T20:30:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-recurrent-hyperkalemia-in-patients-with-chronic-kidney-disease/2026-03-03T14:20:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-long-term-effectiveness-of-risankizumab-among-patients-with-moderate-to-severe-psoriasis-analysis-from-an-international-medical-chart-review-rapid-study/2024-10-09T19:44:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-considerations-related-to-biosimilar-market-entry/2024-10-24T20:06:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-centanafadine-in-adults-with-attention-deficithyperactivity-disorder-a-matching-adjusted-indirect-comparison-vs-lisdexamfetamine-dimesylate-atomoxetine-hydrochloride-and-viloxazine-extended-release/2025-09-12T14:48:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-preferences-of-adult-patients-with-attention-deficithyperactivity-disorder-a-discrete-choice-experiment/2025-09-12T14:49:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-for-patients-with-brca12-positive-metastatic-castration-resistant-prostate-cancer/2024-10-14T17:20:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-real-world-on-label-treatment-persistence-in-patients-with-psoriatic-arthritis-receiving-guselkumab-versus-subcutaneous-tumor-necrosis-factor-inhibitors/2024-10-14T17:31:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/long-term-temporal-trends-of-real-world-healthcare-costs-associated-with-nivolumab-plus-ipilimumab-and-pembrolizumab-plus-axitinib-as-first-line-treatment-for-advanced-or-metastatic-renal-cell-carcinoma/2024-10-14T17:59:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-matching-adjusted-indirect-comparison-of-centanafadine-versus-lisdexamfetamine-methylphenidate-and-atomoxetine-in-adults-with-attention-deficithyperactivity-disorder-long-term-safety-and-efficacy/2025-09-12T14:50:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/first-line-nivolumab-plus-relatlimab-versus-nivolumab-plus-ipilimumab-in-advanced-melanoma-an-indirect-treatment-comparison-using-relativity-047-and-checkmate-067-trial-data/2025-07-07T17:51:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-long-term-persistence-and-surgical-procedure-free-period-among-bio-naive-patients-with-crohns-disease-and-fistula-initiated-on-ustekinumab/2026-02-19T20:36:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-persistence-among-advanced-therapy-naive-or-experienced-patients-with-ulcerative-colitis-initiated-on-ustekinumab-or-adalimumab/2026-02-19T20:35:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/transfusion-related-cost-offsets-and-time-burden-in-patients-with-myelofibrosis-on-momelotinib-vs-danazol-from-momentum/2024-10-14T19:07:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-resource-use-after-osimertinib-discontinuation-in-patients-with-egfr-metastatic-nsclc/2024-10-14T19:22:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-dupilumab-and-omalizumab-on-asthma-exacerbations-and-systemic-corticosteroid-prescriptions-real-world-us-advantage-study/2024-10-14T19:31:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/seizure-burden-and-healthcare-resource-utilization-among-people-living-with-drug-resistant-focal-epilepsy-in-the-united-states/2025-07-16T13:22:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-prevalence-of-adverse-events-with-first-line-systemic-therapies-among-patients-with-metastatic-castration-sensitive-prostate-cancer/2024-10-14T19:48:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-benefit-analysis-of-novel-treatments-for-patients-with-generalized-myasthenia-gravis/2024-10-29T13:37:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/webinar-recap-the-microsoft-case-and-todays-big-tech-wars-a-peek-into-the-past-to-see-the-future/2025-01-03T23:34:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/co-located-load-market-economic-and-ratemaking-implications/2024-10-31T13:15:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-benralizumab-among-patients-with-asthma-and-concomitant-chronic-obstructive-pulmonary-disease/2024-11-05T22:04:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-of-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-patients-who-relapse-or-are-refractory-to-ibrutinib/2025-01-03T20:26:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/interlocking-directorates-in-the-crosshairs-of-regulation/2024-11-05T17:28:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mission-impossible-teresa-riberas-mission-letter-and-the-future-of-eu-merger-review/2024-12-05T20:00:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adjusting-patent-royalty-rates-for-inflation/2024-11-21T14:41:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-relationship-between-pricing-transparency-and-price-competition-in-the-us-health-care-industry/2024-11-25T14:47:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/conversation-about-2023-dojftc-merger-guidelines/2025-01-03T14:59:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-impact-of-luspatercept-on-red-blood-cell-transfusions-among-patients-with-myelodysplastic-syndromes-a-united-states-healthcare-claims-database-study/2025-01-03T19:59:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recent-developments-in-labor-market-antitrust-enforcement-in-the-united-states-europe-canada-and-china/2026-01-02T18:51:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/hyperkalemia-and-the-risks-of-adverse-cardiovascular-outcomes-in-patients-with-chronic-kidney-disease/2026-03-03T14:16:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pd-l1-testing-patterns-in-recurrentmetastatic-head-and-neck-squamous-cell-carcinoma-rm-hnscc-in-the-u-s/2025-01-22T21:34:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-use-and-medical-costs-among-patients-with-major-depressive-disorder-and-acute-suicidal-ideation-or-behavior-initiated-on-esketamine-nasal-spray-or-traditional-treatments-in-the-united-states/2026-02-19T20:35:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/racial-differences-in-survival-and-healthcare-resource-utilization-among-medicaid-insured-adults-with-metastatic-prostate-cancer/2025-02-04T19:16:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-burden-treatment-and-disease-control-in-patients-with-chronic-spontaneous-urticaria-real-world-evidence/2025-02-04T19:32:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risdiplam-utilization-adherence-and-associated-health-care-costs-for-patients-with-spinal-muscular-atrophy-a-united-states-retrospective-claims-database-analysis/2025-02-04T19:49:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/an-access-focused-patient-centric-value-assessment-framework-for-medication-formulary-decision-making-in-immune-mediated-inflammatory-diseases/2025-02-21T14:00:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-survival-and-economic-burden-among-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-in-the-united-states/2026-03-03T14:17:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiology-and-burden-of-focal-segmental-glomerulosclerosis-among-united-states-veterans-an-analysis-of-veterans-affairs-data/2025-02-04T20:12:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-fluticasone-furoateumeclidiniumvilanterol-and-budesonideglycopyrrolateformoterol-fumarate-among-us-patients-with-chronic-obstructive-pulmonary-disease/2025-02-10T19:02:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-following-ibrutinib-dose-reduction-in-patients-with-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma/2025-02-28T14:46:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evolving-concept-of-value-in-health-economics-and-outcomes-research-emerging-tools-for-innovation-and-access-to-cell-and-gene-therapies-for-rare-diseases/2025-02-18T16:10:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-persistence-among-anti-tumor-necrosis-factor-experienced-patients-with-ulcerative-colitis-switching-to-a-biologic-with-a-different-mode-of-action-or-cycling-to-another-anti-tumor-necrosis-factor-agent/2026-02-19T20:33:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/medicare-advantage-population-in-the-united-states-outcomes-of-patients-with-asthma-treated-with-icslaba-before-and-after-initiation-with-fluticasone-furoateumeclidiniumvilanterol-ffumecvi/2025-02-18T16:27:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-time-to-next-treatment-or-death-between-front-line-daratumumab-lenalidomide-and-dexamethasone-drd-versus-bortezomib-lenalidomide-and-dexamethasone-vrd-among-transplant-ineligible-patients-with-multiple-myeloma/2025-02-28T20:39:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-and-persistence-with-single-inhaler-triple-therapy-among-patients-with-copd-using-commercial-and-medicare-advantage-us-health-plan-claims-data/2025-02-18T17:58:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-social-determinants-of-health-on-esketamine-nasal-spray-initiation-among-patients-with-treatment-resistant-depression-in-the-united-states/2025-02-18T18:21:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-following-biochemical-recurrence-after-definitive-therapy-with-a-short-prostate-specific-antigen-doubling-time-potential-role-of-early-secondary-treatment/2025-02-18T18:58:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-economic-burden-of-recurrence-in-elderly-patients-with-completely-resected-stage-iibiic-or-iii-melanoma-an-analysis-of-the-surveillance-epidemiology-and-end-results-medicare-linked-database/2025-02-18T19:10:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overall-burden-and-impact-on-health-related-quality-of-life-associated-with-intravesical-treatment-of-patients-with-non-muscle-invasive-bladder-cancer-in-the-united-states/2025-02-21T15:42:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-and-clinical-burden-of-major-depressive-disorder-with-insomnia-symptoms-in-commercially-and-medicaid-insured-adults-in-the-united-states-a-retrospective-matched-cohort-study/2026-02-19T20:34:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-perioperative-treatment-patterns-and-economic-burden-of-recurrence-in-early-stage-her2-negative-breast-cancer-a-seer-medicare-study/2025-02-21T16:04:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/transfusion-related-cost-and-time-burden-offsets-in-patients-with-myelofibrosis-treated-with-momelotinib-in-the-simplify-1-and-simplify-2-trials/2025-02-21T16:13:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/correlation-between-disease-free-survival-endpoints-and-overall-survival-in-elderly-patients-with-early-stage-her2-negative-breast-cancer-a-seer-medicare-analysis/2025-02-21T16:30:55+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-healthcare-resource-utilization-of-alzheimers-disease-in-the-early-and-advanced-stages-a-retrospective-cohort-study/2025-02-21T16:39:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/modeling-the-health-and-economic-implications-of-adopting-a-1-dose-9-valent-human-papillomavirus-vaccination-program-in-adolescents-in-lowmiddle-income-countries-an-analysis-of-indonesia/2025-10-14T13:41:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-diagnostic-referral-and-treatment-patterns-in-early-alzheimers-disease-among-community-based-practices-in-the-united-states/2025-02-21T16:51:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-next-generation-sequencing-vs-polymerase-chain-reaction-testing-on-payer-costs-and-clinical-outcomes-throughout-the-treatment-journeys-of-patients-with-metastatic-non-small-cell-lung-cancer/2025-02-28T20:39:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-costs-among-patients-with-relapsedrefractory-multiple-myeloma-treated-with-ixazomib-or-daratumumab-in-combination-with-lenalidomide-and-dexamethasone-in-the-united-states/2025-07-16T13:27:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-preferences-of-physicians-treating-adult-patients-with-attention-deficithyperactivity-disorder-in-the-united-states-and-canada-a-discrete-choice-experiment/2025-09-12T14:44:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-associated-with-first-versus-subsequent-use-of-cariprazine-for-bipolar-i-disorder/2025-02-24T18:32:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-healthcare-resource-utilization-healthcare-costs-and-injurious-falls-among-elderly-patients-with-geographic-atrophy/2025-02-24T18:48:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-mepolizumab-treatment-in-eosinophilic-granulomatosis-with-polyangiitis-reduces-disease-burden-in-the-united-states/2025-02-24T18:57:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-survival-outcomes-among-androgen-receptor-pathway-inhibitor-experienced-patients-with-metastatic-castration-resistant-prostate-cancer/2025-02-25T15:56:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-phosphorodiamidate-morpholino-oligomer-treatment-patterns-for-patients-with-duchenne-muscular-dystrophy-a-marketscan-claims-analysis/2025-02-25T16:02:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-journey-and-healthcare-resource-use-among-patients-with-alcohol-use-disorder-who-initiated-extended-release-naltrexone-an-analysis-of-veterans-affairs-data/2025-02-25T16:16:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-factors-for-empiric-treatment-failure-in-us-female-outpatients-with-uncomplicated-urinary-tract-infection-an-observational-study/2025-02-25T16:26:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-evaluation-of-treatment-patterns-and-clinical-outcomes-among-patients-with-chronic-myeloid-leukemia-in-chronic-phase-treated-with-asciminib-in-clinical-practice-in-the-united-states-real-world-asciminib-treatment-outcomes-in-cml-cp/2025-02-25T16:47:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/descriptive-analysis-of-types-and-diagnoses-associated-with-lower-extremity-amputation-analysis-of-the-us-veterans-health-administration-database-2019-2023/2025-02-25T17:05:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-humanistic-burden-of-immunoglobulin-a-nephropathy-on-patients-and-care-partners-in-the-united-states/2025-02-25T17:51:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/identification-of-cytokine-release-syndrome-and-indicators-of-severity-in-retrospective-databases-among-patients-receiving-immunotherapy/2025-02-28T20:42:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patterns-of-hiv-treatment-preferences-among-people-with-diverse-demographic-social-and-behavioral-characteristics-who-are-living-with-hiv-in-the-united-states/2025-02-25T18:18:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/costs-of-adverse-events-in-patients-with-advanced-or-metastatic-renal-cell-carcinoma-with-first-line-treatment/2025-02-25T18:26:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-perioperative-treatment-patterns-and-burden-of-recurrent-disease-in-patients-with-high-risk-endometrial-cancer-a-seer-medicare-study/2025-07-16T13:25:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characterization-of-patients-with-duchenne-muscular-dystrophy-across-previously-developed-health-states/2025-02-25T18:41:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/adherence-to-first-line-intravesical-bacillus-calmette-guerin-therapy-in-the-context-of-guideline-recommendations-for-us-patients-with-high-risk-non-muscle-invasive-bladder-cancer/2025-02-25T19:08:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pre-exposure-prophylaxis-for-the-prevention-of-hiv-1-an-assessment-of-oral-pre-exposure-prophylaxis-usage-patterns-first-evidence-of-hiv-1-and-hiv-1-risk-factors-in-the-united-states/2025-02-25T19:17:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fluticasone-furoateumeclidiniumvilanterol-initiation-following-a-copd-exacerbation-benefits-of-prompt-initiation-on-copd-outcomes/2025-02-25T19:26:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overall-survival-in-real-world-patients-with-unresectable-hepatocellular-carcinoma-receiving-atezolizumab-plus-bevacizumab-versus-sorafenib-or-lenvatinib-as-first-line-therapy-findings-from-the-national-veterans-health-administration-database/2025-02-25T19:59:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/antihyperglycemic-treatment-patterns-for-chronic-kidney-disease-and-type-2-diabetes/2025-02-25T20:10:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-impact-of-rotavirus-vaccination-in-china/2025-02-26T20:20:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/quality-of-life-and-outcomes-associated-with-adverse-effects-in-pediatric-patients-with-attention-deficithyperactivity-disorder-and-their-parentscaregivers/2025-09-12T14:50:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/estimation-of-health-state-utility-values-for-immunoglobulin-a-nephropathy-a-time-trade-off-analysis/2025-02-26T20:40:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/non-medical-switching-or-discontinuation-patterns-among-patients-with-non-valvular-atrial-fibrillation-treated-with-direct-oral-anticoagulants-in-the-united-states-a-claims-based-analysis/2025-02-28T20:43:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-clinical-outcomes-and-treatment-patterns-among-black-and-non-black-patients-with-prostate-cancer-initiated-on-apalutamide-in-a-urology-setting/2025-02-26T21:06:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/homologous-recombination-repair-testing-patterns-and-outcomes-in-mcrpc-by-alteration-status-and-race/2025-02-26T21:17:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-outcomes-of-first-line-treatment-with-anti-pdl1-based-combination-therapy-for-nonsquamous-metastatic-non-small-cell-lung-cancer-a-multiregional-chart-review-in-europe-japan-and-the-united-states/2025-02-26T21:26:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-retrospective-longitudinal-registry-study-on-the-long-term-durability-of-ivacaftor-treatment-in-people-with-cystic-fibrosis/2025-02-26T21:34:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/understanding-the-impact-of-slowing-disease-progression-for-individuals-with-biomarker-confirmed-early-symptomatic-alzheimers-disease/2025-02-26T21:44:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-satisfaction-unmet-needs-and-new-treatment-expectations-for-vasomotor-symptoms-due-to-menopause-womens-and-physicians-opinions/2025-02-26T21:52:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lessons-learned-from-the-kroger-albertsons-merger-case/2025-03-04T16:11:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lawmakers-shouldnt-overlook-rare-disease-therapies-value/2025-03-24T14:16:27+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-diagnostic-referral-and-treatment-patterns-in-early-alzheimers-disease-among-community-based-practices-in-the-united-states2/2025-04-08T15:29:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-current-landscape-of-gastric-cancer-and-gastroesophageal-junction-cancer-diagnosis-and-treatment-in-china-a-comprehensive-nationwide-cohort-analysis/2025-04-22T19:57:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/platform-mergers-in-the-digital-age-economics-regulation-and-enforcement/2025-04-30T14:01:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/controller-induced-depression-possible-but-not-expected/2025-05-02T19:18:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-clinical-outcomes-among-patients-with-metastatic-prostate-cancer-harboring-homologous-recombination-repair-mutations2/2025-05-05T16:14:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/reductions-in-medical-visits-and-hospitalizations-following-berotralstat-initiation-in-patients-with-hereditary-angioedema-in-the-united-states/2025-06-03T14:08:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-of-patients-with-lower-risk-myelodysplastic-syndromes-treated-with-luspatercept-versus-erythropoiesis-stimulating-agents-a-united-states-healthcare-claims-database-study/2025-06-13T19:07:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/non-optimal-treatment-with-first-tyrosine-kinase-inhibitor-and-associated-economic-burden-in-chronic-myeloid-leukemia/2025-06-13T19:14:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-per-outcome-of-nivolumab-relatlimab-vs-braf-mek-inhibitor-combinations-for-first-line-treatment-of-braf-mutant-advanced-melanoma/2025-06-13T19:22:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-use-and-clinical-events-associated-with-neutropenia-among-adult-kidney-transplant-recipients-receiving-valganciclovir-or-ganciclovir-prophylaxis-a-matched-case-control-cohort-study/2025-06-13T19:29:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/modeling-the-economic-impact-of-different-testing-strategies-for-meningitisencephalitis-in-adult-patients-from-a-us-hospital-perspective/2025-06-16T19:00:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-monitoring-and-treatment-patterns-of-von-hippel-lindau-disease-associated-renal-cell-carcinoma-in-the-united-states/2025-06-17T14:29:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-access-barriers-to-rifaximin-among-patients-with-hepatic-encephalopathy-using-adjudicated-claims-data/2025-06-17T15:17:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-healthcare-resource-use-among-veterans-initiating-medication-for-incident-moderate-to-severe-alcohol-use-disorder/2025-06-25T19:13:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/webinar-recap-us-v-google-what-lies-ahead/2025-06-26T19:15:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recent-reports-shed-light-on-section-340bs-effectiveness/2025-06-27T17:59:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/global-merger-control-innovation/2025-06-30T18:09:20+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-who-why-and-where-of-biometric-privacy-litigation-an-empirical-analysis-of-bipa-cases-2015-2024/2025-07-02T17:18:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-glucocorticoid-use-and-risk-of-toxicities-among-patients-with-immunoglobulin-g4-related-disease-a-retrospective-us-based-claims-study/2025-07-02T15:46:59+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/agitation-in-individuals-with-alzheimers-disease-an-assessment-of-behaviors-using-the-cohen-mansfield-agitation-inventory-in-community-dwellers-and-impact-on-caregiver-experience/2026-02-19T17:20:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-outcomes-in-people-with-von-willebrand-disease-treated-prophylactically-with-recombinant-von-willebrand-factor-in-the-united-states/2025-07-02T18:18:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluation-of-real-world-treatment-patterns-and-healthcare-resource-utilization-in-patients-with-chronic-refractory-gout-in-the-united-states/2025-07-02T18:27:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overall-survival-in-patients-with-metastatic-castration-sensitive-prostate-cancer-treated-with-apalutamide-versus-abiraterone-acetate-a-head-to-head-analysis-of-real-world-patients-in-the-usa/2025-07-02T18:33:02+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-regorafenib-dose-optimization-for-refractory-metastatic-colorectal-cancer/2025-07-02T18:49:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overall-survival-among-patients-with-activated-phosphoinositide-3-kinase-delta-syndrome-apds/2026-03-30T19:30:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-immunoglobulin-replacement-for-hypogammaglobulinemia-and-infections-in-multiple-myeloma/2025-07-02T19:24:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-comparison-of-healthcare-resource-utilization-and-costs-between-patients-with-chronic-lymphocytic-leukemia-treated-with-first-line-ibrutinib-or-acalabrutinib-using-two-large-us-real-world-databases/2025-07-02T19:37:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-clinical-outcomes-of-patients-with-systemic-light-chain-amyloidosis-in-the-united-states-evidence-from-real-world-clinical-practice/2025-07-02T19:44:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/oral-anticoagulant-use-among-medicare-patients-newly-diagnosed-with-venous-thromboembolism-vte-factors-associated-with-treatment-status/2025-07-02T20:16:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-maintenance-treatment-patterns-among-patients-with-advanced-non-small-cell-lung-cancer/2025-07-02T20:25:09+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/epidemiology-and-economic-burden-of-diagnosed-congenital-cytomegalovirus-infection-in-the-first-2-years-of-life-among-commercially-insured-and-medicaid-insured-individuals-in-the-united-states/2025-07-02T20:33:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/study-of-persistence-and-adherence-to-adt-in-prostate-cancer-relugolix-degarelix-and-gnrh-agonists-in-the-us/2025-07-02T20:38:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-treatment-escalation-on-rehospitalization-among-patients-with-pulmonary-arterial-hypertension/2025-07-02T20:53:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-current-landscape-of-gastric-cancer-and-gastroesophageal-junction-cancer-diagnosis-and-treatment-in-china-a-comprehensive-nationwide-cohort-analysis2/2025-07-02T21:10:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/out-of-pocket-costs-for-direct-oral-anticoagulants-and-prescription-abandonment-among-patients-with-nonvalvular-atrial-fibrillation-or-venous-thromboembolism/2025-07-08T14:56:07+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-preferences-for-cdk46-inhibitor-treatments-in-hrher2-early-breast-cancer-a-discrete-choice-survey-study/2025-07-08T15:21:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-assessment-of-all-cause-hospital-readmissions-among-pulmonary-embolism-patients-treated-with-rivaroxaban-versus-apixaban/2025-07-08T15:29:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-treatment-of-covid-19-with-sotrovimab-on-post-acute-sequelae-of-covid-19-pasc-an-analysis-of-national-covid-cohort-collaborative-n3c-data/2025-07-08T15:46:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/newer-glucagon-like-peptide-1-receptor-agonists-are-associated-with-improved-glycemic-control-in-us-adults-with-type-2-diabetes-a-population-level-time-series-analysis/2025-07-08T15:52:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-healthcare-resource-utilization-and-costs-among-patients-diagnosed-with-locally-advancedmetastatic-urothelial-carcinoma-prior-to-receiving-enfortumab-vedotin-a-real-world-evidence-study/2026-03-03T14:10:00+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/characteristics-and-real-world-outcomes-of-patients-treated-with-fecal-microbiota-live-jslm-rbl-for-the-prevention-of-recurrent-clostridioides-difficile-infection/2025-07-16T18:19:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cluster-analysis-of-clinical-remission-and-relapse-patterns-in-chronic-urticaria-results-from-the-predict-cu-study/2025-07-16T18:41:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/visualizing-ambulatory-performance-by-age-and-rates-of-decline-among-patients-with-duchenne-muscular-dystrophy/2025-07-16T19:31:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-effectiveness-of-chemoimmunotherapy-and-novel-therapies-for-patients-with-relapsedrefractory-aggressive-large-b-cell-lymphoma/2026-03-30T19:29:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/esketamine-nasal-spray-vs-quetiapine-extended-release-examining-work-productivity-loss-and-related-costs-in-patients-with-treatment-resistant-depression/2025-07-16T19:52:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-cariprazine-on-body-weight-and-blood-pressure-among-adults-with-bipolar-i-disorder-schizophrenia-or-major-depressive-disorder-in-a-real-world-setting/2025-07-16T19:59:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-real-world-impact-of-cariprazine-on-short-and-long-term-disability-outcomes-among-commercially-insured-patients-in-the-united-states/2025-07-16T20:10:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparison-of-the-relative-vaccine-effectiveness-of-mrna-1283-vs-bnt162b2-vaccines-against-symptomatic-covid-19-among-us-adults/2025-10-14T13:46:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evolving-concept-of-value-in-health-economics-and-outcomes-research-emerging-tools-for-innovation-and-access-to-cell-and-gene-therapies-for-rare-diseases2/2025-07-22T16:55:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-rise-of-surveillance-pricing/2025-12-22T18:12:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-clinical-burden-of-friedreich-ataxia-in-the-united-states-a-retrospective-claims-database-analysis/2025-07-23T17:27:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-dry-age-related-macular-degeneration-on-daily-activities-and-quality-of-life-interview-findings-from-patients-and-caregivers-relative-to-a-general-population/2026-02-10T19:12:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mental-health-related-disability-days-and-costs-among-patients-with-treatment-resistant-depression-initiated-on-esketamine-nasal-spray-and-conventional-therapies-in-the-usa/2025-07-30T18:12:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effectiveness-and-safety-of-rivaroxaban-vs-warfarin-in-patients-with-pulmonary-embolism-and-right-ventricular-dysfunction-a-retrospective-cohort-study/2025-07-30T14:01:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-cohort-study-of-elderly-users-of-single-or-multiple-inhaler-triple-therapy-for-the-treatment-of-asthma-in-the-usa/2025-07-30T18:23:23+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-invasive-escherichia-coli-e-coli-disease-after-elective-urologic-procedures-among-older-adults-in-the-united-states/2025-09-12T14:45:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-prevalence-of-potential-drug-drug-interactions-associated-with-oral-advanced-therapies-indicated-for-ulcerative-colitis/2025-07-30T19:09:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-trends-and-future-projections-of-the-prevalence-of-cirrhosis-and-hepatic-encephalopathy-among-commercially-and-medicare-insured-adults-in-the-united-states/2025-07-30T19:50:47+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-of-using-cariprazine-as-the-first-versus-subsequent-adjunctive-therapy-for-major-depressive-disorder/2025-07-30T19:59:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-survival-and-economic-burden-among-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-in-the-united-states2/2026-03-03T14:19:33+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/recap-of-doj-ftc-labor-antitrust-guidance-2-0-whats-new-webinar/2025-08-08T13:29:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/meeting-forecasted-growth-in-electricity-demand/2025-08-21T14:19:51+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-screening-role-of-covenant-heterogeneity/2026-01-04T22:08:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-federal-securities-class-action-stats-in-25-so-far/2025-09-04T17:08:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/aba-antitrust-webinar-recap-what-comes-next-competition-across-the-uk-eu-and-us/2026-01-02T17:47:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/securitization-using-a-well-established-tool-to-support-a-more-affordable-energy-transition-in-massachusetts/2025-09-10T16:04:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/bryan-v-del-monte-foods/2025-10-01T17:47:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-role-of-private-equity-in-the-entrepreneurial-ecosystem/2025-09-18T18:39:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-courts-may-interpret-data-driven-healthcare-fraud-suits/2025-10-23T13:56:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/dexit-reincorporation-data-seem-to-support-the-hype/2026-03-06T15:23:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/time-and-cost-burden-associated-with-docetaxel-in-patients-with-metastatic-castration-sensitive-prostate-cancer-initiating-an-androgen-receptor-pathway-inhibitor-based-regimen/2025-10-31T17:18:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-outcomes-between-tarlatamab-and-real-world-physicians-choice-of-therapies-for-previously-treated-extensive-stage-small-cell-lung-cancer/2025-10-31T17:38:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/disease-burden-and-treatment-patterns-amongst-patients-with-haemophilia-a-in-china-a-retrospective-database-analysis-study/2025-11-04T16:13:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-use-and-costs-among-patients-with-covid-19-in-the-united-states/2025-11-04T16:21:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessing-the-burden-of-outpatient-urinary-tract-infections-in-the-united-states-analysis-of-nationwide-ambulatory-data-2016-2019/2025-11-04T16:28:54+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-utility-analysis-of-endovascular-ultrasound-renal-denervation-to-treat-resistant-hypertension-in-the-united-states/2025-11-04T16:35:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-burden-of-recurrent-disease-in-high-risk-endometrial-cancer/2025-11-04T16:49:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predictors-of-frontline-doublet-or-triplet-regimen-initiation-in-transplant-ineligible-newly-diagnosed-multiple-myeloma/2025-11-04T18:43:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-phosphorodiamidate-morpholino-oligomer-treatment-patterns-in-duchenne-muscular-dystrophy-a-claims-based-analysis/2025-11-04T18:49:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/pharma-copay-programs-raise-complex-economic-questions/2025-11-05T19:42:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/descriptive-characterization-of-ambulatory-health-states-in-duchenne-muscular-dystrophy-motor-function-trajectories-and-times-to-loss-of-ambulation/2025-11-11T18:49:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prostate-specific-antigen-reduction-after-androgen-receptor-pathway-inhibitor-initiation-real-world-comparison-of-disease-progression-among-patients-with-metastatic-castration-sensitive-prostate-cancer/2026-02-19T20:32:11+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-comparative-effectiveness-of-biologic-therapies-in-severe-asthma-eu-advantage/2025-11-12T20:15:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/profiles-of-medicaid-beneficiaries-with-treatment-resistant-depression-initiated-on-esketamine-nasal-spray/2025-11-12T20:21:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/changes-in-urine-albumin-to-creatinine-ratio-and-health-care-resource-utilization-and-costs-in-patients-with-type-2-diabetes-and-chronic-kidney-disease/2025-11-12T20:30:18+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/private-enforcement-of-abuse-of-dominance-damages-in-the-eu-and-germany/2025-11-17T14:54:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/bictegravir-emtricitabine-and-tenofovir-alafenamide-versus-ritonavir-boosted-protease-inhibitor-based-antiretroviral-therapy-in-people-with-hiv-and-viral-suppression-on-second-line-therapy-in-haiti-an-open-label-randomised-non-inferiority-trial/2025-11-18T16:59:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-use-healthcare-costs-and-unmet-needs-among-patients-treated-for-egfr-mutated-advanced-or-metastatic-non-small-cell-lung-cancer/2025-11-18T17:45:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-disability-outcomes-among-patients-treated-with-cariprazine-vs-other-atypical-antipsychotics-as-adjunctive-treatment-for-major-depressive-disorder/2025-11-18T17:53:25+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/lower-risk-of-cardiovascular-events-in-patients-initiated-on-semaglutide-2-4-mg-in-the-real-world-results-from-the-score-study-semaglutide-effects-on-cardiovascular-outcomes-in-people-with-overweight-or-obesity-in-the-real-world/2025-11-18T18:09:17+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-costs-associated-with-adverse-events-in-pediatric-patients-with-attention-deficithyperactivity-disorder-adhd-a-claims-based-study/2025-11-18T18:15:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-claims-analysis-of-the-epidemiology-and-economic-burden-of-diagnosed-congenital-cytomegalovirus-in-japan/2025-11-25T14:38:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparative-effectiveness-of-ffumecvi-and-budglyform-in-patients-with-copd-stepping-up-from-dual-therapy/2025-11-25T14:46:24+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-patient-reported-depression-severity-in-subpopulation-of-escape-trd-study-esketamine-nasal-spray-versus-quetiapine-extended-release-for-treatment-resistant-depression/2025-11-25T15:00:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-economic-burden-of-disease-recurrence-in-patients-with-muscle-invasive-bladder-cancer-a-population-level-claims-based-analysis/2025-11-25T15:21:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/mepolizumab-for-the-management-of-chronic-rhinosinusitis-with-nasal-polyps-across-the-united-states-a-retrospective-study/2026-03-30T19:31:35+00:00weekly0.5https://www.analysisgroup.com/Insights/publishing/real-world-clinical-outcomes-of-cabozantinib-as-a-second-line-treatment-for-advanced-hepatocellular-carcinoma-a-retrospective-us-claims-analysis/2025-11-25T15:36:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/how-store-brand-evolution-may-influence-ip-cases/2025-11-25T20:09:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/association-between-exon-skipping-therapy-with-eteplirsen-and-cardiac-outcomes-in-duchenne-muscular-dystrophy/2025-12-01T19:55:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/patient-and-physician-preferences-for-maintenance-treatment-in-advanced-non-small-cell-lung-cancer-insights-into-treatment-selection/2025-12-01T20:06:32+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-and-characteristics-of-patients-with-hereditary-angioedema-treated-with-lanadelumab-a-us-retrospective-chart-review/2025-12-02T17:01:43+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/effects-of-adjunctive-cariprazine-formulary-restrictions-in-major-depressive-disorder/2025-12-03T21:31:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-of-high-risk-patients-with-polycythemia-vera-after-suboptimal-response-to-first-line-therapy-who-switched-to-ruxolitinib-versus-nonswitchers-results-from-the-pv-switch-study/2025-12-03T21:38:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-with-asciminib-after-a-prior-tyrosine-kinase-inhibitor-in-patients-with-chronic-phase-chronic-myeloid-leukemia/2025-12-09T16:26:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/indirect-comparison-of-linvoseltamab-versus-teclistamab-for-the-treatment-of-triple-class-exposed-relapsedrefractory-multiple-myeloma/2025-12-09T18:03:34+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/avapritinib-versus-midostaurin-or-cladribine-in-advanced-systemic-mastocytosis-a-retrospective-real-world-external-control-study/2025-12-09T18:12:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-prevalence-and-outcomes-of-patients-with-paroxysmal-nocturnal-hemoglobinuria-treated-with-c5-inhibitors-in-the-us-a-retrospective-claims-database-analysis/2025-12-09T18:36:36+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prevalence-treatment-patterns-burden-and-factors-related-to-treatment-failure-with-sodium-glucose-cotransporter-2-inhibitor-in-adults-with-type-2-diabetes-in-the-united-states/2025-12-09T18:51:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/psychometric-evaluation-of-novel-hyperphagia-questionnaires-in-a-real-world-setting-for-patients-with-a-rare-mc4r-pathway-disease/2026-03-03T14:14:05+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/sustainability-in-the-new-eumr-guidelines-time-for-an-efficient-look-at-efficiencies/2025-12-11T16:40:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/health-care-resource-utilization-and-costs-associated-with-switching-versus-augmenting-antidepressant-monotherapy-in-second-line-treatment-of-major-depressive-disorder/2025-12-11T19:10:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-and-treatment-patterns-among-patients-with-mantle-cell-lymphoma-in-the-united-states-a-retrospective-study-of-administrative-claims-data/2025-12-11T19:16:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-resource-utilization-and-costs-among-patients-with-metastatic-castration-sensitive-prostate-cancer-initiated-on-apalutamide-or-enzalutamide-in-the-united-states-2019-2023/2025-12-11T19:23:15+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/assessment-of-real-world-disease-severity-in-patients-with-eosinophilic-esophagitis-in-the-united-states/2025-12-11T19:49:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/barriers-to-ai-inputs-implications-for-competition-and-innovation/2025-12-15T16:52:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/new-pagereal-world-treatment-patterns-and-management-gaps-of-lumbar-disc-herniation-in-the-united-states/2025-12-16T02:48:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/temporal-trends-in-vaccination-and-antibiotic-use-among-young-children-in-the-united-states-2000-2019/2025-12-16T02:58:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-burden-of-propionic-acidemia-in-the-united-states-a-claims-based-study-by-age-stratum/2025-12-16T03:06:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-effectiveness-analysis-of-pembrolizumab-as-an-adjuvant-treatment-of-early-stage-non-small-cell-lung-cancer-following-complete-resection-and-platinum-based-chemotherapy-in-canada/2025-12-16T03:12:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/predicting-trajectories-of-the-north-star-ambulatory-assessment-total-score-in-duchenne-muscular-dystrophy/2025-12-16T03:21:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/high-disease-burden-and-oral-corticosteroid-use-in-patients-with-hypereosinophilic-syndrome-and-eosinophilic-granulomatosis-with-polyangiitis-country-level-insights-into-real-world-management-in-europe/2025-12-16T03:28:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-humanistic-burden-of-focal-segmental-glomerulosclerosis-on-patients-and-care-partners-in-the-united-states/2025-12-16T03:39:56+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/renin-angiotensin-aldosterone-system-inhibitor-dosing-after-initiation-of-outpatient-sodium-zirconium-cyclosilicate-therapy-the-galvanize-raasi-real-world-evidence-study/2026-03-03T14:14:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-events-and-healthcare-resource-utilization-associated-with-neutropenia-and-leukopenia-among-adult-kidney-transplant-recipients-receiving-valganciclovir/2025-12-16T04:06:21+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-per-responder-for-teclistamab-and-elranatamab-in-relapsed-or-refractory-multiple-myeloma-in-the-united-states/2025-12-16T04:22:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-experiences-using-atezolizumab-bevacizumab-for-the-treatment-of-unresectable-hepatocellular-carcinoma-a-multicenter-study/2025-12-16T04:30:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-propionic-acidemia-in-the-united-states-a-claims-based-study/2025-12-16T04:37:39+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/comparison-of-real-world-outcomes-between-patients-with-brca12-positive-and-homologous-recombination-repair-negative-metastatic-castration-sensitive-prostate-cancer/2025-12-16T04:44:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/steroid-sparing-benefits-of-biologic-use-in-hypereosinophilic-syndrome-and-substantial-disease-burden-across-subtypes/2025-12-16T04:51:03+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-patients-with-chronic-idiopathic-constipation-in-the-usa-before-and-after-prucalopride-initiation/2025-12-16T05:05:50+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/prurigo-nodularis-patient-reported-burden-of-sickness-pn-trek-a-cross-sectional-survey-of-patient-reported-burden-of-disease-in-patients-with-pn-from-the-us/2025-12-16T14:48:37+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/overall-survival-with-apalutamide-versus-enzalutamide-in-metastatic-castration-sensitive-prostate-cancer/2025-12-16T14:54:14+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/global-assessment-of-health-utilities-associated-with-pneumococcal-disease-in-children-targeted-literature-reviews/2025-12-16T15:00:08+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/cost-per-remitter-for-esketamine-nasal-spray-versus-quetiapine-for-treatment-resistant-depression/2025-12-16T15:12:28+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/a-matching-adjusted-indirect-comparison-maic-of-centanafadine-versus-methylphenidate-hydrochloride-in-adults-with-attention-deficithyperactivity-disorder-adhd-short-term-safety-and-efficacy-outcomes-comparaison-indirecte-ajustee-par-appariement-ma/2025-12-17T15:28:13+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-interplay-of-consumer-privacy-competition-and-regulation/2026-01-02T17:46:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-of-patients-with-basal-cell-carcinoma-using-sonidegib-and-vismodegib-discontinuation-rates-and-clinical-conditions-during-treatment/2025-12-28T19:46:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/body-weight-distribution-of-us-patients-with-myasthenia-gravis/2025-12-28T19:53:49+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-clinical-outcomes-and-biopsy-patterns-of-older-patients-with-unresected-non-small-cell-lung-cancer-treated-with-primary-stereotactic-body-radiotherapy/2025-12-28T20:03:45+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/treatment-patterns-disease-recurrence-and-overall-survival-in-patients-with-muscle-invasive-bladder-cancer-after-radical-cystectomy-a-population-level-claims-based-analysis/2025-12-28T20:29:01+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-outcomes-in-patients-with-cll-treated-with-btki-at-a-large-us-cancer-center/2025-12-28T20:35:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-overall-survival-comparison-between-first-line-bruton-tyrosine-kinase-inhibitors-in-treating-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-an-analysis-of-veterans-health-administration-data/2025-12-28T20:49:30+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-burden-of-primary-biliary-cholangitis-by-line-of-therapy-in-the-united-states/2025-12-28T20:55:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/on-label-treatment-persistence-through-24-months-among-patients-with-active-psoriatic-arthritis-initiating-guselkumab-or-subcutaneous-tumor-necrosis-factor-inhibitors/2025-12-28T22:31:52+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/economic-impact-of-using-cariprazine-as-the-first-versus-subsequent-adjunctive-therapy-for-medicaid-beneficiaries-with-major-depressive-disorder/2025-12-28T22:38:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-in-patients-with-chronic-rhinosinusitis-with-nasal-polyps-who-initiated-dupilumab-a-us-claims-analysis/2026-01-06T19:56:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-comparison-of-on-label-treatment-persistence-through-24-months-between-patients-with-psoriatic-arthritis-initiating-guselkumab-or-subcutaneous-interleukin-17a-inhibitors/2026-01-06T20:15:06+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-clinical-outcomes-of-patients-with-treatment-naive-and-relapsedrefractory-diffuse-large-b-cell-lymphoma-in-the-united-states/2026-01-07T15:05:16+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/the-clinical-burden-of-hypereosinophilic-syndrome-in-a-large-united-states-cohort/2026-01-07T15:09:12+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-health-care-resource-utilization-and-costs-among-patients-with-activated-phosphoinositide-3-kinase-delta-pi3k-syndrome-in-the-united-states/2026-01-07T15:14:19+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/retrospective-analysis-of-racial-differences-in-treatment-patterns-and-prostate-specific-antigen-responses-among-patients-with-prostate-cancer-treated-with-relugolix-in-the-veterans-health-administration/2026-01-07T15:22:42+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/evaluation-of-event-free-survival-as-a-surrogate-endpoint-for-overall-survival-in-muscle-invasive-bladder-cancer-following-neoadjuvant-treatment-a-systematic-review-and-meta-analysis/2026-01-26T17:01:44+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/impact-of-increased-patient-out-of-pocket-costs-on-oral-anticoagulant-discontinuation-among-medicare-beneficiaries-with-atrial-fibrillation-treated-with-apixaban/2026-01-16T16:10:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/exacerbation-reduction-in-patients-with-asthma-following-escalation-to-ffumecvi-from-icslaba-retrospective-cohort-study/2026-01-07T16:06:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/sodium-zirconium-cyclosilicate-duration-and-hyperkalemia-related-healthcare-encounters-in-patients-with-heart-failure-and-cardiorenal-dysfunction-the-galvanize-outcome-study/2026-03-03T14:12:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-health-care-resource-utilization-and-costs-among-patients-with-activated-phosphoinositide-3-kinase-delta-pi3k-syndrome-in-the-united-states2/2026-01-07T16:21:26+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/change-in-urine-albumin-to-creatinine-ratio-and-clinical-outcomes-in-patients-with-chronic-kidney-disease-and-type-2-diabetes/2026-01-07T16:28:46+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/efficacy-of-intravitreal-pegcetacoplan-vs-avacincaptad-pegol-in-patients-with-geographic-atrophy/2026-01-07T16:40:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/burden-of-illness-and-unmet-needs-in-patients-with-erythropoietic-protoporphyria-and-x-linked-protoporphyria-a-large-us-nationwide-claims-analysis/2026-01-07T16:47:53+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/healthcare-cost-comparison-between-first-line-ibrutinib-and-acalabrutinib-in-chronic-lymphocytic-leukemia-patients-in-the-veterans-affairs/2026-01-07T16:54:48+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/clinical-and-economic-impact-of-recurrence-in-unresected-non-small-cell-lung-cancer-treated-with-primary-stereotactic-body-radiotherapy-a-real-world-study-using-seer-medicare-data/2026-01-07T17:59:57+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/real-world-treatment-patterns-and-clinical-outcomes-among-elderly-patients-with-locoregionally-advanced-head-and-neck-squamous-cell-carcinoma-in-the-united-states/2026-01-07T18:12:31+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/risk-of-progression-and-costs-of-care-for-patients-with-type-2-diabetes-and-chronic-kidney-disease/2026-01-07T18:45:41+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/acquihires-in-the-technology-sector-antitrust-scrutiny-through-the-lens-of-economics/2026-01-20T17:48:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/event-free-survival-and-complete-response-rate-as-surrogate-endpoints-for-overall-survival-in-high-risk-non-muscle-invasive-bladder-cancer-a-meta-analysis-of-bacillus-calmette-guerinnaive-or-remote-cases/2026-01-26T16:47:04+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/will-the-new-eumr-guidelines-be-a-significant-impediment-to-sustainability/2026-01-27T17:21:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/sustainability-considerations-in-eu-merger-control/2026-01-27T17:24:22+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/attack-rate-reductions-following-berotralstat-initiation-among-us-patients-with-hereditary-angioedema-in-the-real-world/2026-03-30T19:23:10+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/emerging-economic-trends-humira-and-adalimumab-biosimilars-competition/2026-02-05T17:05:58+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/target-date-funds-an-analysis-of-strategies-and-performance/2026-03-10T21:23:29+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/aba-antitrust-webinar-recap-the-next-big-thing/2026-02-18T15:40:38+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/sub-annual-capacity-market-construct-for-pjm/2026-02-26T18:50:40+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/instruments-de-defense-commerciale-de-lue-pourquoi-les-entreprises-doivent-sen-emparer/2026-03-31T15:22:35+00:00weekly0.7https://www.analysisgroup.com/Insights/publishing/fdas-biosimilarity-guidance-holds-uncertain-implications/2026-04-03T14:16:36+00:00weekly0.7https://www.analysisgroup.com/people/chinese/eric-wu/2024-01-11T10:36:28+00:00weekly0.7https://www.analysisgroup.com/people/chinese/gordon-liu/2026-03-20T13:49:54+00:00weekly0.7https://www.analysisgroup.com/people/chinese/jun-liu/2024-01-11T10:36:28+00:00weekly0.7https://www.analysisgroup.com/people/french/jimmy-royer/2025-02-10T15:37:44+00:00weekly0.7https://www.analysisgroup.com/people/french/lisa-b--pinheiro/2025-08-22T16:26:48+00:00weekly0.7https://www.analysisgroup.com/people/french/patrick-lefebvre/2025-01-07T15:43:38+00:00weekly0.7https://www.analysisgroup.com/people/french/marc-van-audenrode/2024-01-11T10:36:29+00:00weekly0.7https://www.analysisgroup.com/people/french/paul-e--greenberg/2025-02-10T15:45:52+00:00weekly0.7https://www.analysisgroup.com/people/french/pierre-y--cremieux/2025-06-02T19:49:53+00:00weekly0.7https://www.analysisgroup.com/people/french/marissa-ginn/2024-01-11T10:36:29+00:00weekly0.7https://www.analysisgroup.com/people/french/eric-qiong-wu/2024-01-11T10:36:29+00:00weekly0.7https://www.analysisgroup.com/people/french/richard-m--starfield/2024-01-11T10:36:30+00:00weekly0.7https://www.analysisgroup.com/people/french/emmanuel-frot/2024-06-11T17:44:34+00:00weekly0.7https://www.analysisgroup.com/people/french/eric-qiong-wu---paris/2024-01-11T10:36:30+00:00weekly0.7https://www.analysisgroup.com/people/french/jimmy-royer---brussels/2025-02-10T15:38:59+00:00weekly0.7https://www.analysisgroup.com/people/french/lisa-b--pinheiro---brussels/2025-08-22T16:27:29+00:00weekly0.7https://www.analysisgroup.com/people/french/marc-van-audenrode---paris/2024-01-11T10:36:30+00:00weekly0.7https://www.analysisgroup.com/people/french/pierre-y--cremieux---brussels/2025-06-02T19:52:52+00:00weekly0.7https://www.analysisgroup.com/people/french/richard-m--starfield---paris/2024-01-11T10:36:30+00:00weekly0.7https://www.analysisgroup.com/people/french/laura-o-laughlin/2025-02-10T15:43:28+00:00weekly0.7https://www.analysisgroup.com/people/french/annie-guerin/2024-01-11T10:40:31+00:00weekly0.7https://www.analysisgroup.com/people/french/anne-catherine-faye/2024-01-11T10:40:56+00:00weekly0.7https://www.analysisgroup.com/people/french/martin-cloutier/2024-01-11T10:40:56+00:00weekly0.7https://www.analysisgroup.com/people/french/juliette-caminade/2026-01-27T16:48:39+00:00weekly0.7https://www.analysisgroup.com/people/french/dominic-pilon/2024-01-11T10:41:38+00:00weekly0.7https://www.analysisgroup.com/people/french/ajay-jyoti/2024-01-11T10:42:19+00:00weekly0.7https://www.analysisgroup.com/people/french/marjolaine-gauthier-loiselle/2024-01-11T10:42:26+00:00weekly0.7https://www.analysisgroup.com/people/french/nick-dadson/2024-01-11T10:42:28+00:00weekly0.7https://www.analysisgroup.com/people/french/pierre-lissot/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/people/french/bruno-emond/2024-01-11T10:42:49+00:00weekly0.7https://www.analysisgroup.com/people/french/alix-duhaime-ross/2024-01-11T10:43:39+00:00weekly0.7https://www.analysisgroup.com/people/french/michal-k-popiel/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/people/french/dominick-latremouille-viau/2024-01-11T10:43:44+00:00weekly0.7https://www.analysisgroup.com/people/french/david-j-hutchings/2025-02-10T15:42:44+00:00weekly0.7https://www.analysisgroup.com/people/french/ludmila-rovba/2024-01-11T10:36:14+00:00weekly0.7https://www.analysisgroup.com/people/french/irina-pivneva/2024-01-19T19:46:01+00:00weekly0.7https://www.analysisgroup.com/people/french/philipp-tillmann/2024-06-24T13:15:12+00:00weekly0.7https://www.analysisgroup.com/people/french/catherine-gendron-saulnier/2024-03-18T19:32:08+00:00weekly0.7https://www.analysisgroup.com/people/french/patrick-s-gagnon/2024-07-23T14:17:44+00:00weekly0.7https://www.analysisgroup.com/people/french/cyril-hariton/2025-10-28T19:54:26+00:00weekly0.7https://www.analysisgroup.com/people/french/pierre-regibeau/2025-10-22T13:36:22+00:00weekly0.5https://www.analysisgroup.com/people/french/rene-ricol/2026-02-05T01:25:38+00:00weekly0.7https://www.analysisgroup.com/people/french/jean-charles-de-lasteyrie/2026-02-05T01:26:08+00:00weekly0.7https://www.analysisgroup.com/people/french/gilles-de-courcel/2026-02-05T01:26:22+00:00weekly0.7https://www.analysisgroup.com/people/french/pierre-deheunynck/2026-02-05T01:26:49+00:00weekly0.7https://www.analysisgroup.com/people/french/melanie-segard/2026-02-05T01:27:12+00:00weekly0.7https://www.analysisgroup.com/people/french/nadine-raffoul/2026-02-05T01:27:30+00:00weekly0.7https://www.analysisgroup.com/people/french/philippe-steing/2026-02-05T01:27:49+00:00weekly0.7https://www.analysisgroup.com/people/french/gilles-vantelon/2026-02-05T01:28:06+00:00weekly0.7https://www.analysisgroup.com/people/french/armelle-deydier/2026-02-05T01:28:25+00:00weekly0.7https://www.analysisgroup.com/people/french/marie-glomet/2026-02-05T01:28:48+00:00weekly0.7https://www.analysisgroup.com/people/french/cedric-vignolles/2026-02-05T01:29:06+00:00weekly0.7https://www.analysisgroup.com/people/managers/christine-bieri/2024-01-11T10:36:31+00:00weekly0.7https://www.analysisgroup.com/people/managers/thomas-zimmerfaust/2024-01-11T10:36:36+00:00weekly0.7https://www.analysisgroup.com/people/managers/rebecca-burne/2025-10-07T17:19:15+00:00weekly0.7https://www.analysisgroup.com/people/managers/erin-cook/2026-02-25T19:37:53+00:00weekly0.7https://www.analysisgroup.com/people/managers/jessica-lu/2024-01-11T10:41:31+00:00weekly0.7https://www.analysisgroup.com/people/managers/david-proudman/2025-06-16T19:00:44+00:00weekly0.7https://www.analysisgroup.com/people/managers/christine-tewfik/2025-06-26T19:15:07+00:00weekly0.7https://www.analysisgroup.com/people/managers/jutong-pan/2024-01-11T10:42:31+00:00weekly0.7https://www.analysisgroup.com/people/managers/max-leroux/2026-03-09T18:57:50+00:00weekly0.7https://www.analysisgroup.com/people/managers/solvejg-wewel/2025-01-14T16:49:29+00:00weekly0.7https://www.analysisgroup.com/people/managers/lola-segura-varo/2024-12-18T19:21:29+00:00weekly0.7https://www.analysisgroup.com/people/managers/diego-a.-focanti2024-07-01T14:54:33+00:00weekly0.7https://www.analysisgroup.com/people/managers/gao-meng/2025-02-07T16:31:05+00:00weekly0.7https://www.analysisgroup.com/people/managers/qing-liu/2025-12-16T02:57:59+00:00weekly0.7https://www.analysisgroup.com/people/managers/mario-luca/2025-06-30T18:09:22+00:00weekly0.7https://www.analysisgroup.com/people/managers/nicolae-done/2025-12-16T03:21:44+00:00weekly0.7https://www.analysisgroup.com/people/managers/jessica-burley/2024-10-10T21:10:27+00:00weekly0.7https://www.analysisgroup.com/people/managers/erik-martino/2024-11-07T15:29:53+00:00weekly0.7https://www.analysisgroup.com/people/managers/robert-j.-bobby-calzaretta2024-01-11T10:42:34+00:00weekly0.7https://www.analysisgroup.com/people/managers/lucien-frys/2024-12-18T19:30:05+00:00weekly0.7https://www.analysisgroup.com/people/managers/aolin-wang/2026-01-07T15:38:21+00:00weekly0.7https://www.analysisgroup.com/people/managers/nisha-hazra/2025-12-16T03:39:56+00:00weekly0.7https://www.analysisgroup.com/people/managers/jason-doran/2026-04-03T13:54:21+00:00weekly0.7https://www.analysisgroup.com/people/managers/xiaoyu-nie/2025-11-25T15:36:48+00:00weekly0.7https://www.analysisgroup.com/people/managers/roy-roth/2024-01-11T10:42:41+00:00weekly0.7https://www.analysisgroup.com/people/managers/hela-romdhani/2026-01-07T16:47:50+00:00weekly0.7https://www.analysisgroup.com/people/managers/su-zhang/2026-01-07T18:06:35+00:00weekly0.7https://www.analysisgroup.com/people/managers/kai-jye-lou/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/people/managers/lamiya-sheikh/2024-01-11T10:42:42+00:00weekly0.7https://www.analysisgroup.com/people/managers/thomas-polley/2024-01-11T10:42:46+00:00weekly0.7https://www.analysisgroup.com/people/managers/juan-carvajal/2026-03-25T14:22:37+00:00weekly0.7https://www.analysisgroup.com/people/managers/carmine-rossi/2026-02-25T16:25:15+00:00weekly0.7https://www.analysisgroup.com/people/managers/samuel-spare/2025-08-21T19:59:28+00:00weekly0.7https://www.analysisgroup.com/people/managers/nathan-shekita/2024-01-11T10:43:42+00:00weekly0.7https://www.analysisgroup.com/people/managers/sean-mccoy/2025-09-04T20:28:53+00:00weekly0.7https://www.analysisgroup.com/people/managers/phillip-h-ross/2026-02-26T18:53:11+00:00weekly0.7https://www.analysisgroup.com/people/managers/christopher-m-lako/2026-01-07T19:24:54+00:00weekly0.7https://www.analysisgroup.com/people/managers/chelsey-yang/2025-12-03T18:31:52+00:00weekly0.7https://www.analysisgroup.com/people/managers/jenny-shen/2025-08-08T13:29:39+00:00weekly0.7https://www.analysisgroup.com/people/managers/hunter-lent/2026-01-23T23:06:27+00:00weekly0.7https://www.analysisgroup.com/people/managers/michael-bender/2025-03-26T14:41:40+00:00weekly0.7https://www.analysisgroup.com/people/managers/cecilia-caliandro/2026-02-09T15:29:50+00:00weekly0.7https://www.analysisgroup.com/people/managers/yi-zhong/2025-12-01T19:55:03+00:00weekly0.7https://www.analysisgroup.com/people/managers/todor-totev/2025-12-16T04:30:38+00:00weekly0.7https://www.analysisgroup.com/people/managers/thomas-cornwall/2025-10-07T17:19:16+00:00weekly0.7https://www.analysisgroup.com/people/managers/arjun-dasgupta/2025-01-08T15:57:51+00:00weekly0.7https://www.analysisgroup.com/people/managers/elizabeth-serra/2025-07-02T15:46:56+00:00weekly0.7https://www.analysisgroup.com/people/managers/timothy-j-spittle/2026-01-15T19:22:07+00:00weekly0.7https://www.analysisgroup.com/people/managers/sean-macknight/2026-02-04T16:16:06+00:00weekly0.7https://www.analysisgroup.com/people/managers/iain-snoddy/2024-01-11T10:43:13+00:00weekly0.7https://www.analysisgroup.com/people/managers/jonathan-freimark/2025-06-17T14:29:49+00:00weekly0.7https://www.analysisgroup.com/people/managers/maria-mercedes-marimer-guevara/2026-03-24T15:36:27+00:00weekly0.7https://www.analysisgroup.com/people/managers/anastasia-bogdanova/2024-09-20T14:24:49+00:00weekly0.7https://www.analysisgroup.com/people/managers/cheryl-xiang/2025-12-16T04:06:20+00:00weekly0.7https://www.analysisgroup.com/people/managers/shannon-e.-ward2023-12-22T19:24:44+00:00weekly0.7https://www.analysisgroup.com/people/managers/matt-infante/2025-02-05T14:00:00+00:00weekly0.7https://www.analysisgroup.com/people/managers/schuyler-m.-livingston2024-03-01T14:52:14+00:00weekly0.7https://www.analysisgroup.com/people/managers/jacquelyn-gillette/2024-01-19T18:36:48+00:00weekly0.7https://www.analysisgroup.com/people/managers/taiji-wang/2025-03-18T19:03:05+00:00weekly0.7https://www.analysisgroup.com/people/managers/wei-song/2025-10-07T17:19:28+00:00weekly0.7https://www.analysisgroup.com/people/managers/aozhou-wu/2026-01-26T16:50:40+00:00weekly0.7https://www.analysisgroup.com/people/managers/jeffrey-denault/2024-03-05T18:28:40+00:00weekly0.7https://www.analysisgroup.com/people/managers/catherine-nguyen/2025-10-27T14:07:02+00:00weekly0.7https://www.analysisgroup.com/people/managers/bill-quirk/2024-03-04T17:01:40+00:00weekly0.7https://www.analysisgroup.com/people/managers/anthony-nasr/2025-09-04T17:26:06+00:00weekly0.7https://www.analysisgroup.com/people/managers/yanwen-xie/2025-05-07T18:45:14+00:00weekly0.7https://www.analysisgroup.com/people/managers/hailey-nguyen/2025-05-02T19:18:08+00:00weekly0.7https://www.analysisgroup.com/people/managers/alexander-graupner/2024-03-12T16:47:21+00:00weekly0.7https://www.analysisgroup.com/people/managers/jessica-maitland/2025-12-03T18:31:42+00:00weekly0.7https://www.analysisgroup.com/people/managers/yan-chen/2026-01-07T16:28:45+00:00weekly0.7https://www.analysisgroup.com/people/managers/olivia-althans/2026-03-25T14:22:42+00:00weekly0.7https://www.analysisgroup.com/people/managers/laura-morrison/2025-11-18T17:45:27+00:00weekly0.7https://www.analysisgroup.com/people/managers/molly-frean/2025-07-16T19:31:36+00:00weekly0.7https://www.analysisgroup.com/people/managers/kailash-neelakantan/2025-06-02T18:31:01+00:00weekly0.7https://www.analysisgroup.com/people/managers/daniel-stuart/2026-01-15T20:51:59+00:00weekly0.7https://www.analysisgroup.com/people/managers/kritika-narula/2025-12-17T15:14:14+00:00weekly0.7https://www.analysisgroup.com/people/managers/krisztina-horvath/2026-02-26T17:29:56+00:00weekly0.7https://www.analysisgroup.com/people/managers/lu-jinks/2024-09-30T13:19:25+00:00weekly0.7https://www.analysisgroup.com/people/managers/yao-wang/2025-12-01T20:06:30+00:00weekly0.7https://www.analysisgroup.com/people/managers/rebecca-regan/2025-06-02T18:31:02+00:00weekly0.7https://www.analysisgroup.com/people/managers/kirsten-clinton/2025-06-04T14:52:11+00:00weekly0.7https://www.analysisgroup.com/people/managers/conlan-orino/2024-05-23T19:08:38+00:00weekly0.7https://www.analysisgroup.com/people/managers/yiqiao-xin/2025-06-13T19:22:53+00:00weekly0.7https://www.analysisgroup.com/people/managers/mirko-fillbrunn/2026-02-23T15:08:48+00:00weekly0.7https://www.analysisgroup.com/people/managers/ivan-kirov/2026-03-24T15:36:28+00:00weekly0.7https://www.analysisgroup.com/people/managers/zsolt-udvari/2026-02-09T15:29:51+00:00weekly0.7https://www.analysisgroup.com/people/managers/deepshekhar-gupta/2025-12-28T19:46:33+00:00weekly0.7https://www.analysisgroup.com/people/managers/david-tsui/2025-08-28T18:03:07+00:00weekly0.7https://www.analysisgroup.com/people/managers/mandy-du/2026-02-10T16:10:49+00:00weekly0.7https://www.analysisgroup.com/people/managers/stephanie-cheng/2026-03-13T10:49:45+00:00weekly0.7https://www.analysisgroup.com/people/managers/justin-latorraca/2025-11-25T20:10:05+00:00weekly0.7https://www.analysisgroup.com/people/managers/daniel-dougherty/2025-01-29T19:21:14+00:00weekly0.7https://www.analysisgroup.com/people/managers/maksym-khomenko/2026-02-03T21:40:29+00:00weekly0.7https://www.analysisgroup.com/people/managers/nicolas-benelli/2025-02-06T16:00:50+00:00weekly0.7https://www.analysisgroup.com/people/managers/angela-lax/2026-01-07T16:54:46+00:00weekly0.7https://www.analysisgroup.com/people/managers/yunus-cem-yilmaz/2025-02-13T15:31:32+00:00weekly0.7https://www.analysisgroup.com/people/managers/viraj-jorapur/2025-02-13T18:25:44+00:00weekly0.7https://www.analysisgroup.com/people/managers/trevor-marrero/2025-08-01T14:56:56+00:00weekly0.7https://www.analysisgroup.com/people/managers/jarone-gittens/2026-01-23T23:06:26+00:00weekly0.7https://www.analysisgroup.com/people/managers/soojin-kim/2025-09-02T15:08:58+00:00weekly0.7https://www.analysisgroup.com/people/managers/elena-nota/2025-02-28T15:01:10+00:00weekly0.7https://www.analysisgroup.com/people/managers/clayton-mersmann/2025-03-03T18:41:44+00:00weekly0.7https://www.analysisgroup.com/people/managers/samantha-kaufhold/2025-10-28T14:13:49+00:00weekly0.7https://www.analysisgroup.com/people/managers/alex-iselin/2025-03-04T16:29:40+00:00weekly0.7https://www.analysisgroup.com/people/managers/samantha-murphy/2026-02-27T18:20:30+00:00weekly0.7https://www.analysisgroup.com/people/managers/harrison-holtz/2025-03-26T14:40:32+00:00weekly0.7https://www.analysisgroup.com/people/managers/kate-uthe/2025-03-26T15:00:46+00:00weekly0.7https://www.analysisgroup.com/people/managers/lohit-korrapati/2025-10-28T14:09:58+00:00weekly0.7https://www.analysisgroup.com/people/managers/calvin-amin/2025-04-03T19:23:41+00:00weekly0.7https://www.analysisgroup.com/people/managers/shimin-bi/2025-04-08T17:25:35+00:00weekly0.7https://www.analysisgroup.com/people/managers/brandon-norton/2025-04-08T17:43:05+00:00weekly0.7https://www.analysisgroup.com/people/managers/jean-louis-barnwell/2025-04-08T20:05:11+00:00weekly0.7https://www.analysisgroup.com/people/managers/diego-vega-san-martin/2025-05-07T13:38:16+00:00weekly0.7https://www.analysisgroup.com/people/managers/hugues-dastarac/2025-06-25T17:51:52+00:00weekly0.7https://www.analysisgroup.com/people/managers/mu-cheng/2025-12-16T04:37:39+00:00weekly0.7https://www.analysisgroup.com/people/managers/aditya-mohan/2025-08-14T14:25:44+00:00weekly0.5https://www.analysisgroup.com/people/managers/dheeraj-chaudhary/2025-09-22T20:40:48+00:00weekly0.5https://www.analysisgroup.com/people/managers/muath-ibaid/2026-01-15T20:47:51+00:00weekly0.5https://www.analysisgroup.com/people/managers/ruozhou-yan/2025-10-06T13:09:30+00:00weekly0.7https://www.analysisgroup.com/people/managers/andres-gomez-lievano/2025-11-11T18:49:08+00:00weekly0.5https://www.analysisgroup.com/people/managers/neal-tan/2026-01-07T19:24:52+00:00weekly0.5https://www.analysisgroup.com/people/managers/jacob-judd/2026-02-05T20:39:13+00:00weekly0.5https://www.analysisgroup.com/people/managers/roksana-ghanbariamin/2026-02-06T14:07:05+00:00weekly0.5https://www.analysisgroup.com/people/managers/zhen-chris-chen/2026-02-06T14:16:47+00:00weekly0.7https://www.analysisgroup.com/people/managers/jacob-klimek/2026-02-09T15:08:34+00:00weekly0.7https://www.analysisgroup.com/people/managers/lillian-gao/2026-02-10T19:09:22+00:00weekly0.5https://www.analysisgroup.com/people/managers/kristina-komissarova/2026-02-10T19:31:56+00:00weekly0.7https://www.analysisgroup.com/people/managers/yan-meng/2026-02-25T16:25:16+00:00weekly0.5https://www.analysisgroup.com/people/managers/stephanie-leary/2026-02-18T15:57:59+00:00weekly0.5https://www.analysisgroup.com/people/managers/rebecca-bungay/2026-02-25T16:25:14+00:00weekly0.5https://www.analysisgroup.com/people/managers/erin-denison/2026-02-19T19:14:37+00:00weekly0.7https://www.analysisgroup.com/people/managers/porpong-paul-boonmak/2026-02-23T16:41:55+00:00weekly0.5https://www.analysisgroup.com/people/managers/nicholas-mulford/2026-02-19T21:02:00+00:00weekly0.5https://www.analysisgroup.com/people/managers/ashish-aggarwal/2026-02-19T21:06:25+00:00weekly0.7https://www.analysisgroup.com/people/managers/eric-he/2026-02-20T14:32:47+00:00weekly0.7https://www.analysisgroup.com/people/managers/john-dooley/2026-02-23T21:59:12+00:00weekly0.5https://www.analysisgroup.com/people/managers/joe-briesemeister/2026-02-25T15:50:39+00:00weekly0.7https://www.analysisgroup.com/people/managers/ali-greatsinger/2026-03-03T14:25:51+00:00weekly0.5https://www.analysisgroup.com/people/managers/grace-howland/2026-03-05T14:56:11+00:00weekly0.5https://www.analysisgroup.com/people/managers/sienna-kim/2026-03-10T18:56:33+00:00weekly0.5https://www.analysisgroup.com/people/managers/rolando-campusano/2026-03-25T14:58:19+00:00weekly0.5https://www.analysisgroup.com/people/managers/harriet-ho/2026-03-13T18:36:55+00:00weekly0.5https://www.analysisgroup.com/people/managers/samuel-wascher/2026-03-19T19:02:46+00:00weekly0.5https://www.analysisgroup.com/people/managers/ramya-ramasubramanian/2026-03-30T19:31:35+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/antoine-chapsal/2026-02-03T21:46:35+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/elyse-swallow/2025-12-03T18:31:49+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/min-yang/2026-01-06T19:56:41+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/maral-dersarkissian/2026-02-25T16:25:07+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/patrick-lefebvre/2026-01-06T20:15:03+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/michael-holland/2024-01-11T10:36:37+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/aaron-yeater/2026-03-25T17:46:23+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/lisa-b--pinheiro/2026-01-14T18:53:23+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/crystal-pike/2024-01-11T10:36:37+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/dov-rothman/2025-11-07T17:35:58+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/james-signorovitch/2026-02-25T16:50:55+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/pierre-y--cremieux/2026-02-12T16:11:21+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/brian-s--gorin/2025-04-01T19:48:03+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/jeffrey-h--kinrich/2026-03-05T15:58:57+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/john-c--jarosz/2026-04-03T13:54:22+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/marc-van-audenrode/2024-01-11T10:36:39+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/paul-e--greenberg/2025-02-10T15:44:56+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/rebecca-kirk-fair/2026-04-01T20:52:52+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/alan-g--white/2026-03-12T17:30:18+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/t--christopher-borek/2026-01-15T16:40:26+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/edward-tuttle/2025-12-01T19:55:01+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/laurits-r--christensen/2025-03-07T18:58:04+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/d--lee-heavner/2026-02-13T19:41:32+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/mark-h--egland/2025-09-17T14:05:30+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/richard-m--starfield/2026-03-24T15:36:21+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/maureen-m--chakraborty/2026-01-07T19:24:55+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/nicholas-i--crew/2024-01-11T10:36:41+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/mei-sheng-duh/2026-02-25T16:25:09+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/justin-n--mclean/2026-01-23T23:06:28+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/gaurav-jetley/2026-04-02T14:04:13+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/mark-howrey/2025-09-04T17:08:06+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/eric-q--wu/2026-01-07T16:54:47+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/martha-s--samuelson/2025-11-07T17:35:58+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/bruce-e--stangle/2025-11-07T17:35:59+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/adam-decter/2025-02-06T21:21:28+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/andrew-wong/2024-07-03T13:58:19+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/michael-beauregard/2026-02-03T21:46:34+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/coreen-mccool/2024-01-11T10:36:42+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/mark-a-gustafson/2026-03-30T13:52:14+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/michael-cliff/2025-10-17T19:08:48+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/andrea-okie/2025-12-12T15:38:29+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/marissa-ginn/2026-02-03T21:46:39+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/divya-mathur/2026-02-03T21:46:44+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/lauren-r--kindler/2025-05-30T14:47:21+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/kris-comeaux/2025-10-16T14:39:56+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/mihran-yenikomshian/2026-03-24T15:36:22+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/stephen-fink/2025-11-05T19:42:26+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/brad-rice/2026-02-13T20:37:31+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/lauren-hunt/2026-01-27T20:20:57+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/keith-betts/2026-01-07T18:45:40+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/emily-cotton/2025-04-18T13:00:08+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/pavel-darling/2026-02-05T17:06:28+00:00weekly0.5https://www.analysisgroup.com/people/managing-principals/kenneth-weinstein/2024-03-19T18:27:46+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/hongbo-yang/2026-02-25T16:25:17+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/kevin-gallagher/2024-11-20T19:00:28+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/maria-garibotti/2026-02-17T17:25:54+00:00weekly0.5https://www.analysisgroup.com/people/managing-principals/jee-yeon-lehmann/2026-03-25T14:22:41+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/annie-guerin/2025-12-09T18:36:35+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/andree-anne-fournier/2026-02-05T17:06:27+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/noam-kirson/2025-12-16T15:11:55+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/samuel-weglein/2025-09-26T20:33:58+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/ted-davis/2025-11-25T21:40:43+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/sueyoung-min/2024-01-11T10:41:17+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/michael-barrett/2024-01-11T10:42:07+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/david-j-hutchings/2025-02-10T15:42:25+00:00weekly0.7https://www.analysisgroup.com/people/managing-principals/aditi-mehta/2026-04-01T17:15:46+00:00weekly0.5https://www.analysisgroup.com/people/senior-advisors/almudena-arcelus/2025-08-05T20:12:29+00:00weekly0.7https://www.analysisgroup.com/people/senior-advisors/david-w--sosa/2025-08-05T20:13:40+00:00weekly0.5https://www.analysisgroup.com/people/senior-advisors/keith-r--ugone/2025-11-07T17:36:00+00:00weekly0.5https://www.analysisgroup.com/people/senior-advisors/bruce-f-deal/2026-01-30T14:13:42+00:00weekly0.5https://www.analysisgroup.com/people/senior-advisors/r--jeffrey-malinak/2026-01-15T20:36:51+00:00weekly0.7https://www.analysisgroup.com/people/senior-advisors/bruce-a--strombom/2025-08-05T20:14:46+00:00weekly0.7https://www.analysisgroup.com/people/senior-advisors/carla-s-mulhern/2025-08-05T20:15:03+00:00weekly0.7https://www.analysisgroup.com/people/senior-advisors/jeffrey-a--cohen/2025-11-07T17:35:51+00:00weekly0.7https://www.analysisgroup.com/people/senior-advisors/susan-f--tierney/2026-01-15T20:38:17+00:00weekly0.7https://www.analysisgroup.com/people/senior-advisors/tamar-sisitsky/2025-08-05T20:15:45+00:00weekly0.7https://www.analysisgroup.com/people/senior-advisors/james-rosberg/2025-08-05T20:16:01+00:00weekly0.5https://www.analysisgroup.com/people/senior-advisors/richard-a--mortimer/2026-04-03T13:54:23+00:00weekly0.7https://www.analysisgroup.com/people/senior-advisors/daniel-j--slottje/2025-08-05T20:16:58+00:00weekly0.7https://www.analysisgroup.com/people/senior-advisors/tim-giles/2025-11-07T17:35:54+00:00weekly0.7https://www.analysisgroup.com/people/senior-advisors/kenneth-grant/2026-03-26T15:47:10+00:00weekly0.5https://www.analysisgroup.com/people/senior-advisors/pierre-regibeau/2026-03-03T15:31:47+00:00weekly0.5https://www.analysisgroup.com/people/senior-advisors/tim-allen/2026-03-26T15:51:01+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/ludmila-rovba/2025-12-03T15:27:10+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/anne-catherine-faye/2025-03-26T15:52:53+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/rajeev-ayyagari/2025-12-16T05:05:49+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/martin-cloutier/2025-12-17T15:27:35+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/eileen-lu/2026-04-02T14:22:04+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/jenny-zhou/2025-12-16T03:39:55+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/shogo-hamasaki/2026-01-15T16:40:28+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/andrew-clarke/2025-08-05T19:49:04+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/urvi-desai/2025-12-16T15:11:57+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/stephen-kiebzak/2025-08-25T13:44:01+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/lynn-huynh/2025-12-28T20:35:44+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/david-smith/2026-04-02T14:16:46+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/mark-berberian/2025-12-01T18:41:17+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/kristof-zetenyi/2026-03-31T18:22:35+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/nathan-trujillo/2026-03-30T13:52:30+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/david-toniatti/2026-03-25T17:46:25+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/yan-song/2026-01-26T16:50:39+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/jinlin-song/2025-11-18T18:09:17+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/dominic-pilon/2026-02-25T16:25:13+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/elizabeth-milsark/2026-03-24T15:36:25+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/anna-gumen/2024-02-06T17:56:02+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/tracy-danner/2024-01-11T10:36:35+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/nick-dadson/2026-03-25T14:54:37+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/megan-accordino/2026-01-28T18:00:29+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/federico-mantovanelli/2026-03-25T14:22:44+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/yao-lu/2026-01-21T20:15:58+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/fan-mu/2026-01-07T16:54:48+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/catherine-alford/2024-12-10T18:34:39+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/andrew-j--ungerer/2025-03-07T18:58:04+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/michael-schreck/2024-01-11T10:36:35+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/marjolaine-gauthier-loiselle/2025-12-17T15:27:34+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/joshua-levine/2024-01-11T10:36:36+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/lucia-tiererova/2024-01-11T10:36:36+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/gautam-sajeev/2025-12-16T03:21:44+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/john-m--browning/2026-03-31T18:22:30+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/peter-hess/2025-05-28T17:59:30+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/mike-nguyen/2024-01-11T10:37:11+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/peter-p--simon/2025-07-24T15:31:19+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/ajay-jyoti/2024-02-27T14:35:20+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/steven-s--saeger/2025-05-12T20:25:49+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/andrew-stichman/2025-12-03T15:27:11+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/shannon-n--seitz/2026-03-24T15:36:26+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/peter-finch/2025-08-19T14:11:21+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/ahmer-nabi/2026-02-13T19:41:32+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/lindsay-greenbaum/2026-03-24T15:36:24+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/jonathan-borck/2026-01-04T22:37:24+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/federico-temerlin/2025-02-10T17:25:41+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/markus-von-wartburg/2025-05-20T17:37:10+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/john-drum/2026-04-02T14:04:14+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/carletta-wong/2026-03-24T15:36:27+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/sumon-mazumdar/2024-11-25T17:29:54+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/joshua-white/2026-02-09T15:29:49+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/dominick-latremouille-viau/2026-01-07T15:38:20+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/thomas-mcgahee/2025-11-04T22:00:32+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/christopher-llop/2025-11-25T21:17:52+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/nori-mehta/2025-10-08T16:53:22+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/ben-samuels/2025-05-28T17:59:31+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/nicholas-van-niel/2026-02-12T18:17:14+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/alix-duhaime-ross/2025-12-03T15:27:10+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/rebecca-scott/2025-04-30T13:33:48+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/oscar-patterson-lomba/2025-12-11T19:49:48+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/priyanka-bobbili/2026-02-25T16:25:11+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/debbie-goldschmidt/2025-11-25T14:38:40+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/viviana-garcia-horton/2025-12-09T18:03:32+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/philippe-thompson-leduc/2026-02-19T19:35:26+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/atang-gilika/2025-11-24T14:37:57+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/catherine-gendron-saulnier/2024-11-19T22:04:28+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/wei-gao/2026-01-07T15:22:41+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/irina-pivneva/2026-03-27T15:08:27+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/joseph-cavicchi/2026-02-26T18:53:11+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/christopher-ody/2026-03-25T14:22:38+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/daria-z.-killebrew2024-01-11T10:41:04+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/lucia-antras/2024-01-11T10:41:04+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/veronica-huan/2025-08-25T18:24:08+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/david-a.-glick2025-05-19T15:45:58+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/bruno-emond/2026-02-25T16:25:12+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/jia-zhong/2025-12-03T18:31:55+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/weiguang-xue/2026-02-25T16:25:18+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/ishita-rajani/2026-02-03T21:46:45+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/joseph-maloney/2024-08-08T15:46:05+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/alex-fiore/2025-05-19T15:45:57+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/della-cummings/2024-06-26T17:22:33+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/carlos-chiapa/2026-02-03T21:46:37+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/patrick-s-gagnon/2025-10-07T17:19:19+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/kerri-holmsten/2025-12-12T15:38:29+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/alex-robinson/2025-10-10T14:36:05+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/aaron-kelley/2024-01-11T10:41:21+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/rozi-kepes/2026-03-24T15:36:25+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/phil-hall-partyka/2025-01-27T15:13:50+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/masha-zhdanava/2025-12-03T18:31:54+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/charles-wu/2026-01-15T20:47:50+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/hadrien-vasdeboncoeur/2026-01-07T19:24:54+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/philipp-tillmann/2025-12-18T15:24:58+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/igor-karagodsky/2025-11-05T19:42:25+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/michal-k.-popiel2024-11-11T17:58:53+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/ella-x.-du2025-07-02T20:25:08+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/michaela-johnson/2025-11-11T18:49:06+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/yan-wang/2025-12-09T18:51:01+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/evan-carter/2024-11-13T14:31:21+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/kate-hanford/2026-01-07T16:57:43+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/yuan-tian/2026-03-31T18:22:36+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/enrico-zanardo/2025-12-30T15:10:46+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/andrea-hugill/2025-11-25T21:39:46+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/guillaume-germain/2026-01-07T16:21:25+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/katrina-messina/2025-03-26T15:09:46+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/jess-marden/2025-07-02T20:33:16+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/kate-schofield/2026-01-15T16:40:30+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/ann-murray/2024-08-15T13:09:25+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/laszlo-jakab/2024-11-20T14:37:46+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/ngoc-pham/2024-04-04T17:15:13+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/anne-cai/2025-09-15T17:33:30+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/james-bernard/2025-03-25T16:28:37+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/michael-carson/2026-02-05T17:06:29+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/olga-kozlova-guglielmi/2026-04-01T15:32:40+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/rongzhang-wang/2024-04-04T17:15:17+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/jonathan-e-baker/2025-11-25T21:41:23+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/owen-hearey/2026-03-31T18:22:35+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/david-a-maber/2026-02-23T16:14:46+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/haimin-zhang/2025-09-17T14:12:53+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/brendan-rogers/2025-12-12T15:47:22+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/george-derpanopoulos/2025-07-24T15:31:21+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/erica-vansant/2024-04-04T17:15:14+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/ilona-mostipan/2025-09-17T13:42:38+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/lolo-palacios/2026-03-24T15:36:26+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/jane-choi/2025-09-09T18:05:17+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/leah-kitashima/2024-04-17T15:35:24+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/rachel-bechek/2026-01-08T19:47:22+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/hyun-lee/2025-12-01T18:41:18+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/bruno-martins/2026-01-27T18:49:44+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/mary-reiser/2025-03-25T16:28:41+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/emily-gao/2026-04-01T14:41:11+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/kale-kponee-shovein/2026-01-26T16:50:39+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/douglas-oreagan/2026-04-01T14:42:55+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/dylan-kellachan/2025-11-25T21:42:17+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/marisa-carlos/2026-02-04T16:48:25+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/susan-ou/2026-02-09T22:14:26+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/marianne-cunnington/2025-08-06T17:43:02+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/jaclyn-cotton/2026-01-07T19:24:53+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/emma-xiaoxiao-dong/2025-09-04T17:08:07+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/cameron-fowler/2026-01-27T16:35:50+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/marcello-c.-santana2025-03-25T16:28:41+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/maria-marta-laurito/2026-04-01T15:36:46+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/dasha-anosova/2026-01-13T17:19:37+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/carlo-gallimberti/2026-04-01T14:38:53+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/pierre-lissot/2026-03-31T15:22:49+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/steve-allen/2026-03-12T17:30:20+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/katie-williams/2026-02-13T19:41:33+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/riccardo-marchingiglio/2026-04-01T17:15:47+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/brynna-carswell-smith/2026-03-19T20:51:28+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/kimberly-attia/2026-01-29T21:24:51+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/luxi-wang/2025-02-05T14:00:00+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/arielle-bensimon/2025-12-16T04:22:03+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/gregory-d-weiss/2026-03-09T19:47:31+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/rosamond-mate/2026-01-02T16:48:51+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/maja-glowka/2025-11-07T17:35:55+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/yeseul-hyun/2026-03-25T14:22:43+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/mickey-ferri/2025-06-04T13:00:44+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/ashley-lee/2025-03-25T16:28:40+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/nicholas-blair/2026-01-23T16:07:54+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/peter-c-jones/2026-03-02T16:41:58+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/peter-c-chen/2026-03-24T13:56:52+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/david-a-thompson/2026-04-02T14:04:18+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/rose-chang/2026-01-07T16:40:20+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/stefano-parravano/2026-02-12T22:08:22+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/xinglei-chai/2025-10-31T17:38:38+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/benjamin-march/2025-04-09T18:53:32+00:00weekly0.7https://www.analysisgroup.com/people/vice-presidents/cyril-hariton/2026-02-11T18:40:20+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/sofia-hussain/2026-04-02T14:04:16+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/ali-dahir/2026-02-02T21:14:10+00:00weekly0.5https://www.analysisgroup.com/people/vice-presidents/briana-ohaver/2026-04-01T15:52:54+00:00weekly0.5https://www.analysisgroup.com/careers/why-analysis-group/our-people/2026-04-02T15:55:48+00:00weekly0.7https://www.analysisgroup.com/careers/why-analysis-group/benefits/2025-12-24T17:49:49+00:00weekly0.7https://www.analysisgroup.com/careers/why-analysis-group/growing-careers-at-analysis-group/2025-04-28T20:17:59+00:00weekly0.7https://www.analysisgroup.com/practices/data-science-ai-statistical-modeling/data-visualization-real-time-analyses-and-interactive-platforms/2025-06-18T15:33:46+00:00weekly0.7https://www.analysisgroup.com/practices/data-science-ai-statistical-modeling/econometric-modeling/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/practices/data-science-ai-statistical-modeling/machine-learning-ai/2025-06-18T16:01:21+00:00weekly0.7https://www.analysisgroup.com/practices/data-science-ai-statistical-modeling/natural-language-processing/2025-10-06T17:58:43+00:00weekly0.7https://www.analysisgroup.com/practices/data-science-ai-statistical-modeling/predictive-analytics-and-optimization/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/practices/data-science-ai-statistical-modeling/statistical-sampling/2024-01-11T10:40:30+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/analysis-group-forum-2015-year-in-review/2024-01-11T10:40:36+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/analysis-group-forum-spring-2017/2024-01-11T10:40:35+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/analysis-group-forum-summer-2018/2024-01-11T10:41:00+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/analysis-group-forum-spring-2019/2024-01-11T10:41:05+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/analysis-group-forum-2020/2025-03-26T18:38:00+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/forum-2021/2024-01-11T10:42:00+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/forum-2022/2024-01-11T10:42:37+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/forum-2023/2024-11-15T17:46:21+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/forum-2024/2026-03-30T13:50:13+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/forum-2025/2025-10-08T21:02:19+00:00weekly0.7https://www.analysisgroup.com/forums-and-bulletins/forums/forum-2026/2026-03-31T14:37:31+00:00weekly0.7https://www.analysisgroup.com/practices/tax/tax-related-valuation/2024-01-11T10:41:46+00:00weekly0.7https://www.analysisgroup.com/practices/tax/transaction-analysis/2024-01-11T10:41:46+00:00weekly0.7https://www.analysisgroup.com/practices/tax/transfer-pricing/2024-01-11T10:41:46+00:00weekly0.7https://www.analysisgroup.com/careers/what-is-economic-consulting/life-cycle-of-an-heor-case-relaxicalm-study/2026-02-20T20:02:51+00:00weekly0.7https://www.analysisgroup.com/careers/what-is-economic-consulting/life-cycle-of-a-litigation-case-pear-tv-damages-litigation/2026-02-20T20:12:45+00:00weekly0.7https://www.analysisgroup.com/about/diversity-equity-and-inclusion-at-analysis-group/rise-at-ag-externship/2026-01-09T20:06:37+00:00weekly0.7https://www.analysisgroup.com/about/diversity-equity-and-inclusion-at-analysis-group/ignite-at-ag-externship/2026-02-13T18:10:29+00:00weekly0.7https://www.analysisgroup.com/practices/environmental-social-governance/esg-accounting-finance-governance/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/practices/environmental-social-governance/esg-consumer-behavior/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/practices/environmental-social-governance/climate-change-environmental-sustainability/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/practices/environmental-social-governance/social-impact-business-practices/2024-01-11T10:42:47+00:00weekly0.7https://www.analysisgroup.com/people/ricol-lasteyrie/rene-ricol/2026-02-02T15:52:45+00:00weekly0.7https://www.analysisgroup.com/people/ricol-lasteyrie/jean-charles-de-lasteyrie/2026-02-02T16:11:44+00:00weekly0.7https://www.analysisgroup.com/people/ricol-lasteyrie/gilles-de-courcel/2026-02-02T16:53:13+00:00weekly0.7https://www.analysisgroup.com/people/ricol-lasteyrie/pierre-deheunynck/2026-02-02T17:13:18+00:00weekly0.7https://www.analysisgroup.com/people/ricol-lasteyrie/melanie-segard/2026-02-02T17:54:39+00:00weekly0.7https://www.analysisgroup.com/people/ricol-lasteyrie/nadine-raffoul/2026-02-02T18:07:18+00:00weekly0.7https://www.analysisgroup.com/people/ricol-lasteyrie/philippe-steing/2026-02-02T18:27:44+00:00weekly0.7https://www.analysisgroup.com/people/ricol-lasteyrie/gilles-vantelon/2026-02-02T18:47:54+00:00weekly0.7https://www.analysisgroup.com/people/ricol-lasteyrie/armelle-deydier/2026-02-02T19:02:15+00:00weekly0.7https://www.analysisgroup.com/people/ricol-lasteyrie/marie-glomet/2026-02-02T19:19:50+00:00weekly0.7https://www.analysisgroup.com/people/ricol-lasteyrie/cedric-vignolles/2026-02-02T19:33:02+00:00weekly0.7https://www.analysisgroup.com/Error/bulletin-landing-page/2024-01-11T10:43:47+00:00weekly0.8https://www.analysisgroup.com/contact-us/contact-us-thank-you/2024-02-14T18:45:11+00:00weekly0.8https://www.analysisgroup.com/policy/website-privacy-statement/2025-07-23T22:05:11+00:00weekly0.8https://www.analysisgroup.com/policy/terms-of-use/2025-07-23T22:04:11+00:00weekly0.8https://www.analysisgroup.com/policy/privacy-notice-eu-uk-applicants/2025-07-23T22:06:43+00:00weekly0.8https://www.analysisgroup.com/policy/privacy-notice-eu-uk-applicants-french/2025-07-23T22:06:10+00:00weekly0.8https://www.analysisgroup.com/policy/privacy-notice-ca-applicants/2026-03-25T19:23:04+00:00weekly0.8https://www.analysisgroup.com/policy/US-privacy-notice/2025-07-23T21:57:32+00:00weekly0.8https://www.analysisgroup.com/policy/groupe-danalyse-analysis-group-privacy-notice-for-quebec-job-applicants-english/2025-07-23T22:07:47+00:00weekly0.8https://www.analysisgroup.com/policy/groupe-danalyse-analysis-group-privacy-notice-for-quebec-job-applicants-french/2025-07-23T22:08:13+00:00weekly0.8https://www.analysisgroup.com/policy/analysis-group-privacy-notice-for-eu-and-uk-job-applicants-dutch/2025-07-23T22:07:20+00:00weekly0.8https://www.analysisgroup.com/policy/analysis-group-eu-uk-privacy-notice-english/2025-07-23T22:09:29+00:00weekly0.8https://www.analysisgroup.com/policy/analysis-group-eu-uk-privacy-notice-french/2025-07-23T22:10:04+00:00weekly0.8https://www.analysisgroup.com/policy/modern-slavery-act-statement/2026-02-27T17:50:23+00:00weekly0.8https://www.analysisgroup.com/practices/antitrust-competition/2025-09-23T21:48:20+00:00weekly0.8https://www.analysisgroup.com/practices/class-certification/2025-07-17T17:52:28+00:00weekly0.8https://www.analysisgroup.com/practices/commercial-disputes/2025-07-17T17:52:48+00:00weekly0.8https://www.analysisgroup.com/practices/damages/2022-01-27T15:54:26+00:00weekly0.8https://www.analysisgroup.com/practices/energy-climate-natural-resources/2025-07-17T17:35:25+00:00weekly0.8https://www.analysisgroup.com/practices/heor-epidemiology-and-market-access/2024-02-07T15:37:54+00:00weekly0.8https://www.analysisgroup.com/practices/erisa/2022-10-20T17:13:39+00:00weekly0.8https://www.analysisgroup.com/practices/government-and-corporate-investigations/2023-01-13T12:44:39+00:00weekly0.8https://www.analysisgroup.com/practices/health-care/2026-03-13T13:09:21+00:00weekly0.8https://www.analysisgroup.com/practices/insurance/2023-09-22T19:57:55+00:00weekly0.8https://www.analysisgroup.com/practices/intellectual-property/2022-05-02T15:01:48+00:00weekly0.8https://www.analysisgroup.com/practices/international-arbitration/2024-08-15T13:57:38+00:00weekly0.8https://www.analysisgroup.com/practices/labor-and-employment/2024-05-01T15:53:34+00:00weekly0.8https://www.analysisgroup.com/practices/media-entertainment-and-communications/2023-01-13T12:44:39+00:00weekly0.8https://www.analysisgroup.com/practices/privacy-and-data-security/2024-01-11T10:43:49+00:00weekly0.8https://www.analysisgroup.com/practices/securities-financial-products-and-institutions/2023-01-13T12:44:39+00:00weekly0.8https://www.analysisgroup.com/practices/strategy-policy-and-analytics/2026-03-26T20:57:22+00:00weekly0.8https://www.analysisgroup.com/practices/marketing-consumer-behavior-surveys/2026-02-09T16:48:06+00:00weekly0.8https://www.analysisgroup.com/practices/accounting/2025-06-05T18:41:21+00:00weekly0.8https://www.analysisgroup.com/practices/technology/2025-09-16T20:51:01+00:00weekly0.8https://www.analysisgroup.com/practices/transaction-and-governance-litigation/2023-01-13T12:44:39+00:00weekly0.8https://www.analysisgroup.com/practices/valuation/2025-08-27T19:21:16+00:00weekly0.8https://www.analysisgroup.com/practices/data-science-ai-statistical-modeling/2025-06-18T15:23:14+00:00weekly0.8https://www.analysisgroup.com/practices/tax/2024-01-11T10:43:46+00:00weekly0.8https://www.analysisgroup.com/practices/bankruptcy-insolvency/2024-01-11T10:43:46+00:00weekly0.8https://www.analysisgroup.com/practices/environmental-social-governance/2024-01-11T10:43:46+00:00weekly0.8https://www.analysisgroup.com/forums-and-bulletins/forum/2026-02-02T16:04:38+00:00weekly0.8https://www.analysisgroup.com/about/locations/2025-03-26T18:06:34+00:00weekly0.8https://www.analysisgroup.com/about/our-work/2025-09-09T20:05:02+00:00weekly0.8https://www.analysisgroup.com/about/diversity-equity-and-inclusion-at-analysis-group/2026-01-22T20:44:40+00:00weekly0.8https://www.analysisgroup.com/about/pro-bono/2025-01-07T20:09:35+00:00weekly0.8https://www.analysisgroup.com/careers/why-analysis-group/2026-03-27T15:12:50+00:00weekly0.8https://www.analysisgroup.com/careers/career-path/2025-12-24T21:53:45+00:00weekly0.8https://www.analysisgroup.com/careers/faqs/2025-12-24T17:50:02+00:00weekly0.8https://www.analysisgroup.com/careers/what-is-economic-consulting/2026-03-23T15:02:26+00:00weekly0.8https://www.analysisgroup.com/people/2025-10-14T18:48:02+00:00weekly0.9https://www.analysisgroup.com/about/2025-09-09T20:07:50+00:00weekly0.9https://www.analysisgroup.com/careers/2026-03-27T15:16:20+00:00weekly0.5https://www.analysisgroup.com/Insights/2025-10-14T18:48:07+00:00weekly0.9https://www.analysisgroup.com/practices/2026-01-07T18:50:11+00:00weekly0.5https://www.analysisgroup.com/news-and-events/2025-10-14T18:48:13+00:00weekly0.9https://www.analysisgroup.com/search-results/2025-10-14T18:48:20+00:00weekly0.9https://www.analysisgroup.com/forums-and-bulletins/2024-01-11T10:43:50+00:00weekly0.9https://www.analysisgroup.com/contact-us/2024-07-29T13:37:14+00:00weekly0.9https://www.analysisgroup.com/policy/2026-02-27T17:50:37+00:00weekly0.9https://www.analysisgroup.com/sign-up/2025-09-17T19:08:23+00:00weekly0.9https://www.analysisgroup.com/sign-up-thank-you/2024-01-11T10:43:50+00:00weekly0.9https://www.analysisgroup.com/Error/2024-02-06T23:16:09+00:00weekly0.9https://www.analysisgroup.com/error404/2024-01-11T10:43:50+00:00weekly0.9https://www.analysisgroup.com/analyst-pay/2025-11-04T17:52:50+00:00weekly0.9https://www.analysisgroup.com/associate-pay/2025-11-04T17:53:23+00:00weekly0.9https://www.analysisgroup.com/summer-analyst-pay/2025-11-12T17:34:50+00:00weekly0.9https://www.analysisgroup.com/summer-associate-pay/2025-11-12T17:35:12+00:00weekly0.9https://www.analysisgroup.com/general-terms-and-conditions-for-analysis-group-sas/2024-01-11T10:43:51+00:00weekly0.9https://www.analysisgroup.com/sitemap/2024-04-16T17:34:25+00:00weekly0.9https://www.analysisgroup.com/2026-04-03T15:43:29+00:00weekly1